data_2dgs_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2dgs _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.909 0.385 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -102.38 143.28 32.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 33.0 pt -126.55 152.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -97.08 109.03 21.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.445 HG12 ' CG1' ' A' ' 120' ' ' ILE . 90.5 t -104.43 113.02 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.65 176.51 16.38 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.95 5.42 46.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.459 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 51.2 mt -52.75 138.02 43.38 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 111.161 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.52 24.22 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.712 2.275 . . . . 0.0 112.363 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.444 ' CE1' HH11 ' A' ' 152' ' ' ARG . 41.1 t-80 -82.93 10.34 8.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.39 -20.21 8.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.469 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 11.6 t -80.5 142.15 34.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.09 -171.88 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -48.16 -57.93 5.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.6 m -47.01 -60.14 2.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 129' ' ' LEU . 1.7 mp0 -53.83 -63.45 1.15 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.89 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 128' ' ' GLU . 63.5 mt -34.31 -62.5 0.33 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -59.02 -52.03 67.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -50.5 -22.52 1.98 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.451 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 13.4 t80 -104.65 -20.62 13.59 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -102.49 15.49 29.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.937 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 32.1 pttt -94.14 -16.44 23.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 3.7 pttm -76.14 -36.67 58.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -67.95 -26.57 66.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.876 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.39 -114.69 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 66.3 t -144.16 116.71 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 111.137 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.82 113.53 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 76.5 p -90.11 -36.0 15.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -143.52 152.29 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.869 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -134.82 101.99 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.7 t -87.92 143.86 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.147 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.456 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 6.0 mtt -144.94 131.47 19.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 71.1 mt -96.12 131.89 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.108 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.443 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.58 164.52 10.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 43.9 t0 -85.99 112.14 20.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.81 -60.9 0.36 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 148' ' ' ALA . 0.3 OUTLIER -36.14 -45.44 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -81.44 -39.33 25.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 59.73 54.27 4.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.444 HH11 ' CE1' ' A' ' 122' ' ' HIS . 9.0 ttm180 -165.37 138.74 3.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.612 0.72 . . . . 0.0 110.878 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.456 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.6 Cg_endo -69.76 114.22 3.63 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.739 2.292 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.4 mtt180 -56.09 -54.42 45.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.04 39.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.527 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -169.39 166.59 10.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.874 0.369 . . . . 0.0 110.916 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.24 -157.26 28.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -137.36 165.91 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 11.8 mt -149.2 134.07 10.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.0 m -101.34 145.06 29.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.537 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -114.52 -177.7 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -86.85 -41.97 13.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . 0.416 ' O ' ' C ' ' A' ' 164' ' ' GLU . 0.8 OUTLIER -125.25 128.54 48.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.868 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 163' ' ' ASP . 10.1 tm-20 -36.3 -37.7 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.917 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.423 ' O ' ' C ' ' A' ' 166' ' ' SER . 15.7 mt-30 -42.08 -60.45 1.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.537 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 1.3 m -36.67 -53.43 0.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 70.5 t -45.24 -58.68 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.144 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -50.21 -55.01 17.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.841 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -45.44 -51.08 11.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.906 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.58 -51.39 63.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 39.8 t -47.63 -60.5 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -41.83 -51.95 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -59.26 -41.98 90.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 48.17 28.17 1.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.849 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 5.1 m-85 -173.0 151.35 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.507 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 74.5 m-70 -160.29 147.64 16.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.832 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -102.33 90.0 3.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 72.5 mt -110.23 110.31 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 10.2 mtt 63.48 44.81 5.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.875 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.93 43.11 99.64 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.471 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.8 tppt? -149.61 145.46 26.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.19 107.83 19.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.1 t -93.54 129.12 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -87.32 135.79 33.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.905 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.477 HG21 ' CD2' ' A' ' 176' ' ' HIS . 56.1 t -132.62 132.48 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 7.5 mmmm -136.21 159.73 40.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -67.89 114.22 6.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 179.943 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.942 0.401 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 tttt -97.88 144.52 27.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 20.2 pt -126.07 149.14 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.3 t80 -96.39 113.71 25.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.918 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.4 t -110.28 116.31 52.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.54 -179.54 16.06 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.85 14.46 44.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.472 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 59.3 mt -62.45 138.36 96.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.629 0.728 . . . . 0.0 111.128 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.78 159.96 51.46 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.67 2.246 . . . . 0.0 112.337 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -68.2 -4.1 12.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.833 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.411 ' O ' ' C ' ' A' ' 124' ' ' CYS . 9.5 m120 -100.23 -62.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.429 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 35.3 t -37.62 120.96 0.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.4 -172.24 13.76 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -46.24 -65.68 0.52 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.3 m -44.13 -59.13 2.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 129' ' ' LEU . 67.1 mm-40 -49.67 -65.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.847 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 128' ' ' GLU . 39.5 mt -34.38 -54.63 0.52 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.467 ' O ' ' N ' ' A' ' 133' ' ' PHE . 14.4 mtp180 -63.69 -59.99 3.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -42.75 -25.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 12.2 t80 -100.66 -24.82 14.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.529 ' CD2' HD13 ' A' ' 159' ' ' ILE . 14.3 m-85 -97.91 13.76 29.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -93.12 -29.77 15.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.6 pttt -61.67 -33.85 74.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -68.87 -42.85 76.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.898 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -166.19 -108.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.485 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.65 109.91 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.468 HG13 ' CG2' ' A' ' 159' ' ' ILE . 29.1 t -75.21 119.55 23.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.163 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 33.2 p -93.81 -36.31 12.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.149 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -140.55 153.03 45.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.63 101.95 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.097 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.458 HG13 ' N ' ' A' ' 144' ' ' MET . 62.3 t -88.73 141.14 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.088 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.458 ' N ' HG13 ' A' ' 143' ' ' VAL . 4.3 mtt -143.33 138.99 29.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.6 mt -105.48 132.4 52.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -171.69 165.06 6.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.882 -179.972 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 26.2 t0 -84.39 113.9 21.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.85 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.74 -58.48 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -42.5 -43.56 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 10.5 tppt? -77.48 -41.33 39.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 60.02 46.92 10.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 0.4 OUTLIER -160.6 138.58 7.21 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.577 0.704 . . . . 0.0 110.862 -179.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.445 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.84 110.77 2.65 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.7 2.267 . . . . 0.0 112.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 19.1 mtt-85 -50.3 -55.79 13.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.99 42.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -173.29 159.94 3.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.882 0.373 . . . . 0.0 110.85 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.04 -158.66 31.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.495 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -139.64 162.18 35.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.529 HD13 ' CD2' ' A' ' 133' ' ' PHE . 14.4 mt -144.91 139.37 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 159' ' ' ILE . 28.1 m -105.29 141.29 37.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.55 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 34.5 m-85 -112.51 174.01 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -79.91 -40.39 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.915 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . 0.44 ' O ' ' C ' ' A' ' 164' ' ' GLU . 27.4 m-20 -126.16 123.37 38.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.865 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.44 ' C ' ' O ' ' A' ' 163' ' ' ASP . 8.4 tp10 -35.18 -41.15 0.15 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.838 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.427 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.0 mm-40 -35.79 -60.89 0.5 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.55 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 68.7 m -39.29 -59.25 1.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' A' ' 166' ' ' SER . 67.1 t -35.32 -47.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.135 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -65.53 -52.33 53.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -43.43 -50.46 6.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.404 ' O ' ' C ' ' A' ' 171' ' ' VAL . . . -68.04 -66.0 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.404 ' C ' ' O ' ' A' ' 170' ' ' ALA . 88.8 t -37.1 -52.37 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 59.9 t-20 -37.41 -65.49 0.31 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' MET . . . . . 0.516 ' HE3' ' CE1' ' A' ' 176' ' ' HIS . 7.5 mtm -57.91 -32.24 67.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.914 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.513 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 18.2 t-160 50.17 26.81 2.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.524 ' C ' ' CD2' ' A' ' 176' ' ' HIS . 7.8 m-85 -169.45 150.31 4.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.524 ' CD2' ' C ' ' A' ' 175' ' ' PHE . 24.1 m-70 -160.9 150.03 16.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.843 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -105.73 94.48 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.913 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 70.3 mt -111.4 114.43 47.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 13.5 mtt 61.86 39.64 13.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.94 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.04 54.07 29.88 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -164.64 142.95 6.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.41 117.95 23.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.923 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.2 t -105.43 122.52 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.171 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -80.79 138.18 36.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 94.4 t -139.72 135.61 39.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -147.21 169.41 19.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 22.1 mtt180 -69.12 114.22 7.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.853 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.096 179.9 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.923 0.392 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -91.43 143.38 26.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 22.7 pt -127.56 148.13 32.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.403 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 17.1 t80 -92.53 112.95 25.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.815 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.415 HG12 ' CG1' ' A' ' 120' ' ' ILE . 91.1 t -109.51 117.3 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.136 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.86 -177.47 15.21 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.508 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.41 23.07 47.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.461 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.439 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 64.3 mt -69.85 137.45 87.68 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.657 0.742 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.451 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.2 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.691 2.261 . . . . 0.0 112.31 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -81.6 3.63 24.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -110.07 -27.14 9.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.451 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.5 t -74.89 123.99 26.07 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.35 -173.55 13.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.72 -62.37 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.972 0.415 . . . . 0.0 110.885 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 51.9 m -43.14 -63.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.088 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 129' ' ' LEU . 0.9 OUTLIER -49.47 -62.24 1.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 128' ' ' GLU . 35.3 mt -34.35 -49.21 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.89 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 50.4 mtt180 -67.49 -51.44 51.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -55.2 -16.71 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.469 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 15.9 t80 -108.74 -20.83 12.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.513 ' CE2' HD13 ' A' ' 159' ' ' ILE . 11.4 m-85 -105.5 16.49 25.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.875 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.2 ptpt -94.76 -26.17 16.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -68.06 -38.46 82.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.883 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -63.26 -35.11 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . 0.483 ' O ' ' CG2' ' A' ' 138' ' ' VAL . . . -173.45 -98.08 0.11 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.476 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 137' ' ' GLY . 56.2 t -161.42 109.99 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.876 0.37 . . . . 0.0 111.134 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.23 113.52 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 17.7 p -90.55 -37.73 13.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -141.23 153.04 45.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 63.5 t -134.28 100.69 3.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.8 t -85.71 142.16 13.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.469 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 5.7 mtt -145.03 133.24 21.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.837 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 59.2 mt -97.95 136.85 27.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.451 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.9 3.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.944 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.453 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -86.3 113.72 22.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.453 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.27 -62.27 0.28 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 17.7 tt0 -36.25 -47.29 0.57 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.837 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -77.33 -40.77 43.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 60.08 51.71 5.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.451 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 2.1 ttp180 -163.89 138.86 4.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.634 0.731 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.469 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.3 Cg_endo -69.81 110.56 2.6 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.643 2.229 . . . . 0.0 112.316 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.3 mtt180 -50.97 -52.4 43.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.4 40.24 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -170.2 162.35 8.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.868 0.366 . . . . 0.0 110.893 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.408 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.73 -150.79 19.75 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 15.9 m-85 -145.97 168.99 19.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 0.0 110.901 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.513 HD13 ' CE2' ' A' ' 133' ' ' PHE . 20.5 mt -151.55 138.16 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 161' ' ' PHE . 28.7 m -103.49 142.92 33.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.138 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.498 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 57.7 m-85 -113.27 170.03 8.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -73.98 -38.73 64.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.861 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -131.02 137.2 49.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.448 ' O ' ' N ' ' A' ' 167' ' ' VAL . 11.4 tm-20 -44.93 -47.17 11.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.8 tt0 -34.74 -48.42 0.38 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.94 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.498 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 66.0 m -50.35 -46.7 55.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.448 ' N ' ' O ' ' A' ' 164' ' ' GLU . 58.0 t -50.89 -55.56 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.157 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -53.62 -47.36 70.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.813 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -49.08 -55.79 11.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.907 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.95 -58.26 6.6 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.439 ' O ' ' N ' ' A' ' 174' ' ' HIS . 94.0 t -44.17 -61.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.108 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 171' ' ' VAL . 28.3 t30 -35.76 -46.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.2 mmm -69.9 -43.42 71.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.538 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 16.5 t-160 59.06 26.94 15.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.0 m-85 -171.55 154.32 3.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.865 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 93.2 m-70 -160.66 162.77 32.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.832 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -117.95 92.4 3.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 55.9 mt -112.21 127.24 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.143 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.0 mmt 52.63 33.38 13.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.96 52.06 25.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.482 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -159.03 145.81 17.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.863 0.364 . . . . 0.0 110.869 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.2 tppt? -82.17 111.17 18.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.854 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.3 t -100.97 121.58 51.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -80.79 144.86 31.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 52.7 t -141.1 131.72 27.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.156 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.5 mtpt -142.95 144.48 32.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.915 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.452 ' CZ ' ' HB3' ' A' ' 187' ' ' ARG . 7.4 mtp-105 -50.62 120.81 5.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.082 179.956 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.864 0.364 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -93.24 151.93 19.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 18.1 pt -134.7 152.25 32.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.11 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 27.7 t80 -98.95 108.74 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 90.8 t -104.48 114.36 43.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.84 170.83 16.12 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 72.36 14.19 77.07 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.442 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.473 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 34.2 mt -62.74 137.41 96.64 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.641 0.734 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.77 161.0 47.6 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.707 2.271 . . . . 0.0 112.324 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.0 2.41 10.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.404 ' C ' ' SD ' ' A' ' 179' ' ' MET . 8.8 m-20 -107.72 -23.56 12.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.864 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.468 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 25.4 t -82.07 143.1 31.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -145.51 -171.98 15.54 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.534 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -42.95 -66.18 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.7 m -40.17 -65.73 0.38 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 129' ' ' LEU . 3.9 mp0 -48.33 -61.68 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 128' ' ' GLU . 80.7 mt -34.4 -50.61 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.911 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -71.32 -53.4 14.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 41.4 mm-40 -46.99 -22.31 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.524 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 32.6 t80 -103.85 -36.79 7.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.897 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.564 ' CE2' HD13 ' A' ' 159' ' ' ILE . 16.8 m-85 -84.9 10.23 12.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.885 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.448 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 8.6 ptpt -91.0 -29.78 17.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . 0.448 ' N ' ' HG3' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -69.97 -17.42 63.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.913 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -89.54 -19.88 24.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.22 -118.07 0.65 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.538 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.6 t -146.02 106.88 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.89 0.376 . . . . 0.0 111.119 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.52 111.09 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 43.3 p -88.03 -39.76 14.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.152 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -136.97 151.11 48.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 86.4 t -134.36 106.22 7.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.454 HG12 ' N ' ' A' ' 144' ' ' MET . 60.7 t -96.7 139.31 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.191 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.503 ' CE ' ' CB ' ' A' ' 153' ' ' PRO . 14.4 mtp -141.1 130.57 23.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -91.46 137.21 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.447 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.72 165.13 4.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.937 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.443 ' O ' ' C ' ' A' ' 148' ' ' ALA . 39.3 t0 -85.13 113.49 21.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.59 -58.72 0.41 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.107 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -41.47 -43.87 2.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.436 ' N ' ' O ' ' A' ' 147' ' ' ASP . 9.5 tptm -78.14 -40.85 36.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 60.01 48.02 9.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.447 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.6 ttp85 -161.63 138.95 6.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.626 0.727 . . . . 0.0 110.816 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.503 ' CB ' ' CE ' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 113.8 3.49 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.645 2.23 . . . . 0.0 112.348 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 33.7 mtp85 -55.48 -57.04 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 167.8 41.66 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.503 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -172.55 157.13 3.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.918 0.39 . . . . 0.0 110.834 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.41 -154.42 24.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.507 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -140.1 166.13 25.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.813 0.34 . . . . 0.0 110.919 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.564 HD13 ' CE2' ' A' ' 133' ' ' PHE . 17.3 mt -150.0 142.39 17.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.102 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.4 m -109.82 141.12 42.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.11 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.562 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 39.4 m-85 -110.39 176.98 4.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -82.47 -36.17 26.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -131.96 131.34 42.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.849 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -40.8 -41.49 1.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.839 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -37.56 -53.95 1.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.562 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 22.4 m -46.27 -54.37 8.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 63.8 t -40.71 -56.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.134 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 169' ' ' GLN . 38.8 t0 -56.29 -64.13 0.96 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 168' ' ' ASP . 50.9 mt-30 -34.69 -43.92 0.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -75.15 -62.47 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.084 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.441 HG23 ' CG ' ' A' ' 187' ' ' ARG . 51.4 t -42.74 -54.24 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -40.64 -51.61 2.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.4 mmm -64.37 -31.97 73.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 13.3 t-160 48.61 26.46 1.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.1 m-85 -169.28 148.46 3.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.848 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.524 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 91.9 m-70 -155.07 152.43 29.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.84 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -108.13 104.07 13.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 52.4 mt -126.23 113.09 32.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' MET . . . . . 0.404 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 9.1 mtt 60.62 42.56 13.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 46.74 93.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.495 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.8 tptt -153.41 145.93 24.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -87.25 110.74 20.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.5 t -97.8 115.03 36.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -76.77 141.6 40.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 20.3 t -138.57 131.55 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 11.4 mtmt -138.34 149.99 46.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.947 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.441 ' CG ' HG23 ' A' ' 171' ' ' VAL . 14.0 mtt180 -53.07 123.77 12.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 179.923 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.7 ttmt -100.14 137.18 38.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 29.2 pt -119.65 153.38 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.147 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -101.87 107.61 18.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.421 ' CG2' HG21 ' A' ' 185' ' ' VAL . 88.1 t -103.36 117.65 49.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.141 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.69 -177.42 15.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.52 13.73 39.1 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.467 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.47 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 35.5 mt -61.65 137.15 94.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 0.0 111.15 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.1 Cg_endo -69.67 161.85 44.32 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.444 ' ND1' ' O ' ' A' ' 122' ' ' HIS . 2.8 p80 -77.58 8.66 4.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.873 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.459 ' O ' ' CE ' ' A' ' 179' ' ' MET . 47.5 t30 -117.09 -15.12 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.458 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 2.7 t -83.55 153.22 24.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -158.92 169.6 35.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.517 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 125' ' ' GLY . 0.6 OUTLIER -35.97 -59.4 0.6 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.893 0.377 . . . . 0.0 110.893 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.9 m -42.62 -53.94 4.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -65.25 -55.93 15.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.428 ' O ' ' N ' ' A' ' 133' ' ' PHE . 60.6 mt -42.6 -58.85 2.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.933 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 68.1 mtp180 -54.51 -56.72 15.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -50.87 -33.5 24.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.5 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.0 t80 -89.64 -20.06 24.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.428 ' N ' ' O ' ' A' ' 129' ' ' LEU . 11.1 m-85 -105.31 17.74 23.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -92.59 -39.15 11.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.3 ptpt -57.39 -31.14 65.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.869 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -73.99 -32.48 63.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.891 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.55 -118.9 0.54 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 60.2 t -145.04 106.23 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 21.5 t -68.71 108.66 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.117 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 16.5 p -86.03 -38.0 18.33 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -140.67 155.53 46.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 85.0 t -136.89 106.35 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.166 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.428 HG11 ' N ' ' A' ' 144' ' ' MET . 47.5 t -93.96 138.7 19.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.122 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.461 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 4.8 mtt -139.17 136.33 34.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.1 mt -101.43 131.76 48.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.445 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.16 164.84 7.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.3 t0 -85.41 112.4 20.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.865 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.5 -60.56 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 tm-20 -38.52 -45.45 1.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 9.3 tppt? -78.52 -40.51 34.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 60.07 53.11 4.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.911 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 15.4 ttp85 -165.44 138.34 3.56 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.601 0.715 . . . . 0.0 110.922 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.461 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.2 Cg_endo -69.81 111.44 2.82 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.684 2.256 . . . . 0.0 112.315 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.6 mtp85 -52.0 -50.77 60.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 161.27 39.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -169.69 161.45 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.519 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 165.42 -151.05 19.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.459 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.519 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 10.1 m-85 -146.03 166.31 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.869 0.366 . . . . 0.0 110.866 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.407 HD12 ' CD2' ' A' ' 133' ' ' PHE . 18.2 mt -150.4 136.78 12.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.13 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.433 HG23 ' N ' ' A' ' 161' ' ' PHE . 36.5 m -103.82 143.4 32.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.514 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.9 m-85 -112.44 176.46 5.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.925 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -77.91 -39.04 44.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.71 145.21 49.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 165' ' ' GLN . 34.8 tt0 -48.81 -44.39 39.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.918 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.418 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.1 tt0 -34.76 -49.6 0.43 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.514 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 20.0 m -53.65 -52.08 61.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 70.4 t -47.41 -47.1 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -63.56 -52.62 60.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -47.67 -51.58 21.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.891 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.89 -56.44 7.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 40.3 t -43.6 -57.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -38.74 -62.04 0.66 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.885 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.3 mmm -48.6 -42.45 33.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.6 t-160 54.01 25.72 5.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.521 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -172.37 144.8 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.898 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.5 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 64.8 m-70 -156.21 158.74 38.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -110.33 103.68 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 34.2 mt -130.05 131.34 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.089 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 123' ' ' ASN . 11.9 mmt 62.52 25.74 15.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.914 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.01 85.01 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.457 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 9.1 ttmm -128.29 162.17 27.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.866 0.365 . . . . 0.0 110.876 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 5.8 tptm -88.74 128.68 35.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.5 t -112.46 121.61 65.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.096 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -81.37 145.21 30.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.421 HG21 ' CG2' ' A' ' 117' ' ' VAL . 42.7 t -142.29 126.91 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mmmt -138.04 143.92 40.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -56.69 118.54 4.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.842 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 179.905 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.918 0.389 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.7 ttmt -117.67 148.65 41.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.7 pt -129.22 155.33 41.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 7.3 t80 -104.74 102.37 11.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.8 t -93.3 125.42 45.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.109 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.1 -177.28 14.79 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.52 8.69 10.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.467 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 55.3 mt -58.71 137.61 86.58 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.638 0.732 . . . . 0.0 111.117 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.467 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.76 169.79 18.09 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.0 p-80 -85.92 15.21 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -123.67 -26.86 4.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.497 ' N ' ' SD ' ' A' ' 179' ' ' MET . 24.1 t -72.18 118.92 15.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.68 -174.32 16.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.495 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -41.45 -63.94 0.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.951 0.405 . . . . 0.0 110.863 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 46.0 m -41.9 -54.9 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.102 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 129' ' ' LEU . 61.1 mm-40 -54.41 -66.18 0.44 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.431 ' C ' ' O ' ' A' ' 128' ' ' GLU . 51.5 mt -34.53 -60.34 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 5.6 mtp-105 -58.9 -57.0 15.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.863 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -46.44 -25.8 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.3 t80 -102.46 -20.7 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.928 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.554 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.6 m-85 -104.47 9.8 35.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 130' ' ' ARG . 48.2 pttt -91.33 -17.61 25.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.88 -38.57 57.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.915 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -69.18 -29.38 67.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.31 -124.17 0.79 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.7 t -138.61 105.3 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.126 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 38.6 t -65.16 110.0 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.079 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 46.2 p -87.74 -38.46 15.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.129 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -137.38 147.43 45.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.859 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.27 94.46 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.412 HG11 ' N ' ' A' ' 144' ' ' MET . 72.3 t -89.99 137.9 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.12 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.47 ' HE3' ' CB ' ' A' ' 153' ' ' PRO . 8.8 mtp -137.57 142.7 41.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 73.3 mt -106.58 133.53 50.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.37 165.08 5.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.903 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 29.1 t0 -85.83 113.5 22.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.33 -62.13 0.29 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.108 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 148' ' ' ALA . 42.5 tt0 -36.38 -46.26 0.53 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -78.99 -40.55 31.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 60.0 47.84 9.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.9 ttp180 -158.29 138.32 8.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.623 0.725 . . . . 0.0 110.893 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.47 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.75 110.6 2.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.724 2.282 . . . . 0.0 112.32 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -51.62 -53.53 37.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.851 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 120' ' ' ILE . . . 163.03 41.39 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.534 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -170.7 160.6 7.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.914 0.388 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.23 -159.01 32.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 15.8 m-85 -137.81 161.11 37.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.82 0.343 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.554 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.1 mt -148.19 140.73 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.073 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.461 ' N ' HG22 ' A' ' 159' ' ' ILE . 23.6 m -107.13 144.23 34.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.451 ' N ' HG21 ' A' ' 160' ' ' THR . 54.8 m-85 -113.29 167.52 10.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -70.53 -43.17 70.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -122.06 140.53 52.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 165' ' ' GLN . 7.9 tp10 -49.67 -46.39 49.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.401 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.4 tt0 -38.24 -51.88 1.48 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.418 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 50.6 m -44.58 -57.05 3.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 166' ' ' SER . 38.4 t -37.68 -59.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 169' ' ' GLN . 46.9 t0 -50.53 -61.65 2.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.807 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 168' ' ' ASP . 76.0 mt-30 -35.73 -48.91 0.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.62 -57.89 4.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.118 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 174' ' ' HIS . 75.2 t -47.13 -60.39 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 171' ' ' VAL . 7.5 t30 -35.07 -61.08 0.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 27.5 mmm -51.08 -41.45 59.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.904 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.522 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.6 t-160 55.94 26.23 9.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.8 m-85 -171.87 148.32 2.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.566 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 52.7 m-70 -155.44 155.83 34.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -112.37 85.84 2.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . 0.421 ' C ' ' HG2' ' A' ' 179' ' ' MET . 78.8 mt -96.66 126.24 49.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.15 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' MET . . . . . 0.497 ' SD ' ' N ' ' A' ' 124' ' ' CYS . 2.0 ptm 38.81 48.22 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.5 67.74 1.94 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.418 ' NZ ' ' HB2' ' A' ' 181' ' ' LYS . 0.3 OUTLIER -175.13 142.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.815 0.34 . . . . 0.0 110.897 -179.946 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.8 tptm -85.04 102.37 13.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.884 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.08 117.34 38.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.139 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . 0.482 ' O ' ' CG2' ' A' ' 185' ' ' VAL . 10.1 tt0 -72.92 162.19 29.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.906 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.482 ' CG2' ' O ' ' A' ' 184' ' ' GLU . 72.3 t -161.12 131.02 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mttm -137.19 143.31 42.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.42 ' HB2' ' NH1' ' A' ' 187' ' ' ARG . 10.4 ttm105 -56.96 114.16 1.99 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.862 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 179.904 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 115' ' ' ILE . 21.3 ttmt -105.23 149.55 25.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . 0.433 ' N ' ' HG2' ' A' ' 114' ' ' LYS . 24.0 pt -129.6 156.85 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.454 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 8.0 t80 -104.58 106.45 16.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.05 114.42 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.154 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -118.43 -177.64 16.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.432 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.04 26.63 58.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.471 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.455 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 60.7 mt -75.46 137.9 71.12 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.631 0.729 . . . . 0.0 111.12 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.465 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.7 Cg_endo -69.72 165.11 32.02 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.706 2.27 . . . . 0.0 112.374 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -77.3 0.54 21.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -105.42 -32.89 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.465 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 21.4 t -68.8 118.81 12.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.39 -179.27 15.85 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 55.9 tt0 -39.89 -67.59 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.876 0.369 . . . . 0.0 110.853 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.1 m -40.67 -60.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.121 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 16.7 mm-40 -49.73 -61.22 2.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.427 ' C ' ' O ' ' A' ' 128' ' ' GLU . 41.9 mt -35.97 -55.67 0.74 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.471 ' CZ ' ' HB3' ' A' ' 130' ' ' ARG . 11.1 mtp-105 -64.03 -54.7 30.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -47.52 -20.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -107.46 -25.42 11.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.457 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.4 m-85 -97.98 15.34 24.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.8 ptpt -95.22 -10.69 29.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.94 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.2 pttm -81.69 -34.56 30.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -72.14 -23.29 61.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.33 -118.96 0.69 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 88.2 t -140.03 116.14 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 24.9 t -80.66 111.12 16.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.6 p -89.1 -34.95 16.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -142.02 157.82 44.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.3 t -139.05 104.94 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.172 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.418 HG11 ' N ' ' A' ' 144' ' ' MET . 48.1 t -90.79 139.27 17.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.149 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.435 ' HE3' ' CB ' ' A' ' 153' ' ' PRO . 5.3 mtt -142.25 133.7 26.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 70.7 mt -99.21 133.82 40.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.22 165.96 5.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.941 -179.987 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.455 ' O ' ' C ' ' A' ' 148' ' ' ALA . 21.8 t0 -84.88 113.23 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.455 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.16 -58.29 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.056 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -42.41 -44.45 3.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 147' ' ' ASP . 2.8 mptm? -77.22 -40.82 43.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 60.09 43.5 14.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.866 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 3.8 ttp180 -155.92 138.47 10.38 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.6 0.714 . . . . 0.0 110.886 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.435 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.77 110.87 2.66 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.335 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.9 mtp85 -50.86 -55.89 14.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.18 41.77 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -172.34 162.95 5.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.449 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 162.79 -154.51 25.49 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.451 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 4.7 m-85 -141.95 167.03 23.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.891 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.457 HD12 ' CD2' ' A' ' 133' ' ' PHE . 8.9 mt -150.1 139.85 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.137 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.443 ' N ' HG23 ' A' ' 159' ' ' ILE . 89.3 m -106.33 144.82 32.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.153 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.471 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 53.1 m-85 -115.13 175.02 5.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -78.65 -43.25 26.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 164' ' ' GLU . 3.4 m-20 -123.97 125.59 44.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.874 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 163' ' ' ASP . 23.1 tt0 -35.17 -39.03 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.419 ' C ' ' O ' ' A' ' 164' ' ' GLU . 3.8 mm100 -36.03 -59.33 0.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.471 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 1.1 m -41.87 -58.35 2.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.809 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 166' ' ' SER . 58.6 t -36.12 -54.42 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -58.54 -60.3 4.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.1 mt-30 -39.9 -48.84 2.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.92 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.48 -54.94 13.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.464 HG21 ' N ' ' A' ' 187' ' ' ARG . 67.9 t -46.21 -60.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.167 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.428 ' C ' ' O ' ' A' ' 171' ' ' VAL . 12.3 t-20 -35.84 -67.8 0.15 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.832 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 86.2 mtp -46.44 -42.14 14.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.3 t-160 54.74 30.61 13.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.824 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -173.57 155.17 2.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 77.8 m-70 -160.57 162.82 33.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -119.39 91.52 3.57 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 58.2 mt -112.23 135.09 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.146 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.7 mmm 46.14 40.78 7.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.885 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.34 57.4 18.42 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.2 tmtm? -166.09 151.33 8.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -84.5 116.7 23.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.9 t -105.78 120.41 56.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -82.15 146.78 29.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.471 HG23 ' CD2' ' A' ' 176' ' ' HIS . 69.2 t -144.49 134.31 19.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -139.18 149.1 44.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.464 ' N ' HG21 ' A' ' 171' ' ' VAL . 28.7 ttp180 -59.9 119.21 7.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.932 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.116 179.978 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.919 0.39 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -92.72 150.01 20.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.908 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . 0.434 HD12 ' CG2' ' A' ' 117' ' ' VAL . 20.0 pt -131.09 155.16 41.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -104.39 105.54 15.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.434 ' CG2' HD12 ' A' ' 115' ' ' ILE . 94.8 t -101.11 115.32 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.146 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.01 177.98 16.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.06 11.69 55.7 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.473 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 55.9 mt -57.85 138.84 82.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.642 0.734 . . . . 0.0 111.13 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.2 Cg_endo -69.79 171.96 13.55 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.658 2.239 . . . . 0.0 112.359 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.493 ' O ' ' CG ' ' A' ' 122' ' ' HIS . 12.1 t60 -76.58 -5.14 46.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.452 ' O ' ' C ' ' A' ' 124' ' ' CYS . 7.7 m120 -102.43 -62.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.456 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.3 t -34.38 128.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -127.34 -154.82 8.62 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.444 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -66.33 -60.87 2.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.942 0.401 . . . . 0.0 110.921 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 53.3 m -48.55 -58.36 4.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.091 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -46.63 -61.95 1.6 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 35.5 mt -39.74 -52.13 2.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.917 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.481 ' O ' ' N ' ' A' ' 134' ' ' LYS . 74.0 mtm180 -59.85 -52.42 65.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 -53.38 -27.84 26.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.927 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.515 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 9.0 t80 -96.51 -18.96 19.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.946 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -108.17 7.99 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.481 ' N ' ' O ' ' A' ' 130' ' ' ARG . 32.3 pttt -90.77 -28.46 18.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.2 ptpt -66.47 -25.94 66.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.867 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -78.66 -37.8 41.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -167.92 -112.25 0.26 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.463 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 86.5 t -147.47 112.33 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 111.056 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 70.7 t -75.16 103.78 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.112 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -79.24 -40.9 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.18 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.25 152.98 46.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.5 t -132.46 102.43 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.08 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.8 t -89.44 143.59 10.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.462 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.4 mtt -145.41 134.18 22.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 55.6 mt -98.76 130.66 47.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.169 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.454 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -170.09 164.66 9.34 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 150' ' ' LYS . 46.0 t0 -82.91 113.34 20.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.841 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.9 -52.46 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -48.0 -42.47 28.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.442 ' N ' ' O ' ' A' ' 147' ' ' ASP . 63.3 mttt -79.19 -38.43 35.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.948 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 58.19 51.41 8.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 13.1 ttm180 -164.95 138.42 3.88 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.61 0.719 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.462 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.72 113.54 3.4 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.742 2.295 . . . . 0.0 112.364 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.1 mtt180 -54.69 -55.47 29.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.32 40.59 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -171.39 164.76 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.902 0.382 . . . . 0.0 110.877 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.74 -161.04 33.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -137.73 162.85 32.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 160' ' ' THR . 15.8 mt -146.39 140.49 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.095 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.435 HG21 ' N ' ' A' ' 161' ' ' PHE . 41.0 m -108.78 139.88 42.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.435 ' N ' HG21 ' A' ' 160' ' ' THR . 34.9 m-85 -109.27 172.51 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.43 -30.03 47.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.928 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -137.43 147.21 45.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -55.56 -45.77 77.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.878 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -41.59 -42.29 2.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 6.1 m -55.84 -54.38 45.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 42.1 t -47.34 -51.31 6.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.154 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 18.6 t0 -52.92 -52.53 57.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 14.3 mm-40 -42.27 -44.37 3.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.12 -64.55 1.11 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 68.8 t -37.81 -50.25 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.097 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -39.2 -67.99 0.19 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' MET . . . . . 0.56 ' HE1' ' CE1' ' A' ' 176' ' ' HIS . 9.0 mtm -54.76 -43.41 72.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 17.6 t-160 61.17 26.48 16.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.1 m-85 -172.01 134.72 0.77 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.56 ' CE1' ' HE1' ' A' ' 173' ' ' MET . 57.0 m-70 -145.41 161.58 39.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -114.24 98.24 6.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 38.7 mt -118.65 129.07 75.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 51.07 41.89 27.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 60.73 63.65 4.79 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.489 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -174.15 149.21 1.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 9.7 tppt? -85.74 102.36 13.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.2 t -89.71 115.61 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.131 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -77.82 144.17 37.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.904 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 88.2 t -143.44 128.44 15.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -133.34 151.48 51.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.1 ttt-85 -66.4 108.53 2.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.908 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.889 0.376 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -105.19 145.23 30.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 16.2 pt -126.79 155.34 37.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.156 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -104.7 106.1 16.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.433 ' CG1' HD11 ' A' ' 120' ' ' ILE . 99.5 t -102.74 122.97 55.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -125.83 -174.94 14.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.07 16.77 14.55 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.503 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.468 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 59.9 mt -64.45 138.1 97.34 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.651 0.739 . . . . 0.0 111.143 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.468 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.06 25.56 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.633 2.222 . . . . 0.0 112.349 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -81.38 2.59 27.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.853 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -107.48 -29.02 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.464 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.1 t -72.96 135.39 45.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -139.26 175.71 21.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' GLY . 22.8 tt0 -34.57 -70.17 0.08 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.888 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 126' ' ' GLU . 22.0 m -36.36 -65.34 0.28 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.121 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 129' ' ' LEU . 36.8 mm-40 -47.65 -63.07 1.15 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.439 ' C ' ' O ' ' A' ' 128' ' ' GLU . 67.8 mt -34.38 -45.15 0.22 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.417 ' O ' ' N ' ' A' ' 134' ' ' LYS . 22.5 mtt180 -67.39 -56.73 8.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -46.88 -26.66 1.03 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.949 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.535 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -98.26 -31.41 12.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.532 ' CD2' HD12 ' A' ' 159' ' ' ILE . 24.8 m-85 -97.02 16.86 18.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 17.0 pttp -95.32 -27.9 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -68.08 -34.05 75.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.922 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -66.65 -31.53 72.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -178.86 -106.14 0.2 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 83.2 t -151.74 111.53 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.96 114.67 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 72.5 p -91.81 -38.29 12.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.161 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -140.51 154.16 46.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.5 t -134.7 100.92 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.459 HG12 ' N ' ' A' ' 144' ' ' MET . 65.3 t -83.28 141.9 14.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.459 ' N ' HG12 ' A' ' 143' ' ' VAL . 5.8 mtt -145.3 135.02 23.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.4 mt -101.02 136.45 32.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.105 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.06 166.03 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.45 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -88.88 113.52 24.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.52 -58.71 0.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.104 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.403 ' C ' ' O ' ' A' ' 148' ' ' ALA . 34.2 tt0 -37.52 -45.25 0.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.863 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 6.4 tptm -82.35 -39.08 23.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.09 47.11 9.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.7 ttp85 -157.74 139.07 9.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.652 0.739 . . . . 0.0 110.864 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 109.75 2.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.717 2.278 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 30.7 mtp180 -49.39 -54.11 19.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.888 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.0 42.34 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -172.88 160.03 4.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.884 0.374 . . . . 0.0 110.866 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.15 -152.82 22.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.507 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -142.34 167.25 22.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.936 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.532 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.7 mt -148.81 138.52 16.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 161' ' ' PHE . 61.9 m -103.0 148.77 25.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.454 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 67.2 m-85 -119.83 175.43 5.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -79.49 -42.7 24.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.905 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -126.47 134.78 50.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 165' ' ' GLN . 39.2 tt0 -43.52 -44.25 5.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 164' ' ' GLU . 65.1 tt0 -35.66 -45.73 0.39 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.454 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 3.8 m -51.6 -55.69 17.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 80.0 t -40.75 -57.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -50.21 -51.77 41.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.867 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 20.6 mm100 -48.0 -57.77 5.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -59.51 -58.92 6.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 174' ' ' HIS . 70.3 t -44.28 -62.88 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.2 t-20 -34.65 -55.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.87 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 25.6 mmm -57.29 -42.84 82.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.0 t-160 54.53 26.71 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.4 m-85 -172.5 154.39 3.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.535 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 88.3 m-70 -159.81 157.76 29.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -116.29 84.04 2.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . 0.407 HD12 ' CG2' ' A' ' 183' ' ' VAL . 66.8 mt -97.33 108.68 21.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.162 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 23.7 mtm 61.01 44.86 9.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.98 37.96 94.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 35.0 tptt -139.29 136.69 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 110.883 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.22 100.99 10.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . 0.407 ' CG2' HD12 ' A' ' 178' ' ' ILE . 2.6 t -93.21 129.63 43.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -87.67 148.01 24.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.428 HG21 ' CG2' ' A' ' 117' ' ' VAL . 67.1 t -147.58 138.75 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.109 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.1 mtmm -141.15 169.57 17.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.0 tmm_? -80.83 114.03 19.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.127 179.928 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.876 0.37 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -102.22 145.55 29.26 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 25.1 pt -126.08 154.3 35.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -104.21 101.98 11.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.465 ' CG2' HG22 ' A' ' 185' ' ' VAL . 98.2 t -95.66 119.11 43.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.129 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.71 177.43 16.43 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.516 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.87 28.62 63.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.492 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.46 ' CG1' HG11 ' A' ' 117' ' ' VAL . 32.3 mt -75.82 137.01 69.95 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.606 0.717 . . . . 0.0 111.104 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.461 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.8 Cg_endo -69.72 166.98 25.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.657 2.238 . . . . 0.0 112.351 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -77.1 -3.49 39.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.878 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -100.82 -37.34 8.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.461 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.1 t -67.93 125.35 26.01 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.449 ' N ' ' OE1' ' A' ' 128' ' ' GLU . . . -129.9 -165.61 11.66 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.528 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -53.53 -64.53 0.79 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.92 0.39 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 87.3 m -44.14 -54.29 5.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.449 ' OE1' ' N ' ' A' ' 125' ' ' GLY . 12.2 mp0 -57.16 -63.44 1.22 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 133' ' ' PHE . 61.0 mt -34.31 -46.96 0.28 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 30.7 mtp85 -69.74 -51.14 36.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -50.22 -19.2 0.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.921 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.427 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 12.6 t80 -108.97 -24.05 11.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.509 ' CD2' HD12 ' A' ' 159' ' ' ILE . 17.1 m-85 -98.35 9.99 41.8 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -86.85 -25.47 24.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -69.45 -39.61 77.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -64.58 -25.94 68.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.904 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 176.5 -113.79 0.45 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.465 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.5 t -147.95 106.14 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.848 0.356 . . . . 0.0 111.154 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.18 116.51 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.172 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 79.5 p -93.68 -35.42 12.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.108 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.69 152.61 45.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.93 97.69 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.139 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 144' ' ' MET . 59.3 t -81.84 142.74 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.095 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.466 ' N ' HG13 ' A' ' 143' ' ' VAL . 4.3 mtt -145.15 136.7 25.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 56.8 mt -104.36 131.36 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.45 166.75 6.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 148' ' ' ALA . 48.0 t0 -91.49 109.75 21.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.13 -46.24 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 148' ' ' ALA . 1.5 tm-20 -35.3 -47.03 0.39 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -99.31 -28.69 13.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 59.78 50.06 7.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.0 ttp85 -149.73 138.58 12.53 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.613 0.72 . . . . 0.0 110.891 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.418 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.5 Cg_endo -69.71 110.62 2.59 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.352 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -50.24 -54.02 24.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.844 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.49 40.67 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.482 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -172.61 160.12 4.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 168.03 -155.56 26.44 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.441 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' A' ' 143' ' ' VAL . 29.2 m-85 -142.52 162.45 35.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.787 0.327 . . . . 0.0 110.879 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.509 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.9 mt -146.0 139.72 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.089 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.454 ' N ' HG21 ' A' ' 159' ' ' ILE . 84.7 m -106.87 139.72 40.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.536 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 55.1 m-85 -109.08 179.24 4.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -86.23 -38.17 17.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . 0.415 ' O ' ' C ' ' A' ' 164' ' ' GLU . 6.5 m-20 -128.77 127.53 42.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.849 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 163' ' ' ASP . 26.8 tt0 -36.04 -42.19 0.28 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.403 ' O ' ' C ' ' A' ' 166' ' ' SER . 3.9 mt-30 -36.93 -61.42 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.536 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 7.2 m -38.32 -59.52 0.88 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 53.6 t -38.88 -63.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.157 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -43.9 -60.77 1.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -40.14 -53.41 2.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.36 -55.4 24.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 187' ' ' ARG . 69.4 t -47.26 -61.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 171' ' ' VAL . 16.2 t-20 -37.67 -64.91 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 74.8 mtp -49.29 -45.43 45.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.835 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.8 t-160 60.03 28.07 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.5 m-85 -171.72 154.1 3.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.477 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 80.0 m-70 -159.38 156.64 28.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -113.09 91.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 56.7 mt -111.05 134.21 54.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.113 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 47.99 36.19 5.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.78 46.04 85.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.463 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.429 ' HZ1' ' N ' ' A' ' 121' ' ' PRO . 0.0 OUTLIER -153.61 147.18 25.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.875 -179.963 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.13 113.65 20.78 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.913 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.1 t -105.16 127.39 59.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -83.81 150.53 25.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.86 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.465 HG22 ' CG2' ' A' ' 117' ' ' VAL . 23.8 t -151.14 131.93 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -136.86 149.05 47.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.468 ' N ' HG23 ' A' ' 171' ' ' VAL . 12.1 ttt180 -62.87 124.89 22.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.132 179.906 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.855 0.359 . . . . 0.0 110.854 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -99.95 150.54 22.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.867 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.9 pt -131.33 154.79 41.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -103.76 102.98 12.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.441 HG11 ' CG1' ' A' ' 120' ' ' ILE . 83.8 t -97.95 112.84 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.24 173.7 15.37 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.479 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.01 63.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.439 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 42.1 mt -54.91 137.8 64.93 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.629 0.728 . . . . 0.0 111.152 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 163.99 36.25 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.644 2.229 . . . . 0.0 112.353 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.6 t-160 -68.99 -6.28 26.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.836 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 124' ' ' CYS . 19.6 t-20 -100.25 -64.22 1.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.461 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 43.7 t -35.13 126.57 0.56 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.75 -164.11 11.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -54.8 -66.24 0.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -42.54 -61.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.166 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 129' ' ' LEU . 9.5 mm-40 -49.42 -63.23 1.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.44 HD13 ' CE ' ' A' ' 144' ' ' MET . 44.9 mt -37.84 -55.16 1.22 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 63.8 mtp180 -56.11 -56.0 26.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.859 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -50.33 -44.34 54.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.563 ' CD2' HG12 ' A' ' 178' ' ' ILE . 6.4 t80 -74.03 -22.54 59.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.461 ' CD2' HD13 ' A' ' 159' ' ' ILE . 25.2 m-85 -105.32 15.8 26.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.5 ptmt -90.48 -37.79 13.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.92 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -60.47 -37.93 82.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -67.28 -30.01 69.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.85 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.63 -116.48 0.48 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.528 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 19.7 t -148.57 106.61 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.436 HG13 ' CG2' ' A' ' 159' ' ' ILE . 8.1 t -69.42 119.06 14.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.175 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 78.3 p -99.77 -37.57 9.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -134.03 141.31 47.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.876 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 94.0 t -127.74 93.62 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.17 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.7 t -89.42 134.41 28.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.44 ' CE ' HD13 ' A' ' 129' ' ' LEU . 8.3 mtp -135.96 133.39 37.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 57.5 mt -92.11 134.24 30.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.52 165.91 5.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.981 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 16.5 t0 -84.53 112.62 20.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.856 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.24 -59.98 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -40.87 -45.8 2.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 147' ' ' ASP . 23.7 mttp -75.75 -41.01 54.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 60.07 48.02 8.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.3 ttm180 -160.4 138.55 7.35 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.563 0.697 . . . . 0.0 110.9 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 116.35 4.52 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.718 2.279 . . . . 0.0 112.346 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.5 mtp180 -58.76 -55.36 36.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.62 39.37 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.4 p90 -170.4 160.95 7.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.876 0.369 . . . . 0.0 110.893 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -158.15 30.96 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -138.86 161.62 36.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.359 . . . . 0.0 110.893 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.461 HD13 ' CD2' ' A' ' 133' ' ' PHE . 8.6 mt -147.59 139.28 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.14 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.421 HG21 ' N ' ' A' ' 161' ' ' PHE . 41.1 m -109.21 140.02 43.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.449 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.8 m-85 -108.53 169.45 8.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -75.81 -34.55 60.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 34.6 m-20 -129.62 141.5 50.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -52.31 -45.14 65.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.914 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -40.68 -44.66 2.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.9 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.449 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 17.4 m -54.04 -41.91 68.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.401 ' CG1' ' HG3' ' A' ' 187' ' ' ARG . 38.5 t -58.53 -58.94 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.139 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -49.95 -42.87 49.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -55.23 -55.35 32.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.0 -56.57 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 98.4 t -48.06 -44.56 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.186 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -50.23 -51.53 43.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.914 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.2 mmm -62.59 -36.07 81.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.8 t-160 49.31 25.22 1.2 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 8.7 m-85 -170.13 145.99 2.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.491 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 46.9 m-70 -155.94 162.8 40.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -119.74 94.2 4.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . 0.563 HG12 ' CD2' ' A' ' 132' ' ' TYR . 44.8 mt -113.34 120.61 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.5 mmt 59.9 34.25 21.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.69 46.97 58.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -153.5 148.55 26.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 8.2 tptm -86.84 108.51 18.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.6 t -98.51 120.99 48.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.143 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -82.73 147.58 28.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 41.1 t -143.17 132.49 20.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.146 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mttp -137.06 136.71 38.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.401 ' HG3' ' CG1' ' A' ' 167' ' ' VAL . 34.9 ttt180 -52.45 123.16 10.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.126 179.912 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.433 ' O ' ' CG2' ' A' ' 160' ' ' THR . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.95 0.405 . . . . 0.0 110.92 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt -127.67 141.13 51.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 18.1 pt -121.08 151.51 24.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.497 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 6.4 t80 -101.88 105.02 15.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.877 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.417 HG11 ' CG1' ' A' ' 120' ' ' ILE . 94.0 t -97.92 121.73 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.129 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -127.6 175.42 18.28 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.95 18.89 62.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.446 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 40.2 mt -65.76 136.83 95.98 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.639 0.733 . . . . 0.0 111.144 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.467 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.8 Cg_endo -69.81 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 0.0 112.344 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -75.29 1.62 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.444 ' C ' ' SD ' ' A' ' 179' ' ' MET . 27.7 t-20 -107.29 -23.1 12.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.467 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 13.5 t -80.48 128.45 33.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -130.8 176.83 18.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.5 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.42 ' C ' ' O ' ' A' ' 125' ' ' GLY . 30.5 tt0 -35.99 -61.01 0.51 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.909 0.385 . . . . 0.0 110.863 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 65.9 m -46.39 -60.15 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 35.8 mm-40 -49.98 -61.9 1.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.895 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.427 ' C ' ' O ' ' A' ' 128' ' ' GLU . 62.5 mt -35.73 -56.01 0.69 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.944 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 62.3 mtp180 -61.76 -55.03 34.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -44.34 -29.53 0.69 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.878 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.431 ' CD2' HG12 ' A' ' 178' ' ' ILE . 11.9 t80 -98.53 -27.4 14.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.935 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.553 ' CD2' HD12 ' A' ' 159' ' ' ILE . 21.4 m-85 -95.1 13.34 25.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptpt -93.93 -9.73 36.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 pttt -84.71 -36.5 21.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -65.02 -35.04 79.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.58 -102.14 0.15 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.461 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 40.9 t -157.95 105.73 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 21.2 t -66.18 119.24 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.14 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 14.4 p -99.09 -37.14 9.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.189 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -135.31 148.78 49.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.872 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 97.6 t -132.07 94.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.135 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.435 HG12 ' N ' ' A' ' 144' ' ' MET . 60.9 t -90.48 138.09 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.104 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.461 ' HE3' ' CB ' ' A' ' 153' ' ' PRO . 9.2 mtp -137.37 136.06 37.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 58.7 mt -97.66 135.27 32.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.11 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.467 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -173.57 164.58 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.91 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.4 t0 -83.05 112.73 20.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.65 -62.75 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.125 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -38.91 -42.96 0.9 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.431 ' N ' ' O ' ' A' ' 147' ' ' ASP . 70.0 mttt -79.44 -37.42 37.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 54.88 53.09 10.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.956 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.467 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 11.5 ttt180 -164.72 137.98 3.9 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.578 0.704 . . . . 0.0 110.894 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.461 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.71 116.99 4.81 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.338 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -59.89 -54.64 43.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.28 39.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -169.3 164.92 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.826 0.346 . . . . 0.0 110.91 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.71 -163.33 35.69 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -133.22 161.82 33.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.784 0.326 . . . . 0.0 110.94 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.553 HD12 ' CD2' ' A' ' 133' ' ' PHE . 10.2 mt -148.63 137.51 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.463 HG21 ' N ' ' A' ' 161' ' ' PHE . 32.8 m -106.15 143.14 34.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.463 ' N ' HG21 ' A' ' 160' ' ' THR . 39.2 m-85 -111.23 176.14 5.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.4 tt0 -77.67 -44.83 26.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.896 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . 0.469 ' CB ' ' HG2' ' A' ' 165' ' ' GLN . 0.9 OUTLIER -121.54 128.56 52.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -42.02 -23.77 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.469 ' HG2' ' CB ' ' A' ' 163' ' ' ASP . 5.4 pt20 -48.51 -53.4 18.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.921 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.456 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 5.1 m -49.26 -55.95 10.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.846 -179.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 53.3 t -37.68 -55.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.078 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . 0.426 ' OD1' ' C ' ' A' ' 168' ' ' ASP . 0.6 OUTLIER -62.13 -46.3 89.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.874 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -52.0 -52.51 50.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.49 -56.45 15.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.075 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 187' ' ' ARG . 43.2 t -44.63 -55.83 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -38.07 -67.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 83.4 mtp -48.38 -46.29 36.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 19.0 t-160 62.04 26.89 16.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 9.2 m-85 -171.31 150.83 2.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.855 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.4 m-70 -156.7 151.38 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.849 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -107.67 98.98 8.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.888 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . 0.431 HG12 ' CD2' ' A' ' 132' ' ' TYR . 71.0 mt -119.89 122.08 67.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' MET . . . . . 0.444 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 12.4 mtt 54.67 41.58 31.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.05 42.65 99.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.4 ' HG3' ' N ' ' A' ' 182' ' ' LYS . 15.2 tptp -148.92 148.65 30.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.826 0.346 . . . . 0.0 110.923 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . 0.4 ' N ' ' HG3' ' A' ' 181' ' ' LYS . 7.6 tppt? -88.34 107.21 18.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.906 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.45 112.38 27.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.174 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -74.87 149.48 39.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 46.3 t -147.13 136.09 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mtmm -139.89 151.66 45.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.893 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.466 ' N ' HG23 ' A' ' 171' ' ' VAL . 25.1 ttp180 -65.25 125.1 23.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.915 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.084 179.931 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.909 0.385 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -88.45 146.6 25.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . 0.467 ' CG2' HG22 ' A' ' 167' ' ' VAL . 21.1 pt -132.29 146.64 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.141 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -89.74 111.98 23.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.928 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 83.6 t -108.72 114.88 47.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.103 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -119.24 -173.29 15.47 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.69 24.14 31.56 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.463 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 63.0 mt -69.48 138.19 88.76 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.668 0.747 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.463 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.73 170.33 16.79 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.731 2.287 . . . . 0.0 112.35 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -86.91 24.17 1.57 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -133.63 -33.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.415 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.9 t -66.9 117.79 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.894 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.47 -175.73 16.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.457 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -42.69 -56.17 3.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 0.0 110.856 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 86.7 m -51.3 -57.69 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 mm-40 -51.73 -52.95 44.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 85.9 mt -44.54 -48.18 10.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.964 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 69.5 mtt180 -69.66 -55.07 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -45.45 -23.98 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.549 ' CD2' HG12 ' A' ' 178' ' ' ILE . 4.3 t80 -103.68 -35.2 8.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.55 ' CE2' HD11 ' A' ' 159' ' ' ILE . 23.7 m-85 -90.33 16.22 9.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -95.23 -23.64 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -71.19 -35.23 71.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.453 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 34.9 m-85 -68.41 -32.59 72.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.77 -111.56 0.29 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.476 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 75.7 t -146.35 110.24 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.837 0.351 . . . . 0.0 111.152 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 93.0 t -72.89 106.05 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.146 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.8 p -79.46 -39.71 31.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -144.73 156.43 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.8 102.56 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.111 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.453 HG12 ' N ' ' A' ' 144' ' ' MET . 60.3 t -84.5 143.53 11.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.121 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.453 ' N ' HG12 ' A' ' 143' ' ' VAL . 4.5 mtt -145.44 139.03 26.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 75.4 mt -107.9 136.22 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.15 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.464 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.91 165.34 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.934 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.9 t0 -86.19 114.29 22.9 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.87 -61.52 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 28.3 tt0 -36.08 -46.01 0.47 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 27.6 mttp -80.08 -40.29 27.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 60.0 48.27 8.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.1 ttp180 -158.98 138.8 8.65 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.609 0.719 . . . . 0.0 110.884 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.451 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.4 Cg_endo -69.77 109.92 2.43 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.271 . . . . 0.0 112.334 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.8 mtt180 -50.17 -50.6 48.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.843 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 159.89 39.89 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -169.0 161.98 10.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.882 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.429 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.15 -150.2 18.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.469 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.429 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 11.3 m-85 -147.72 169.82 18.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.882 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.55 HD11 ' CE2' ' A' ' 133' ' ' PHE . 23.0 mt -151.13 141.81 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.103 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.2 m -106.95 142.27 36.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.15 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 50.1 m-85 -113.83 169.35 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -77.33 -38.37 50.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -130.05 136.57 49.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 165' ' ' GLN . 8.6 tm-20 -45.67 -45.37 14.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.924 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 164' ' ' GLU . 26.3 tt0 -35.29 -47.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 42.9 m -53.15 -54.07 41.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.847 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.467 HG22 ' CG2' ' A' ' 115' ' ' ILE . 53.3 t -43.88 -45.46 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -65.65 -45.49 82.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . 0.453 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 44.3 mm-40 -48.48 -45.42 36.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -76.43 -59.79 2.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 86.4 t -43.12 -51.4 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.14 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -39.71 -63.2 0.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.891 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' MET . . . . . 0.43 ' HE1' ' CE1' ' A' ' 176' ' ' HIS . 15.3 mtm -59.31 -38.33 80.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 15.0 t-160 59.27 25.46 14.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.473 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.9 m-85 -169.82 153.14 4.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.836 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.473 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 62.8 m-70 -159.2 159.42 34.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -116.49 90.31 3.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . 0.549 HG12 ' CD2' ' A' ' 132' ' ' TYR . 51.3 mt -105.69 111.78 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 7.4 mtt 61.84 42.33 10.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.41 47.13 87.57 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.453 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 12.2 tppt? -151.47 140.29 20.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -84.83 102.94 13.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.6 t -92.99 132.86 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.169 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -92.54 144.95 24.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.877 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 32.6 t -141.15 131.34 26.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -143.45 141.53 30.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 13.2 mtm105 -45.79 115.93 1.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.826 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.076 179.913 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.946 0.403 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttpp -92.97 140.99 28.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 28.2 pt -124.49 151.15 29.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.143 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -98.44 108.37 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.912 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 95.4 t -101.21 121.8 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.15 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.7 175.72 18.58 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.67 13.34 60.92 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.467 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 31.2 mt -61.87 137.15 95.26 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.718 . . . . 0.0 111.142 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.467 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.74 163.52 37.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.691 2.261 . . . . 0.0 112.344 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -77.44 1.35 19.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -106.65 -23.72 12.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.467 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 14.0 t -79.85 133.39 36.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.77 -165.59 11.79 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -52.57 -68.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 34.9 m -38.69 -67.8 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.13 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 17.5 mp0 -38.68 -61.33 0.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 73.7 mt -40.68 -46.56 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.909 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.42 ' NH1' ' HB3' ' A' ' 130' ' ' ARG . 14.3 mtp-105 -70.0 -52.3 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -51.92 -23.94 5.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -100.24 -30.21 12.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.524 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.1 m-85 -94.24 13.75 22.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -94.03 -13.75 26.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.0 pttm -79.83 -37.54 34.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -68.62 -33.9 74.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.98 -116.33 0.38 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.474 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 36.1 t -146.16 106.31 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.879 0.371 . . . . 0.0 111.152 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 39.0 t -68.12 115.26 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.094 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 41.8 p -95.94 -39.0 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -133.59 144.06 49.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.34 94.44 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.129 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.0 t -88.7 141.52 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.116 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.446 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 7.6 mtt -140.58 137.1 33.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.9 mt -99.89 126.81 53.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -167.07 165.42 15.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.917 -179.984 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.441 ' O ' ' C ' ' A' ' 148' ' ' ALA . 19.2 t0 -85.33 113.58 21.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.44 -59.13 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.077 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -41.39 -42.88 2.38 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.92 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.427 ' N ' ' O ' ' A' ' 147' ' ' ASP . 19.4 mttp -79.25 -41.08 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.01 50.14 6.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.0 ttm-85 -162.88 138.02 5.2 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.598 0.713 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.446 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.76 112.12 2.99 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.748 2.298 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 67.5 mtp180 -52.65 -57.03 11.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.845 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 169.5 40.54 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.422 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.5 p90 -171.69 165.54 6.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.856 0.36 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.98 -153.97 24.61 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 59.6 m-85 -143.94 160.6 40.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.915 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.524 HD12 ' CD2' ' A' ' 133' ' ' PHE . 7.8 mt -148.42 135.93 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.459 HG23 ' N ' ' A' ' 161' ' ' PHE . 41.9 m -103.87 142.98 33.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.459 ' N ' HG23 ' A' ' 160' ' ' THR . 49.1 m-85 -112.22 168.39 9.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 58.4 tt0 -69.75 -38.65 76.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -131.1 143.68 50.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 165' ' ' GLN . 11.4 tt0 -50.66 -44.31 57.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.417 ' C ' ' O ' ' A' ' 164' ' ' GLU . 34.5 tt0 -36.1 -52.67 0.78 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.1 m -46.37 -55.68 6.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 40.6 t -38.48 -56.57 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.13 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -52.87 -59.09 4.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -39.12 -38.3 0.47 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.931 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.6 -65.37 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.111 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 174' ' ' HIS . 84.1 t -43.98 -55.41 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.129 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.451 ' C ' ' O ' ' A' ' 171' ' ' VAL . 0.7 OUTLIER -34.48 -59.48 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.865 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 60.1 mtp -65.33 -35.18 80.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.515 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.6 t-160 54.69 27.39 8.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.7 m-85 -167.89 152.21 6.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 86.1 m-70 -159.8 147.61 16.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.854 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -103.73 99.24 9.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 58.0 mt -120.66 124.35 72.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.165 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.4 mmt 57.03 34.89 25.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.814 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 67.15 48.84 57.24 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.45 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 5.1 tmtm? -161.01 150.21 16.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . 0.45 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -83.02 126.46 32.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.5 t -114.19 110.87 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.121 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -70.94 143.97 50.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 40.0 t -143.34 131.31 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.161 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.0 mmmt -145.61 144.06 30.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.933 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 14.0 mtp180 -48.17 125.43 9.26 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.109 179.899 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.865 0.364 . . . . 0.0 110.861 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 4.4 ttpm? -104.12 143.7 32.57 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 22.5 pt -125.75 155.37 35.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -103.38 104.48 14.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 79.1 t -99.4 118.85 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -124.54 -172.53 13.59 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.477 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.28 17.78 19.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.479 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.47 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 51.4 mt -64.7 138.31 97.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.68 0.752 . . . . 0.0 111.101 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.5 Cg_endo -69.69 165.62 30.27 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.485 ' ND1' ' NH2' ' A' ' 152' ' ' ARG . 63.9 m-70 -80.58 13.91 2.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.424 ' C ' ' HG3' ' A' ' 179' ' ' MET . 3.3 m120 -122.02 -25.1 5.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.44 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -74.74 133.48 42.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.28 -161.06 10.09 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.508 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.13 -63.52 1.23 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.942 0.401 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 64.1 m -44.49 -59.17 2.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.142 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.44 ' O ' ' C ' ' A' ' 129' ' ' LEU . 57.1 mm-40 -50.35 -63.91 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 128' ' ' GLU . 50.0 mt -34.91 -52.39 0.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.447 ' O ' ' N ' ' A' ' 134' ' ' LYS . 62.7 mtp180 -66.19 -54.15 28.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.864 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 44.2 mm-40 -48.16 -26.5 1.92 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.486 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.7 t80 -100.79 -21.79 15.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -105.79 14.45 28.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.447 ' N ' ' O ' ' A' ' 130' ' ' ARG . 15.5 pttp -94.81 -17.56 22.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.37 -37.98 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -65.17 -34.36 78.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.17 -114.61 0.31 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.43 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 37.5 t -148.1 109.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.834 0.35 . . . . 0.0 111.172 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 47.3 t -74.55 105.99 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.0 p -81.21 -33.05 33.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.12 153.2 37.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 95.6 t -131.34 105.97 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 144' ' ' MET . 49.0 t -91.73 143.16 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.466 ' N ' HG13 ' A' ' 143' ' ' VAL . 7.1 mtt -143.34 133.71 24.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.887 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -97.09 139.82 18.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.449 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -175.05 165.88 3.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.926 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.432 ' O ' ' C ' ' A' ' 148' ' ' ALA . 35.4 t0 -86.67 110.07 19.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.432 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.23 -57.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' ALA . 30.7 tt0 -37.06 -45.35 0.59 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.91 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.33 -37.14 20.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 60.05 52.79 4.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.485 ' NH2' ' ND1' ' A' ' 122' ' ' HIS . 2.1 ttt85 -160.86 138.9 7.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.646 0.736 . . . . 0.0 110.869 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.456 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 117.86 5.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.669 2.246 . . . . 0.0 112.355 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -61.1 -54.27 46.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.14 41.49 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.536 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -173.13 162.46 4.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.19 -153.47 23.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 53.9 m-85 -139.96 164.5 29.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.431 HG23 ' N ' ' A' ' 160' ' ' THR . 21.3 mt -147.13 139.7 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.114 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.438 HG23 ' N ' ' A' ' 161' ' ' PHE . 57.0 m -105.08 142.98 33.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.438 ' N ' HG23 ' A' ' 160' ' ' THR . 46.8 m-85 -115.86 166.35 12.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.903 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -67.39 -42.77 82.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -131.14 141.06 50.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.864 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 165' ' ' GLN . 30.5 tt0 -46.04 -44.39 15.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 164' ' ' GLU . 23.8 tp60 -36.43 -55.67 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.413 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 16.4 m -44.31 -52.41 7.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 73.4 t -44.65 -54.86 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -52.82 -50.67 63.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.1 mm100 -45.86 -50.48 14.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.918 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.06 -53.86 15.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.094 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 172' ' ' ASN . 70.1 t -44.31 -61.79 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.107 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 171' ' ' VAL . 62.7 t30 -35.61 -56.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 1.3 tpt -58.28 -41.51 84.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.92 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.9 t-160 51.15 30.75 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.551 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 4.9 m-85 -173.35 150.62 1.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 89.1 m-70 -161.9 156.97 23.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -111.04 102.36 10.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 31.4 mt -129.06 134.91 63.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.15 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' MET . . . . . 0.424 ' HG3' ' C ' ' A' ' 123' ' ' ASN . 9.8 mmt 54.83 30.55 13.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.63 45.76 65.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.408 ' NZ ' ' HA ' ' A' ' 121' ' ' PRO . 19.9 ttmt -160.15 161.93 33.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.909 0.385 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.62 125.57 34.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.6 t -110.35 115.02 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.157 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -77.32 148.32 35.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 41.9 t -146.89 133.12 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.4 mttm -139.69 169.75 17.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.402 ' HG3' ' CG2' ' A' ' 171' ' ' VAL . 13.9 mtp180 -78.3 117.25 19.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.1 179.964 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 m-20 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.864 0.364 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -98.33 142.38 30.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 30.1 pt -125.24 153.05 32.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.09 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.411 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 30.8 t80 -98.97 105.53 17.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.46 ' CG2' HG23 ' A' ' 185' ' ' VAL . 94.4 t -101.92 114.08 40.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.111 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.06 177.02 16.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.531 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.59 13.26 60.62 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.464 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 29.7 mt -61.86 137.14 95.24 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.473 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 54.4 Cg_endo -69.72 165.41 31.02 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.354 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.7 m-70 -78.68 0.65 25.76 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.827 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.416 ' ND2' ' HB2' ' A' ' 121' ' ' PRO . 0.2 OUTLIER -106.04 -23.8 12.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.889 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.473 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.4 t -81.16 133.1 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.73 -166.81 11.72 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.431 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.452 ' HG2' ' CZ ' ' A' ' 130' ' ' ARG . 12.4 tt0 -54.21 -59.96 3.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.874 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 35.9 m -45.78 -61.78 1.58 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.17 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 129' ' ' LEU . 53.8 mm-40 -47.91 -64.7 0.72 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.421 ' C ' ' O ' ' A' ' 128' ' ' GLU . 62.6 mt -36.22 -58.46 0.68 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.452 ' CZ ' ' HG2' ' A' ' 126' ' ' GLU . 59.7 mtm180 -58.6 -51.06 71.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.3 mm-40 -57.29 -17.42 11.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.487 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 21.5 t80 -108.0 -17.45 14.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.401 ' N ' ' O ' ' A' ' 129' ' ' LEU . 13.3 m-85 -104.18 -6.35 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.885 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.5 pttp -76.58 -21.26 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -69.91 -36.32 75.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.869 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -70.55 -32.25 69.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.75 -111.25 0.26 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.545 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.0 t -150.05 108.12 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.912 0.387 . . . . 0.0 111.117 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 74.0 t -72.53 104.91 2.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.14 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -81.29 -36.8 29.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.146 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -141.33 154.76 45.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.06 105.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 42.9 t -92.83 137.12 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.46 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 5.2 mtt -137.7 136.79 37.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.904 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 62.7 mt -102.1 135.0 41.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.437 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.17 165.44 4.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.973 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 150' ' ' LYS . 48.5 t0 -81.92 113.64 19.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.871 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -37.31 -41.85 0.44 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.09 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -42.78 86.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 147' ' ' ASP . 3.0 mptp? -80.45 -31.41 37.45 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 52.3 44.01 30.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.4 ttm-85 -155.51 138.68 10.77 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.672 0.749 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.46 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.4 Cg_endo -69.77 111.01 2.7 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.655 2.237 . . . . 0.0 112.37 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.406 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 36.0 mtt180 -52.34 -53.08 49.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.73 40.73 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.406 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 35.6 p90 -169.29 163.85 10.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.931 0.396 . . . . 0.0 110.866 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 161.67 -157.87 29.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.506 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.411 ' CD2' ' HA ' ' A' ' 116' ' ' PHE . 12.5 m-85 -139.51 169.98 16.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 12.6 mt -152.68 136.68 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 19.2 m -105.03 135.9 45.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.499 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 35.0 m-85 -104.67 174.11 6.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.82 -40.32 48.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -127.55 137.54 52.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 165' ' ' GLN . 16.1 tm-20 -44.64 -45.71 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.0 tp60 -36.99 -55.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.904 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.499 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 13.1 m -45.58 -49.34 14.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 71.0 t -48.81 -47.17 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.091 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -62.88 -49.35 75.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 31.5 mm-40 -47.82 -48.5 30.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -74.33 -43.95 54.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.464 HG23 ' N ' ' A' ' 187' ' ' ARG . 25.6 t -55.36 -62.35 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 171' ' ' VAL . 2.1 t-20 -36.76 -55.67 0.87 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 98.2 mtp -55.12 -44.0 74.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.879 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.523 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.4 t-160 58.31 25.14 12.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.885 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.523 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.3 m-85 -169.65 152.62 4.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.85 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.487 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 85.3 m-70 -158.5 154.15 26.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.806 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.63 93.8 4.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.856 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 59.2 mt -110.39 115.43 49.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 11.9 mtp 60.87 36.13 19.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.898 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.79 50.49 35.52 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.492 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.6 tmtt? -158.01 146.96 19.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.864 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . 0.457 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.1 OUTLIER -85.03 117.12 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.94 179.838 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.6 t -106.31 118.88 54.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.15 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -76.0 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.46 HG23 ' CG2' ' A' ' 117' ' ' VAL . 44.6 t -146.65 127.4 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt -135.76 146.45 47.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.464 ' N ' HG23 ' A' ' 171' ' ' VAL . 19.7 ttp180 -55.69 108.93 0.49 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.135 179.878 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.845 0.355 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -110.84 150.86 28.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.9 pt -131.85 154.05 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.135 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 10.2 t80 -102.73 103.42 13.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 86.2 t -97.76 115.87 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.97 174.24 16.04 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.95 26.02 71.08 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.485 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 52.7 mt -73.17 138.22 78.84 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.634 0.731 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.77 158.76 55.84 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.72 3.43 6.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -106.89 -37.14 6.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 44.0 t -67.68 136.95 55.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.66 179.54 17.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 125' ' ' GLY . 24.0 tt0 -35.75 -69.68 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.4 m -40.84 -60.0 1.28 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.159 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' LEU . 49.1 mm-40 -44.74 -64.77 0.63 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.444 ' HB3' ' CD1' ' A' ' 159' ' ' ILE . 65.7 mt -35.92 -47.04 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 133' ' ' PHE . 36.7 mtm180 -67.38 -60.75 2.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.866 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -41.81 -25.69 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 11.6 t80 -102.77 -24.18 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.565 ' CD2' HD11 ' A' ' 159' ' ' ILE . 12.8 m-85 -99.74 16.3 24.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.923 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 3.9 ptpp? -95.31 -14.79 23.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -79.09 -37.68 38.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.896 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -67.65 -25.06 65.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.06 -114.69 0.48 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 96.3 t -145.73 111.56 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.097 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 15.6 t -74.53 114.46 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 42.8 p -93.01 -37.29 12.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.75 152.72 45.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -135.02 100.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.452 HG11 ' N ' ' A' ' 144' ' ' MET . 81.4 t -84.98 143.2 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.109 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.452 ' N ' HG11 ' A' ' 143' ' ' VAL . 6.2 mtt -144.29 132.61 21.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 68.4 mt -98.49 134.64 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -172.84 164.56 5.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.96 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.425 ' O ' ' N ' ' A' ' 150' ' ' LYS . 24.3 t0 -85.35 115.6 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.422 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.65 -57.32 0.65 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -42.67 -41.9 3.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 147' ' ' ASP . 16.3 ttmt -80.14 -41.18 25.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 60.08 50.41 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 8.2 ttp85 -164.99 138.93 4.0 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.618 0.723 . . . . 0.0 110.843 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.433 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.77 109.64 2.36 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.734 2.289 . . . . 0.0 112.357 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 32.5 mtp180 -49.58 -51.43 37.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 162.05 39.46 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.499 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -171.2 159.83 6.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.82 -155.08 25.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -139.62 161.45 37.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.914 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.565 HD11 ' CD2' ' A' ' 133' ' ' PHE . 14.7 mt -145.0 141.56 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.467 ' N ' HG21 ' A' ' 159' ' ' ILE . 42.5 m -109.43 141.03 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.173 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.492 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 51.9 m-85 -110.42 177.95 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -80.3 -40.31 27.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.871 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -127.85 146.41 50.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.807 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 165' ' ' GLN . 43.1 tp10 -51.58 -47.05 63.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.0 tt0 -36.63 -44.97 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.492 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 14.6 m -53.49 -47.93 69.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.883 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 37.6 t -51.3 -46.95 34.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.173 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -51.03 -65.73 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.867 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -42.95 -53.58 4.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -52.04 -45.48 64.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.045 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.465 ' O ' ' N ' ' A' ' 174' ' ' HIS . 93.5 t -70.0 -63.88 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.109 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 171' ' ' VAL . 8.3 m-20 -34.16 -43.99 0.17 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 5.2 ttt -68.36 -47.27 67.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.54 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 12.0 t-160 56.85 27.22 12.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.824 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.54 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.0 m-85 -174.18 151.45 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.459 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 72.0 m-70 -158.87 161.49 36.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -117.0 87.15 2.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 63.7 mt -106.61 126.41 62.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.8 mmt 52.36 40.12 28.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.69 47.67 87.34 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.403 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 2.5 tmtt? -155.07 146.93 23.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.808 0.337 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . 0.403 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 6.2 tptm -81.18 117.38 21.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.888 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.9 t -109.41 120.55 60.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -80.45 153.47 28.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 41.4 t -149.48 130.96 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.106 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -141.46 144.26 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.91 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.429 ' N ' HG23 ' A' ' 171' ' ' VAL . 8.7 mtm180 -45.93 124.44 5.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.861 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.897 0.38 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.9 ttpt -97.01 139.1 33.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 20.0 pt -123.42 154.59 29.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.082 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -99.65 103.65 15.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 93.2 t -100.41 111.7 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.14 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.02 -173.05 15.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.506 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.42 12.81 14.1 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.481 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.47 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 54.7 mt -57.3 138.42 80.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.653 0.74 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.9 Cg_endo -69.76 172.42 12.67 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.35 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.449 ' O ' ' NH2' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -85.0 17.89 2.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.823 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -128.29 -29.8 2.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.866 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.44 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -68.06 128.77 37.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.53 173.11 21.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.452 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.444 ' C ' ' O ' ' A' ' 125' ' ' GLY . 29.9 tt0 -34.34 -65.87 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.873 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 99.7 m -40.85 -61.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 129' ' ' LEU . 5.5 mp0 -54.31 -60.58 3.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 59.9 mt -34.39 -45.92 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 26.6 mtt180 -70.38 -55.75 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -46.5 -24.75 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.542 ' CD2' HG12 ' A' ' 178' ' ' ILE . 5.1 t80 -100.95 -29.78 12.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.564 ' CE2' HD13 ' A' ' 159' ' ' ILE . 19.7 m-85 -96.17 15.45 20.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.3 ptpt -95.27 -25.07 16.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.906 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.1 pttm -69.44 -38.83 77.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.867 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -66.02 -31.36 72.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -174.94 -115.24 0.4 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.5 t -146.13 106.42 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.882 0.373 . . . . 0.0 111.088 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 22.9 t -71.22 109.4 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 20.1 p -85.92 -39.78 16.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -139.84 151.98 46.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.9 t -134.01 102.46 4.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.137 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 158' ' ' PHE . 98.6 t -87.33 145.27 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 6.7 mtt -145.58 133.75 21.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.816 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.38 139.63 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.456 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.88 167.03 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 180.0 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.4 t0 -87.16 112.49 22.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.891 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.09 -60.0 0.34 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -39.38 -44.69 1.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 21.1 tttm -79.43 -40.13 30.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.92 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 60.05 45.08 12.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.456 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.8 ttt180 -155.37 138.21 10.48 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.654 0.74 . . . . 0.0 110.848 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 116.02 4.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.675 2.25 . . . . 0.0 112.371 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 41.6 mtp180 -58.67 -56.87 16.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.03 42.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.473 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -173.23 158.17 3.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.92 0.391 . . . . 0.0 110.866 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -151.44 19.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.489 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . 0.4 ' O ' ' O ' ' A' ' 143' ' ' VAL . 86.7 m-85 -138.36 164.69 28.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.823 0.344 . . . . 0.0 110.894 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.564 HD13 ' CE2' ' A' ' 133' ' ' PHE . 19.5 mt -148.31 134.12 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 17.9 m -102.34 143.13 32.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.159 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.524 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 41.5 m-85 -113.19 174.46 5.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.825 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -74.32 -38.76 63.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -135.17 151.38 50.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 165' ' ' GLN . 23.3 tt0 -51.9 -50.69 60.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.441 ' C ' ' O ' ' A' ' 164' ' ' GLU . 31.6 tp60 -34.54 -54.83 0.54 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.524 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 18.6 m -41.54 -58.71 1.83 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.86 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 62.2 t -42.27 -54.87 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.105 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 169' ' ' GLN . 27.5 t0 -47.14 -62.53 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 168' ' ' ASP . 49.1 mt-30 -36.98 -51.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.882 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.79 -67.55 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.448 ' O ' ' C ' ' A' ' 172' ' ' ASN . 98.8 t -39.36 -58.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.9 t30 -34.44 -56.53 0.52 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 85.3 mtp -61.55 -45.02 95.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 62.01 25.97 15.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.3 m-85 -172.85 147.5 1.71 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -156.62 164.56 38.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.87 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -118.76 90.96 3.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . 0.542 HG12 ' CD2' ' A' ' 132' ' ' TYR . 67.9 mt -111.06 119.23 59.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.151 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.5 mmt 60.07 39.63 19.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 54.64 32.69 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.436 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 7.7 tppt? -163.23 145.51 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.367 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 11.7 tptt -82.54 109.0 16.36 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.902 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.07 127.46 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -87.65 140.09 29.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 25.4 t -139.2 136.33 41.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 24.6 mtmt -144.71 175.0 10.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.866 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 8.4 mtp180 -81.17 120.39 24.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.907 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.884 0.374 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -89.58 142.55 27.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . 0.401 ' CG2' HG12 ' A' ' 167' ' ' VAL . 18.7 pt -128.12 148.04 32.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.151 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -93.96 114.61 26.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 81.2 t -111.1 117.16 54.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.115 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.61 176.7 16.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.519 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.442 ' O ' ' NZ ' ' A' ' 181' ' ' LYS . . . 64.39 24.72 69.41 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 57.0 mt -71.87 138.48 82.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.617 0.722 . . . . 0.0 111.142 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.4 Cg_endo -69.78 165.35 31.31 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -78.96 10.99 2.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.415 ' C ' ' HE2' ' A' ' 179' ' ' MET . 0.6 OUTLIER -117.87 -34.48 4.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 -179.944 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.461 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.1 t -68.96 121.43 16.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -121.68 -169.29 13.59 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.98 -59.1 3.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -47.24 -61.19 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.127 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.47 ' HG3' ' CE ' ' A' ' 179' ' ' MET . 65.2 mm-40 -47.67 -65.14 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 40.7 mt -34.03 -49.83 0.36 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.944 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -68.72 -53.99 18.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 23.0 mm-40 -46.2 -23.73 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.509 ' CZ ' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -103.56 -34.65 8.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.02 16.86 8.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -95.29 -23.39 17.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.23 -39.04 68.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.94 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -60.56 -35.5 76.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -173.04 -107.71 0.21 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 93.4 t -152.24 107.9 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.26 107.71 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.133 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.5 p -82.08 -37.16 26.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -143.89 154.8 43.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.7 t -134.96 102.81 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 144' ' ' MET . 59.7 t -89.33 143.65 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.461 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.1 mtt -144.31 135.92 25.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.0 mt -102.26 135.75 37.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.481 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.72 3.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' ALA . 28.8 t0 -85.19 110.4 18.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.857 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.457 ' O ' ' C ' ' A' ' 149' ' ' GLU . . . -34.7 -57.22 0.53 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.066 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.457 ' C ' ' O ' ' A' ' 148' ' ' ALA . 7.9 mm-40 -33.31 -48.32 0.23 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -87.55 -34.93 18.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 5.5 mm-40 59.0 54.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.481 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.9 ttm-85 -158.16 137.65 8.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . 0.461 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.77 110.18 2.49 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.426 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 42.1 mtt180 -51.86 -47.63 64.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 157.93 38.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.489 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.426 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 41.4 p90 -166.52 167.7 15.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.903 0.382 . . . . 0.0 110.907 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.3 -156.72 27.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.499 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -139.48 166.92 23.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.933 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.0 mt -149.53 138.98 15.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 27.3 m -106.87 140.53 39.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.142 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.534 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -110.84 176.67 4.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -78.18 -44.42 25.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -124.82 133.45 53.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -41.26 -43.49 2.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -39.24 -47.77 1.7 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.534 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 70.8 m -50.59 -49.48 56.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.866 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.401 HG12 ' CG2' ' A' ' 115' ' ' ILE . 78.5 t -47.4 -62.39 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -44.96 -53.98 7.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -46.18 -47.48 17.72 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -69.87 -56.06 8.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.1 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 172' ' ' ASN . 91.1 t -49.78 -61.82 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 171' ' ' VAL . 15.0 t-20 -34.35 -62.88 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.875 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 24.2 mmm -49.9 -42.73 48.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.9 t-160 56.18 26.03 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.514 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 6.2 m-85 -169.91 154.01 5.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 84.8 m-70 -160.81 153.97 21.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -112.26 89.31 3.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.858 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 59.6 mt -106.23 109.57 28.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.154 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' MET . . . . . 0.47 ' CE ' ' HG3' ' A' ' 128' ' ' GLU . 5.0 mtm 62.14 43.22 8.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.69 50.72 59.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.46 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.4 tmtt? -155.9 144.83 20.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.846 0.355 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 9.0 tppt? -87.77 112.74 22.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.79 119.56 51.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -79.24 140.73 37.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.413 HG21 ' CD2' ' A' ' 176' ' ' HIS . 67.4 t -139.67 140.2 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.16 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -142.27 162.45 35.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.863 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 17.1 ttt180 -78.01 121.47 24.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.926 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.86 0.362 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.4 ttpt -85.29 142.82 29.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.8 pt -125.91 158.7 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.104 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.408 ' O ' ' CD2' ' A' ' 116' ' ' PHE . 12.3 t80 -105.07 104.65 14.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 71.9 t -100.63 114.33 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.112 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.14 -169.52 13.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.86 12.92 4.03 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.44 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.471 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 54.4 mt -57.39 138.41 81.08 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.609 0.719 . . . . 0.0 111.121 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.471 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.78 -174.24 0.87 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.248 . . . . 0.0 112.339 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.07 3.12 53.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -115.38 -10.71 11.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . 0.46 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.7 t -87.05 125.46 34.12 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.42 -172.86 13.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.512 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -51.18 -66.06 0.45 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 110.867 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.8 m -44.14 -63.59 0.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.152 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -40.55 -58.42 1.6 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.881 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 50.2 mt -40.99 -47.04 2.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' A' ' 132' ' ' TYR . 49.0 mtm180 -66.39 -61.25 2.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.882 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -43.31 -23.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' TYR . . . . . 0.405 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.2 t80 -101.08 -32.83 10.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.933 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -93.52 15.3 16.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 pttt -95.11 -19.32 20.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.3 pttt -73.06 -30.39 63.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.893 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.466 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 44.4 m-85 -74.1 -37.12 64.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.15 -110.52 0.23 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.49 113.08 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.87 0.367 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 57.3 t -74.84 99.88 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 19.2 p -74.8 -42.11 58.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -142.96 155.08 44.63 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.877 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 78.2 t -134.76 104.7 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.121 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.4 t -90.24 144.97 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.156 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 5.0 mtt -143.87 135.13 25.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 69.9 mt -98.38 133.35 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.165 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.452 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.68 165.35 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.449 ' O ' ' C ' ' A' ' 148' ' ' ALA . 22.1 t0 -81.61 110.11 16.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.82 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.449 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.69 -58.15 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.122 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -43.13 -43.67 4.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 35.0 mttm -78.0 -40.35 39.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 59.97 50.28 6.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.933 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.452 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.0 ttt85 -161.65 138.01 6.1 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.627 0.727 . . . . 0.0 110.899 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 121.64 8.33 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.657 2.238 . . . . 0.0 112.349 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.462 ' HD3' ' CZ ' ' A' ' 156' ' ' PHE . 50.5 mtp180 -65.67 -53.95 34.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.869 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.91 38.25 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.45 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.462 ' CZ ' ' HD3' ' A' ' 154' ' ' ARG . 37.1 p90 -168.12 162.84 13.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.857 0.36 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.88 -155.18 26.42 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.467 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -139.55 169.46 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.794 0.33 . . . . 0.0 110.912 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 11.0 mt -151.79 135.44 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.164 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' THR . . . . . 0.404 HG22 ' N ' ' A' ' 161' ' ' PHE . 31.6 m -102.18 140.38 36.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' PHE . . . . . 0.404 ' N ' HG22 ' A' ' 160' ' ' THR . 49.9 m-85 -111.46 172.84 6.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.889 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -73.05 -34.72 66.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -137.94 152.68 49.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 165' ' ' GLN . 12.0 tm-20 -56.36 -49.64 73.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 164' ' ' GLU . 2.0 tp-100 -34.81 -47.28 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 1.2 m -48.34 -54.55 13.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 69.8 t -43.4 -49.9 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.126 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 169' ' ' GLN . 1.2 m-20 -54.37 -61.54 2.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' GLN . . . . . 0.466 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -35.99 -45.57 0.43 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.934 -179.919 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.39 -63.12 1.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.092 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 172' ' ' ASN . 85.1 t -43.16 -54.96 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 171' ' ' VAL . 32.2 t30 -34.65 -50.91 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 41.2 mtp -74.36 -39.91 62.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 16.3 t-160 59.54 27.44 16.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.6 m-85 -169.84 152.68 4.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' HIS . . . . . 0.434 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 90.7 m-70 -157.94 151.74 23.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -107.4 93.55 4.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 53.6 mt -116.23 119.46 62.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 6.9 mmt 56.83 47.47 17.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 56.43 56.16 25.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.529 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' LYS . . . . . 0.402 ' HG3' ' N ' ' A' ' 182' ' ' LYS . 25.5 tptt -165.21 149.33 8.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.84 0.352 . . . . 0.0 110.914 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' LYS . . . . . 0.424 ' HE3' ' CG ' ' A' ' 175' ' ' PHE . 14.4 tptt -90.43 110.39 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 4.1 t -95.21 131.07 43.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.103 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -88.65 146.01 25.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.6 127.18 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.098 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 3.9 mtmp? -142.89 143.57 32.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.915 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -46.76 139.67 5.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.931 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.3 t -108.41 166.31 10.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.861 0.363 . . . . 0.0 110.852 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 29.5 t -123.38 90.84 3.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.868 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 178.02 97.09 0.11 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.465 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.8 p -144.68 124.86 13.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.895 0.378 . . . . 0.0 110.865 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 77.0 p -98.4 -44.58 6.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -43.3 107.22 0.11 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.497 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 m -43.8 -43.59 6.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 51.1 mttm -68.86 139.33 55.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 52.1 p -104.06 96.25 6.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.21 38.74 0.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -102.38 143.28 32.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 33.0 pt -126.55 152.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -97.08 109.03 21.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.445 HG12 ' CG1' ' A' ' 120' ' ' ILE . 90.5 t -104.43 113.02 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.65 176.51 16.38 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.95 5.42 46.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.459 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 51.2 mt -52.75 138.02 43.38 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 111.161 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.52 24.22 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.712 2.275 . . . . 0.0 112.363 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.444 ' CE1' HH11 ' A' ' 152' ' ' ARG . 41.1 t-80 -82.93 10.34 8.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.39 -20.21 8.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.469 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 11.6 t -80.5 142.15 34.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.09 -171.88 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -48.16 -57.93 5.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.6 m -47.01 -60.14 2.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 129' ' ' LEU . 1.7 mp0 -53.83 -63.45 1.15 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.89 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 128' ' ' GLU . 63.5 mt -34.31 -62.5 0.33 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -59.02 -52.03 67.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -50.5 -22.52 1.98 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.451 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 13.4 t80 -104.65 -20.62 13.59 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -102.49 15.49 29.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.937 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 32.1 pttt -94.14 -16.44 23.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 3.7 pttm -76.14 -36.67 58.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -67.95 -26.57 66.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.876 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.39 -114.69 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 66.3 t -144.16 116.71 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 111.137 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.82 113.53 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 76.5 p -90.11 -36.0 15.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -143.52 152.29 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.869 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -134.82 101.99 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.7 t -87.92 143.86 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.147 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.456 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 6.0 mtt -144.94 131.47 19.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 71.1 mt -96.12 131.89 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.108 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.443 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.58 164.52 10.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 43.9 t0 -85.99 112.14 20.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.81 -60.9 0.36 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 148' ' ' ALA . 0.3 OUTLIER -36.14 -45.44 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -81.44 -39.33 25.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 59.73 54.27 4.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.444 HH11 ' CE1' ' A' ' 122' ' ' HIS . 9.0 ttm180 -165.37 138.74 3.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.612 0.72 . . . . 0.0 110.878 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.456 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.6 Cg_endo -69.76 114.22 3.63 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.739 2.292 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.4 mtt180 -56.09 -54.42 45.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.04 39.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.527 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -169.39 166.59 10.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.874 0.369 . . . . 0.0 110.916 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.24 -157.26 28.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -137.36 165.91 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 11.8 mt -149.2 134.07 10.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.0 m -101.34 145.06 29.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.537 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -114.52 -177.7 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -86.85 -41.97 13.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . 0.416 ' O ' ' C ' ' A' ' 164' ' ' GLU . 0.8 OUTLIER -125.25 128.54 48.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.868 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 163' ' ' ASP . 10.1 tm-20 -36.3 -37.7 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.917 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.423 ' O ' ' C ' ' A' ' 166' ' ' SER . 15.7 mt-30 -42.08 -60.45 1.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.537 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 1.3 m -36.67 -53.43 0.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 70.5 t -45.24 -58.68 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.144 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -50.21 -55.01 17.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.841 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -45.44 -51.08 11.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.906 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.58 -51.39 63.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 39.8 t -47.63 -60.5 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -41.83 -51.95 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -59.26 -41.98 90.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 48.17 28.17 1.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.849 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 5.1 m-85 -173.0 151.35 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.507 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 74.5 m-70 -160.29 147.64 16.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.832 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -102.33 90.0 3.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 72.5 mt -110.23 110.31 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 10.2 mtt 63.48 44.81 5.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.875 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.93 43.11 99.64 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.471 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.8 tppt? -149.61 145.46 26.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.19 107.83 19.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.1 t -93.54 129.12 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -87.32 135.79 33.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.905 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.477 HG21 ' CD2' ' A' ' 176' ' ' HIS . 56.1 t -132.62 132.48 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 7.5 mmmm -136.21 159.73 40.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -67.89 114.22 6.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -87.21 160.29 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -123.86 151.77 65.14 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.657 0.742 . . . . 0.0 110.882 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 144.25 53.51 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.658 2.238 . . . . 0.0 112.337 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 30.9 ttp85 -167.67 138.59 2.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.831 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -152.18 162.23 41.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 10.5 t -116.7 40.27 2.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.846 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -115.28 149.86 37.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.4 t -144.29 166.21 25.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.875 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 74.4 p -87.55 152.18 22.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -132.48 146.28 18.05 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.488 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -50.24 0.48 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.677 2.251 . . . . 0.0 112.34 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 82.5 p -172.05 -175.78 1.54 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 4.0 m -62.67 125.14 22.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 77.6 p -99.75 92.47 5.34 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.908 0.385 . . . . 0.0 110.907 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.3 p -153.62 149.95 28.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.51 134.47 12.83 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.431 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.8 m -127.21 117.52 22.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 0.0 110.874 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 m -105.45 43.07 1.15 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.841 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.45 -25.37 6.62 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.483 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 5.0 t -78.76 107.29 11.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.943 0.401 . . . . 0.0 110.824 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 6.5 mtmp? -106.58 132.04 53.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.854 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.0 t -125.97 102.22 7.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.859 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -92.33 34.6 1.03 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.91 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 tttt -97.88 144.52 27.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 20.2 pt -126.07 149.14 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.3 t80 -96.39 113.71 25.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.918 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.4 t -110.28 116.31 52.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.54 -179.54 16.06 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.85 14.46 44.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.472 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 59.3 mt -62.45 138.36 96.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.629 0.728 . . . . 0.0 111.128 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.78 159.96 51.46 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.67 2.246 . . . . 0.0 112.337 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -68.2 -4.1 12.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.833 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.411 ' O ' ' C ' ' A' ' 124' ' ' CYS . 9.5 m120 -100.23 -62.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.429 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 35.3 t -37.62 120.96 0.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.4 -172.24 13.76 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -46.24 -65.68 0.52 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.3 m -44.13 -59.13 2.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 129' ' ' LEU . 67.1 mm-40 -49.67 -65.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.847 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 128' ' ' GLU . 39.5 mt -34.38 -54.63 0.52 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.467 ' O ' ' N ' ' A' ' 133' ' ' PHE . 14.4 mtp180 -63.69 -59.99 3.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -42.75 -25.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 12.2 t80 -100.66 -24.82 14.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.529 ' CD2' HD13 ' A' ' 159' ' ' ILE . 14.3 m-85 -97.91 13.76 29.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -93.12 -29.77 15.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.6 pttt -61.67 -33.85 74.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -68.87 -42.85 76.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.898 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -166.19 -108.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.485 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.65 109.91 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.468 HG13 ' CG2' ' A' ' 159' ' ' ILE . 29.1 t -75.21 119.55 23.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.163 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 33.2 p -93.81 -36.31 12.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.149 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -140.55 153.03 45.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.63 101.95 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.097 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.458 HG13 ' N ' ' A' ' 144' ' ' MET . 62.3 t -88.73 141.14 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.088 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.458 ' N ' HG13 ' A' ' 143' ' ' VAL . 4.3 mtt -143.33 138.99 29.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.6 mt -105.48 132.4 52.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -171.69 165.06 6.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.882 -179.972 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 26.2 t0 -84.39 113.9 21.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.85 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.74 -58.48 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -42.5 -43.56 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 10.5 tppt? -77.48 -41.33 39.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 60.02 46.92 10.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 0.4 OUTLIER -160.6 138.58 7.21 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.577 0.704 . . . . 0.0 110.862 -179.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.445 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.84 110.77 2.65 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.7 2.267 . . . . 0.0 112.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 19.1 mtt-85 -50.3 -55.79 13.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.99 42.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -173.29 159.94 3.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.882 0.373 . . . . 0.0 110.85 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.04 -158.66 31.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.495 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -139.64 162.18 35.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.529 HD13 ' CD2' ' A' ' 133' ' ' PHE . 14.4 mt -144.91 139.37 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 159' ' ' ILE . 28.1 m -105.29 141.29 37.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.55 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 34.5 m-85 -112.51 174.01 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -79.91 -40.39 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.915 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . 0.44 ' O ' ' C ' ' A' ' 164' ' ' GLU . 27.4 m-20 -126.16 123.37 38.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.865 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.44 ' C ' ' O ' ' A' ' 163' ' ' ASP . 8.4 tp10 -35.18 -41.15 0.15 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.838 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.427 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.0 mm-40 -35.79 -60.89 0.5 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.55 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 68.7 m -39.29 -59.25 1.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' A' ' 166' ' ' SER . 67.1 t -35.32 -47.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.135 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -65.53 -52.33 53.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -43.43 -50.46 6.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.404 ' O ' ' C ' ' A' ' 171' ' ' VAL . . . -68.04 -66.0 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.404 ' C ' ' O ' ' A' ' 170' ' ' ALA . 88.8 t -37.1 -52.37 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 59.9 t-20 -37.41 -65.49 0.31 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' MET . . . . . 0.516 ' HE3' ' CE1' ' A' ' 176' ' ' HIS . 7.5 mtm -57.91 -32.24 67.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.914 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.513 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 18.2 t-160 50.17 26.81 2.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.524 ' C ' ' CD2' ' A' ' 176' ' ' HIS . 7.8 m-85 -169.45 150.31 4.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.524 ' CD2' ' C ' ' A' ' 175' ' ' PHE . 24.1 m-70 -160.9 150.03 16.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.843 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -105.73 94.48 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.913 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 70.3 mt -111.4 114.43 47.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 13.5 mtt 61.86 39.64 13.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.94 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.04 54.07 29.88 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -164.64 142.95 6.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.41 117.95 23.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.923 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.2 t -105.43 122.52 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.171 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -80.79 138.18 36.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 94.4 t -139.72 135.61 39.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -147.21 169.41 19.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 22.1 mtt180 -69.12 114.22 7.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.853 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -79.51 177.85 8.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.096 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -134.21 146.31 59.12 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.67 0.747 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 153.04 69.5 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.651 2.234 . . . . 0.0 112.359 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.99 63.71 6.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.48 133.93 15.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.3 t -90.82 -59.01 2.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 46.0 mtmt -98.56 151.68 20.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.2 m -121.11 114.03 20.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 44.6 t -63.06 -55.02 29.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.871 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 131.3 156.29 8.43 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.47 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -24.8 29.21 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.691 2.261 . . . . 0.0 112.354 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -39.65 -53.36 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.821 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 17.2 p 45.78 52.08 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.466 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.9 t -126.3 128.31 46.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.885 0.374 . . . . 0.0 110.832 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.3 t -79.74 156.32 27.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.863 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -172.24 -74.33 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.502 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.9 m -57.37 100.84 0.06 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.892 0.377 . . . . 0.0 110.875 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 t -135.68 156.3 49.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -83.66 52.45 4.72 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.499 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.6 p -92.99 40.28 1.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.894 0.378 . . . . 0.0 110.84 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -53.13 108.99 0.38 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 16.4 m -136.94 119.01 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -82.63 41.94 0.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -91.43 143.38 26.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 22.7 pt -127.56 148.13 32.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.403 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 17.1 t80 -92.53 112.95 25.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.815 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.415 HG12 ' CG1' ' A' ' 120' ' ' ILE . 91.1 t -109.51 117.3 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.136 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.86 -177.47 15.21 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.508 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.41 23.07 47.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.461 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.439 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 64.3 mt -69.85 137.45 87.68 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.657 0.742 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.451 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.2 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.691 2.261 . . . . 0.0 112.31 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -81.6 3.63 24.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -110.07 -27.14 9.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.451 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.5 t -74.89 123.99 26.07 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.35 -173.55 13.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.72 -62.37 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.972 0.415 . . . . 0.0 110.885 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 51.9 m -43.14 -63.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.088 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 129' ' ' LEU . 0.9 OUTLIER -49.47 -62.24 1.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 128' ' ' GLU . 35.3 mt -34.35 -49.21 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.89 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 50.4 mtt180 -67.49 -51.44 51.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -55.2 -16.71 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.469 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 15.9 t80 -108.74 -20.83 12.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.513 ' CE2' HD13 ' A' ' 159' ' ' ILE . 11.4 m-85 -105.5 16.49 25.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.875 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.2 ptpt -94.76 -26.17 16.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -68.06 -38.46 82.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.883 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -63.26 -35.11 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . 0.483 ' O ' ' CG2' ' A' ' 138' ' ' VAL . . . -173.45 -98.08 0.11 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.476 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 137' ' ' GLY . 56.2 t -161.42 109.99 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.876 0.37 . . . . 0.0 111.134 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.23 113.52 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 17.7 p -90.55 -37.73 13.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -141.23 153.04 45.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 63.5 t -134.28 100.69 3.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.8 t -85.71 142.16 13.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.469 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 5.7 mtt -145.03 133.24 21.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.837 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 59.2 mt -97.95 136.85 27.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.451 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.9 3.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.944 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.453 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -86.3 113.72 22.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.453 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.27 -62.27 0.28 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 17.7 tt0 -36.25 -47.29 0.57 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.837 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -77.33 -40.77 43.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 60.08 51.71 5.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.451 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 2.1 ttp180 -163.89 138.86 4.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.634 0.731 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.469 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.3 Cg_endo -69.81 110.56 2.6 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.643 2.229 . . . . 0.0 112.316 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.3 mtt180 -50.97 -52.4 43.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.4 40.24 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -170.2 162.35 8.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.868 0.366 . . . . 0.0 110.893 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.408 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.73 -150.79 19.75 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 15.9 m-85 -145.97 168.99 19.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 0.0 110.901 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.513 HD13 ' CE2' ' A' ' 133' ' ' PHE . 20.5 mt -151.55 138.16 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 161' ' ' PHE . 28.7 m -103.49 142.92 33.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.138 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.498 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 57.7 m-85 -113.27 170.03 8.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -73.98 -38.73 64.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.861 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -131.02 137.2 49.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.448 ' O ' ' N ' ' A' ' 167' ' ' VAL . 11.4 tm-20 -44.93 -47.17 11.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.8 tt0 -34.74 -48.42 0.38 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.94 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.498 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 66.0 m -50.35 -46.7 55.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.448 ' N ' ' O ' ' A' ' 164' ' ' GLU . 58.0 t -50.89 -55.56 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.157 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -53.62 -47.36 70.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.813 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -49.08 -55.79 11.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.907 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.95 -58.26 6.6 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.439 ' O ' ' N ' ' A' ' 174' ' ' HIS . 94.0 t -44.17 -61.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.108 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 171' ' ' VAL . 28.3 t30 -35.76 -46.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.2 mmm -69.9 -43.42 71.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.538 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 16.5 t-160 59.06 26.94 15.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.0 m-85 -171.55 154.32 3.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.865 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 93.2 m-70 -160.66 162.77 32.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.832 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -117.95 92.4 3.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 55.9 mt -112.21 127.24 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.143 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.0 mmt 52.63 33.38 13.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.96 52.06 25.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.482 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -159.03 145.81 17.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.863 0.364 . . . . 0.0 110.869 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.2 tppt? -82.17 111.17 18.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.854 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.3 t -100.97 121.58 51.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -80.79 144.86 31.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 52.7 t -141.1 131.72 27.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.156 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.5 mtpt -142.95 144.48 32.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.915 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.452 ' CZ ' ' HB3' ' A' ' 187' ' ' ARG . 7.4 mtp-105 -50.62 120.81 5.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.73 17.06 1.95 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.082 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -114.49 152.23 45.95 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.64 0.733 . . . . 0.0 110.904 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 157.32 60.75 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.703 2.269 . . . . 0.0 112.32 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 7.4 ptp180 -108.3 86.43 2.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -124.9 -43.96 1.96 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 16.5 m -105.6 91.71 3.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.55 145.65 2.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.927 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' SER . . . . . 0.434 ' O ' ' C ' ' A' ' 196' ' ' SER . 32.0 t -86.37 -48.49 8.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.815 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 195' ' ' SER . 30.8 t -35.46 143.78 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.859 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.0 164.67 9.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.453 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.84 -27.27 26.31 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.657 2.238 . . . . 0.0 112.343 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 29.0 t -69.48 148.81 49.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 1.2 t -121.58 97.85 5.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.908 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.472 -179.959 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 74.6 p -155.29 139.47 16.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.877 0.37 . . . . 0.0 110.864 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.6 p -71.89 90.63 1.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.832 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -102.2 -91.62 2.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.514 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.8 t -94.15 168.59 10.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.858 0.361 . . . . 0.0 110.86 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 70.6 m -129.63 99.2 5.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -85.7 -148.55 11.13 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.452 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 21.7 t -171.35 109.87 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.939 0.399 . . . . 0.0 110.859 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 42.7 mttt 53.04 40.13 30.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.2 t -85.39 176.01 8.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 -119.82 39.5 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -93.24 151.93 19.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 18.1 pt -134.7 152.25 32.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.11 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 27.7 t80 -98.95 108.74 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 90.8 t -104.48 114.36 43.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.84 170.83 16.12 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 72.36 14.19 77.07 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.442 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.473 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 34.2 mt -62.74 137.41 96.64 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.641 0.734 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.77 161.0 47.6 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.707 2.271 . . . . 0.0 112.324 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.0 2.41 10.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.404 ' C ' ' SD ' ' A' ' 179' ' ' MET . 8.8 m-20 -107.72 -23.56 12.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.864 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.468 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 25.4 t -82.07 143.1 31.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -145.51 -171.98 15.54 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.534 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -42.95 -66.18 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.7 m -40.17 -65.73 0.38 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 129' ' ' LEU . 3.9 mp0 -48.33 -61.68 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 128' ' ' GLU . 80.7 mt -34.4 -50.61 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.911 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -71.32 -53.4 14.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 41.4 mm-40 -46.99 -22.31 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.524 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 32.6 t80 -103.85 -36.79 7.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.897 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.564 ' CE2' HD13 ' A' ' 159' ' ' ILE . 16.8 m-85 -84.9 10.23 12.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.885 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.448 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 8.6 ptpt -91.0 -29.78 17.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.448 ' N ' ' HG3' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -69.97 -17.42 63.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.913 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -89.54 -19.88 24.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.22 -118.07 0.65 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.538 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.6 t -146.02 106.88 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.89 0.376 . . . . 0.0 111.119 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.52 111.09 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 43.3 p -88.03 -39.76 14.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.152 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -136.97 151.11 48.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 86.4 t -134.36 106.22 7.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.454 HG12 ' N ' ' A' ' 144' ' ' MET . 60.7 t -96.7 139.31 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.191 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.503 ' CE ' ' CB ' ' A' ' 153' ' ' PRO . 14.4 mtp -141.1 130.57 23.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -91.46 137.21 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.447 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.72 165.13 4.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.937 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.443 ' O ' ' C ' ' A' ' 148' ' ' ALA . 39.3 t0 -85.13 113.49 21.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.59 -58.72 0.41 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.107 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -41.47 -43.87 2.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.436 ' N ' ' O ' ' A' ' 147' ' ' ASP . 9.5 tptm -78.14 -40.85 36.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 60.01 48.02 9.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.447 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.6 ttp85 -161.63 138.95 6.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.626 0.727 . . . . 0.0 110.816 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.503 ' CB ' ' CE ' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 113.8 3.49 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.645 2.23 . . . . 0.0 112.348 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 33.7 mtp85 -55.48 -57.04 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 167.8 41.66 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.503 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -172.55 157.13 3.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.918 0.39 . . . . 0.0 110.834 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.41 -154.42 24.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.507 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -140.1 166.13 25.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.813 0.34 . . . . 0.0 110.919 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.564 HD13 ' CE2' ' A' ' 133' ' ' PHE . 17.3 mt -150.0 142.39 17.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.102 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.4 m -109.82 141.12 42.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.11 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.562 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 39.4 m-85 -110.39 176.98 4.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -82.47 -36.17 26.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -131.96 131.34 42.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.849 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -40.8 -41.49 1.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.839 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -37.56 -53.95 1.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.562 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 22.4 m -46.27 -54.37 8.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 63.8 t -40.71 -56.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.134 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 169' ' ' GLN . 38.8 t0 -56.29 -64.13 0.96 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 168' ' ' ASP . 50.9 mt-30 -34.69 -43.92 0.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -75.15 -62.47 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.084 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.441 HG23 ' CG ' ' A' ' 187' ' ' ARG . 51.4 t -42.74 -54.24 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -40.64 -51.61 2.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.4 mmm -64.37 -31.97 73.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 13.3 t-160 48.61 26.46 1.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.1 m-85 -169.28 148.46 3.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.848 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.524 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 91.9 m-70 -155.07 152.43 29.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.84 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -108.13 104.07 13.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 52.4 mt -126.23 113.09 32.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' MET . . . . . 0.404 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 9.1 mtt 60.62 42.56 13.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 46.74 93.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.495 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.8 tptt -153.41 145.93 24.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -87.25 110.74 20.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.5 t -97.8 115.03 36.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -76.77 141.6 40.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 20.3 t -138.57 131.55 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 11.4 mtmt -138.34 149.99 46.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.947 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.441 ' CG ' HG23 ' A' ' 171' ' ' VAL . 14.0 mtt180 -53.07 123.77 12.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -89.04 15.56 8.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -80.97 152.48 71.65 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.627 0.727 . . . . 0.0 110.879 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -41.75 4.03 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 0.0 112.356 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -145.36 133.81 21.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -38.47 132.07 1.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.826 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.1 t -72.61 142.06 48.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . 0.403 ' NZ ' ' HB3' ' A' ' 194' ' ' LYS . 8.9 mtpm? -149.3 158.75 44.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 17.1 t -104.54 80.44 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.863 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 30.7 t -79.22 150.87 31.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.873 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 47.0 -168.8 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.476 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 131.04 20.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 38.0 t -100.51 -46.87 5.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.1 t -61.93 -55.86 25.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.861 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.461 -179.975 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.3 m -110.68 103.17 11.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.863 0.363 . . . . 0.0 110.837 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.0 m -131.71 115.78 16.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -101.85 44.2 1.57 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.48 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.3 t -45.94 -56.86 4.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.857 0.361 . . . . 0.0 110.856 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 7.3 m -132.8 164.7 26.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.84 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -84.21 111.68 3.5 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.444 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 6.4 t -97.1 87.44 4.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.945 0.402 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 8.8 ptpt -80.48 -21.3 42.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.0 m -56.01 110.54 0.76 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -90.41 48.19 1.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.7 ttmt -100.14 137.18 38.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 29.2 pt -119.65 153.38 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.147 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -101.87 107.61 18.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.421 ' CG2' HG21 ' A' ' 185' ' ' VAL . 88.1 t -103.36 117.65 49.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.141 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.69 -177.42 15.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.52 13.73 39.1 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.467 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.47 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 35.5 mt -61.65 137.15 94.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 0.0 111.15 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.1 Cg_endo -69.67 161.85 44.32 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.444 ' ND1' ' O ' ' A' ' 122' ' ' HIS . 2.8 p80 -77.58 8.66 4.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.873 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.459 ' O ' ' CE ' ' A' ' 179' ' ' MET . 47.5 t30 -117.09 -15.12 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.458 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 2.7 t -83.55 153.22 24.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -158.92 169.6 35.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.517 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 125' ' ' GLY . 0.6 OUTLIER -35.97 -59.4 0.6 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.893 0.377 . . . . 0.0 110.893 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.9 m -42.62 -53.94 4.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -65.25 -55.93 15.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.428 ' O ' ' N ' ' A' ' 133' ' ' PHE . 60.6 mt -42.6 -58.85 2.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.933 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 68.1 mtp180 -54.51 -56.72 15.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -50.87 -33.5 24.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.5 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.0 t80 -89.64 -20.06 24.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.428 ' N ' ' O ' ' A' ' 129' ' ' LEU . 11.1 m-85 -105.31 17.74 23.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -92.59 -39.15 11.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.3 ptpt -57.39 -31.14 65.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.869 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -73.99 -32.48 63.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.891 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.55 -118.9 0.54 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 60.2 t -145.04 106.23 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 21.5 t -68.71 108.66 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.117 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 16.5 p -86.03 -38.0 18.33 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -140.67 155.53 46.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 85.0 t -136.89 106.35 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.166 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.428 HG11 ' N ' ' A' ' 144' ' ' MET . 47.5 t -93.96 138.7 19.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.122 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.461 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 4.8 mtt -139.17 136.33 34.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.1 mt -101.43 131.76 48.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.445 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.16 164.84 7.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.3 t0 -85.41 112.4 20.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.865 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.5 -60.56 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 tm-20 -38.52 -45.45 1.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 9.3 tppt? -78.52 -40.51 34.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 60.07 53.11 4.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.911 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 15.4 ttp85 -165.44 138.34 3.56 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.601 0.715 . . . . 0.0 110.922 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.461 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.2 Cg_endo -69.81 111.44 2.82 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.684 2.256 . . . . 0.0 112.315 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.6 mtp85 -52.0 -50.77 60.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 161.27 39.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -169.69 161.45 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.519 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 165.42 -151.05 19.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.459 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.519 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 10.1 m-85 -146.03 166.31 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.869 0.366 . . . . 0.0 110.866 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.407 HD12 ' CD2' ' A' ' 133' ' ' PHE . 18.2 mt -150.4 136.78 12.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.13 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.433 HG23 ' N ' ' A' ' 161' ' ' PHE . 36.5 m -103.82 143.4 32.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.514 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.9 m-85 -112.44 176.46 5.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.925 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -77.91 -39.04 44.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.71 145.21 49.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 165' ' ' GLN . 34.8 tt0 -48.81 -44.39 39.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.918 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.418 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.1 tt0 -34.76 -49.6 0.43 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.514 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 20.0 m -53.65 -52.08 61.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 70.4 t -47.41 -47.1 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -63.56 -52.62 60.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -47.67 -51.58 21.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.891 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.89 -56.44 7.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 40.3 t -43.6 -57.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -38.74 -62.04 0.66 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.885 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.3 mmm -48.6 -42.45 33.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.6 t-160 54.01 25.72 5.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.521 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -172.37 144.8 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.898 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.5 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 64.8 m-70 -156.21 158.74 38.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -110.33 103.68 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 34.2 mt -130.05 131.34 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.089 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 123' ' ' ASN . 11.9 mmt 62.52 25.74 15.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.914 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.01 85.01 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.457 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 9.1 ttmm -128.29 162.17 27.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.866 0.365 . . . . 0.0 110.876 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 5.8 tptm -88.74 128.68 35.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.5 t -112.46 121.61 65.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.096 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -81.37 145.21 30.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.421 HG21 ' CG2' ' A' ' 117' ' ' VAL . 42.7 t -142.29 126.91 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mmmt -138.04 143.92 40.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -56.69 118.54 4.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.842 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -77.29 169.38 18.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -111.45 147.95 37.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 191' ' ' ARG . 53.8 Cg_endo -69.78 124.47 11.11 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 0.0 112.341 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.438 ' C ' ' O ' ' A' ' 190' ' ' PRO . 0.0 OUTLIER -35.5 125.24 0.65 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -50.99 142.57 11.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 78.8 p -122.2 110.16 15.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -141.05 145.72 36.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.891 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 51.4 m -152.3 167.25 29.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.886 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.7 t -118.92 133.57 55.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 81.24 159.59 23.22 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.87 2.08 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.683 2.255 . . . . 0.0 112.349 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 28.8 m -40.6 131.77 2.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.855 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 25.7 m -89.86 104.73 17.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.843 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.484 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.8 m -76.53 159.93 29.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.351 . . . . 0.0 110.885 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 85.0 p -164.35 141.48 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.57 -143.34 16.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.5 t 53.55 42.53 31.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.855 0.359 . . . . 0.0 110.847 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.8 t -91.51 -44.43 9.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.41 161.17 53.55 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.485 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.0 t -80.87 -54.39 5.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.95 0.405 . . . . 0.0 110.856 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -109.14 88.95 2.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.931 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.5 m -114.42 142.21 46.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -95.66 62.38 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.7 ttmt -117.67 148.65 41.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.7 pt -129.22 155.33 41.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 7.3 t80 -104.74 102.37 11.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.8 t -93.3 125.42 45.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.109 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.1 -177.28 14.79 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.52 8.69 10.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.467 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 55.3 mt -58.71 137.61 86.58 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.638 0.732 . . . . 0.0 111.117 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.467 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.76 169.79 18.09 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.0 p-80 -85.92 15.21 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -123.67 -26.86 4.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.497 ' N ' ' SD ' ' A' ' 179' ' ' MET . 24.1 t -72.18 118.92 15.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.68 -174.32 16.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.495 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -41.45 -63.94 0.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.951 0.405 . . . . 0.0 110.863 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 46.0 m -41.9 -54.9 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.102 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 129' ' ' LEU . 61.1 mm-40 -54.41 -66.18 0.44 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.431 ' C ' ' O ' ' A' ' 128' ' ' GLU . 51.5 mt -34.53 -60.34 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 5.6 mtp-105 -58.9 -57.0 15.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.863 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -46.44 -25.8 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.3 t80 -102.46 -20.7 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.928 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.554 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.6 m-85 -104.47 9.8 35.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 130' ' ' ARG . 48.2 pttt -91.33 -17.61 25.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.88 -38.57 57.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.915 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -69.18 -29.38 67.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.31 -124.17 0.79 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.7 t -138.61 105.3 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.126 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 38.6 t -65.16 110.0 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.079 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 46.2 p -87.74 -38.46 15.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.129 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -137.38 147.43 45.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.859 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.27 94.46 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.412 HG11 ' N ' ' A' ' 144' ' ' MET . 72.3 t -89.99 137.9 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.12 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.47 ' HE3' ' CB ' ' A' ' 153' ' ' PRO . 8.8 mtp -137.57 142.7 41.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 73.3 mt -106.58 133.53 50.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.37 165.08 5.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.903 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 29.1 t0 -85.83 113.5 22.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.33 -62.13 0.29 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.108 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 148' ' ' ALA . 42.5 tt0 -36.38 -46.26 0.53 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -78.99 -40.55 31.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 60.0 47.84 9.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.9 ttp180 -158.29 138.32 8.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.623 0.725 . . . . 0.0 110.893 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.47 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.75 110.6 2.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.724 2.282 . . . . 0.0 112.32 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -51.62 -53.53 37.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.851 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 120' ' ' ILE . . . 163.03 41.39 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.534 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -170.7 160.6 7.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.914 0.388 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.23 -159.01 32.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 15.8 m-85 -137.81 161.11 37.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.82 0.343 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.554 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.1 mt -148.19 140.73 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.073 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.461 ' N ' HG22 ' A' ' 159' ' ' ILE . 23.6 m -107.13 144.23 34.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.451 ' N ' HG21 ' A' ' 160' ' ' THR . 54.8 m-85 -113.29 167.52 10.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -70.53 -43.17 70.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -122.06 140.53 52.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 165' ' ' GLN . 7.9 tp10 -49.67 -46.39 49.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.401 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.4 tt0 -38.24 -51.88 1.48 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.418 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 50.6 m -44.58 -57.05 3.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 166' ' ' SER . 38.4 t -37.68 -59.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 169' ' ' GLN . 46.9 t0 -50.53 -61.65 2.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.807 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 168' ' ' ASP . 76.0 mt-30 -35.73 -48.91 0.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.62 -57.89 4.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.118 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 174' ' ' HIS . 75.2 t -47.13 -60.39 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 171' ' ' VAL . 7.5 t30 -35.07 -61.08 0.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 27.5 mmm -51.08 -41.45 59.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.904 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.522 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.6 t-160 55.94 26.23 9.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.8 m-85 -171.87 148.32 2.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.566 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 52.7 m-70 -155.44 155.83 34.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -112.37 85.84 2.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . 0.421 ' C ' ' HG2' ' A' ' 179' ' ' MET . 78.8 mt -96.66 126.24 49.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.15 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' MET . . . . . 0.497 ' SD ' ' N ' ' A' ' 124' ' ' CYS . 2.0 ptm 38.81 48.22 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.5 67.74 1.94 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.418 ' NZ ' ' HB2' ' A' ' 181' ' ' LYS . 0.3 OUTLIER -175.13 142.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.815 0.34 . . . . 0.0 110.897 -179.946 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.8 tptm -85.04 102.37 13.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.884 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.08 117.34 38.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.139 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . 0.482 ' O ' ' CG2' ' A' ' 185' ' ' VAL . 10.1 tt0 -72.92 162.19 29.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.906 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.482 ' CG2' ' O ' ' A' ' 184' ' ' GLU . 72.3 t -161.12 131.02 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mttm -137.19 143.31 42.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.42 ' HB2' ' NH1' ' A' ' 187' ' ' ARG . 10.4 ttm105 -56.96 114.16 1.99 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.862 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -76.4 97.79 4.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -175.02 155.38 1.83 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.668 0.747 . . . . 0.0 110.858 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 179.45 3.7 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.716 2.277 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -112.62 -59.44 2.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -83.41 99.93 10.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 74.0 p -129.71 128.31 42.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.867 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 25.8 tttm -91.93 86.14 5.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 62.7 p -160.28 152.73 20.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 48.5 t -124.06 83.75 2.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.867 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 75.76 -158.3 49.88 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.431 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 128.85 16.6 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.642 2.228 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.8 m -91.14 105.33 17.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.836 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 18.9 t -104.39 154.47 19.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.882 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.986 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.392 0 N-CA-C 112.519 -0.232 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.9 m -66.9 101.55 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 110.87 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.2 m -69.02 85.04 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.868 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 156.13 96.29 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.3 m -72.14 -59.56 2.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.821 0.343 . . . . 0.0 110.887 -179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.5 t -82.79 85.74 7.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.837 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -74.86 85.27 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.5 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 23.9 p -100.71 -62.97 1.18 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.952 0.406 . . . . 0.0 110.86 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.23 97.34 5.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.0 t -147.02 132.03 18.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.853 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -104.11 56.46 0.72 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 115' ' ' ILE . 21.3 ttmt -105.23 149.55 25.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . 0.433 ' N ' ' HG2' ' A' ' 114' ' ' LYS . 24.0 pt -129.6 156.85 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.454 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 8.0 t80 -104.58 106.45 16.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.05 114.42 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.154 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -118.43 -177.64 16.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.432 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.04 26.63 58.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.471 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.455 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 60.7 mt -75.46 137.9 71.12 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.631 0.729 . . . . 0.0 111.12 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.465 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.7 Cg_endo -69.72 165.11 32.02 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.706 2.27 . . . . 0.0 112.374 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -77.3 0.54 21.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -105.42 -32.89 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.465 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 21.4 t -68.8 118.81 12.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.39 -179.27 15.85 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 55.9 tt0 -39.89 -67.59 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.876 0.369 . . . . 0.0 110.853 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.1 m -40.67 -60.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.121 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 16.7 mm-40 -49.73 -61.22 2.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.427 ' C ' ' O ' ' A' ' 128' ' ' GLU . 41.9 mt -35.97 -55.67 0.74 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.471 ' CZ ' ' HB3' ' A' ' 130' ' ' ARG . 11.1 mtp-105 -64.03 -54.7 30.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -47.52 -20.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -107.46 -25.42 11.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.457 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.4 m-85 -97.98 15.34 24.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.8 ptpt -95.22 -10.69 29.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.94 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.2 pttm -81.69 -34.56 30.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -72.14 -23.29 61.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.33 -118.96 0.69 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 88.2 t -140.03 116.14 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 24.9 t -80.66 111.12 16.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.6 p -89.1 -34.95 16.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -142.02 157.82 44.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.3 t -139.05 104.94 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.172 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.418 HG11 ' N ' ' A' ' 144' ' ' MET . 48.1 t -90.79 139.27 17.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.149 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.435 ' HE3' ' CB ' ' A' ' 153' ' ' PRO . 5.3 mtt -142.25 133.7 26.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 70.7 mt -99.21 133.82 40.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.22 165.96 5.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.941 -179.987 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.455 ' O ' ' C ' ' A' ' 148' ' ' ALA . 21.8 t0 -84.88 113.23 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.455 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.16 -58.29 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.056 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -42.41 -44.45 3.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 147' ' ' ASP . 2.8 mptm? -77.22 -40.82 43.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 60.09 43.5 14.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.866 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 3.8 ttp180 -155.92 138.47 10.38 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.6 0.714 . . . . 0.0 110.886 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.435 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.77 110.87 2.66 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.335 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.9 mtp85 -50.86 -55.89 14.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.18 41.77 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -172.34 162.95 5.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.449 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 162.79 -154.51 25.49 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.451 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 4.7 m-85 -141.95 167.03 23.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.891 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.457 HD12 ' CD2' ' A' ' 133' ' ' PHE . 8.9 mt -150.1 139.85 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.137 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.443 ' N ' HG23 ' A' ' 159' ' ' ILE . 89.3 m -106.33 144.82 32.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.153 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.471 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 53.1 m-85 -115.13 175.02 5.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -78.65 -43.25 26.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 164' ' ' GLU . 3.4 m-20 -123.97 125.59 44.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.874 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 163' ' ' ASP . 23.1 tt0 -35.17 -39.03 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.419 ' C ' ' O ' ' A' ' 164' ' ' GLU . 3.8 mm100 -36.03 -59.33 0.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.471 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 1.1 m -41.87 -58.35 2.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.809 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 166' ' ' SER . 58.6 t -36.12 -54.42 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -58.54 -60.3 4.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.1 mt-30 -39.9 -48.84 2.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.92 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.48 -54.94 13.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.464 HG21 ' N ' ' A' ' 187' ' ' ARG . 67.9 t -46.21 -60.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.167 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.428 ' C ' ' O ' ' A' ' 171' ' ' VAL . 12.3 t-20 -35.84 -67.8 0.15 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.832 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 86.2 mtp -46.44 -42.14 14.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.3 t-160 54.74 30.61 13.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.824 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -173.57 155.17 2.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 77.8 m-70 -160.57 162.82 33.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -119.39 91.52 3.57 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 58.2 mt -112.23 135.09 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.146 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.7 mmm 46.14 40.78 7.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.885 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.34 57.4 18.42 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.2 tmtm? -166.09 151.33 8.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -84.5 116.7 23.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.9 t -105.78 120.41 56.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -82.15 146.78 29.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.471 HG23 ' CD2' ' A' ' 176' ' ' HIS . 69.2 t -144.49 134.31 19.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -139.18 149.1 44.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.464 ' N ' HG21 ' A' ' 171' ' ' VAL . 28.7 ttp180 -59.9 119.21 7.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.932 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.69 15.59 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.116 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -109.6 146.8 34.77 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.637 0.732 . . . . 0.0 110.868 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 170.96 15.38 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.636 2.224 . . . . 0.0 112.324 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -85.65 102.75 13.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -103.57 162.3 13.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.9 m -114.39 -41.25 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 31.7 tptt -156.34 146.18 21.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.89 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 55.5 m -79.96 173.9 12.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 10.6 t -144.62 140.11 28.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.855 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 108.38 147.72 12.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.537 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 126.41 13.28 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.1 t -57.49 145.86 31.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.7 t -111.57 111.76 23.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 -179.999 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 93.0 p -140.93 130.96 24.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.88 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -161.07 131.46 5.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 107.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.501 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 20.2 m -84.58 -49.68 8.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 110.812 -179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 51.1 m -155.55 130.38 9.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -145.88 -111.08 0.69 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.486 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 80.7 p -158.27 121.92 3.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.919 0.39 . . . . 0.0 110.859 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 13.4 pttt -153.38 164.21 38.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.6 t -129.42 142.66 50.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.812 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -88.6 34.2 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -92.72 150.01 20.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.908 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . 0.434 HD12 ' CG2' ' A' ' 117' ' ' VAL . 20.0 pt -131.09 155.16 41.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -104.39 105.54 15.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.434 ' CG2' HD12 ' A' ' 115' ' ' ILE . 94.8 t -101.11 115.32 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.146 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.01 177.98 16.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.06 11.69 55.7 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.473 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 55.9 mt -57.85 138.84 82.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.642 0.734 . . . . 0.0 111.13 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.2 Cg_endo -69.79 171.96 13.55 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.658 2.239 . . . . 0.0 112.359 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.493 ' O ' ' CG ' ' A' ' 122' ' ' HIS . 12.1 t60 -76.58 -5.14 46.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.452 ' O ' ' C ' ' A' ' 124' ' ' CYS . 7.7 m120 -102.43 -62.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.456 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.3 t -34.38 128.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -127.34 -154.82 8.62 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.444 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -66.33 -60.87 2.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.942 0.401 . . . . 0.0 110.921 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 53.3 m -48.55 -58.36 4.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.091 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -46.63 -61.95 1.6 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 35.5 mt -39.74 -52.13 2.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.917 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.481 ' O ' ' N ' ' A' ' 134' ' ' LYS . 74.0 mtm180 -59.85 -52.42 65.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 -53.38 -27.84 26.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.927 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.515 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 9.0 t80 -96.51 -18.96 19.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.946 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -108.17 7.99 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.481 ' N ' ' O ' ' A' ' 130' ' ' ARG . 32.3 pttt -90.77 -28.46 18.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.2 ptpt -66.47 -25.94 66.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.867 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -78.66 -37.8 41.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -167.92 -112.25 0.26 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.463 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 86.5 t -147.47 112.33 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 111.056 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 70.7 t -75.16 103.78 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.112 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -79.24 -40.9 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.18 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.25 152.98 46.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.5 t -132.46 102.43 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.08 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.8 t -89.44 143.59 10.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.462 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.4 mtt -145.41 134.18 22.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 55.6 mt -98.76 130.66 47.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.169 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.454 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -170.09 164.66 9.34 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 150' ' ' LYS . 46.0 t0 -82.91 113.34 20.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.841 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.9 -52.46 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -48.0 -42.47 28.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.442 ' N ' ' O ' ' A' ' 147' ' ' ASP . 63.3 mttt -79.19 -38.43 35.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.948 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 58.19 51.41 8.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 13.1 ttm180 -164.95 138.42 3.88 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.61 0.719 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.462 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.72 113.54 3.4 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.742 2.295 . . . . 0.0 112.364 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.1 mtt180 -54.69 -55.47 29.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.32 40.59 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -171.39 164.76 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.902 0.382 . . . . 0.0 110.877 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.74 -161.04 33.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -137.73 162.85 32.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 160' ' ' THR . 15.8 mt -146.39 140.49 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.095 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.435 HG21 ' N ' ' A' ' 161' ' ' PHE . 41.0 m -108.78 139.88 42.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.435 ' N ' HG21 ' A' ' 160' ' ' THR . 34.9 m-85 -109.27 172.51 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.43 -30.03 47.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.928 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -137.43 147.21 45.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -55.56 -45.77 77.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.878 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -41.59 -42.29 2.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 6.1 m -55.84 -54.38 45.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 42.1 t -47.34 -51.31 6.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.154 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 18.6 t0 -52.92 -52.53 57.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 14.3 mm-40 -42.27 -44.37 3.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.12 -64.55 1.11 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 68.8 t -37.81 -50.25 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.097 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -39.2 -67.99 0.19 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' MET . . . . . 0.56 ' HE1' ' CE1' ' A' ' 176' ' ' HIS . 9.0 mtm -54.76 -43.41 72.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 17.6 t-160 61.17 26.48 16.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.1 m-85 -172.01 134.72 0.77 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.56 ' CE1' ' HE1' ' A' ' 173' ' ' MET . 57.0 m-70 -145.41 161.58 39.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -114.24 98.24 6.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 38.7 mt -118.65 129.07 75.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 51.07 41.89 27.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 60.73 63.65 4.79 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.489 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -174.15 149.21 1.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 9.7 tppt? -85.74 102.36 13.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.2 t -89.71 115.61 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.131 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -77.82 144.17 37.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.904 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 88.2 t -143.44 128.44 15.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -133.34 151.48 51.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.1 ttt-85 -66.4 108.53 2.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -64.82 172.02 3.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -106.0 146.22 32.48 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.69 0.757 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 132.91 24.35 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.639 2.226 . . . . 0.0 112.382 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -71.5 118.55 14.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -107.09 75.71 1.05 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 32.0 t -66.85 151.79 46.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.84 96.35 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.899 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 48.8 m -77.23 123.44 26.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 10.9 t -153.26 134.99 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -169.8 143.6 8.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.465 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 115.04 3.9 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.665 2.243 . . . . 0.0 112.375 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.1 t -121.32 106.19 11.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.885 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 12.5 t -72.76 -57.7 3.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 85.7 p -173.74 156.4 2.87 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.359 . . . . 0.0 110.854 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.8 p -116.66 42.1 2.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 66.75 133.85 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.455 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -108.86 131.45 54.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.366 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -53.94 113.84 1.37 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.831 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 142.54 130.13 2.44 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.463 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 4.1 m -101.44 -51.04 3.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.932 0.396 . . . . 0.0 110.818 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 pttt -86.91 127.0 35.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 113' ' ' ASN . 53.4 p -98.47 -21.83 16.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.879 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.429 ' C ' ' O ' ' A' ' 112' ' ' SER . 2.0 m-20 34.42 41.75 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -105.19 145.23 30.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 16.2 pt -126.79 155.34 37.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.156 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -104.7 106.1 16.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.433 ' CG1' HD11 ' A' ' 120' ' ' ILE . 99.5 t -102.74 122.97 55.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -125.83 -174.94 14.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.07 16.77 14.55 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.503 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.468 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 59.9 mt -64.45 138.1 97.34 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.651 0.739 . . . . 0.0 111.143 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.468 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.06 25.56 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.633 2.222 . . . . 0.0 112.349 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -81.38 2.59 27.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.853 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -107.48 -29.02 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.464 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.1 t -72.96 135.39 45.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -139.26 175.71 21.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' GLY . 22.8 tt0 -34.57 -70.17 0.08 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.888 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 126' ' ' GLU . 22.0 m -36.36 -65.34 0.28 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.121 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 129' ' ' LEU . 36.8 mm-40 -47.65 -63.07 1.15 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.439 ' C ' ' O ' ' A' ' 128' ' ' GLU . 67.8 mt -34.38 -45.15 0.22 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.417 ' O ' ' N ' ' A' ' 134' ' ' LYS . 22.5 mtt180 -67.39 -56.73 8.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -46.88 -26.66 1.03 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.949 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.535 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -98.26 -31.41 12.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.532 ' CD2' HD12 ' A' ' 159' ' ' ILE . 24.8 m-85 -97.02 16.86 18.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 17.0 pttp -95.32 -27.9 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -68.08 -34.05 75.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.922 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -66.65 -31.53 72.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -178.86 -106.14 0.2 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 83.2 t -151.74 111.53 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.96 114.67 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 72.5 p -91.81 -38.29 12.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.161 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -140.51 154.16 46.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.5 t -134.7 100.92 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.459 HG12 ' N ' ' A' ' 144' ' ' MET . 65.3 t -83.28 141.9 14.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.459 ' N ' HG12 ' A' ' 143' ' ' VAL . 5.8 mtt -145.3 135.02 23.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.4 mt -101.02 136.45 32.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.105 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.06 166.03 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.45 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -88.88 113.52 24.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.52 -58.71 0.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.104 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.403 ' C ' ' O ' ' A' ' 148' ' ' ALA . 34.2 tt0 -37.52 -45.25 0.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.863 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 6.4 tptm -82.35 -39.08 23.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.09 47.11 9.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.7 ttp85 -157.74 139.07 9.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.652 0.739 . . . . 0.0 110.864 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 109.75 2.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.717 2.278 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 30.7 mtp180 -49.39 -54.11 19.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.888 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.0 42.34 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -172.88 160.03 4.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.884 0.374 . . . . 0.0 110.866 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.15 -152.82 22.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.507 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -142.34 167.25 22.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.936 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.532 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.7 mt -148.81 138.52 16.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 161' ' ' PHE . 61.9 m -103.0 148.77 25.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.454 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 67.2 m-85 -119.83 175.43 5.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -79.49 -42.7 24.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.905 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -126.47 134.78 50.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 165' ' ' GLN . 39.2 tt0 -43.52 -44.25 5.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 164' ' ' GLU . 65.1 tt0 -35.66 -45.73 0.39 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.454 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 3.8 m -51.6 -55.69 17.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 80.0 t -40.75 -57.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -50.21 -51.77 41.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.867 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 20.6 mm100 -48.0 -57.77 5.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -59.51 -58.92 6.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 174' ' ' HIS . 70.3 t -44.28 -62.88 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.2 t-20 -34.65 -55.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.87 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 25.6 mmm -57.29 -42.84 82.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.0 t-160 54.53 26.71 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.4 m-85 -172.5 154.39 3.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.535 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 88.3 m-70 -159.81 157.76 29.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -116.29 84.04 2.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . 0.407 HD12 ' CG2' ' A' ' 183' ' ' VAL . 66.8 mt -97.33 108.68 21.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.162 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 23.7 mtm 61.01 44.86 9.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.98 37.96 94.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 35.0 tptt -139.29 136.69 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 110.883 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.22 100.99 10.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . 0.407 ' CG2' HD12 ' A' ' 178' ' ' ILE . 2.6 t -93.21 129.63 43.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -87.67 148.01 24.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.428 HG21 ' CG2' ' A' ' 117' ' ' VAL . 67.1 t -147.58 138.75 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.109 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.1 mtmm -141.15 169.57 17.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.0 tmm_? -80.83 114.03 19.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.54 167.11 18.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.127 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -119.0 147.06 41.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.684 0.754 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 176.84 6.24 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.02 172.22 13.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -91.13 121.7 33.14 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.89 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 55.8 p -145.76 140.35 27.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 33.9 tttm -55.4 133.99 50.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 93.4 p -51.68 118.08 3.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 15.5 t -105.39 152.25 23.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -118.83 146.03 18.33 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.24 14.31 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 0.0 112.37 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.1 p -120.11 83.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 41.5 p -89.34 127.54 35.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.451 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.4 m -132.45 88.76 2.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.955 0.407 . . . . 0.0 110.874 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.8 m -122.51 97.23 5.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.868 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 175.58 -124.34 0.99 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.4 m -115.67 42.21 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.834 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 24.5 t -102.67 82.91 2.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.832 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 110' ' ' SER . . . -119.89 -162.88 12.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.491 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 109' ' ' GLY . 40.8 t -35.27 115.06 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.97 0.414 . . . . 0.0 110.895 -179.762 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -39.34 111.48 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 90.5 p -120.42 116.06 24.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.852 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -100.37 37.49 1.67 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -102.22 145.55 29.26 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 25.1 pt -126.08 154.3 35.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -104.21 101.98 11.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.465 ' CG2' HG22 ' A' ' 185' ' ' VAL . 98.2 t -95.66 119.11 43.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.129 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.71 177.43 16.43 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.516 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.87 28.62 63.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.492 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.46 ' CG1' HG11 ' A' ' 117' ' ' VAL . 32.3 mt -75.82 137.01 69.95 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.606 0.717 . . . . 0.0 111.104 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.461 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.8 Cg_endo -69.72 166.98 25.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.657 2.238 . . . . 0.0 112.351 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -77.1 -3.49 39.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.878 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -100.82 -37.34 8.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.461 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.1 t -67.93 125.35 26.01 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.449 ' N ' ' OE1' ' A' ' 128' ' ' GLU . . . -129.9 -165.61 11.66 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.528 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -53.53 -64.53 0.79 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.92 0.39 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 87.3 m -44.14 -54.29 5.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.449 ' OE1' ' N ' ' A' ' 125' ' ' GLY . 12.2 mp0 -57.16 -63.44 1.22 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 133' ' ' PHE . 61.0 mt -34.31 -46.96 0.28 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 30.7 mtp85 -69.74 -51.14 36.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -50.22 -19.2 0.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.921 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.427 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 12.6 t80 -108.97 -24.05 11.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.509 ' CD2' HD12 ' A' ' 159' ' ' ILE . 17.1 m-85 -98.35 9.99 41.8 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -86.85 -25.47 24.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -69.45 -39.61 77.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -64.58 -25.94 68.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.904 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 176.5 -113.79 0.45 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.465 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.5 t -147.95 106.14 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.848 0.356 . . . . 0.0 111.154 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.18 116.51 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.172 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 79.5 p -93.68 -35.42 12.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.108 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.69 152.61 45.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.93 97.69 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.139 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 144' ' ' MET . 59.3 t -81.84 142.74 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.095 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.466 ' N ' HG13 ' A' ' 143' ' ' VAL . 4.3 mtt -145.15 136.7 25.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 56.8 mt -104.36 131.36 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.45 166.75 6.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 148' ' ' ALA . 48.0 t0 -91.49 109.75 21.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.13 -46.24 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 148' ' ' ALA . 1.5 tm-20 -35.3 -47.03 0.39 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -99.31 -28.69 13.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 59.78 50.06 7.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.0 ttp85 -149.73 138.58 12.53 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.613 0.72 . . . . 0.0 110.891 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.418 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.5 Cg_endo -69.71 110.62 2.59 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.352 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -50.24 -54.02 24.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.844 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.49 40.67 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.482 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -172.61 160.12 4.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 168.03 -155.56 26.44 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.441 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' A' ' 143' ' ' VAL . 29.2 m-85 -142.52 162.45 35.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.787 0.327 . . . . 0.0 110.879 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.509 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.9 mt -146.0 139.72 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.089 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.454 ' N ' HG21 ' A' ' 159' ' ' ILE . 84.7 m -106.87 139.72 40.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.536 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 55.1 m-85 -109.08 179.24 4.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -86.23 -38.17 17.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . 0.415 ' O ' ' C ' ' A' ' 164' ' ' GLU . 6.5 m-20 -128.77 127.53 42.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.849 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 163' ' ' ASP . 26.8 tt0 -36.04 -42.19 0.28 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.403 ' O ' ' C ' ' A' ' 166' ' ' SER . 3.9 mt-30 -36.93 -61.42 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.536 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 7.2 m -38.32 -59.52 0.88 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 53.6 t -38.88 -63.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.157 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -43.9 -60.77 1.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -40.14 -53.41 2.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.36 -55.4 24.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 187' ' ' ARG . 69.4 t -47.26 -61.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 171' ' ' VAL . 16.2 t-20 -37.67 -64.91 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 74.8 mtp -49.29 -45.43 45.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.835 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.8 t-160 60.03 28.07 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.5 m-85 -171.72 154.1 3.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.477 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 80.0 m-70 -159.38 156.64 28.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -113.09 91.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 56.7 mt -111.05 134.21 54.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.113 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 47.99 36.19 5.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.78 46.04 85.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.463 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.429 ' HZ1' ' N ' ' A' ' 121' ' ' PRO . 0.0 OUTLIER -153.61 147.18 25.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.875 -179.963 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.13 113.65 20.78 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.913 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.1 t -105.16 127.39 59.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -83.81 150.53 25.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.86 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.465 HG22 ' CG2' ' A' ' 117' ' ' VAL . 23.8 t -151.14 131.93 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -136.86 149.05 47.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.468 ' N ' HG23 ' A' ' 171' ' ' VAL . 12.1 ttt180 -62.87 124.89 22.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.21 162.08 21.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.132 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.49 161.09 25.12 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.444 ' O ' ' C ' ' A' ' 191' ' ' ARG . 54.0 Cg_endo -69.71 -50.8 0.44 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.684 2.256 . . . . 0.0 112.33 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.444 ' C ' ' O ' ' A' ' 190' ' ' PRO . 64.8 mtt-85 34.3 39.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -51.76 147.01 7.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 42.5 m -154.92 143.86 20.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 23.3 ttpt -173.02 136.85 0.68 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.913 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 70.9 m -110.19 100.01 8.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 16.5 t -154.33 131.8 11.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -133.15 78.71 0.35 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -6.87 19.62 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.653 2.235 . . . . 0.0 112.399 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.4 t -109.73 118.16 35.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 3.8 t -129.28 88.51 2.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.83 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.512 -179.974 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.0 m -93.57 92.59 7.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.5 t 64.65 42.45 4.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.84 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -119.56 -134.71 4.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.1 m -39.42 -43.69 1.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 71.6 m -101.11 148.65 24.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.868 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 113.25 -71.45 0.22 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 31.3 m -71.58 156.35 39.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 pttt -39.39 125.53 1.7 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 56.8 m -107.03 120.24 41.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.832 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -86.84 42.51 1.02 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -99.95 150.54 22.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.867 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.9 pt -131.33 154.79 41.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -103.76 102.98 12.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.441 HG11 ' CG1' ' A' ' 120' ' ' ILE . 83.8 t -97.95 112.84 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.24 173.7 15.37 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.479 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.01 63.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.439 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 42.1 mt -54.91 137.8 64.93 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.629 0.728 . . . . 0.0 111.152 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 163.99 36.25 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.644 2.229 . . . . 0.0 112.353 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.6 t-160 -68.99 -6.28 26.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.836 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 124' ' ' CYS . 19.6 t-20 -100.25 -64.22 1.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.461 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 43.7 t -35.13 126.57 0.56 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.75 -164.11 11.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -54.8 -66.24 0.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -42.54 -61.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.166 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 129' ' ' LEU . 9.5 mm-40 -49.42 -63.23 1.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.44 HD13 ' CE ' ' A' ' 144' ' ' MET . 44.9 mt -37.84 -55.16 1.22 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 63.8 mtp180 -56.11 -56.0 26.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.859 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -50.33 -44.34 54.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.563 ' CD2' HG12 ' A' ' 178' ' ' ILE . 6.4 t80 -74.03 -22.54 59.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.461 ' CD2' HD13 ' A' ' 159' ' ' ILE . 25.2 m-85 -105.32 15.8 26.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.5 ptmt -90.48 -37.79 13.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.92 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -60.47 -37.93 82.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -67.28 -30.01 69.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.85 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.63 -116.48 0.48 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.528 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 19.7 t -148.57 106.61 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.436 HG13 ' CG2' ' A' ' 159' ' ' ILE . 8.1 t -69.42 119.06 14.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.175 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 78.3 p -99.77 -37.57 9.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -134.03 141.31 47.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.876 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 94.0 t -127.74 93.62 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.17 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.7 t -89.42 134.41 28.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.44 ' CE ' HD13 ' A' ' 129' ' ' LEU . 8.3 mtp -135.96 133.39 37.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 57.5 mt -92.11 134.24 30.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.52 165.91 5.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.981 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 16.5 t0 -84.53 112.62 20.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.856 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.24 -59.98 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -40.87 -45.8 2.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 147' ' ' ASP . 23.7 mttp -75.75 -41.01 54.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 60.07 48.02 8.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.3 ttm180 -160.4 138.55 7.35 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.563 0.697 . . . . 0.0 110.9 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 116.35 4.52 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.718 2.279 . . . . 0.0 112.346 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.5 mtp180 -58.76 -55.36 36.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.62 39.37 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.4 p90 -170.4 160.95 7.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.876 0.369 . . . . 0.0 110.893 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -158.15 30.96 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -138.86 161.62 36.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.359 . . . . 0.0 110.893 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.461 HD13 ' CD2' ' A' ' 133' ' ' PHE . 8.6 mt -147.59 139.28 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.14 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.421 HG21 ' N ' ' A' ' 161' ' ' PHE . 41.1 m -109.21 140.02 43.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.449 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.8 m-85 -108.53 169.45 8.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -75.81 -34.55 60.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 34.6 m-20 -129.62 141.5 50.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -52.31 -45.14 65.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.914 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -40.68 -44.66 2.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.9 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.449 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 17.4 m -54.04 -41.91 68.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.401 ' CG1' ' HG3' ' A' ' 187' ' ' ARG . 38.5 t -58.53 -58.94 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.139 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -49.95 -42.87 49.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -55.23 -55.35 32.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.0 -56.57 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 98.4 t -48.06 -44.56 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.186 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -50.23 -51.53 43.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.914 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.2 mmm -62.59 -36.07 81.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.8 t-160 49.31 25.22 1.2 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 8.7 m-85 -170.13 145.99 2.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.491 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 46.9 m-70 -155.94 162.8 40.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -119.74 94.2 4.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . 0.563 HG12 ' CD2' ' A' ' 132' ' ' TYR . 44.8 mt -113.34 120.61 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.5 mmt 59.9 34.25 21.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.69 46.97 58.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -153.5 148.55 26.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 8.2 tptm -86.84 108.51 18.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.6 t -98.51 120.99 48.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.143 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -82.73 147.58 28.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 41.1 t -143.17 132.49 20.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.146 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mttp -137.06 136.71 38.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.401 ' HG3' ' CG1' ' A' ' 167' ' ' VAL . 34.9 ttt180 -52.45 123.16 10.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.97 17.0 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.126 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -114.69 144.04 31.13 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.66 0.743 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 127.8 15.05 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.703 2.269 . . . . 0.0 112.294 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 5.7 ttm105 -116.97 90.99 3.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.838 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 22.9 m-20 -139.91 161.47 37.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 99.0 p -45.54 168.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -100.97 126.26 47.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 36.0 p -150.79 130.56 13.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 19.9 t -71.0 -67.33 0.51 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.87 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 137.1 80.8 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.537 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -168.67 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.377 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -103.38 -2.26 27.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.848 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 32.3 t -99.47 -69.19 0.77 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.835 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.507 -179.965 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 85.9 p -82.9 149.7 26.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.857 0.361 . . . . 0.0 110.88 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 43.6 m -57.81 159.13 5.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.88 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 139.89 -154.45 23.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 83.9 p -99.05 133.81 42.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.872 0.367 . . . . 0.0 110.883 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.5 m -88.43 -54.96 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 174.2 162.85 26.61 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.5 t 45.77 40.9 6.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.884 0.373 . . . . 0.0 110.836 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 40.0 tttm -97.82 -35.4 10.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.3 m -149.96 170.73 18.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.871 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.433 ' O ' ' CG2' ' A' ' 160' ' ' THR . 0.8 OUTLIER -125.54 81.28 1.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.92 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt -127.67 141.13 51.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 18.1 pt -121.08 151.51 24.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.497 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 6.4 t80 -101.88 105.02 15.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.877 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.417 HG11 ' CG1' ' A' ' 120' ' ' ILE . 94.0 t -97.92 121.73 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.129 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -127.6 175.42 18.28 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.95 18.89 62.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.446 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 40.2 mt -65.76 136.83 95.98 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.639 0.733 . . . . 0.0 111.144 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.467 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 53.8 Cg_endo -69.81 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 0.0 112.344 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -75.29 1.62 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.444 ' C ' ' SD ' ' A' ' 179' ' ' MET . 27.7 t-20 -107.29 -23.1 12.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.467 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 13.5 t -80.48 128.45 33.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -130.8 176.83 18.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.5 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.42 ' C ' ' O ' ' A' ' 125' ' ' GLY . 30.5 tt0 -35.99 -61.01 0.51 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.909 0.385 . . . . 0.0 110.863 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 65.9 m -46.39 -60.15 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 35.8 mm-40 -49.98 -61.9 1.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.895 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.427 ' C ' ' O ' ' A' ' 128' ' ' GLU . 62.5 mt -35.73 -56.01 0.69 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.944 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 62.3 mtp180 -61.76 -55.03 34.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -44.34 -29.53 0.69 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.878 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.431 ' CD2' HG12 ' A' ' 178' ' ' ILE . 11.9 t80 -98.53 -27.4 14.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.935 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.553 ' CD2' HD12 ' A' ' 159' ' ' ILE . 21.4 m-85 -95.1 13.34 25.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptpt -93.93 -9.73 36.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 pttt -84.71 -36.5 21.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -65.02 -35.04 79.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.58 -102.14 0.15 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.461 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 40.9 t -157.95 105.73 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 21.2 t -66.18 119.24 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.14 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 14.4 p -99.09 -37.14 9.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.189 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -135.31 148.78 49.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.872 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 97.6 t -132.07 94.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.135 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.435 HG12 ' N ' ' A' ' 144' ' ' MET . 60.9 t -90.48 138.09 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.104 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.461 ' HE3' ' CB ' ' A' ' 153' ' ' PRO . 9.2 mtp -137.37 136.06 37.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 58.7 mt -97.66 135.27 32.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.11 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.467 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -173.57 164.58 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.91 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.4 t0 -83.05 112.73 20.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.65 -62.75 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.125 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -38.91 -42.96 0.9 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.431 ' N ' ' O ' ' A' ' 147' ' ' ASP . 70.0 mttt -79.44 -37.42 37.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 54.88 53.09 10.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.956 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.467 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 11.5 ttt180 -164.72 137.98 3.9 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.578 0.704 . . . . 0.0 110.894 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.461 ' CB ' ' HE3' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.71 116.99 4.81 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.338 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -59.89 -54.64 43.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.28 39.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -169.3 164.92 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.826 0.346 . . . . 0.0 110.91 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.71 -163.33 35.69 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -133.22 161.82 33.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.784 0.326 . . . . 0.0 110.94 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.553 HD12 ' CD2' ' A' ' 133' ' ' PHE . 10.2 mt -148.63 137.51 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.463 HG21 ' N ' ' A' ' 161' ' ' PHE . 32.8 m -106.15 143.14 34.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.463 ' N ' HG21 ' A' ' 160' ' ' THR . 39.2 m-85 -111.23 176.14 5.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.4 tt0 -77.67 -44.83 26.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.896 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . 0.469 ' CB ' ' HG2' ' A' ' 165' ' ' GLN . 0.9 OUTLIER -121.54 128.56 52.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -42.02 -23.77 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.469 ' HG2' ' CB ' ' A' ' 163' ' ' ASP . 5.4 pt20 -48.51 -53.4 18.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.921 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.456 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 5.1 m -49.26 -55.95 10.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.846 -179.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 53.3 t -37.68 -55.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.078 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . 0.426 ' OD1' ' C ' ' A' ' 168' ' ' ASP . 0.6 OUTLIER -62.13 -46.3 89.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.874 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -52.0 -52.51 50.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.49 -56.45 15.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.075 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 187' ' ' ARG . 43.2 t -44.63 -55.83 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -38.07 -67.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 83.4 mtp -48.38 -46.29 36.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 19.0 t-160 62.04 26.89 16.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 9.2 m-85 -171.31 150.83 2.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.855 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.4 m-70 -156.7 151.38 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.849 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -107.67 98.98 8.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.888 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . 0.431 HG12 ' CD2' ' A' ' 132' ' ' TYR . 71.0 mt -119.89 122.08 67.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' MET . . . . . 0.444 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 12.4 mtt 54.67 41.58 31.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.05 42.65 99.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.4 ' HG3' ' N ' ' A' ' 182' ' ' LYS . 15.2 tptp -148.92 148.65 30.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.826 0.346 . . . . 0.0 110.923 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . 0.4 ' N ' ' HG3' ' A' ' 181' ' ' LYS . 7.6 tppt? -88.34 107.21 18.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.906 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.45 112.38 27.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.174 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -74.87 149.48 39.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 46.3 t -147.13 136.09 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mtmm -139.89 151.66 45.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.893 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.466 ' N ' HG23 ' A' ' 171' ' ' VAL . 25.1 ttp180 -65.25 125.1 23.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.915 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.09 9.56 6.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.084 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -89.82 150.07 43.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.63 0.729 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 159.82 51.97 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.691 2.261 . . . . 0.0 112.33 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 3.7 mmp_? -56.04 154.27 7.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.421 ' OD1' ' N ' ' A' ' 192' ' ' ASP . 0.4 OUTLIER -70.87 147.14 49.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 7.7 t -133.77 146.05 50.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.876 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.8 mmmm -41.31 152.97 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.891 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 16.7 t -159.52 163.72 34.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 48.9 m -102.71 107.21 18.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 79.56 -169.41 53.49 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.77 -46.86 1.07 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.65 2.233 . . . . 0.0 112.401 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 4.4 m -110.89 169.75 8.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 34.9 p -146.98 177.24 9.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.265 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.995 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.3 t -164.95 132.38 3.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 110.873 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.0 t -78.21 109.62 12.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -95.73 88.23 1.05 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 53.3 p -41.54 126.97 3.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.895 0.379 . . . . 0.0 110.827 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 18.7 t -118.98 -56.53 2.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -67.96 -174.38 8.06 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.481 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.7 t -95.87 -52.96 3.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.939 0.399 . . . . 0.0 110.876 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.4 tmmm? -161.7 119.73 2.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.904 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 49.5 p -155.3 132.02 10.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.869 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -116.34 39.53 3.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.893 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -88.45 146.6 25.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . 0.467 ' CG2' HG22 ' A' ' 167' ' ' VAL . 21.1 pt -132.29 146.64 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.141 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -89.74 111.98 23.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.928 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 83.6 t -108.72 114.88 47.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.103 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -119.24 -173.29 15.47 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.69 24.14 31.56 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.463 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 63.0 mt -69.48 138.19 88.76 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.668 0.747 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.463 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.73 170.33 16.79 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.731 2.287 . . . . 0.0 112.35 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -86.91 24.17 1.57 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -133.63 -33.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.415 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.9 t -66.9 117.79 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.894 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.47 -175.73 16.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.457 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -42.69 -56.17 3.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 0.0 110.856 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 86.7 m -51.3 -57.69 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 mm-40 -51.73 -52.95 44.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 85.9 mt -44.54 -48.18 10.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.964 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 69.5 mtt180 -69.66 -55.07 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -45.45 -23.98 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.549 ' CD2' HG12 ' A' ' 178' ' ' ILE . 4.3 t80 -103.68 -35.2 8.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.55 ' CE2' HD11 ' A' ' 159' ' ' ILE . 23.7 m-85 -90.33 16.22 9.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -95.23 -23.64 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -71.19 -35.23 71.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.453 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 34.9 m-85 -68.41 -32.59 72.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.77 -111.56 0.29 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.476 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 75.7 t -146.35 110.24 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.837 0.351 . . . . 0.0 111.152 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 93.0 t -72.89 106.05 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.146 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.8 p -79.46 -39.71 31.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -144.73 156.43 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.8 102.56 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.111 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.453 HG12 ' N ' ' A' ' 144' ' ' MET . 60.3 t -84.5 143.53 11.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.121 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.453 ' N ' HG12 ' A' ' 143' ' ' VAL . 4.5 mtt -145.44 139.03 26.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 75.4 mt -107.9 136.22 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.15 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.464 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.91 165.34 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.934 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.9 t0 -86.19 114.29 22.9 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.87 -61.52 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 28.3 tt0 -36.08 -46.01 0.47 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 27.6 mttp -80.08 -40.29 27.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 60.0 48.27 8.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.1 ttp180 -158.98 138.8 8.65 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.609 0.719 . . . . 0.0 110.884 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.451 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.4 Cg_endo -69.77 109.92 2.43 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.271 . . . . 0.0 112.334 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.8 mtt180 -50.17 -50.6 48.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.843 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 159.89 39.89 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -169.0 161.98 10.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.882 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.429 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.15 -150.2 18.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.469 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.429 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 11.3 m-85 -147.72 169.82 18.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.882 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.55 HD11 ' CE2' ' A' ' 133' ' ' PHE . 23.0 mt -151.13 141.81 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.103 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.2 m -106.95 142.27 36.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.15 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 50.1 m-85 -113.83 169.35 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -77.33 -38.37 50.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -130.05 136.57 49.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 165' ' ' GLN . 8.6 tm-20 -45.67 -45.37 14.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.924 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 164' ' ' GLU . 26.3 tt0 -35.29 -47.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 42.9 m -53.15 -54.07 41.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.847 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.467 HG22 ' CG2' ' A' ' 115' ' ' ILE . 53.3 t -43.88 -45.46 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -65.65 -45.49 82.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . 0.453 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 44.3 mm-40 -48.48 -45.42 36.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -76.43 -59.79 2.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 86.4 t -43.12 -51.4 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.14 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -39.71 -63.2 0.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.891 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' MET . . . . . 0.43 ' HE1' ' CE1' ' A' ' 176' ' ' HIS . 15.3 mtm -59.31 -38.33 80.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 15.0 t-160 59.27 25.46 14.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.473 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.9 m-85 -169.82 153.14 4.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.836 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.473 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 62.8 m-70 -159.2 159.42 34.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -116.49 90.31 3.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . 0.549 HG12 ' CD2' ' A' ' 132' ' ' TYR . 51.3 mt -105.69 111.78 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 7.4 mtt 61.84 42.33 10.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.41 47.13 87.57 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.453 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 12.2 tppt? -151.47 140.29 20.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -84.83 102.94 13.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.6 t -92.99 132.86 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.169 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -92.54 144.95 24.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.877 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 32.6 t -141.15 131.34 26.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -143.45 141.53 30.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 13.2 mtm105 -45.79 115.93 1.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.826 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -76.19 128.64 35.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.076 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -48.42 153.47 1.32 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 131.5 21.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.71 2.274 . . . . 0.0 112.366 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 26.2 ttm180 -75.88 100.75 4.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.849 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -115.98 87.14 2.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.7 t -131.29 121.0 23.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.822 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 2.4 ttmm -104.06 156.76 17.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.898 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 50.9 m -149.87 176.91 10.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 51.6 p -117.71 -40.97 2.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.851 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -171.25 -148.79 6.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -0.64 7.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.659 2.239 . . . . 0.0 112.316 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 37.2 m -50.57 135.33 23.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 69.7 m -91.42 -53.14 4.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 179.986 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.413 ' O ' ' C ' ' A' ' 104' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 103' ' ' GLY . 20.9 m -36.45 123.09 0.78 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.911 0.386 . . . . 0.0 110.843 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.8 p -41.6 126.14 2.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -117.7 148.51 18.67 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.452 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.9 m -79.12 90.65 4.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.854 0.359 . . . . 0.0 110.847 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 74.4 p -47.14 169.07 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 158.08 -83.23 0.14 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.486 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 7.4 t -79.4 111.12 15.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.89 0.376 . . . . 0.0 110.807 -179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.3 ttmt -105.66 110.59 22.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.86 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.4 p -101.92 108.06 19.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.835 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -113.14 39.58 2.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttpp -92.97 140.99 28.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 28.2 pt -124.49 151.15 29.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.143 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -98.44 108.37 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.912 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 95.4 t -101.21 121.8 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.15 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.7 175.72 18.58 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.67 13.34 60.92 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.467 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 31.2 mt -61.87 137.15 95.26 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.718 . . . . 0.0 111.142 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.467 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.74 163.52 37.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.691 2.261 . . . . 0.0 112.344 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -77.44 1.35 19.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -106.65 -23.72 12.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.467 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 14.0 t -79.85 133.39 36.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.77 -165.59 11.79 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -52.57 -68.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 34.9 m -38.69 -67.8 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.13 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 17.5 mp0 -38.68 -61.33 0.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 73.7 mt -40.68 -46.56 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.909 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.42 ' NH1' ' HB3' ' A' ' 130' ' ' ARG . 14.3 mtp-105 -70.0 -52.3 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -51.92 -23.94 5.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -100.24 -30.21 12.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.524 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.1 m-85 -94.24 13.75 22.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -94.03 -13.75 26.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.0 pttm -79.83 -37.54 34.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -68.62 -33.9 74.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.98 -116.33 0.38 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.474 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 36.1 t -146.16 106.31 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.879 0.371 . . . . 0.0 111.152 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 39.0 t -68.12 115.26 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.094 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 41.8 p -95.94 -39.0 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -133.59 144.06 49.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.34 94.44 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.129 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.0 t -88.7 141.52 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.116 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.446 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 7.6 mtt -140.58 137.1 33.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.9 mt -99.89 126.81 53.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -167.07 165.42 15.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.917 -179.984 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.441 ' O ' ' C ' ' A' ' 148' ' ' ALA . 19.2 t0 -85.33 113.58 21.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.44 -59.13 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.077 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -41.39 -42.88 2.38 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.92 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.427 ' N ' ' O ' ' A' ' 147' ' ' ASP . 19.4 mttp -79.25 -41.08 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.01 50.14 6.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.0 ttm-85 -162.88 138.02 5.2 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.598 0.713 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.446 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.76 112.12 2.99 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.748 2.298 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 67.5 mtp180 -52.65 -57.03 11.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.845 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 169.5 40.54 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.422 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.5 p90 -171.69 165.54 6.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.856 0.36 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.98 -153.97 24.61 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 59.6 m-85 -143.94 160.6 40.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.915 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.524 HD12 ' CD2' ' A' ' 133' ' ' PHE . 7.8 mt -148.42 135.93 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.459 HG23 ' N ' ' A' ' 161' ' ' PHE . 41.9 m -103.87 142.98 33.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.459 ' N ' HG23 ' A' ' 160' ' ' THR . 49.1 m-85 -112.22 168.39 9.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 58.4 tt0 -69.75 -38.65 76.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -131.1 143.68 50.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 165' ' ' GLN . 11.4 tt0 -50.66 -44.31 57.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.417 ' C ' ' O ' ' A' ' 164' ' ' GLU . 34.5 tt0 -36.1 -52.67 0.78 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.1 m -46.37 -55.68 6.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 40.6 t -38.48 -56.57 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.13 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -52.87 -59.09 4.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -39.12 -38.3 0.47 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.931 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.6 -65.37 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.111 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 174' ' ' HIS . 84.1 t -43.98 -55.41 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.129 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.451 ' C ' ' O ' ' A' ' 171' ' ' VAL . 0.7 OUTLIER -34.48 -59.48 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.865 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 60.1 mtp -65.33 -35.18 80.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.515 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.6 t-160 54.69 27.39 8.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.7 m-85 -167.89 152.21 6.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 86.1 m-70 -159.8 147.61 16.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.854 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -103.73 99.24 9.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 58.0 mt -120.66 124.35 72.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.165 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.4 mmt 57.03 34.89 25.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.814 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 67.15 48.84 57.24 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.45 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 5.1 tmtm? -161.01 150.21 16.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . 0.45 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -83.02 126.46 32.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.5 t -114.19 110.87 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.121 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -70.94 143.97 50.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 40.0 t -143.34 131.31 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.161 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.0 mmmt -145.61 144.06 30.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.933 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 14.0 mtp180 -48.17 125.43 9.26 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.73 -179.68 7.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.109 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -99.88 149.79 36.27 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.641 0.734 . . . . 0.0 110.863 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 141.51 45.43 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.56 -65.2 1.04 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.838 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 34.1 t0 -87.0 107.17 18.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 85.1 p -92.87 112.03 23.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.858 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.49 140.53 29.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.912 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 77.6 p -90.96 172.43 8.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.853 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 45.9 m -108.76 172.22 6.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -79.11 -78.29 0.86 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 126.48 13.36 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.721 2.281 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 3.8 m -67.99 -48.21 66.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 3.9 t -96.61 147.55 23.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.89 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.474 -179.963 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 51.4 p -105.35 171.62 7.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.883 0.373 . . . . 0.0 110.859 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 17.3 m -112.67 99.69 8.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.859 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -111.83 112.31 3.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.525 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 69.5 m 62.86 41.3 8.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 m -110.53 81.76 1.49 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 136.61 148.95 5.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.462 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.3 t -110.07 164.79 12.28 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.99 0.424 . . . . 0.0 110.845 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.2 mtmm 50.55 50.24 19.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.929 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 m -102.31 -23.18 14.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 58.71 40.6 23.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 4.4 ttpm? -104.12 143.7 32.57 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 22.5 pt -125.75 155.37 35.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -103.38 104.48 14.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 79.1 t -99.4 118.85 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -124.54 -172.53 13.59 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.477 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.28 17.78 19.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.479 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.47 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 51.4 mt -64.7 138.31 97.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.68 0.752 . . . . 0.0 111.101 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.5 Cg_endo -69.69 165.62 30.27 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.485 ' ND1' ' NH2' ' A' ' 152' ' ' ARG . 63.9 m-70 -80.58 13.91 2.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.424 ' C ' ' HG3' ' A' ' 179' ' ' MET . 3.3 m120 -122.02 -25.1 5.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.44 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -74.74 133.48 42.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.28 -161.06 10.09 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.508 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.13 -63.52 1.23 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.942 0.401 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 64.1 m -44.49 -59.17 2.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.142 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.44 ' O ' ' C ' ' A' ' 129' ' ' LEU . 57.1 mm-40 -50.35 -63.91 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 128' ' ' GLU . 50.0 mt -34.91 -52.39 0.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.447 ' O ' ' N ' ' A' ' 134' ' ' LYS . 62.7 mtp180 -66.19 -54.15 28.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.864 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 44.2 mm-40 -48.16 -26.5 1.92 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.486 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.7 t80 -100.79 -21.79 15.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -105.79 14.45 28.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.447 ' N ' ' O ' ' A' ' 130' ' ' ARG . 15.5 pttp -94.81 -17.56 22.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.37 -37.98 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -65.17 -34.36 78.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.17 -114.61 0.31 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.43 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 37.5 t -148.1 109.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.834 0.35 . . . . 0.0 111.172 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 47.3 t -74.55 105.99 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.0 p -81.21 -33.05 33.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.12 153.2 37.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 95.6 t -131.34 105.97 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 144' ' ' MET . 49.0 t -91.73 143.16 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.466 ' N ' HG13 ' A' ' 143' ' ' VAL . 7.1 mtt -143.34 133.71 24.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.887 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -97.09 139.82 18.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.449 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -175.05 165.88 3.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.926 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.432 ' O ' ' C ' ' A' ' 148' ' ' ALA . 35.4 t0 -86.67 110.07 19.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.432 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.23 -57.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' ALA . 30.7 tt0 -37.06 -45.35 0.59 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.91 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.33 -37.14 20.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 60.05 52.79 4.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.485 ' NH2' ' ND1' ' A' ' 122' ' ' HIS . 2.1 ttt85 -160.86 138.9 7.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.646 0.736 . . . . 0.0 110.869 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.456 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 117.86 5.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.669 2.246 . . . . 0.0 112.355 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -61.1 -54.27 46.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.14 41.49 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.536 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -173.13 162.46 4.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.19 -153.47 23.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 53.9 m-85 -139.96 164.5 29.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.431 HG23 ' N ' ' A' ' 160' ' ' THR . 21.3 mt -147.13 139.7 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.114 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.438 HG23 ' N ' ' A' ' 161' ' ' PHE . 57.0 m -105.08 142.98 33.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.438 ' N ' HG23 ' A' ' 160' ' ' THR . 46.8 m-85 -115.86 166.35 12.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.903 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -67.39 -42.77 82.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -131.14 141.06 50.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.864 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 165' ' ' GLN . 30.5 tt0 -46.04 -44.39 15.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 164' ' ' GLU . 23.8 tp60 -36.43 -55.67 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.413 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 16.4 m -44.31 -52.41 7.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 73.4 t -44.65 -54.86 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -52.82 -50.67 63.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.1 mm100 -45.86 -50.48 14.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.918 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.06 -53.86 15.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.094 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 172' ' ' ASN . 70.1 t -44.31 -61.79 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.107 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 171' ' ' VAL . 62.7 t30 -35.61 -56.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 1.3 tpt -58.28 -41.51 84.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.92 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.9 t-160 51.15 30.75 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.551 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 4.9 m-85 -173.35 150.62 1.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 89.1 m-70 -161.9 156.97 23.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -111.04 102.36 10.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 31.4 mt -129.06 134.91 63.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.15 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' MET . . . . . 0.424 ' HG3' ' C ' ' A' ' 123' ' ' ASN . 9.8 mmt 54.83 30.55 13.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.63 45.76 65.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.408 ' NZ ' ' HA ' ' A' ' 121' ' ' PRO . 19.9 ttmt -160.15 161.93 33.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.909 0.385 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.62 125.57 34.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.6 t -110.35 115.02 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.157 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -77.32 148.32 35.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 41.9 t -146.89 133.12 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.4 mttm -139.69 169.75 17.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.402 ' HG3' ' CG2' ' A' ' 171' ' ' VAL . 13.9 mtp180 -78.3 117.25 19.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -86.0 16.89 3.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.1 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -123.47 152.46 64.8 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.612 0.72 . . . . 0.0 110.901 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 165.1 32.12 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.689 2.259 . . . . 0.0 112.341 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.44 ' O ' ' C ' ' A' ' 192' ' ' ASP . 2.4 tmm_? -70.01 132.04 45.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.44 ' C ' ' O ' ' A' ' 191' ' ' ARG . 26.2 t70 -35.17 148.28 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.858 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.2 m -98.02 120.53 38.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.851 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -75.45 138.67 41.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.906 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.9 t -132.96 153.88 51.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.798 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 39.6 t -116.33 150.95 36.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.893 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 116.81 141.6 7.09 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.68 117.38 5.05 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.72 2.28 . . . . 0.0 112.315 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 67.0 m -131.64 86.0 2.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.8 m -69.97 -50.81 38.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.491 -179.97 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.416 ' O ' ' C ' ' A' ' 104' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 105' ' ' SER . 33.7 m -36.6 -45.9 0.54 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.893 0.378 . . . . 0.0 110.855 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 104' ' ' SER . 9.7 m -35.21 113.31 0.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -114.75 101.29 1.06 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.518 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.3 t -98.87 38.29 1.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.91 0.386 . . . . 0.0 110.897 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 64.8 m -74.85 82.6 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.832 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 144.23 114.31 0.94 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.522 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.9 t -63.16 177.75 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 110.837 -179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -83.23 -41.69 18.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.2 t -50.76 108.8 0.26 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 m-20 -86.0 50.51 1.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.864 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -98.33 142.38 30.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 30.1 pt -125.24 153.05 32.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.09 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.411 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 30.8 t80 -98.97 105.53 17.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.46 ' CG2' HG23 ' A' ' 185' ' ' VAL . 94.4 t -101.92 114.08 40.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.111 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.06 177.02 16.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.531 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.59 13.26 60.62 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.464 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 29.7 mt -61.86 137.14 95.24 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.473 ' HG2' ' CB ' ' A' ' 124' ' ' CYS . 54.4 Cg_endo -69.72 165.41 31.02 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.354 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.7 m-70 -78.68 0.65 25.76 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.827 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.416 ' ND2' ' HB2' ' A' ' 121' ' ' PRO . 0.2 OUTLIER -106.04 -23.8 12.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.889 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.473 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.4 t -81.16 133.1 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.73 -166.81 11.72 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.431 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.452 ' HG2' ' CZ ' ' A' ' 130' ' ' ARG . 12.4 tt0 -54.21 -59.96 3.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.874 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 35.9 m -45.78 -61.78 1.58 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.17 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 129' ' ' LEU . 53.8 mm-40 -47.91 -64.7 0.72 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.421 ' C ' ' O ' ' A' ' 128' ' ' GLU . 62.6 mt -36.22 -58.46 0.68 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.452 ' CZ ' ' HG2' ' A' ' 126' ' ' GLU . 59.7 mtm180 -58.6 -51.06 71.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.3 mm-40 -57.29 -17.42 11.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.487 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 21.5 t80 -108.0 -17.45 14.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.401 ' N ' ' O ' ' A' ' 129' ' ' LEU . 13.3 m-85 -104.18 -6.35 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.885 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.5 pttp -76.58 -21.26 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -69.91 -36.32 75.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.869 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -70.55 -32.25 69.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.75 -111.25 0.26 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.545 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.0 t -150.05 108.12 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.912 0.387 . . . . 0.0 111.117 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 74.0 t -72.53 104.91 2.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.14 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -81.29 -36.8 29.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.146 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -141.33 154.76 45.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.06 105.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 42.9 t -92.83 137.12 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.46 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 5.2 mtt -137.7 136.79 37.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.904 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 62.7 mt -102.1 135.0 41.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.437 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.17 165.44 4.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.973 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 150' ' ' LYS . 48.5 t0 -81.92 113.64 19.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.871 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -37.31 -41.85 0.44 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.09 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -42.78 86.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 147' ' ' ASP . 3.0 mptp? -80.45 -31.41 37.45 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 52.3 44.01 30.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.4 ttm-85 -155.51 138.68 10.77 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.672 0.749 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.46 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.4 Cg_endo -69.77 111.01 2.7 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.655 2.237 . . . . 0.0 112.37 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.406 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 36.0 mtt180 -52.34 -53.08 49.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.73 40.73 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.406 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 35.6 p90 -169.29 163.85 10.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.931 0.396 . . . . 0.0 110.866 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 161.67 -157.87 29.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.506 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.411 ' CD2' ' HA ' ' A' ' 116' ' ' PHE . 12.5 m-85 -139.51 169.98 16.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 12.6 mt -152.68 136.68 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 19.2 m -105.03 135.9 45.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.499 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 35.0 m-85 -104.67 174.11 6.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.82 -40.32 48.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -127.55 137.54 52.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 165' ' ' GLN . 16.1 tm-20 -44.64 -45.71 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.0 tp60 -36.99 -55.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.904 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.499 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 13.1 m -45.58 -49.34 14.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 71.0 t -48.81 -47.17 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.091 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -62.88 -49.35 75.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 31.5 mm-40 -47.82 -48.5 30.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -74.33 -43.95 54.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.464 HG23 ' N ' ' A' ' 187' ' ' ARG . 25.6 t -55.36 -62.35 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 171' ' ' VAL . 2.1 t-20 -36.76 -55.67 0.87 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 98.2 mtp -55.12 -44.0 74.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.879 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.523 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.4 t-160 58.31 25.14 12.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.885 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.523 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.3 m-85 -169.65 152.62 4.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.85 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.487 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 85.3 m-70 -158.5 154.15 26.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.806 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.63 93.8 4.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.856 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 59.2 mt -110.39 115.43 49.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 11.9 mtp 60.87 36.13 19.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.898 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.79 50.49 35.52 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.492 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.6 tmtt? -158.01 146.96 19.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.864 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . 0.457 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.1 OUTLIER -85.03 117.12 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.94 179.838 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.6 t -106.31 118.88 54.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.15 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -76.0 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.46 HG23 ' CG2' ' A' ' 117' ' ' VAL . 44.6 t -146.65 127.4 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt -135.76 146.45 47.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.464 ' N ' HG23 ' A' ' 171' ' ' VAL . 19.7 ttp180 -55.69 108.93 0.49 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -67.49 142.21 56.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.135 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -85.64 152.57 57.35 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.674 0.75 . . . . 0.0 110.896 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 119.67 6.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.713 2.275 . . . . 0.0 112.354 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 13.2 mmm180 -73.51 92.65 1.91 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -166.44 120.96 1.12 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 54.2 p -90.64 48.89 1.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.825 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 28.5 mtmt 55.59 43.84 27.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.936 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 11.8 t -44.41 124.19 3.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.892 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 29.9 t -99.1 121.37 40.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.841 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -133.91 145.34 17.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.456 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 104.93 1.4 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.722 2.281 . . . . 0.0 112.303 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.2 m -164.72 127.12 2.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 29.8 m -113.84 138.38 50.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.492 -179.973 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 t 50.47 42.2 26.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.871 0.367 . . . . 0.0 110.829 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 m -68.77 97.9 0.86 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -98.9 108.64 3.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.504 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 5.0 t -75.0 147.12 41.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.878 0.37 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 65.1 p -93.74 -42.51 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.889 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 53.84 -147.76 19.37 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.501 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 78.7 p -135.23 143.98 46.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.983 0.421 . . . . 0.0 110.847 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 11.7 pttt -59.25 99.73 0.06 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.945 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.1 m -149.46 -175.39 4.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.889 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -80.74 55.34 2.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -110.84 150.86 28.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.9 pt -131.85 154.05 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.135 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 10.2 t80 -102.73 103.42 13.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 86.2 t -97.76 115.87 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.97 174.24 16.04 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.95 26.02 71.08 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.485 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 52.7 mt -73.17 138.22 78.84 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.634 0.731 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.77 158.76 55.84 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.72 3.43 6.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -106.89 -37.14 6.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 44.0 t -67.68 136.95 55.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.66 179.54 17.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 125' ' ' GLY . 24.0 tt0 -35.75 -69.68 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.4 m -40.84 -60.0 1.28 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.159 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' LEU . 49.1 mm-40 -44.74 -64.77 0.63 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.444 ' HB3' ' CD1' ' A' ' 159' ' ' ILE . 65.7 mt -35.92 -47.04 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 133' ' ' PHE . 36.7 mtm180 -67.38 -60.75 2.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.866 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -41.81 -25.69 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 11.6 t80 -102.77 -24.18 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.565 ' CD2' HD11 ' A' ' 159' ' ' ILE . 12.8 m-85 -99.74 16.3 24.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.923 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 3.9 ptpp? -95.31 -14.79 23.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -79.09 -37.68 38.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.896 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -67.65 -25.06 65.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.06 -114.69 0.48 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 96.3 t -145.73 111.56 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.097 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 15.6 t -74.53 114.46 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 42.8 p -93.01 -37.29 12.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.75 152.72 45.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -135.02 100.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.452 HG11 ' N ' ' A' ' 144' ' ' MET . 81.4 t -84.98 143.2 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.109 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.452 ' N ' HG11 ' A' ' 143' ' ' VAL . 6.2 mtt -144.29 132.61 21.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 68.4 mt -98.49 134.64 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -172.84 164.56 5.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.96 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.425 ' O ' ' N ' ' A' ' 150' ' ' LYS . 24.3 t0 -85.35 115.6 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.422 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.65 -57.32 0.65 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -42.67 -41.9 3.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 147' ' ' ASP . 16.3 ttmt -80.14 -41.18 25.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 60.08 50.41 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 8.2 ttp85 -164.99 138.93 4.0 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.618 0.723 . . . . 0.0 110.843 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.433 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.77 109.64 2.36 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.734 2.289 . . . . 0.0 112.357 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 32.5 mtp180 -49.58 -51.43 37.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 162.05 39.46 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.499 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -171.2 159.83 6.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.82 -155.08 25.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -139.62 161.45 37.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.914 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.565 HD11 ' CD2' ' A' ' 133' ' ' PHE . 14.7 mt -145.0 141.56 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.467 ' N ' HG21 ' A' ' 159' ' ' ILE . 42.5 m -109.43 141.03 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.173 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.492 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 51.9 m-85 -110.42 177.95 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -80.3 -40.31 27.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.871 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -127.85 146.41 50.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.807 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 165' ' ' GLN . 43.1 tp10 -51.58 -47.05 63.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.0 tt0 -36.63 -44.97 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.492 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 14.6 m -53.49 -47.93 69.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.883 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 37.6 t -51.3 -46.95 34.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.173 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -51.03 -65.73 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.867 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -42.95 -53.58 4.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -52.04 -45.48 64.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.045 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.465 ' O ' ' N ' ' A' ' 174' ' ' HIS . 93.5 t -70.0 -63.88 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.109 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 171' ' ' VAL . 8.3 m-20 -34.16 -43.99 0.17 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 5.2 ttt -68.36 -47.27 67.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.54 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 12.0 t-160 56.85 27.22 12.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.824 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.54 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.0 m-85 -174.18 151.45 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.459 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 72.0 m-70 -158.87 161.49 36.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -117.0 87.15 2.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 63.7 mt -106.61 126.41 62.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.8 mmt 52.36 40.12 28.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.69 47.67 87.34 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.403 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 2.5 tmtt? -155.07 146.93 23.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.808 0.337 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . 0.403 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 6.2 tptm -81.18 117.38 21.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.888 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.9 t -109.41 120.55 60.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -80.45 153.47 28.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 41.4 t -149.48 130.96 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.106 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -141.46 144.26 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.91 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.429 ' N ' HG23 ' A' ' 171' ' ' VAL . 8.7 mtm180 -45.93 124.44 5.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.861 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.31 11.97 6.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -82.07 151.2 66.42 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.616 0.722 . . . . 0.0 110.9 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.7 127.9 15.32 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.706 2.271 . . . . 0.0 112.374 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 24.4 mmt180 -75.91 100.99 5.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -174.87 172.49 2.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 95.9 p -100.69 114.11 27.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.4 ptpp? -79.9 173.07 12.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 3.0 m -118.41 -58.13 2.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.906 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 46.9 t -144.97 117.98 8.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.864 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -98.56 -148.54 23.65 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 112.91 3.22 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.653 2.235 . . . . 0.0 112.359 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 19.8 m -56.0 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 4.2 t -39.47 149.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.809 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.491 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.1 p -122.95 91.09 3.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.914 0.388 . . . . 0.0 110.832 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 49.2 m -117.96 83.99 2.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.78 -104.06 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.533 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.0 p -139.99 139.07 35.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.899 0.38 . . . . 0.0 110.855 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -158.05 175.95 13.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -57.18 -175.26 0.31 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 72.7 p -118.49 -35.25 3.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.965 0.412 . . . . 0.0 110.88 -179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.82 146.92 2.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 70.6 p -99.3 114.92 28.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.869 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -90.64 40.2 1.01 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.9 ttpt -97.01 139.1 33.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 20.0 pt -123.42 154.59 29.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.082 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -99.65 103.65 15.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 93.2 t -100.41 111.7 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.14 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.02 -173.05 15.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.506 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.42 12.81 14.1 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.481 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.47 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 54.7 mt -57.3 138.42 80.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.653 0.74 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.9 Cg_endo -69.76 172.42 12.67 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.35 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.449 ' O ' ' NH2' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -85.0 17.89 2.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.823 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -128.29 -29.8 2.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.866 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.44 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -68.06 128.77 37.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.53 173.11 21.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.452 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.444 ' C ' ' O ' ' A' ' 125' ' ' GLY . 29.9 tt0 -34.34 -65.87 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.873 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 99.7 m -40.85 -61.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 129' ' ' LEU . 5.5 mp0 -54.31 -60.58 3.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 59.9 mt -34.39 -45.92 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 26.6 mtt180 -70.38 -55.75 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -46.5 -24.75 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.542 ' CD2' HG12 ' A' ' 178' ' ' ILE . 5.1 t80 -100.95 -29.78 12.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.564 ' CE2' HD13 ' A' ' 159' ' ' ILE . 19.7 m-85 -96.17 15.45 20.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.3 ptpt -95.27 -25.07 16.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.906 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.1 pttm -69.44 -38.83 77.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.867 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -66.02 -31.36 72.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -174.94 -115.24 0.4 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.5 t -146.13 106.42 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.882 0.373 . . . . 0.0 111.088 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 22.9 t -71.22 109.4 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 20.1 p -85.92 -39.78 16.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -139.84 151.98 46.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.9 t -134.01 102.46 4.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.137 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 158' ' ' PHE . 98.6 t -87.33 145.27 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 6.7 mtt -145.58 133.75 21.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.816 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.38 139.63 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.456 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.88 167.03 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 180.0 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.4 t0 -87.16 112.49 22.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.891 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.09 -60.0 0.34 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -39.38 -44.69 1.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 21.1 tttm -79.43 -40.13 30.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.92 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 60.05 45.08 12.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.456 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.8 ttt180 -155.37 138.21 10.48 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.654 0.74 . . . . 0.0 110.848 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 116.02 4.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.675 2.25 . . . . 0.0 112.371 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 41.6 mtp180 -58.67 -56.87 16.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.03 42.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.473 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -173.23 158.17 3.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.92 0.391 . . . . 0.0 110.866 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -151.44 19.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.489 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . 0.4 ' O ' ' O ' ' A' ' 143' ' ' VAL . 86.7 m-85 -138.36 164.69 28.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.823 0.344 . . . . 0.0 110.894 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.564 HD13 ' CE2' ' A' ' 133' ' ' PHE . 19.5 mt -148.31 134.12 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 17.9 m -102.34 143.13 32.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.159 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.524 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 41.5 m-85 -113.19 174.46 5.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.825 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -74.32 -38.76 63.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -135.17 151.38 50.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 165' ' ' GLN . 23.3 tt0 -51.9 -50.69 60.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.441 ' C ' ' O ' ' A' ' 164' ' ' GLU . 31.6 tp60 -34.54 -54.83 0.54 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.524 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 18.6 m -41.54 -58.71 1.83 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.86 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 62.2 t -42.27 -54.87 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.105 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 169' ' ' GLN . 27.5 t0 -47.14 -62.53 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 168' ' ' ASP . 49.1 mt-30 -36.98 -51.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.882 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.79 -67.55 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.448 ' O ' ' C ' ' A' ' 172' ' ' ASN . 98.8 t -39.36 -58.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.9 t30 -34.44 -56.53 0.52 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 85.3 mtp -61.55 -45.02 95.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 62.01 25.97 15.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.3 m-85 -172.85 147.5 1.71 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -156.62 164.56 38.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.87 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -118.76 90.96 3.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . 0.542 HG12 ' CD2' ' A' ' 132' ' ' TYR . 67.9 mt -111.06 119.23 59.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.151 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.5 mmt 60.07 39.63 19.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 54.64 32.69 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.436 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 7.7 tppt? -163.23 145.51 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.367 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 11.7 tptt -82.54 109.0 16.36 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.902 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.07 127.46 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -87.65 140.09 29.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 25.4 t -139.2 136.33 41.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 24.6 mtmt -144.71 175.0 10.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.866 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 8.4 mtp180 -81.17 120.39 24.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.98 174.92 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -97.7 153.45 38.27 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.611 0.72 . . . . 0.0 110.944 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 0.0 6.29 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.663 2.242 . . . . 0.0 112.355 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? 54.93 48.36 20.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.905 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.421 ' O ' ' CG ' ' A' ' 192' ' ' ASP . 0.6 OUTLIER -119.31 116.54 26.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.865 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 22.1 t -117.47 88.15 2.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.834 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 32.7 tttp 40.59 41.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.918 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 1.4 t -64.03 102.24 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.886 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 2.1 t -108.16 115.93 31.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.829 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -162.8 -157.72 9.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 97.0 0.61 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.706 2.271 . . . . 0.0 112.367 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 80.7 p -106.31 43.96 1.1 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.825 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 64.3 m -56.63 157.17 5.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.869 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 179.99 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.2 t -73.05 87.46 1.37 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.889 0.376 . . . . 0.0 110.878 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -79.91 94.83 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -113.76 127.11 7.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.496 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 61.6 m -99.24 -56.99 2.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.92 0.391 . . . . 0.0 110.835 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 9.3 t -45.84 -60.71 2.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -48.79 -60.8 5.69 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.527 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 89.9 p -97.38 112.68 24.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.965 0.412 . . . . 0.0 110.896 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 4.0 mtmp? -90.08 130.23 36.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 7.3 t -124.72 126.54 45.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 -87.47 43.14 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -89.58 142.55 27.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . 0.401 ' CG2' HG12 ' A' ' 167' ' ' VAL . 18.7 pt -128.12 148.04 32.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.151 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -93.96 114.61 26.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 81.2 t -111.1 117.16 54.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.115 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.61 176.7 16.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.519 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.442 ' O ' ' NZ ' ' A' ' 181' ' ' LYS . . . 64.39 24.72 69.41 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 57.0 mt -71.87 138.48 82.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.617 0.722 . . . . 0.0 111.142 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.4 Cg_endo -69.78 165.35 31.31 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -78.96 10.99 2.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.415 ' C ' ' HE2' ' A' ' 179' ' ' MET . 0.6 OUTLIER -117.87 -34.48 4.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 -179.944 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.461 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.1 t -68.96 121.43 16.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -121.68 -169.29 13.59 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.98 -59.1 3.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -47.24 -61.19 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.127 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.47 ' HG3' ' CE ' ' A' ' 179' ' ' MET . 65.2 mm-40 -47.67 -65.14 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 40.7 mt -34.03 -49.83 0.36 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.944 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -68.72 -53.99 18.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 23.0 mm-40 -46.2 -23.73 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.509 ' CZ ' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -103.56 -34.65 8.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.02 16.86 8.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -95.29 -23.39 17.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.23 -39.04 68.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.94 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -60.56 -35.5 76.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -173.04 -107.71 0.21 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 93.4 t -152.24 107.9 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.26 107.71 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.133 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.5 p -82.08 -37.16 26.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -143.89 154.8 43.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.7 t -134.96 102.81 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 144' ' ' MET . 59.7 t -89.33 143.65 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.461 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.1 mtt -144.31 135.92 25.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.0 mt -102.26 135.75 37.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.481 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.72 3.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' ALA . 28.8 t0 -85.19 110.4 18.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.857 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.457 ' O ' ' C ' ' A' ' 149' ' ' GLU . . . -34.7 -57.22 0.53 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.066 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.457 ' C ' ' O ' ' A' ' 148' ' ' ALA . 7.9 mm-40 -33.31 -48.32 0.23 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -87.55 -34.93 18.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 5.5 mm-40 59.0 54.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.481 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.9 ttm-85 -158.16 137.65 8.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . 0.461 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.77 110.18 2.49 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.426 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 42.1 mtt180 -51.86 -47.63 64.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 157.93 38.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.489 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.426 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 41.4 p90 -166.52 167.7 15.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.903 0.382 . . . . 0.0 110.907 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.3 -156.72 27.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.499 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -139.48 166.92 23.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.933 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.0 mt -149.53 138.98 15.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 27.3 m -106.87 140.53 39.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.142 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.534 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -110.84 176.67 4.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -78.18 -44.42 25.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -124.82 133.45 53.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -41.26 -43.49 2.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -39.24 -47.77 1.7 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.534 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 70.8 m -50.59 -49.48 56.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.866 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.401 HG12 ' CG2' ' A' ' 115' ' ' ILE . 78.5 t -47.4 -62.39 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -44.96 -53.98 7.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -46.18 -47.48 17.72 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -69.87 -56.06 8.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.1 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 172' ' ' ASN . 91.1 t -49.78 -61.82 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 171' ' ' VAL . 15.0 t-20 -34.35 -62.88 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.875 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 24.2 mmm -49.9 -42.73 48.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.9 t-160 56.18 26.03 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.514 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 6.2 m-85 -169.91 154.01 5.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 84.8 m-70 -160.81 153.97 21.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -112.26 89.31 3.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.858 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 59.6 mt -106.23 109.57 28.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.154 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' MET . . . . . 0.47 ' CE ' ' HG3' ' A' ' 128' ' ' GLU . 5.0 mtm 62.14 43.22 8.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.69 50.72 59.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.46 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.4 tmtt? -155.9 144.83 20.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.846 0.355 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 9.0 tppt? -87.77 112.74 22.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.79 119.56 51.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -79.24 140.73 37.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.413 HG21 ' CD2' ' A' ' 176' ' ' HIS . 67.4 t -139.67 140.2 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.16 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -142.27 162.45 35.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.863 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 17.1 ttt180 -78.01 121.47 24.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.15 15.54 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -118.58 150.73 48.68 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.89 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 26.0 ptt85 -52.65 128.9 27.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.896 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.14 110.37 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.89 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.2 m -85.18 92.61 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.854 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 20.6 mtpt -115.68 177.08 4.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.867 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 46.6 t -100.73 84.11 2.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 51.6 p -39.09 148.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.844 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -147.39 84.88 0.17 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.446 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -0.13 6.44 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.674 2.25 . . . . 0.0 112.345 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 70.6 p -57.8 144.08 39.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.821 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 16.7 m -107.55 141.4 39.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.803 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 179.995 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -77.18 121.14 23.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.89 0.376 . . . . 0.0 110.796 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 86.2 p -83.41 139.88 32.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.866 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 161.65 -58.67 0.3 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.459 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 m -83.04 81.27 8.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.853 0.359 . . . . 0.0 110.854 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.2 m -154.36 150.61 28.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.914 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.15 -83.62 0.18 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.454 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.6 m -47.83 168.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.859 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -42.13 127.16 3.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.2 m -148.04 134.38 19.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -105.82 24.27 12.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.841 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.4 ttpt -85.29 142.82 29.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 21.8 pt -125.91 158.7 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.104 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.408 ' O ' ' CD2' ' A' ' 116' ' ' PHE . 12.3 t80 -105.07 104.65 14.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 71.9 t -100.63 114.33 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.112 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.14 -169.52 13.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.86 12.92 4.03 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.44 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.471 ' CG2' ' HD2' ' A' ' 121' ' ' PRO . 54.4 mt -57.39 138.41 81.08 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.609 0.719 . . . . 0.0 111.121 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.471 ' HD2' ' CG2' ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.78 -174.24 0.87 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.248 . . . . 0.0 112.339 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.07 3.12 53.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -115.38 -10.71 11.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . 0.46 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.7 t -87.05 125.46 34.12 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.42 -172.86 13.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.512 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -51.18 -66.06 0.45 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 110.867 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.8 m -44.14 -63.59 0.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.152 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -40.55 -58.42 1.6 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.881 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 50.2 mt -40.99 -47.04 2.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' A' ' 132' ' ' TYR . 49.0 mtm180 -66.39 -61.25 2.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.882 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -43.31 -23.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' TYR . . . . . 0.405 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.2 t80 -101.08 -32.83 10.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.933 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -93.52 15.3 16.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 pttt -95.11 -19.32 20.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.3 pttt -73.06 -30.39 63.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.893 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.466 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 44.4 m-85 -74.1 -37.12 64.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.15 -110.52 0.23 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.49 113.08 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.87 0.367 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 57.3 t -74.84 99.88 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 19.2 p -74.8 -42.11 58.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -142.96 155.08 44.63 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.877 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 78.2 t -134.76 104.7 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.121 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.4 t -90.24 144.97 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.156 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 5.0 mtt -143.87 135.13 25.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 69.9 mt -98.38 133.35 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.165 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.452 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.68 165.35 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.449 ' O ' ' C ' ' A' ' 148' ' ' ALA . 22.1 t0 -81.61 110.11 16.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.82 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.449 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.69 -58.15 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.122 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -43.13 -43.67 4.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 35.0 mttm -78.0 -40.35 39.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 59.97 50.28 6.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.933 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.452 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.0 ttt85 -161.65 138.01 6.1 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.627 0.727 . . . . 0.0 110.899 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 121.64 8.33 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.657 2.238 . . . . 0.0 112.349 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.462 ' HD3' ' CZ ' ' A' ' 156' ' ' PHE . 50.5 mtp180 -65.67 -53.95 34.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.869 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.91 38.25 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.45 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.462 ' CZ ' ' HD3' ' A' ' 154' ' ' ARG . 37.1 p90 -168.12 162.84 13.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.857 0.36 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.88 -155.18 26.42 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.467 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -139.55 169.46 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.794 0.33 . . . . 0.0 110.912 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 11.0 mt -151.79 135.44 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.164 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' THR . . . . . 0.404 HG22 ' N ' ' A' ' 161' ' ' PHE . 31.6 m -102.18 140.38 36.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' PHE . . . . . 0.404 ' N ' HG22 ' A' ' 160' ' ' THR . 49.9 m-85 -111.46 172.84 6.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.889 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -73.05 -34.72 66.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -137.94 152.68 49.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 165' ' ' GLN . 12.0 tm-20 -56.36 -49.64 73.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 164' ' ' GLU . 2.0 tp-100 -34.81 -47.28 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 1.2 m -48.34 -54.55 13.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 69.8 t -43.4 -49.9 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.126 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 169' ' ' GLN . 1.2 m-20 -54.37 -61.54 2.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' GLN . . . . . 0.466 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -35.99 -45.57 0.43 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.934 -179.919 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.39 -63.12 1.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.092 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 172' ' ' ASN . 85.1 t -43.16 -54.96 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 171' ' ' VAL . 32.2 t30 -34.65 -50.91 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 41.2 mtp -74.36 -39.91 62.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 16.3 t-160 59.54 27.44 16.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.6 m-85 -169.84 152.68 4.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' HIS . . . . . 0.434 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 90.7 m-70 -157.94 151.74 23.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -107.4 93.55 4.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' ILE . . . . . . . . . . . . . 53.6 mt -116.23 119.46 62.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 6.9 mmt 56.83 47.47 17.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 56.43 56.16 25.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.529 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.402 ' HG3' ' N ' ' A' ' 182' ' ' LYS . 25.5 tptt -165.21 149.33 8.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.84 0.352 . . . . 0.0 110.914 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' LYS . . . . . 0.424 ' HE3' ' CG ' ' A' ' 175' ' ' PHE . 14.4 tptt -90.43 110.39 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 4.1 t -95.21 131.07 43.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.103 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -88.65 146.01 25.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.6 127.18 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.098 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 3.9 mtmp? -142.89 143.57 32.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.915 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -46.76 139.67 5.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -105.65 16.4 25.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -126.9 151.43 73.87 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.61 0.719 . . . . 0.0 110.884 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 164.13 35.66 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.241 . . . . 0.0 112.384 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 28.3 ptt-85 -84.34 168.17 15.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -67.74 129.76 40.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 17.0 m -104.42 -56.4 2.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.814 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 67.9 tttt -80.73 136.48 36.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.936 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 8.6 t -107.91 106.44 16.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 47.5 m -107.03 -58.16 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.896 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 111.21 -175.9 18.05 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.485 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 172.89 11.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.644 2.229 . . . . 0.0 112.376 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.5 t -48.71 -48.72 40.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.899 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 88.3 p 43.17 42.11 3.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.861 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.466 -179.951 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.909 0.385 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -102.38 143.28 32.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 167' ' ' VAL . 33.0 pt -126.55 152.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -97.08 109.03 21.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 185' ' ' VAL . 90.5 t -104.43 113.02 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.65 176.51 16.38 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.95 5.42 46.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.459 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.2 mt -52.75 138.02 43.38 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 111.161 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.606 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.52 24.22 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.712 2.275 . . . . 0.0 112.363 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.456 ' CE1' HH11 ' A' ' 152' ' ' ARG . 41.1 t-80 -82.93 10.34 8.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.39 -20.21 8.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.482 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 11.6 t -80.5 142.15 34.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.09 -171.88 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -48.16 -57.93 5.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.6 m -47.01 -60.14 2.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 129' ' ' LEU . 1.7 mp0 -53.83 -63.45 1.15 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.89 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 128' ' ' GLU . 63.5 mt -34.31 -62.5 0.33 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.654 ' CG ' HG21 ' A' ' 142' ' ' VAL . 51.0 mtp180 -59.02 -52.03 67.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -50.5 -22.52 1.98 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.45 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 13.4 t80 -104.65 -20.62 13.59 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.468 ' CE2' HD12 ' A' ' 159' ' ' ILE . 20.8 m-85 -102.49 15.49 29.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.937 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 32.1 pttt -94.14 -16.44 23.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 3.7 pttm -76.14 -36.67 58.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -67.95 -26.57 66.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.876 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.39 -114.69 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 66.3 t -144.16 116.71 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 111.137 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 43.3 t -79.82 113.53 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 76.5 p -90.11 -36.0 15.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -143.52 152.29 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.869 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.654 HG21 ' CG ' ' A' ' 130' ' ' ARG . 57.8 t -134.82 101.99 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.7 t -87.92 143.86 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.147 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.621 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 6.0 mtt -144.94 131.47 19.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.54 HD11 ' HE1' ' A' ' 158' ' ' PHE . 71.1 mt -96.12 131.89 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.108 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.443 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.58 164.52 10.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 43.9 t0 -85.99 112.14 20.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.81 -60.9 0.36 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 148' ' ' ALA . 0.3 OUTLIER -36.14 -45.44 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -81.44 -39.33 25.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 59.73 54.27 4.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.456 HH11 ' CE1' ' A' ' 122' ' ' HIS . 9.0 ttm180 -165.37 138.74 3.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.612 0.72 . . . . 0.0 110.878 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.621 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.6 Cg_endo -69.76 114.22 3.63 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.739 2.292 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.4 mtt180 -56.09 -54.42 45.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.04 39.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.527 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -169.39 166.59 10.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.874 0.369 . . . . 0.0 110.916 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.24 -157.26 28.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.54 ' HE1' HD11 ' A' ' 145' ' ' ILE . 32.1 m-85 -137.36 165.91 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.468 HD12 ' CE2' ' A' ' 133' ' ' PHE . 11.8 mt -149.2 134.07 10.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.0 m -101.34 145.06 29.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -114.52 -177.7 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -86.85 -41.97 13.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' ASP . . . . . 0.416 ' O ' ' C ' ' A' ' 164' ' ' GLU . 0.8 OUTLIER -125.25 128.54 48.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.868 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 163' ' ' ASP . 10.1 tm-20 -36.3 -37.7 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.917 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.423 ' O ' ' C ' ' A' ' 166' ' ' SER . 15.7 mt-30 -42.08 -60.45 1.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 1.3 m -36.67 -53.43 0.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 115' ' ' ILE . 70.5 t -45.24 -58.68 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.144 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -50.21 -55.01 17.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.841 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -45.44 -51.08 11.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.906 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.53 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -64.58 -51.39 63.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 39.8 t -47.63 -60.5 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -41.83 -51.95 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -59.26 -41.98 90.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 48.17 28.17 1.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.849 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 5.1 m-85 -173.0 151.35 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.507 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 50.1 m80 -160.29 147.64 16.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.832 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -102.33 90.0 3.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.813 HD12 HG21 ' A' ' 183' ' ' VAL . 72.5 mt -110.23 110.31 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 10.2 mtt 63.48 44.81 5.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.875 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.93 43.11 99.64 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.471 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.8 tppt? -149.61 145.46 26.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.19 107.83 19.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.813 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -93.54 129.12 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -87.32 135.79 33.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.905 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 117' ' ' VAL . 56.1 t -132.62 132.48 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 7.5 mmmm -136.21 159.73 40.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -67.89 114.22 6.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 179.943 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.942 0.401 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 tttt -97.88 144.52 27.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.913 HG22 HG13 ' A' ' 167' ' ' VAL . 20.2 pt -126.07 149.14 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.099 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.3 t80 -96.39 113.71 25.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.918 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 185' ' ' VAL . 87.4 t -110.28 116.31 52.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.131 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.54 -179.54 16.06 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.85 14.46 44.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.472 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.631 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.3 mt -62.45 138.36 96.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.629 0.728 . . . . 0.0 111.128 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.78 159.96 51.46 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.67 2.246 . . . . 0.0 112.337 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -68.2 -4.1 12.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.833 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.411 ' O ' ' C ' ' A' ' 124' ' ' CYS . 9.5 m120 -100.23 -62.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.446 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 35.3 t -37.62 120.96 0.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.4 -172.24 13.76 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -46.24 -65.68 0.52 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.3 m -44.13 -59.13 2.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 129' ' ' LEU . 67.1 mm-40 -49.67 -65.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.847 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.605 HD11 ' CE ' ' A' ' 144' ' ' MET . 39.5 mt -34.38 -54.63 0.52 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.493 ' CG ' HG21 ' A' ' 142' ' ' VAL . 14.4 mtp180 -63.69 -59.99 3.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -42.75 -25.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 12.2 t80 -100.66 -24.82 14.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 159' ' ' ILE . 14.3 m-85 -97.91 13.76 29.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -93.12 -29.77 15.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.6 pttt -61.67 -33.85 74.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -68.87 -42.85 76.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.898 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -166.19 -108.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.485 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.65 109.91 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 29.1 t -75.21 119.55 23.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.163 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 33.2 p -93.81 -36.31 12.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.149 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -140.55 153.03 45.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.493 HG21 ' CG ' ' A' ' 130' ' ' ARG . 61.2 t -133.63 101.95 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 62.3 t -88.73 141.14 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.088 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.605 ' CE ' HD11 ' A' ' 129' ' ' LEU . 4.3 mtt -143.33 138.99 29.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.417 HD11 ' HE1' ' A' ' 158' ' ' PHE . 64.6 mt -105.48 132.4 52.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -171.69 165.06 6.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.882 -179.972 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 26.2 t0 -84.39 113.9 21.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.85 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.74 -58.48 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -42.5 -43.56 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 10.5 tppt? -77.48 -41.33 39.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 60.02 46.92 10.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 0.4 OUTLIER -160.6 138.58 7.21 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.577 0.704 . . . . 0.0 110.862 -179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.47 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.84 110.77 2.65 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.7 2.267 . . . . 0.0 112.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 19.1 mtt-85 -50.3 -55.79 13.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.99 42.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -173.29 159.94 3.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.882 0.373 . . . . 0.0 110.85 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.04 -158.66 31.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.495 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.417 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.6 m-85 -139.64 162.18 35.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.548 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.4 mt -144.91 139.37 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.1 m -105.29 141.29 37.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.565 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 34.5 m-85 -112.51 174.01 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -79.91 -40.39 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.915 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' ASP . . . . . 0.44 ' O ' ' C ' ' A' ' 164' ' ' GLU . 27.4 m-20 -126.16 123.37 38.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.865 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.44 ' C ' ' O ' ' A' ' 163' ' ' ASP . 8.4 tp10 -35.18 -41.15 0.15 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.838 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.427 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.5 mm100 -35.79 -60.89 0.5 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.565 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 68.7 m -39.29 -59.25 1.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.913 HG13 HG22 ' A' ' 115' ' ' ILE . 67.1 t -35.32 -47.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.135 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -65.53 -52.33 53.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -43.43 -50.46 6.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.404 ' O ' ' C ' ' A' ' 171' ' ' VAL . . . -68.04 -66.0 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 167' ' ' VAL . 88.8 t -37.1 -52.37 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 59.9 t-20 -37.41 -65.49 0.31 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 7.5 mtm -57.91 -32.24 67.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.914 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.513 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 18.2 t-160 50.17 26.81 2.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.52 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 7.8 m-85 -169.45 150.31 4.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 19.7 m80 -160.9 150.03 16.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.843 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -105.73 94.48 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.913 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.725 HD12 HG21 ' A' ' 183' ' ' VAL . 70.3 mt -111.4 114.43 47.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 13.5 mtt 61.86 39.64 13.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.94 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.04 54.07 29.88 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -164.64 142.95 6.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.41 117.95 23.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.923 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.725 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -105.43 122.52 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -80.79 138.18 36.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 117' ' ' VAL . 94.4 t -139.72 135.61 39.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.123 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -147.21 169.41 19.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 22.1 mtt180 -69.12 114.22 7.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.853 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.096 179.9 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.923 0.392 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -91.43 143.38 26.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.707 HG22 HG13 ' A' ' 167' ' ' VAL . 22.7 pt -127.56 148.13 32.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.408 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 17.1 t80 -92.53 112.95 25.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.815 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 185' ' ' VAL . 91.1 t -109.51 117.3 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.136 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.86 -177.47 15.21 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.508 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.41 23.07 47.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.461 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.604 HG23 ' HD2' ' A' ' 121' ' ' PRO . 64.3 mt -69.85 137.45 87.68 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.657 0.742 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.604 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.691 2.261 . . . . 0.0 112.31 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -81.6 3.63 24.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -110.07 -27.14 9.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.5 t -74.89 123.99 26.07 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.35 -173.55 13.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.72 -62.37 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.972 0.415 . . . . 0.0 110.885 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 51.9 m -43.14 -63.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.088 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 129' ' ' LEU . 0.9 OUTLIER -49.47 -62.24 1.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.735 HD11 ' HE3' ' A' ' 144' ' ' MET . 35.3 mt -34.35 -49.21 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.89 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.493 ' HE ' HG23 ' A' ' 142' ' ' VAL . 50.4 mtt180 -67.49 -51.44 51.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' GLU . . . . . 0.405 ' HA ' ' CE ' ' A' ' 134' ' ' LYS . 34.4 mt-10 -55.2 -16.71 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.469 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 15.9 t80 -108.74 -20.83 12.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.522 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.4 m-85 -105.5 16.49 25.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.875 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.405 ' CE ' ' HA ' ' A' ' 131' ' ' GLU . 12.2 ptpt -94.76 -26.17 16.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -68.06 -38.46 82.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.883 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -63.26 -35.11 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' GLY . . . . . 0.574 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -173.45 -98.08 0.11 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.476 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 137' ' ' GLY . 56.2 t -161.42 109.99 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.876 0.37 . . . . 0.0 111.134 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.489 HG21 ' HA ' ' A' ' 130' ' ' ARG . 17.0 t -75.23 113.52 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 17.7 p -90.55 -37.73 13.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -141.23 153.04 45.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.493 HG23 ' HE ' ' A' ' 130' ' ' ARG . 63.5 t -134.28 100.69 3.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.8 t -85.71 142.16 13.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.735 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.7 mtt -145.03 133.24 21.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.837 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.515 HD11 ' HE1' ' A' ' 158' ' ' PHE . 59.2 mt -97.95 136.85 27.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.451 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.9 3.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.944 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.453 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -86.3 113.72 22.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.453 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.27 -62.27 0.28 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 17.7 tt0 -36.25 -47.29 0.57 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.837 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -77.33 -40.77 43.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 60.08 51.71 5.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.451 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 2.1 ttp180 -163.89 138.86 4.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.634 0.731 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 110.56 2.6 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.643 2.229 . . . . 0.0 112.316 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.3 mtt180 -50.97 -52.4 43.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.4 40.24 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -170.2 162.35 8.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.868 0.366 . . . . 0.0 110.893 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.408 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.73 -150.79 19.75 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.515 ' HE1' HD11 ' A' ' 145' ' ' ILE . 15.9 m-85 -145.97 168.99 19.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 0.0 110.901 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.597 HD11 HD22 ' A' ' 129' ' ' LEU . 20.5 mt -151.55 138.16 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.7 m -103.49 142.92 33.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.138 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.516 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 57.7 m-85 -113.27 170.03 8.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -73.98 -38.73 64.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.861 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -131.02 137.2 49.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.448 ' O ' ' N ' ' A' ' 167' ' ' VAL . 11.4 tm-20 -44.93 -47.17 11.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.8 tt0 -34.74 -48.42 0.38 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.94 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.516 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 66.0 m -50.35 -46.7 55.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.707 HG13 HG22 ' A' ' 115' ' ' ILE . 58.0 t -50.89 -55.56 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.157 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -53.62 -47.36 70.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.813 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -49.08 -55.79 11.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.907 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.95 -58.26 6.6 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.793 HG21 ' HG3' ' A' ' 187' ' ' ARG . 94.0 t -44.17 -61.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.108 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 171' ' ' VAL . 28.3 t30 -35.76 -46.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.2 mmm -69.9 -43.42 71.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.538 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 16.5 t-160 59.06 26.94 15.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.0 m-85 -171.55 154.32 3.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.865 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 62.2 m80 -160.66 162.77 32.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.832 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -117.95 92.4 3.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.819 HD12 HG21 ' A' ' 183' ' ' VAL . 55.9 mt -112.21 127.24 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.143 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.0 mmt 52.63 33.38 13.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.96 52.06 25.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.482 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -159.03 145.81 17.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.863 0.364 . . . . 0.0 110.869 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.2 tppt? -82.17 111.17 18.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.854 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.819 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -100.97 121.58 51.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -80.79 144.86 31.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 117' ' ' VAL . 52.7 t -141.1 131.72 27.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.156 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.5 mtpt -142.95 144.48 32.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.915 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.793 ' HG3' HG21 ' A' ' 171' ' ' VAL . 7.4 mtp-105 -50.62 120.81 5.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.082 179.956 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.864 0.364 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 18.9 ttmt -93.24 151.93 19.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.673 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -134.7 152.25 32.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.11 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 27.7 t80 -98.95 108.74 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 185' ' ' VAL . 90.8 t -104.48 114.36 43.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.84 170.83 16.12 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 72.36 14.19 77.07 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.442 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.579 HG23 ' HD2' ' A' ' 121' ' ' PRO . 34.2 mt -62.74 137.41 96.64 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.641 0.734 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.77 161.0 47.6 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.707 2.271 . . . . 0.0 112.324 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.0 2.41 10.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.404 ' C ' ' SD ' ' A' ' 179' ' ' MET . 8.8 m-20 -107.72 -23.56 12.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.864 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.478 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 25.4 t -82.07 143.1 31.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -145.51 -171.98 15.54 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.534 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.418 ' HA ' HD12 ' A' ' 129' ' ' LEU . 45.9 tt0 -42.95 -66.18 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.7 m -40.17 -65.73 0.38 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 129' ' ' LEU . 3.9 mp0 -48.33 -61.68 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.757 HD11 ' HE3' ' A' ' 144' ' ' MET . 80.7 mt -34.4 -50.61 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.911 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.488 ' CG ' HG21 ' A' ' 142' ' ' VAL . 47.0 mtp180 -71.32 -53.4 14.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 41.4 mm-40 -46.99 -22.31 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.524 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 32.6 t80 -103.85 -36.79 7.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.897 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.551 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.8 m-85 -84.9 10.23 12.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.885 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 8.6 ptpt -91.0 -29.78 17.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LYS . . . . . 0.453 ' N ' ' HG3' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -69.97 -17.42 63.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.913 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -89.54 -19.88 24.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.22 -118.07 0.65 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.538 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.6 t -146.02 106.88 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.89 0.376 . . . . 0.0 111.119 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.429 HG21 ' HA ' ' A' ' 130' ' ' ARG . 5.2 t -73.52 111.09 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' THR . . . . . 0.404 HG22 ' OE1' ' A' ' 162' ' ' GLU . 43.3 p -88.03 -39.76 14.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.152 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -136.97 151.11 48.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.488 HG21 ' CG ' ' A' ' 130' ' ' ARG . 86.4 t -134.36 106.22 7.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.7 t -96.7 139.31 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.191 179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.757 ' HE3' HD11 ' A' ' 129' ' ' LEU . 14.4 mtp -141.1 130.57 23.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -91.46 137.21 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.447 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.72 165.13 4.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.937 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.443 ' O ' ' C ' ' A' ' 148' ' ' ALA . 39.3 t0 -85.13 113.49 21.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.59 -58.72 0.41 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.107 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -41.47 -43.87 2.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.436 ' N ' ' O ' ' A' ' 147' ' ' ASP . 9.5 tptm -78.14 -40.85 36.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 60.01 48.02 9.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.447 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.6 ttp85 -161.63 138.95 6.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.626 0.727 . . . . 0.0 110.816 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.503 ' CB ' ' CE ' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 113.8 3.49 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.645 2.23 . . . . 0.0 112.348 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 33.7 mtp85 -55.48 -57.04 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 167.8 41.66 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.503 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -172.55 157.13 3.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.918 0.39 . . . . 0.0 110.834 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.41 -154.42 24.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.507 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -140.1 166.13 25.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.813 0.34 . . . . 0.0 110.919 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.551 HD12 ' CD2' ' A' ' 133' ' ' PHE . 17.3 mt -150.0 142.39 17.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.102 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.4 m -109.82 141.12 42.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.11 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.581 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 39.4 m-85 -110.39 176.98 4.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.404 ' OE1' HG22 ' A' ' 140' ' ' THR . 17.8 tp10 -82.47 -36.17 26.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -131.96 131.34 42.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.849 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -40.8 -41.49 1.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.839 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -37.56 -53.95 1.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.581 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 22.4 m -46.27 -54.37 8.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.673 HG13 HG22 ' A' ' 115' ' ' ILE . 63.8 t -40.71 -56.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.134 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 169' ' ' GLN . 38.8 t0 -56.29 -64.13 0.96 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 168' ' ' ASP . 50.9 mt-30 -34.69 -43.92 0.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -75.15 -62.47 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.084 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.527 HG21 ' CG ' ' A' ' 187' ' ' ARG . 51.4 t -42.74 -54.24 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -40.64 -51.61 2.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.4 mmm -64.37 -31.97 73.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 13.3 t-160 48.61 26.46 1.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.1 m-85 -169.28 148.46 3.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.848 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.524 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 68.2 m80 -155.07 152.43 29.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.84 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -108.13 104.07 13.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.996 HD12 HG21 ' A' ' 183' ' ' VAL . 52.4 mt -126.23 113.09 32.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.404 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 9.1 mtt 60.62 42.56 13.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 46.74 93.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.495 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.8 tptt -153.41 145.93 24.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -87.25 110.74 20.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.996 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -97.8 115.03 36.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -76.77 141.6 40.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 117' ' ' VAL . 20.3 t -138.57 131.55 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 11.4 mtmt -138.34 149.99 46.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.947 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.527 ' CG ' HG21 ' A' ' 171' ' ' VAL . 14.0 mtt180 -53.07 123.77 12.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.7 ttmt -100.14 137.18 38.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.728 HG22 HG13 ' A' ' 167' ' ' VAL . 29.2 pt -119.65 153.38 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.147 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -101.87 107.61 18.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 185' ' ' VAL . 88.1 t -103.36 117.65 49.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.141 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.69 -177.42 15.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.52 13.73 39.1 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.467 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.567 HG23 ' HD2' ' A' ' 121' ' ' PRO . 35.5 mt -61.65 137.15 94.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 0.0 111.15 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.567 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.1 Cg_endo -69.67 161.85 44.32 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.433 ' ND1' ' O ' ' A' ' 122' ' ' HIS . 2.8 p80 -77.58 8.66 4.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.873 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.459 ' O ' ' CE ' ' A' ' 179' ' ' MET . 47.5 t30 -117.09 -15.12 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 2.7 t -83.55 153.22 24.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -158.92 169.6 35.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.517 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 125' ' ' GLY . 0.6 OUTLIER -35.97 -59.4 0.6 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.893 0.377 . . . . 0.0 110.893 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.9 m -42.62 -53.94 4.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -65.25 -55.93 15.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.476 HD13 HD11 ' A' ' 159' ' ' ILE . 60.6 mt -42.6 -58.85 2.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.933 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.642 ' HA ' HG21 ' A' ' 139' ' ' VAL . 68.1 mtp180 -54.51 -56.72 15.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -50.87 -33.5 24.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.504 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.0 t80 -89.64 -20.06 24.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.431 ' CD2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-85 -105.31 17.74 23.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -92.59 -39.15 11.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.3 ptpt -57.39 -31.14 65.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.869 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -73.99 -32.48 63.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.891 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.55 -118.9 0.54 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 60.2 t -145.04 106.23 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.642 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.5 t -68.71 108.66 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.117 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 16.5 p -86.03 -38.0 18.33 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -140.67 155.53 46.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.416 HG21 ' CG ' ' A' ' 130' ' ' ARG . 85.0 t -136.89 106.35 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.166 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.5 t -93.96 138.7 19.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.122 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.8 mtt -139.17 136.33 34.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.1 mt -101.43 131.76 48.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.445 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.16 164.84 7.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.3 t0 -85.41 112.4 20.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.865 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.5 -60.56 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 tm-20 -38.52 -45.45 1.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 9.3 tppt? -78.52 -40.51 34.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 60.07 53.11 4.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.911 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 15.4 ttp85 -165.44 138.34 3.56 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.601 0.715 . . . . 0.0 110.922 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 111.44 2.82 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.684 2.256 . . . . 0.0 112.315 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.6 mtp85 -52.0 -50.77 60.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 161.27 39.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -169.69 161.45 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.519 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 165.42 -151.05 19.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.459 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.519 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 10.1 m-85 -146.03 166.31 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.869 0.366 . . . . 0.0 110.866 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.476 HD11 HD13 ' A' ' 129' ' ' LEU . 18.2 mt -150.4 136.78 12.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.13 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 36.5 m -103.82 143.4 32.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.536 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.9 m-85 -112.44 176.46 5.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.925 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -77.91 -39.04 44.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.71 145.21 49.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 165' ' ' GLN . 34.8 tt0 -48.81 -44.39 39.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.918 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.418 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.1 tt0 -34.76 -49.6 0.43 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.536 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 20.0 m -53.65 -52.08 61.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.728 HG13 HG22 ' A' ' 115' ' ' ILE . 70.4 t -47.41 -47.1 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -63.56 -52.62 60.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -47.67 -51.58 21.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.891 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.89 -56.44 7.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.647 HG23 ' O ' ' A' ' 167' ' ' VAL . 40.3 t -43.6 -57.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -38.74 -62.04 0.66 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.885 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.3 mmm -48.6 -42.45 33.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.6 t-160 54.01 25.72 5.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.521 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -172.37 144.8 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.898 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.504 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 64.8 m-70 -156.21 158.74 38.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -110.33 103.68 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.772 HD12 HG21 ' A' ' 183' ' ' VAL . 34.2 mt -130.05 131.34 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.089 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 123' ' ' ASN . 11.9 mmt 62.52 25.74 15.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.914 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.01 85.01 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.46 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 9.1 ttmm -128.29 162.17 27.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.866 0.365 . . . . 0.0 110.876 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 5.8 tptm -88.74 128.68 35.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.772 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -112.46 121.61 65.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.096 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -81.37 145.21 30.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 117' ' ' VAL . 42.7 t -142.29 126.91 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mmmt -138.04 143.92 40.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -56.69 118.54 4.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.842 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 179.905 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.425 ' O ' HG23 ' A' ' 160' ' ' THR . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.918 0.389 . . . . 0.0 110.874 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.7 ttmt -117.67 148.65 41.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.79 HG22 HG13 ' A' ' 167' ' ' VAL . 21.7 pt -129.22 155.33 41.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 7.3 t80 -104.74 102.37 11.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 185' ' ' VAL . 84.8 t -93.3 125.42 45.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.109 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.1 -177.28 14.79 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.52 8.69 10.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.629 HD11 HG12 ' A' ' 117' ' ' VAL . 55.3 mt -58.71 137.61 86.58 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.638 0.732 . . . . 0.0 111.117 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.593 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.76 169.79 18.09 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.0 p-80 -85.92 15.21 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.3 m120 -123.67 -26.86 4.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.498 ' SG ' HG21 ' A' ' 178' ' ' ILE . 24.1 t -72.18 118.92 15.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.68 -174.32 16.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.495 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -41.45 -63.94 0.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.951 0.405 . . . . 0.0 110.863 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 46.0 m -41.9 -54.9 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.102 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 129' ' ' LEU . 61.1 mm-40 -54.41 -66.18 0.44 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.663 HD11 ' CE ' ' A' ' 144' ' ' MET . 51.5 mt -34.53 -60.34 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.613 ' HA ' HG21 ' A' ' 139' ' ' VAL . 5.6 mtp-105 -58.9 -57.0 15.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.863 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -46.44 -25.8 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.568 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.3 t80 -102.46 -20.7 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.928 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.569 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.6 m-85 -104.47 9.8 35.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 130' ' ' ARG . 48.2 pttt -91.33 -17.61 25.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.88 -38.57 57.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.915 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -69.18 -29.38 67.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.31 -124.17 0.79 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.7 t -138.61 105.3 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.126 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.613 HG21 ' HA ' ' A' ' 130' ' ' ARG . 38.6 t -65.16 110.0 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.079 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 46.2 p -87.74 -38.46 15.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.129 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -137.38 147.43 45.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.859 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.27 94.46 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 72.3 t -89.99 137.9 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.12 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.663 ' CE ' HD11 ' A' ' 129' ' ' LEU . 8.8 mtp -137.57 142.7 41.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 73.3 mt -106.58 133.53 50.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.37 165.08 5.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.903 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 29.1 t0 -85.83 113.5 22.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.33 -62.13 0.29 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.108 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 148' ' ' ALA . 42.5 tt0 -36.38 -46.26 0.53 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -78.99 -40.55 31.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 60.0 47.84 9.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.9 ttp180 -158.29 138.32 8.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.623 0.725 . . . . 0.0 110.893 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.462 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.75 110.6 2.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.724 2.282 . . . . 0.0 112.32 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -51.62 -53.53 37.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.851 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 120' ' ' ILE . . . 163.03 41.39 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.534 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -170.7 160.6 7.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.914 0.388 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.23 -159.01 32.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 15.8 m-85 -137.81 161.11 37.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.82 0.343 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.569 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.1 mt -148.19 140.73 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.073 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 113' ' ' ASN . 23.6 m -107.13 144.23 34.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.437 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 54.8 m-85 -113.29 167.52 10.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -70.53 -43.17 70.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -122.06 140.53 52.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 165' ' ' GLN . 7.9 tp10 -49.67 -46.39 49.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.401 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.4 tt0 -38.24 -51.88 1.48 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.437 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 50.6 m -44.58 -57.05 3.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.79 HG13 HG22 ' A' ' 115' ' ' ILE . 38.4 t -37.68 -59.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 169' ' ' GLN . 46.9 t0 -50.53 -61.65 2.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.807 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 168' ' ' ASP . 76.0 mt-30 -35.73 -48.91 0.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.62 -57.89 4.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.118 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 174' ' ' HIS . 75.2 t -47.13 -60.39 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 171' ' ' VAL . 7.5 t30 -35.07 -61.08 0.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 27.5 mmm -51.08 -41.45 59.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.904 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.522 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.6 t-160 55.94 26.23 9.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.8 m-85 -171.87 148.32 2.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.568 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 52.7 m-70 -155.44 155.83 34.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -112.37 85.84 2.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.897 HD12 HG21 ' A' ' 183' ' ' VAL . 78.8 mt -96.66 126.24 49.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.15 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.833 ' HG2' HG22 ' A' ' 178' ' ' ILE . 2.0 ptm 38.81 48.22 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.5 67.74 1.94 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.41 ' NZ ' ' HB2' ' A' ' 181' ' ' LYS . 0.3 OUTLIER -175.13 142.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.815 0.34 . . . . 0.0 110.897 -179.946 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.8 tptm -85.04 102.37 13.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.884 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.897 HG21 HD12 ' A' ' 178' ' ' ILE . 3.0 t -95.08 117.34 38.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.139 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 184' ' ' GLU . . . . . 0.543 ' O ' HG23 ' A' ' 185' ' ' VAL . 10.1 tt0 -72.92 162.19 29.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.906 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 117' ' ' VAL . 72.3 t -161.12 131.02 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mttm -137.19 143.31 42.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.434 ' HB2' ' NH1' ' A' ' 187' ' ' ARG . 10.4 ttm105 -56.96 114.16 1.99 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.862 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 179.904 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.438 ' HG2' ' N ' ' A' ' 115' ' ' ILE . 21.3 ttmt -105.23 149.55 25.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.647 HG22 HG13 ' A' ' 167' ' ' VAL . 24.0 pt -129.6 156.85 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.454 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 8.0 t80 -104.58 106.45 16.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 185' ' ' VAL . 89.3 t -103.05 114.42 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -118.43 -177.64 16.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.432 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.04 26.63 58.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.471 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.623 HG23 ' HD2' ' A' ' 121' ' ' PRO . 60.7 mt -75.46 137.9 71.12 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.631 0.729 . . . . 0.0 111.12 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.72 165.11 32.02 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.706 2.27 . . . . 0.0 112.374 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -77.3 0.54 21.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -105.42 -32.89 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 21.4 t -68.8 118.81 12.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.39 -179.27 15.85 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.52 ' HA ' HD12 ' A' ' 129' ' ' LEU . 55.9 tt0 -39.89 -67.59 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.876 0.369 . . . . 0.0 110.853 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.1 m -40.67 -60.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.121 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 16.7 mm-40 -49.73 -61.22 2.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.612 HD11 ' CE ' ' A' ' 144' ' ' MET . 41.9 mt -35.97 -55.67 0.74 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.486 ' HG2' HG11 ' A' ' 139' ' ' VAL . 11.1 mtp-105 -64.03 -54.7 30.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -47.52 -20.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -107.46 -25.42 11.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.591 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.4 m-85 -97.98 15.34 24.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.8 ptpt -95.22 -10.69 29.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.94 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.2 pttm -81.69 -34.56 30.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -72.14 -23.29 61.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.33 -118.96 0.69 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 88.2 t -140.03 116.14 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' A' ' 130' ' ' ARG . 24.9 t -80.66 111.12 16.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.6 p -89.1 -34.95 16.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -142.02 157.82 44.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.424 HG21 ' CG ' ' A' ' 130' ' ' ARG . 99.3 t -139.05 104.94 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.172 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.79 139.27 17.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.149 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.612 ' CE ' HD11 ' A' ' 129' ' ' LEU . 5.3 mtt -142.25 133.7 26.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.438 HD11 ' HE1' ' A' ' 158' ' ' PHE . 70.7 mt -99.21 133.82 40.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.22 165.96 5.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.941 -179.987 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.455 ' O ' ' C ' ' A' ' 148' ' ' ALA . 21.8 t0 -84.88 113.23 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.455 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.16 -58.29 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.056 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -42.41 -44.45 3.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 147' ' ' ASP . 2.8 mptm? -77.22 -40.82 43.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 60.09 43.5 14.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.866 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 3.8 ttp180 -155.92 138.47 10.38 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.6 0.714 . . . . 0.0 110.886 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.589 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.77 110.87 2.66 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.335 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.9 mtp85 -50.86 -55.89 14.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.18 41.77 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -172.34 162.95 5.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.449 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 162.79 -154.51 25.49 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.451 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 4.7 m-85 -141.95 167.03 23.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.891 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.591 HD12 ' CD2' ' A' ' 133' ' ' PHE . 8.9 mt -150.1 139.85 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.137 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.3 m -106.33 144.82 32.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.471 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 53.1 m-85 -115.13 175.02 5.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -78.65 -43.25 26.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 164' ' ' GLU . 3.4 m-20 -123.97 125.59 44.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.874 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 163' ' ' ASP . 23.1 tt0 -35.17 -39.03 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.419 ' C ' ' O ' ' A' ' 164' ' ' GLU . 3.8 mm100 -36.03 -59.33 0.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.471 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 1.1 m -41.87 -58.35 2.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.809 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 171' ' ' VAL . 58.6 t -36.12 -54.42 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -58.54 -60.3 4.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.1 mt-30 -39.9 -48.84 2.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.92 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.48 -54.94 13.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 167' ' ' VAL . 67.9 t -46.21 -60.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.167 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.428 ' C ' ' O ' ' A' ' 171' ' ' VAL . 12.3 t-20 -35.84 -67.8 0.15 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.832 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 86.2 mtp -46.44 -42.14 14.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.3 t-160 54.74 30.61 13.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.824 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -173.57 155.17 2.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.525 ' CD2' ' O ' ' A' ' 175' ' ' PHE . 39.3 m80 -160.57 162.82 33.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -119.39 91.52 3.57 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 183' ' ' VAL . 58.2 mt -112.23 135.09 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.7 mmm 46.14 40.78 7.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.885 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.34 57.4 18.42 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.412 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.2 tmtm? -166.09 151.33 8.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 182' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.5 OUTLIER -84.5 116.7 23.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.895 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.854 HG21 HD12 ' A' ' 178' ' ' ILE . 3.9 t -105.78 120.41 56.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -82.15 146.78 29.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 117' ' ' VAL . 69.2 t -144.49 134.31 19.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -139.18 149.1 44.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 28.7 ttp180 -59.9 119.21 7.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.932 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.116 179.978 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.919 0.39 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -92.72 150.01 20.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.908 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.863 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -131.09 155.16 41.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -104.39 105.54 15.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 185' ' ' VAL . 94.8 t -101.11 115.32 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.146 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.01 177.98 16.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.06 11.69 55.7 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.668 HG23 ' HD2' ' A' ' 121' ' ' PRO . 55.9 mt -57.85 138.84 82.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.642 0.734 . . . . 0.0 111.13 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.668 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.2 Cg_endo -69.79 171.96 13.55 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.658 2.239 . . . . 0.0 112.359 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 122' ' ' HIS . 3.4 t-80 -76.58 -5.14 46.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.452 ' O ' ' C ' ' A' ' 124' ' ' CYS . 7.7 m120 -102.43 -62.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.472 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.3 t -34.38 128.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -127.34 -154.82 8.62 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.444 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -66.33 -60.87 2.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.942 0.401 . . . . 0.0 110.921 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 53.3 m -48.55 -58.36 4.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.091 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.41 ' CD ' ' H ' ' A' ' 128' ' ' GLU . 6.2 mp0 -46.63 -61.95 1.6 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 35.5 mt -39.74 -52.13 2.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.917 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.589 ' HG2' HG11 ' A' ' 139' ' ' VAL . 74.0 mtm180 -59.85 -52.42 65.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 -53.38 -27.84 26.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.927 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.518 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 9.0 t80 -96.51 -18.96 19.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.946 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.486 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.4 m-85 -108.17 7.99 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.871 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.481 ' N ' ' O ' ' A' ' 130' ' ' ARG . 32.3 pttt -90.77 -28.46 18.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.2 ptpt -66.47 -25.94 66.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.867 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -78.66 -37.8 41.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -167.92 -112.25 0.26 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.463 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 86.5 t -147.47 112.33 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 111.056 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 70.7 t -75.16 103.78 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.112 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -79.24 -40.9 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.18 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.25 152.98 46.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.5 t -132.46 102.43 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.08 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.8 t -89.44 143.59 10.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.44 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.4 mtt -145.41 134.18 22.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.413 HD11 ' HE1' ' A' ' 158' ' ' PHE . 55.6 mt -98.76 130.66 47.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.169 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.454 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -170.09 164.66 9.34 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 150' ' ' LYS . 46.0 t0 -82.91 113.34 20.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.841 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.9 -52.46 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -48.0 -42.47 28.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.442 ' N ' ' O ' ' A' ' 147' ' ' ASP . 63.3 mttt -79.19 -38.43 35.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.948 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 58.19 51.41 8.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 13.1 ttm180 -164.95 138.42 3.88 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.61 0.719 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.44 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.72 113.54 3.4 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.742 2.295 . . . . 0.0 112.364 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.1 mtt180 -54.69 -55.47 29.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.32 40.59 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CA ' HD12 ' A' ' 120' ' ' ILE . 35.8 p90 -171.39 164.76 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.902 0.382 . . . . 0.0 110.877 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.74 -161.04 33.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.413 ' HE1' HD11 ' A' ' 145' ' ' ILE . 12.8 m-85 -137.73 162.85 32.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.486 HD12 ' CD2' ' A' ' 133' ' ' PHE . 15.8 mt -146.39 140.49 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.095 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.0 m -108.78 139.88 42.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -109.27 172.51 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.901 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.43 -30.03 47.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.928 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -137.43 147.21 45.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -55.56 -45.77 77.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.878 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -41.59 -42.29 2.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 6.1 m -55.84 -54.38 45.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.863 HG13 HG22 ' A' ' 115' ' ' ILE . 42.1 t -47.34 -51.31 6.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.154 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 18.6 t0 -52.92 -52.53 57.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 14.3 mm-40 -42.27 -44.37 3.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.12 -64.55 1.11 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.405 HG11 ' HB2' ' A' ' 187' ' ' ARG . 68.8 t -37.81 -50.25 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.097 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -39.2 -67.99 0.19 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 9.0 mtm -54.76 -43.41 72.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 17.6 t-160 61.17 26.48 16.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.1 m-85 -172.01 134.72 0.77 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.518 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 51.4 m80 -145.41 161.58 39.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -114.24 98.24 6.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.787 HD12 HG21 ' A' ' 183' ' ' VAL . 38.7 mt -118.65 129.07 75.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 51.07 41.89 27.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 60.73 63.65 4.79 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.489 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -174.15 149.21 1.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 9.7 tppt? -85.74 102.36 13.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.787 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -89.71 115.61 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -77.82 144.17 37.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.904 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 117' ' ' VAL . 88.2 t -143.44 128.44 15.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 186' ' ' LYS . . . . . 0.413 ' HD3' ' CD2' ' A' ' 174' ' ' HIS . 21.8 mmmt -133.34 151.48 51.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.405 ' HB2' HG11 ' A' ' 171' ' ' VAL . 12.1 ttt-85 -66.4 108.53 2.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.908 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.889 0.376 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -105.19 145.23 30.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.573 HG22 HG13 ' A' ' 167' ' ' VAL . 16.2 pt -126.79 155.34 37.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.156 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -104.7 106.1 16.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 185' ' ' VAL . 99.5 t -102.74 122.97 55.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -125.83 -174.94 14.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.07 16.77 14.55 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.503 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.627 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.9 mt -64.45 138.1 97.34 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.651 0.739 . . . . 0.0 111.143 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.627 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.06 25.56 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.633 2.222 . . . . 0.0 112.349 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -81.38 2.59 27.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.853 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -107.48 -29.02 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.481 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.1 t -72.96 135.39 45.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -139.26 175.71 21.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.473 ' HA ' HD12 ' A' ' 129' ' ' LEU . 22.8 tt0 -34.57 -70.17 0.08 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.888 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 126' ' ' GLU . 22.0 m -36.36 -65.34 0.28 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.121 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 129' ' ' LEU . 36.8 mm-40 -47.65 -63.07 1.15 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.67 HD11 ' HE3' ' A' ' 144' ' ' MET . 67.8 mt -34.38 -45.15 0.22 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.478 ' HE ' HG23 ' A' ' 142' ' ' VAL . 22.5 mtt180 -67.39 -56.73 8.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -46.88 -26.66 1.03 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.949 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -98.26 -31.41 12.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CD2' HD12 ' A' ' 159' ' ' ILE . 24.8 m-85 -97.02 16.86 18.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 17.0 pttp -95.32 -27.9 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -68.08 -34.05 75.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.922 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -66.65 -31.53 72.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -178.86 -106.14 0.2 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 83.2 t -151.74 111.53 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.406 HG21 ' HA ' ' A' ' 130' ' ' ARG . 42.6 t -76.96 114.67 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 72.5 p -91.81 -38.29 12.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.161 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -140.51 154.16 46.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.478 HG23 ' HE ' ' A' ' 130' ' ' ARG . 84.5 t -134.7 100.92 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 65.3 t -83.28 141.9 14.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.67 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.8 mtt -145.3 135.02 23.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.4 mt -101.02 136.45 32.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.105 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.06 166.03 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.45 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -88.88 113.52 24.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.52 -58.71 0.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.104 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.403 ' C ' ' O ' ' A' ' 148' ' ' ALA . 34.2 tt0 -37.52 -45.25 0.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.863 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 6.4 tptm -82.35 -39.08 23.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.09 47.11 9.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.7 ttp85 -157.74 139.07 9.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.652 0.739 . . . . 0.0 110.864 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 109.75 2.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.717 2.278 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 30.7 mtp180 -49.39 -54.11 19.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.888 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.0 42.34 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -172.88 160.03 4.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.884 0.374 . . . . 0.0 110.866 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.15 -152.82 22.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.507 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -142.34 167.25 22.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.936 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.7 mt -148.81 138.52 16.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 61.9 m -103.0 148.77 25.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.464 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 67.2 m-85 -119.83 175.43 5.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -79.49 -42.7 24.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.905 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -126.47 134.78 50.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 165' ' ' GLN . 39.2 tt0 -43.52 -44.25 5.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 164' ' ' GLU . 65.1 tt0 -35.66 -45.73 0.39 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.464 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 3.8 m -51.6 -55.69 17.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.573 HG13 HG22 ' A' ' 115' ' ' ILE . 80.0 t -40.75 -57.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -50.21 -51.77 41.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.867 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 20.6 mm100 -48.0 -57.77 5.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -59.51 -58.92 6.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 174' ' ' HIS . 70.3 t -44.28 -62.88 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.2 t-20 -34.65 -55.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.87 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 25.6 mmm -57.29 -42.84 82.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.0 t-160 54.53 26.71 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.4 m-85 -172.5 154.39 3.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.53 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 88.3 m-70 -159.81 157.76 29.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -116.29 84.04 2.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.998 HD12 HG21 ' A' ' 183' ' ' VAL . 66.8 mt -97.33 108.68 21.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.162 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 23.7 mtm 61.01 44.86 9.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.98 37.96 94.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 35.0 tptt -139.29 136.69 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 110.883 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.22 100.99 10.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.998 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -93.21 129.63 43.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -87.67 148.01 24.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 117' ' ' VAL . 67.1 t -147.58 138.75 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.109 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.1 mtmm -141.15 169.57 17.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.0 tmm_? -80.83 114.03 19.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.127 179.928 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.876 0.37 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -102.22 145.55 29.26 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.754 HG22 HG13 ' A' ' 167' ' ' VAL . 25.1 pt -126.08 154.3 35.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -104.21 101.98 11.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 185' ' ' VAL . 98.2 t -95.66 119.11 43.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.129 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.71 177.43 16.43 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.516 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.87 28.62 63.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.492 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.55 HG23 ' HD2' ' A' ' 121' ' ' PRO . 32.3 mt -75.82 137.01 69.95 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.606 0.717 . . . . 0.0 111.104 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.55 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.72 166.98 25.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.657 2.238 . . . . 0.0 112.351 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -77.1 -3.49 39.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.878 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -100.82 -37.34 8.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.1 t -67.93 125.35 26.01 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.442 ' N ' ' OE1' ' A' ' 128' ' ' GLU . . . -129.9 -165.61 11.66 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.528 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -53.53 -64.53 0.79 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.92 0.39 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 87.3 m -44.14 -54.29 5.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.442 ' OE1' ' N ' ' A' ' 125' ' ' GLY . 12.2 mp0 -57.16 -63.44 1.22 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 133' ' ' PHE . 61.0 mt -34.31 -46.96 0.28 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 30.7 mtp85 -69.74 -51.14 36.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -50.22 -19.2 0.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.921 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.427 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 12.6 t80 -108.97 -24.05 11.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.566 ' CE2' HD12 ' A' ' 159' ' ' ILE . 17.1 m-85 -98.35 9.99 41.8 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -86.85 -25.47 24.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -69.45 -39.61 77.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -64.58 -25.94 68.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.904 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 176.5 -113.79 0.45 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.465 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.5 t -147.95 106.14 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.848 0.356 . . . . 0.0 111.154 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.18 116.51 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.172 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 79.5 p -93.68 -35.42 12.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.108 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.69 152.61 45.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.93 97.69 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.139 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' A' ' 158' ' ' PHE . 59.3 t -81.84 142.74 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.095 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.3 mtt -145.15 136.7 25.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 56.8 mt -104.36 131.36 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.45 166.75 6.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 148' ' ' ALA . 48.0 t0 -91.49 109.75 21.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.13 -46.24 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 148' ' ' ALA . 1.5 tm-20 -35.3 -47.03 0.39 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -99.31 -28.69 13.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 59.78 50.06 7.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.0 ttp85 -149.73 138.58 12.53 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.613 0.72 . . . . 0.0 110.891 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.519 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.5 Cg_endo -69.71 110.62 2.59 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.352 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -50.24 -54.02 24.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.844 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.49 40.67 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.482 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -172.61 160.12 4.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 168.03 -155.56 26.44 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.441 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' A' ' 143' ' ' VAL . 29.2 m-85 -142.52 162.45 35.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.787 0.327 . . . . 0.0 110.879 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.566 HD12 ' CE2' ' A' ' 133' ' ' PHE . 13.9 mt -146.0 139.72 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.089 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 84.7 m -106.87 139.72 40.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.554 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 55.1 m-85 -109.08 179.24 4.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -86.23 -38.17 17.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' ASP . . . . . 0.415 ' O ' ' C ' ' A' ' 164' ' ' GLU . 6.5 m-20 -128.77 127.53 42.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.849 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 163' ' ' ASP . 26.8 tt0 -36.04 -42.19 0.28 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.403 ' O ' ' C ' ' A' ' 166' ' ' SER . 3.9 mt-30 -36.93 -61.42 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.554 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 7.2 m -38.32 -59.52 0.88 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.754 HG13 HG22 ' A' ' 115' ' ' ILE . 53.6 t -38.88 -63.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.157 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -43.9 -60.77 1.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -40.14 -53.41 2.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.36 -55.4 24.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.416 HG21 ' CB ' ' A' ' 187' ' ' ARG . 69.4 t -47.26 -61.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 171' ' ' VAL . 16.2 t-20 -37.67 -64.91 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 74.8 mtp -49.29 -45.43 45.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.835 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.8 t-160 60.03 28.07 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.5 m-85 -171.72 154.1 3.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.477 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 80.0 m-70 -159.38 156.64 28.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -113.09 91.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 183' ' ' VAL . 56.7 mt -111.05 134.21 54.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.113 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 47.99 36.19 5.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.78 46.04 85.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.463 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.424 ' HZ2' ' CA ' ' A' ' 121' ' ' PRO . 0.0 OUTLIER -153.61 147.18 25.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.875 -179.963 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.13 113.65 20.78 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.913 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -105.16 127.39 59.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -83.81 150.53 25.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.86 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 117' ' ' VAL . 23.8 t -151.14 131.93 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -136.86 149.05 47.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.416 ' CB ' HG21 ' A' ' 171' ' ' VAL . 12.1 ttt180 -62.87 124.89 22.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.132 179.906 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.855 0.359 . . . . 0.0 110.854 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -99.95 150.54 22.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.867 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.502 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.33 154.79 41.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -103.76 102.98 12.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 185' ' ' VAL . 83.8 t -97.95 112.84 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.24 173.7 15.37 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.479 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.01 63.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.439 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.596 HG23 ' HD2' ' A' ' 121' ' ' PRO . 42.1 mt -54.91 137.8 64.93 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.629 0.728 . . . . 0.0 111.152 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 163.99 36.25 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.644 2.229 . . . . 0.0 112.353 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.6 t-160 -68.99 -6.28 26.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.836 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 124' ' ' CYS . 19.6 t-20 -100.25 -64.22 1.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 43.7 t -35.13 126.57 0.56 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.75 -164.11 11.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -54.8 -66.24 0.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -42.54 -61.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.166 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 129' ' ' LEU . 9.5 mm-40 -49.42 -63.23 1.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.526 HD11 ' CE ' ' A' ' 144' ' ' MET . 44.9 mt -37.84 -55.16 1.22 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.708 ' HA ' HG21 ' A' ' 139' ' ' VAL . 63.8 mtp180 -56.11 -56.0 26.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -50.33 -44.34 54.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.583 ' CD2' HG12 ' A' ' 178' ' ' ILE . 6.4 t80 -74.03 -22.54 59.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 159' ' ' ILE . 25.2 m-85 -105.32 15.8 26.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.5 ptmt -90.48 -37.79 13.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.92 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -60.47 -37.93 82.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -67.28 -30.01 69.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.85 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.63 -116.48 0.48 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.528 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 19.7 t -148.57 106.61 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.708 HG21 ' HA ' ' A' ' 130' ' ' ARG . 8.1 t -69.42 119.06 14.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.175 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 78.3 p -99.77 -37.57 9.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -134.03 141.31 47.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.876 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.537 HG21 ' CG ' ' A' ' 130' ' ' ARG . 94.0 t -127.74 93.62 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.17 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.7 t -89.42 134.41 28.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.543 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 8.3 mtp -135.96 133.39 37.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.531 HD11 ' HE1' ' A' ' 158' ' ' PHE . 57.5 mt -92.11 134.24 30.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.52 165.91 5.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.981 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 16.5 t0 -84.53 112.62 20.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.856 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.24 -59.98 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -40.87 -45.8 2.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 23.7 mttp -75.75 -41.01 54.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 60.07 48.02 8.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.3 ttm180 -160.4 138.55 7.35 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.563 0.697 . . . . 0.0 110.9 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.543 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.79 116.35 4.52 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.718 2.279 . . . . 0.0 112.346 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.5 mtp180 -58.76 -55.36 36.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.62 39.37 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.4 p90 -170.4 160.95 7.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.876 0.369 . . . . 0.0 110.893 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -158.15 30.96 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.531 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.8 m-85 -138.86 161.62 36.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.359 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 133' ' ' PHE . 8.6 mt -147.59 139.28 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.14 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 m -109.21 140.02 43.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.47 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.8 m-85 -108.53 169.45 8.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -75.81 -34.55 60.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 34.6 m-20 -129.62 141.5 50.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -52.31 -45.14 65.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.914 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -40.68 -44.66 2.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.9 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.47 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 17.4 m -54.04 -41.91 68.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 115' ' ' ILE . 38.5 t -58.53 -58.94 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.139 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -49.95 -42.87 49.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -55.23 -55.35 32.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.0 -56.57 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 98.4 t -48.06 -44.56 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.186 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -50.23 -51.53 43.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.914 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.2 mmm -62.59 -36.07 81.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.8 t-160 49.31 25.22 1.2 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 8.7 m-85 -170.13 145.99 2.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.493 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 49.0 m80 -155.94 162.8 40.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -119.74 94.2 4.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.743 HD12 HG21 ' A' ' 183' ' ' VAL . 44.8 mt -113.34 120.61 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.5 mmt 59.9 34.25 21.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.69 46.97 58.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -153.5 148.55 26.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 8.2 tptm -86.84 108.51 18.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.743 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -98.51 120.99 48.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -82.73 147.58 28.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 117' ' ' VAL . 41.1 t -143.17 132.49 20.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.146 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mttp -137.06 136.71 38.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.419 ' HG3' ' CG1' ' A' ' 167' ' ' VAL . 34.9 ttt180 -52.45 123.16 10.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.126 179.912 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.853 ' O ' HG23 ' A' ' 160' ' ' THR . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.95 0.405 . . . . 0.0 110.92 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt -127.67 141.13 51.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.425 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -121.08 151.51 24.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.497 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 6.4 t80 -101.88 105.02 15.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.877 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 185' ' ' VAL . 94.0 t -97.92 121.73 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.129 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -127.6 175.42 18.28 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.95 18.89 62.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.56 HG23 ' HD2' ' A' ' 121' ' ' PRO . 40.2 mt -65.76 136.83 95.98 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.639 0.733 . . . . 0.0 111.144 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.56 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 0.0 112.344 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -75.29 1.62 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.444 ' C ' ' SD ' ' A' ' 179' ' ' MET . 27.7 t-20 -107.29 -23.1 12.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 13.5 t -80.48 128.45 33.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -130.8 176.83 18.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.5 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.603 ' HG3' HG11 ' A' ' 142' ' ' VAL . 30.5 tt0 -35.99 -61.01 0.51 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.909 0.385 . . . . 0.0 110.863 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 65.9 m -46.39 -60.15 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 35.8 mm-40 -49.98 -61.9 1.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.895 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.439 HD13 HD11 ' A' ' 159' ' ' ILE . 62.5 mt -35.73 -56.01 0.69 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.944 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.535 ' HA ' HG21 ' A' ' 139' ' ' VAL . 62.3 mtp180 -61.76 -55.03 34.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -44.34 -29.53 0.69 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.878 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.449 ' CD2' HG12 ' A' ' 178' ' ' ILE . 11.9 t80 -98.53 -27.4 14.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.935 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.563 ' CE2' HD12 ' A' ' 159' ' ' ILE . 21.4 m-85 -95.1 13.34 25.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptpt -93.93 -9.73 36.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 pttt -84.71 -36.5 21.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -65.02 -35.04 79.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' GLY . . . . . 0.487 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -172.58 -102.14 0.15 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.461 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 137' ' ' GLY . 40.9 t -157.95 105.73 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.535 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.2 t -66.18 119.24 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.14 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 14.4 p -99.09 -37.14 9.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.189 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -135.31 148.78 49.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.872 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.603 HG11 ' HG3' ' A' ' 126' ' ' GLU . 97.6 t -132.07 94.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.135 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.9 t -90.48 138.09 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.104 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.401 ' HE3' HD11 ' A' ' 129' ' ' LEU . 9.2 mtp -137.37 136.06 37.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.562 HD11 ' HE1' ' A' ' 158' ' ' PHE . 58.7 mt -97.66 135.27 32.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.467 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -173.57 164.58 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.91 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.4 t0 -83.05 112.73 20.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.65 -62.75 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.125 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -38.91 -42.96 0.9 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 147' ' ' ASP . 70.0 mttt -79.44 -37.42 37.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 54.88 53.09 10.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.956 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.467 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 11.5 ttt180 -164.72 137.98 3.9 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.578 0.704 . . . . 0.0 110.894 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 116.99 4.81 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.338 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -59.89 -54.64 43.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.28 39.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -169.3 164.92 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.826 0.346 . . . . 0.0 110.91 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.71 -163.33 35.69 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.562 ' HE1' HD11 ' A' ' 145' ' ' ILE . 45.4 m-85 -133.22 161.82 33.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.784 0.326 . . . . 0.0 110.94 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.563 HD12 ' CE2' ' A' ' 133' ' ' PHE . 10.2 mt -148.63 137.51 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 113' ' ' ASN . 32.8 m -106.15 143.14 34.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.456 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 39.2 m-85 -111.23 176.14 5.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.4 tt0 -77.67 -44.83 26.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.896 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' ASP . . . . . 0.467 ' CB ' ' HG2' ' A' ' 165' ' ' GLN . 0.9 OUTLIER -121.54 128.56 52.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -42.02 -23.77 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.467 ' HG2' ' CB ' ' A' ' 163' ' ' ASP . 5.4 pt20 -48.51 -53.4 18.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.921 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.456 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 5.1 m -49.26 -55.95 10.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.846 -179.756 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 171' ' ' VAL . 53.3 t -37.68 -55.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.078 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 168' ' ' ASP . . . . . 0.426 ' OD1' ' C ' ' A' ' 168' ' ' ASP . 0.6 OUTLIER -62.13 -46.3 89.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.874 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -52.0 -52.51 50.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.49 -56.45 15.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.075 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 167' ' ' VAL . 43.2 t -44.63 -55.83 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -38.07 -67.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 83.4 mtp -48.38 -46.29 36.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 19.0 t-160 62.04 26.89 16.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 9.2 m-85 -171.31 150.83 2.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.855 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.4 m-70 -156.7 151.38 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.849 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -107.67 98.98 8.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.888 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.851 HD12 HG21 ' A' ' 183' ' ' VAL . 71.0 mt -119.89 122.08 67.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.444 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 12.4 mtt 54.67 41.58 31.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.05 42.65 99.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 15.2 tptp -148.92 148.65 30.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.826 0.346 . . . . 0.0 110.923 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 7.6 tppt? -88.34 107.21 18.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.906 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.851 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -95.45 112.38 27.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.174 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -74.87 149.48 39.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 117' ' ' VAL . 46.3 t -147.13 136.09 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mtmm -139.89 151.66 45.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.893 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -65.25 125.1 23.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.915 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.084 179.931 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.909 0.385 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -88.45 146.6 25.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.76 HG22 HG13 ' A' ' 167' ' ' VAL . 21.1 pt -132.29 146.64 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.141 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -89.74 111.98 23.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.928 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 185' ' ' VAL . 83.6 t -108.72 114.88 47.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.103 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -119.24 -173.29 15.47 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.69 24.14 31.56 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 121' ' ' PRO . 63.0 mt -69.48 138.19 88.76 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.668 0.747 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.641 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.73 170.33 16.79 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.731 2.287 . . . . 0.0 112.35 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -86.91 24.17 1.57 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -133.63 -33.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.434 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.9 t -66.9 117.79 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.894 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.47 -175.73 16.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.457 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -42.69 -56.17 3.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 0.0 110.856 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 86.7 m -51.3 -57.69 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 mm-40 -51.73 -52.95 44.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.528 HD22 HD11 ' A' ' 159' ' ' ILE . 85.9 mt -44.54 -48.18 10.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.964 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.564 ' HG2' HG11 ' A' ' 139' ' ' VAL . 69.5 mtt180 -69.66 -55.07 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -45.45 -23.98 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.572 ' CD2' HG12 ' A' ' 178' ' ' ILE . 4.3 t80 -103.68 -35.2 8.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.582 ' CE2' HD12 ' A' ' 159' ' ' ILE . 23.7 m-85 -90.33 16.22 9.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -95.23 -23.64 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -71.19 -35.23 71.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.471 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 34.9 m-85 -68.41 -32.59 72.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.77 -111.56 0.29 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.476 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 75.7 t -146.35 110.24 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.837 0.351 . . . . 0.0 111.152 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.564 HG11 ' HG2' ' A' ' 130' ' ' ARG . 93.0 t -72.89 106.05 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.146 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.8 p -79.46 -39.71 31.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -144.73 156.43 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.409 HG11 HD12 ' A' ' 129' ' ' LEU . 96.1 t -134.8 102.56 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.111 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.5 143.53 11.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.5 mtt -145.44 139.03 26.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.872 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.443 HD11 ' HE1' ' A' ' 158' ' ' PHE . 75.4 mt -107.9 136.22 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.15 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.464 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.91 165.34 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.934 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.9 t0 -86.19 114.29 22.9 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.87 -61.52 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 28.3 tt0 -36.08 -46.01 0.47 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 27.6 mttp -80.08 -40.29 27.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 60.0 48.27 8.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.1 ttp180 -158.98 138.8 8.65 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.609 0.719 . . . . 0.0 110.884 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 109.92 2.43 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.271 . . . . 0.0 112.334 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.8 mtt180 -50.17 -50.6 48.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.843 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 159.89 39.89 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -169.0 161.98 10.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.882 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.429 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.15 -150.2 18.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.469 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.443 ' HE1' HD11 ' A' ' 145' ' ' ILE . 11.3 m-85 -147.72 169.82 18.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.882 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.582 HD12 ' CE2' ' A' ' 133' ' ' PHE . 23.0 mt -151.13 141.81 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.103 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.2 m -106.95 142.27 36.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.15 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.577 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 50.1 m-85 -113.83 169.35 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -77.33 -38.37 50.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -130.05 136.57 49.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 165' ' ' GLN . 8.6 tm-20 -45.67 -45.37 14.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.924 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 164' ' ' GLU . 26.3 tt0 -35.29 -47.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.577 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 42.9 m -53.15 -54.07 41.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.847 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.76 HG13 HG22 ' A' ' 115' ' ' ILE . 53.3 t -43.88 -45.46 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -65.65 -45.49 82.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' GLN . . . . . 0.471 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 44.3 mm-40 -48.48 -45.42 36.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -76.43 -59.79 2.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.633 HG21 ' HG3' ' A' ' 187' ' ' ARG . 86.4 t -43.12 -51.4 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.14 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -39.71 -63.2 0.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.891 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 15.3 mtm -59.31 -38.33 80.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 15.0 t-160 59.27 25.46 14.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.473 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.9 m-85 -169.82 153.14 4.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.836 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.473 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 37.9 m80 -159.2 159.42 34.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -116.49 90.31 3.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 183' ' ' VAL . 51.3 mt -105.69 111.78 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 7.4 mtt 61.84 42.33 10.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.41 47.13 87.57 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.453 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.404 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 12.2 tppt? -151.47 140.29 20.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.894 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -84.83 102.94 13.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.92 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -92.99 132.86 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.169 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -92.54 144.95 24.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.877 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 117' ' ' VAL . 32.6 t -141.15 131.34 26.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -143.45 141.53 30.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.633 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.2 mtm105 -45.79 115.93 1.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.826 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.076 179.913 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.946 0.403 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttpp -92.97 140.99 28.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.622 HG22 HG13 ' A' ' 167' ' ' VAL . 28.2 pt -124.49 151.15 29.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.143 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -98.44 108.37 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.912 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 185' ' ' VAL . 95.4 t -101.21 121.8 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.15 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.7 175.72 18.58 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.67 13.34 60.92 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.561 HG23 ' HD2' ' A' ' 121' ' ' PRO . 31.2 mt -61.87 137.15 95.26 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.718 . . . . 0.0 111.142 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.561 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.74 163.52 37.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.691 2.261 . . . . 0.0 112.344 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -77.44 1.35 19.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -106.65 -23.72 12.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 14.0 t -79.85 133.39 36.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.77 -165.59 11.79 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.593 ' HG3' HG11 ' A' ' 142' ' ' VAL . 38.2 tt0 -52.57 -68.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 34.9 m -38.69 -67.8 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.13 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 17.5 mp0 -38.68 -61.33 0.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 ' CE ' ' A' ' 144' ' ' MET . 73.7 mt -40.68 -46.56 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.909 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.482 ' HA ' HG21 ' A' ' 139' ' ' VAL . 14.3 mtp-105 -70.0 -52.3 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -51.92 -23.94 5.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -100.24 -30.21 12.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.531 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.1 m-85 -94.24 13.75 22.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -94.03 -13.75 26.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.0 pttm -79.83 -37.54 34.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -68.62 -33.9 74.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.98 -116.33 0.38 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.474 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 36.1 t -146.16 106.31 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.879 0.371 . . . . 0.0 111.152 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 130' ' ' ARG . 39.0 t -68.12 115.26 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.094 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 41.8 p -95.94 -39.0 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -133.59 144.06 49.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.593 HG11 ' HG3' ' A' ' 126' ' ' GLU . 72.6 t -130.34 94.44 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.129 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.0 t -88.7 141.52 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.116 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.511 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 7.6 mtt -140.58 137.1 33.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.9 mt -99.89 126.81 53.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -167.07 165.42 15.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.917 -179.984 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.441 ' O ' ' C ' ' A' ' 148' ' ' ALA . 19.2 t0 -85.33 113.58 21.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.44 -59.13 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.077 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -41.39 -42.88 2.38 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.92 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.427 ' N ' ' O ' ' A' ' 147' ' ' ASP . 19.4 mttp -79.25 -41.08 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.01 50.14 6.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.0 ttm-85 -162.88 138.02 5.2 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.598 0.713 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.511 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.76 112.12 2.99 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.748 2.298 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 67.5 mtp180 -52.65 -57.03 11.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.845 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 169.5 40.54 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.422 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.5 p90 -171.69 165.54 6.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.856 0.36 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.98 -153.97 24.61 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 59.6 m-85 -143.94 160.6 40.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.915 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.531 HD12 ' CD2' ' A' ' 133' ' ' PHE . 7.8 mt -148.42 135.93 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.9 m -103.87 142.98 33.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -112.22 168.39 9.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 58.4 tt0 -69.75 -38.65 76.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -131.1 143.68 50.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 165' ' ' GLN . 11.4 tt0 -50.66 -44.31 57.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.417 ' C ' ' O ' ' A' ' 164' ' ' GLU . 34.5 tt0 -36.1 -52.67 0.78 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.1 m -46.37 -55.68 6.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.622 HG13 HG22 ' A' ' 115' ' ' ILE . 40.6 t -38.48 -56.57 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.13 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -52.87 -59.09 4.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -39.12 -38.3 0.47 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.931 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.457 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -77.6 -65.37 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.111 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.66 HG21 ' HG3' ' A' ' 187' ' ' ARG . 84.1 t -43.98 -55.41 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.129 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.451 ' C ' ' O ' ' A' ' 171' ' ' VAL . 0.7 OUTLIER -34.48 -59.48 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.865 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 60.1 mtp -65.33 -35.18 80.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.515 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.6 t-160 54.69 27.39 8.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.7 m-85 -167.89 152.21 6.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 55.1 m80 -159.8 147.61 16.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.854 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -103.73 99.24 9.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.81 HD12 HG21 ' A' ' 183' ' ' VAL . 58.0 mt -120.66 124.35 72.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.165 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.4 mmt 57.03 34.89 25.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.814 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 67.15 48.84 57.24 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 5.1 tmtm? -161.01 150.21 16.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 182' ' ' LYS . . . . . 0.461 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -83.02 126.46 32.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.81 HG21 HD12 ' A' ' 178' ' ' ILE . 5.5 t -114.19 110.87 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.121 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -70.94 143.97 50.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 117' ' ' VAL . 40.0 t -143.34 131.31 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.161 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.0 mmmt -145.61 144.06 30.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.933 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.66 ' HG3' HG21 ' A' ' 171' ' ' VAL . 14.0 mtp180 -48.17 125.43 9.26 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.109 179.899 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.865 0.364 . . . . 0.0 110.861 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 4.4 ttpm? -104.12 143.7 32.57 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.848 HG22 HG13 ' A' ' 167' ' ' VAL . 22.5 pt -125.75 155.37 35.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -103.38 104.48 14.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 185' ' ' VAL . 79.1 t -99.4 118.85 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -124.54 -172.53 13.59 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.477 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.28 17.78 19.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.479 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.634 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.4 mt -64.7 138.31 97.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.68 0.752 . . . . 0.0 111.101 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.5 Cg_endo -69.69 165.62 30.27 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.485 ' ND1' ' NH2' ' A' ' 152' ' ' ARG . 63.9 m-70 -80.58 13.91 2.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.434 ' C ' ' HG3' ' A' ' 179' ' ' MET . 3.3 m120 -122.02 -25.1 5.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.453 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -74.74 133.48 42.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.28 -161.06 10.09 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.508 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.13 -63.52 1.23 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.942 0.401 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 64.1 m -44.49 -59.17 2.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.142 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.44 ' O ' ' C ' ' A' ' 129' ' ' LEU . 57.1 mm-40 -50.35 -63.91 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 128' ' ' GLU . 50.0 mt -34.91 -52.39 0.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.447 ' O ' ' N ' ' A' ' 134' ' ' LYS . 62.7 mtp180 -66.19 -54.15 28.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.864 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 44.2 mm-40 -48.16 -26.5 1.92 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.483 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.7 t80 -100.79 -21.79 15.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -105.79 14.45 28.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.447 ' N ' ' O ' ' A' ' 130' ' ' ARG . 15.5 pttp -94.81 -17.56 22.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.37 -37.98 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -65.17 -34.36 78.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.17 -114.61 0.31 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.43 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 37.5 t -148.1 109.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.834 0.35 . . . . 0.0 111.172 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.418 HG11 ' HG2' ' A' ' 130' ' ' ARG . 47.3 t -74.55 105.99 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.0 p -81.21 -33.05 33.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.12 153.2 37.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.411 HG21 ' CG ' ' A' ' 130' ' ' ARG . 95.6 t -131.34 105.97 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 49.0 t -91.73 143.16 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.405 ' HE3' HD11 ' A' ' 129' ' ' LEU . 7.1 mtt -143.34 133.71 24.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.887 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 158' ' ' PHE . 63.2 mt -97.09 139.82 18.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.449 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -175.05 165.88 3.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.926 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.432 ' O ' ' C ' ' A' ' 148' ' ' ALA . 35.4 t0 -86.67 110.07 19.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.432 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.23 -57.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' ALA . 30.7 tt0 -37.06 -45.35 0.59 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.91 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.33 -37.14 20.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 60.05 52.79 4.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.485 ' NH2' ' ND1' ' A' ' 122' ' ' HIS . 2.1 ttt85 -160.86 138.9 7.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.646 0.736 . . . . 0.0 110.869 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 117.86 5.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.669 2.246 . . . . 0.0 112.355 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -61.1 -54.27 46.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.14 41.49 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.536 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -173.13 162.46 4.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.19 -153.47 23.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.557 ' HE1' HD11 ' A' ' 145' ' ' ILE . 53.9 m-85 -139.96 164.5 29.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 21.3 mt -147.13 139.7 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 57.0 m -105.08 142.98 33.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.434 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 46.8 m-85 -115.86 166.35 12.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.903 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -67.39 -42.77 82.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -131.14 141.06 50.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.864 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 165' ' ' GLN . 30.5 tt0 -46.04 -44.39 15.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 164' ' ' GLU . 23.8 tp60 -36.43 -55.67 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.434 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 16.4 m -44.31 -52.41 7.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.848 HG13 HG22 ' A' ' 115' ' ' ILE . 73.4 t -44.65 -54.86 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -52.82 -50.67 63.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.1 mm100 -45.86 -50.48 14.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.918 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.06 -53.86 15.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.094 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.84 HG21 ' HG3' ' A' ' 187' ' ' ARG . 70.1 t -44.31 -61.79 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.107 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 171' ' ' VAL . 62.7 t30 -35.61 -56.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 1.3 tpt -58.28 -41.51 84.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.92 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.9 t-160 51.15 30.75 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.551 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 4.9 m-85 -173.35 150.62 1.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 56.1 m80 -161.9 156.97 23.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -111.04 102.36 10.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.922 HD12 HG21 ' A' ' 183' ' ' VAL . 31.4 mt -129.06 134.91 63.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.15 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.434 ' HG3' ' C ' ' A' ' 123' ' ' ASN . 9.8 mmt 54.83 30.55 13.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.63 45.76 65.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.404 ' NZ ' ' HA ' ' A' ' 121' ' ' PRO . 19.9 ttmt -160.15 161.93 33.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.909 0.385 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.62 125.57 34.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.922 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -110.35 115.02 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.157 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 184' ' ' GLU . . . . . 0.404 ' HG2' ' CD2' ' A' ' 174' ' ' HIS . 9.4 tt0 -77.32 148.32 35.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.886 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 117' ' ' VAL . 41.9 t -146.89 133.12 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.4 mttm -139.69 169.75 17.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.84 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.9 mtp180 -78.3 117.25 19.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.1 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 m-20 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.864 0.364 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -98.33 142.38 30.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.925 HG22 HG13 ' A' ' 167' ' ' VAL . 30.1 pt -125.24 153.05 32.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.09 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.414 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 30.8 t80 -98.97 105.53 17.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 185' ' ' VAL . 94.4 t -101.92 114.08 40.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.111 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.06 177.02 16.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.531 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.59 13.26 60.62 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.558 HG23 ' HD2' ' A' ' 121' ' ' PRO . 29.7 mt -61.86 137.14 95.24 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.558 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.4 Cg_endo -69.72 165.41 31.02 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.354 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.7 m-70 -78.68 0.65 25.76 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.827 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -106.04 -23.8 12.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.889 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.486 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.4 t -81.16 133.1 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.73 -166.81 11.72 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.431 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.463 ' HG2' ' CZ ' ' A' ' 130' ' ' ARG . 12.4 tt0 -54.21 -59.96 3.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.874 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 35.9 m -45.78 -61.78 1.58 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.17 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 129' ' ' LEU . 53.8 mm-40 -47.91 -64.7 0.72 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.441 HD22 ' HE2' ' A' ' 133' ' ' PHE . 62.6 mt -36.22 -58.46 0.68 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.521 ' HG2' HG11 ' A' ' 139' ' ' VAL . 59.7 mtm180 -58.6 -51.06 71.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.3 mm-40 -57.29 -17.42 11.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.491 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 21.5 t80 -108.0 -17.45 14.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.542 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.3 m-85 -104.18 -6.35 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.885 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.5 pttp -76.58 -21.26 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -69.91 -36.32 75.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.869 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -70.55 -32.25 69.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.75 -111.25 0.26 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.545 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.0 t -150.05 108.12 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.912 0.387 . . . . 0.0 111.117 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.521 HG11 ' HG2' ' A' ' 130' ' ' ARG . 74.0 t -72.53 104.91 2.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.14 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -81.29 -36.8 29.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.146 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -141.33 154.76 45.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.06 105.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 42.9 t -92.83 137.12 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.436 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 5.2 mtt -137.7 136.79 37.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.904 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.401 HD11 ' HE1' ' A' ' 158' ' ' PHE . 62.7 mt -102.1 135.0 41.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.437 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.17 165.44 4.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.973 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 150' ' ' LYS . 48.5 t0 -81.92 113.64 19.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.871 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.409 ' O ' ' HG3' ' A' ' 151' ' ' GLN . . . -37.31 -41.85 0.44 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.09 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -42.78 86.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 147' ' ' ASP . 3.0 mptp? -80.45 -31.41 37.45 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 148' ' ' ALA . 6.1 mt-30 52.3 44.01 30.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.4 ttm-85 -155.51 138.68 10.77 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.672 0.749 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.436 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.4 Cg_endo -69.77 111.01 2.7 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.655 2.237 . . . . 0.0 112.37 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.419 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 36.0 mtt180 -52.34 -53.08 49.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.73 40.73 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.419 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 35.6 p90 -169.29 163.85 10.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.931 0.396 . . . . 0.0 110.866 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 161.67 -157.87 29.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.506 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.414 ' CD2' ' HA ' ' A' ' 116' ' ' PHE . 12.5 m-85 -139.51 169.98 16.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.542 HD12 ' CE2' ' A' ' 133' ' ' PHE . 12.6 mt -152.68 136.68 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 19.2 m -105.03 135.9 45.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.52 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 35.0 m-85 -104.67 174.11 6.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.82 -40.32 48.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -127.55 137.54 52.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 165' ' ' GLN . 16.1 tm-20 -44.64 -45.71 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.0 tp60 -36.99 -55.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.904 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.52 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 13.1 m -45.58 -49.34 14.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.925 HG13 HG22 ' A' ' 115' ' ' ILE . 71.0 t -48.81 -47.17 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.091 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -62.88 -49.35 75.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 31.5 mm-40 -47.82 -48.5 30.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -74.33 -43.95 54.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.62 HG23 ' O ' ' A' ' 167' ' ' VAL . 25.6 t -55.36 -62.35 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 171' ' ' VAL . 2.1 t-20 -36.76 -55.67 0.87 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 98.2 mtp -55.12 -44.0 74.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.879 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.523 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.4 t-160 58.31 25.14 12.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.885 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.523 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.3 m-85 -169.65 152.62 4.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.85 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.491 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.6 m80 -158.5 154.15 26.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.806 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.63 93.8 4.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.856 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.933 HD12 HG21 ' A' ' 183' ' ' VAL . 59.2 mt -110.39 115.43 49.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 11.9 mtp 60.87 36.13 19.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.898 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.79 50.49 35.52 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.492 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.464 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.6 tmtt? -158.01 146.96 19.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.864 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 182' ' ' LYS . . . . . 0.464 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.1 OUTLIER -85.03 117.12 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.94 179.838 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.933 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -106.31 118.88 54.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.15 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -76.0 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 117' ' ' VAL . 44.6 t -146.65 127.4 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt -135.76 146.45 47.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 19.7 ttp180 -55.69 108.93 0.49 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.881 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.135 179.878 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.845 0.355 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -110.84 150.86 28.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.417 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.85 154.05 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.135 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 10.2 t80 -102.73 103.42 13.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 185' ' ' VAL . 86.2 t -97.76 115.87 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.97 174.24 16.04 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.95 26.02 71.08 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.485 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.624 HG23 ' HD2' ' A' ' 121' ' ' PRO . 52.7 mt -73.17 138.22 78.84 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.634 0.731 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.624 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.77 158.76 55.84 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.72 3.43 6.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -106.89 -37.14 6.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.544 ' SG ' HG21 ' A' ' 178' ' ' ILE . 44.0 t -67.68 136.95 55.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.429 ' H ' ' CG ' ' A' ' 128' ' ' GLU . . . -135.66 179.54 17.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 125' ' ' GLY . 24.0 tt0 -35.75 -69.68 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.4 m -40.84 -60.0 1.28 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.159 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.429 ' CG ' ' H ' ' A' ' 125' ' ' GLY . 49.1 mm-40 -44.74 -64.77 0.63 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.55 HD11 ' HE3' ' A' ' 144' ' ' MET . 65.7 mt -35.92 -47.04 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.523 ' HA ' HG21 ' A' ' 139' ' ' VAL . 36.7 mtm180 -67.38 -60.75 2.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.866 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -41.81 -25.69 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 11.6 t80 -102.77 -24.18 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.584 ' CE2' HD12 ' A' ' 159' ' ' ILE . 12.8 m-85 -99.74 16.3 24.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.923 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 3.9 ptpp? -95.31 -14.79 23.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -79.09 -37.68 38.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.896 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.416 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 39.0 m-85 -67.65 -25.06 65.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.06 -114.69 0.48 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 96.3 t -145.73 111.56 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.097 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.523 HG21 ' HA ' ' A' ' 130' ' ' ARG . 15.6 t -74.53 114.46 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 42.8 p -93.01 -37.29 12.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.75 152.72 45.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -135.02 100.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 81.4 t -84.98 143.2 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.109 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.55 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.2 mtt -144.29 132.61 21.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.476 HD11 ' HE1' ' A' ' 158' ' ' PHE . 68.4 mt -98.49 134.64 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -172.84 164.56 5.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.96 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' ALA . 24.3 t0 -85.35 115.6 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.422 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.65 -57.32 0.65 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -42.67 -41.9 3.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.412 ' N ' ' O ' ' A' ' 147' ' ' ASP . 16.3 ttmt -80.14 -41.18 25.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 60.08 50.41 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 8.2 ttp85 -164.99 138.93 4.0 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.618 0.723 . . . . 0.0 110.843 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.428 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.77 109.64 2.36 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.734 2.289 . . . . 0.0 112.357 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 32.5 mtp180 -49.58 -51.43 37.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 162.05 39.46 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.499 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -171.2 159.83 6.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.82 -155.08 25.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.476 ' HE1' HD11 ' A' ' 145' ' ' ILE . 51.2 m-85 -139.62 161.45 37.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.7 mt -145.0 141.56 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 42.5 m -109.43 141.03 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.173 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.508 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 51.9 m-85 -110.42 177.95 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -80.3 -40.31 27.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.871 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -127.85 146.41 50.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.807 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 165' ' ' GLN . 43.1 tp10 -51.58 -47.05 63.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.0 tt0 -36.63 -44.97 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.508 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 14.6 m -53.49 -47.93 69.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.883 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.417 HG13 HG22 ' A' ' 115' ' ' ILE . 37.6 t -51.3 -46.95 34.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.173 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -51.03 -65.73 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.867 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 41.7 mt-30 -42.95 -53.58 4.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.627 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -52.04 -45.48 64.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.045 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.8 HG21 ' HG3' ' A' ' 187' ' ' ARG . 93.5 t -70.0 -63.88 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.109 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 171' ' ' VAL . 8.3 m-20 -34.16 -43.99 0.17 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 5.2 ttt -68.36 -47.27 67.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.54 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 12.0 t-160 56.85 27.22 12.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.824 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.54 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.0 m-85 -174.18 151.45 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.459 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 45.6 m80 -158.87 161.49 36.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -117.0 87.15 2.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.857 HD12 HG21 ' A' ' 183' ' ' VAL . 63.7 mt -106.61 126.41 62.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.111 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.409 ' HG2' HG22 ' A' ' 178' ' ' ILE . 3.8 mmt 52.36 40.12 28.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.69 47.67 87.34 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.416 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 2.5 tmtt? -155.07 146.93 23.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.808 0.337 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 182' ' ' LYS . . . . . 0.416 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 6.2 tptm -81.18 117.38 21.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.888 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.857 HG21 HD12 ' A' ' 178' ' ' ILE . 2.9 t -109.41 120.55 60.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -80.45 153.47 28.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 117' ' ' VAL . 41.4 t -149.48 130.96 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -141.46 144.26 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.91 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.8 ' HG3' HG21 ' A' ' 171' ' ' VAL . 8.7 mtm180 -45.93 124.44 5.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.861 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.897 0.38 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.9 ttpt -97.01 139.1 33.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.939 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -123.42 154.59 29.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -99.65 103.65 15.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 185' ' ' VAL . 93.2 t -100.41 111.7 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.02 -173.05 15.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.506 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.42 12.81 14.1 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.481 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.65 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.7 mt -57.3 138.42 80.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.653 0.74 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.65 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.9 Cg_endo -69.76 172.42 12.67 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.35 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.449 ' O ' ' NH2' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -85.0 17.89 2.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.823 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -128.29 -29.8 2.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.866 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.456 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -68.06 128.77 37.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.53 173.11 21.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.452 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.444 ' C ' ' O ' ' A' ' 125' ' ' GLY . 29.9 tt0 -34.34 -65.87 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.873 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 99.7 m -40.85 -61.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 129' ' ' LEU . 5.5 mp0 -54.31 -60.58 3.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.644 HD11 ' HE3' ' A' ' 144' ' ' MET . 59.9 mt -34.39 -45.92 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HA ' HG21 ' A' ' 139' ' ' VAL . 26.6 mtt180 -70.38 -55.75 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -46.5 -24.75 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.56 ' CD2' HG12 ' A' ' 178' ' ' ILE . 5.1 t80 -100.95 -29.78 12.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.576 ' CE2' HD12 ' A' ' 159' ' ' ILE . 19.7 m-85 -96.17 15.45 20.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.3 ptpt -95.27 -25.07 16.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.906 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.1 pttm -69.44 -38.83 77.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.867 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -66.02 -31.36 72.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -174.94 -115.24 0.4 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.5 t -146.13 106.42 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.882 0.373 . . . . 0.0 111.088 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.452 HG21 ' HA ' ' A' ' 130' ' ' ARG . 22.9 t -71.22 109.4 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.088 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 20.1 p -85.92 -39.78 16.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -139.84 151.98 46.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.9 t -134.01 102.46 4.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.137 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 158' ' ' PHE . 98.6 t -87.33 145.27 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.644 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.7 mtt -145.58 133.75 21.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.816 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.38 139.63 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.456 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.88 167.03 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 180.0 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.4 t0 -87.16 112.49 22.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.891 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.09 -60.0 0.34 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -39.38 -44.69 1.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 21.1 tttm -79.43 -40.13 30.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.92 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 60.05 45.08 12.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.456 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.8 ttt180 -155.37 138.21 10.48 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.654 0.74 . . . . 0.0 110.848 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 116.02 4.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.675 2.25 . . . . 0.0 112.371 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 41.6 mtp180 -58.67 -56.87 16.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.03 42.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.473 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -173.23 158.17 3.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.92 0.391 . . . . 0.0 110.866 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -151.44 19.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.489 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' PHE . . . . . 0.4 ' O ' ' O ' ' A' ' 143' ' ' VAL . 86.7 m-85 -138.36 164.69 28.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.823 0.344 . . . . 0.0 110.894 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.576 HD12 ' CE2' ' A' ' 133' ' ' PHE . 19.5 mt -148.31 134.12 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 17.9 m -102.34 143.13 32.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.159 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 41.5 m-85 -113.19 174.46 5.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.825 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -74.32 -38.76 63.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -135.17 151.38 50.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 165' ' ' GLN . 23.3 tt0 -51.9 -50.69 60.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.441 ' C ' ' O ' ' A' ' 164' ' ' GLU . 31.6 tp60 -34.54 -54.83 0.54 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.545 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 18.6 m -41.54 -58.71 1.83 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.86 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.939 HG13 HG22 ' A' ' 115' ' ' ILE . 62.2 t -42.27 -54.87 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.105 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 168' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 169' ' ' GLN . 27.5 t0 -47.14 -62.53 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 169' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 168' ' ' ASP . 49.1 mt-30 -36.98 -51.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.882 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.79 -67.55 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.448 ' O ' ' C ' ' A' ' 172' ' ' ASN . 98.8 t -39.36 -58.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.9 t30 -34.44 -56.53 0.52 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 85.3 mtp -61.55 -45.02 95.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 62.01 25.97 15.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.3 m-85 -172.85 147.5 1.71 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' HIS . . . . . . . . . . . . . 45.7 m80 -156.62 164.56 38.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.87 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -118.76 90.96 3.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.666 HD12 HG21 ' A' ' 183' ' ' VAL . 67.9 mt -111.06 119.23 59.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.151 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.5 mmt 60.07 39.63 19.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 54.64 32.69 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.436 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 7.7 tppt? -163.23 145.51 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.367 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 11.7 tptt -82.54 109.0 16.36 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.902 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.666 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -97.07 127.46 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -87.65 140.09 29.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 117' ' ' VAL . 25.4 t -139.2 136.33 41.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 24.6 mtmt -144.71 175.0 10.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.866 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.429 ' CG ' HG21 ' A' ' 171' ' ' VAL . 8.4 mtp180 -81.17 120.39 24.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.875 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.907 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.884 0.374 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -89.58 142.55 27.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.977 HG22 HG13 ' A' ' 167' ' ' VAL . 18.7 pt -128.12 148.04 32.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.151 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -93.96 114.61 26.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 185' ' ' VAL . 81.2 t -111.1 117.16 54.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.115 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.61 176.7 16.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.519 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.39 24.72 69.41 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.636 HG23 ' HD2' ' A' ' 121' ' ' PRO . 57.0 mt -71.87 138.48 82.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.617 0.722 . . . . 0.0 111.142 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.636 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.4 Cg_endo -69.78 165.35 31.31 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -78.96 10.99 2.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.87 -34.48 4.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.1 t -68.96 121.43 16.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -121.68 -169.29 13.59 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.98 -59.1 3.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -47.24 -61.19 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.127 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HG3' ' CE ' ' A' ' 179' ' ' MET . 65.2 mm-40 -47.67 -65.14 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 40.7 mt -34.03 -49.83 0.36 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.944 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -68.72 -53.99 18.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 23.0 mm-40 -46.2 -23.73 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.507 ' CZ ' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -103.56 -34.65 8.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.02 16.86 8.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -95.29 -23.39 17.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.23 -39.04 68.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.94 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -60.56 -35.5 76.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -173.04 -107.71 0.21 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 93.4 t -152.24 107.9 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.26 107.71 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.133 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.5 p -82.08 -37.16 26.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -143.89 154.8 43.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.7 t -134.96 102.81 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 59.7 t -89.33 143.65 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.458 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.1 mtt -144.31 135.92 25.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.0 mt -102.26 135.75 37.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.481 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.72 3.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' ALA . 28.8 t0 -85.19 110.4 18.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.857 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.457 ' O ' ' C ' ' A' ' 149' ' ' GLU . . . -34.7 -57.22 0.53 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.066 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.457 ' C ' ' O ' ' A' ' 148' ' ' ALA . 7.9 mm-40 -33.31 -48.32 0.23 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -87.55 -34.93 18.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 5.5 mm-40 59.0 54.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.481 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.9 ttm-85 -158.16 137.65 8.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' PRO . . . . . 0.458 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.77 110.18 2.49 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.438 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 42.1 mtt180 -51.86 -47.63 64.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 157.93 38.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.489 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 41.4 p90 -166.52 167.7 15.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.903 0.382 . . . . 0.0 110.907 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.3 -156.72 27.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.499 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -139.48 166.92 23.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.933 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.0 mt -149.53 138.98 15.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 27.3 m -106.87 140.53 39.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.142 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' PHE . . . . . 0.551 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -110.84 176.67 4.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -78.18 -44.42 25.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -124.82 133.45 53.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -41.26 -43.49 2.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -39.24 -47.77 1.7 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.551 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 70.8 m -50.59 -49.48 56.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.866 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.977 HG13 HG22 ' A' ' 115' ' ' ILE . 78.5 t -47.4 -62.39 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -44.96 -53.98 7.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -46.18 -47.48 17.72 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -69.87 -56.06 8.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.1 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 172' ' ' ASN . 91.1 t -49.78 -61.82 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 171' ' ' VAL . 15.0 t-20 -34.35 -62.88 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.875 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 24.2 mmm -49.9 -42.73 48.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.9 t-160 56.18 26.03 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.514 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 6.2 m-85 -169.91 154.01 5.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 84.8 m-70 -160.81 153.97 21.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -112.26 89.31 3.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.858 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.959 HD12 HG21 ' A' ' 183' ' ' VAL . 59.6 mt -106.23 109.57 28.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.154 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.468 ' CE ' ' HG3' ' A' ' 128' ' ' GLU . 5.0 mtm 62.14 43.22 8.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.69 50.72 59.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 181' ' ' LYS . . . . . 0.468 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.4 tmtt? -155.9 144.83 20.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.846 0.355 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 182' ' ' LYS . . . . . 0.468 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 9.0 tppt? -87.77 112.74 22.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.959 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -102.79 119.56 51.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.149 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -79.24 140.73 37.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 117' ' ' VAL . 67.4 t -139.67 140.2 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.16 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -142.27 162.45 35.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.863 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 17.1 ttt180 -78.01 121.47 24.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.926 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.86 0.362 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.4 ttpt -85.29 142.82 29.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ILE . . . . . 0.652 HG22 HG13 ' A' ' 167' ' ' VAL . 21.8 pt -125.91 158.7 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.104 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 12.3 t80 -105.07 104.65 14.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 185' ' ' VAL . 71.9 t -100.63 114.33 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.112 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.14 -169.52 13.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.86 12.92 4.03 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.44 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.653 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.4 mt -57.39 138.41 81.08 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.609 0.719 . . . . 0.0 111.121 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.653 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.78 -174.24 0.87 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.248 . . . . 0.0 112.339 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.07 3.12 53.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -115.38 -10.71 11.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' CYS . . . . . 0.474 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.7 t -87.05 125.46 34.12 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.42 -172.86 13.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.512 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.416 ' HA ' HD12 ' A' ' 129' ' ' LEU . 47.2 tt0 -51.18 -66.06 0.45 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.8 m -44.14 -63.59 0.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.152 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -40.55 -58.42 1.6 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.881 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.48 HD11 ' HE3' ' A' ' 144' ' ' MET . 50.2 mt -40.99 -47.04 2.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.597 ' HA ' HG21 ' A' ' 139' ' ' VAL . 49.0 mtm180 -66.39 -61.25 2.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.882 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -43.31 -23.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' TYR . . . . . 0.405 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.2 t80 -101.08 -32.83 10.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.933 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.409 ' CD2' HD12 ' A' ' 159' ' ' ILE . 12.2 m-85 -93.52 15.3 16.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.851 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 pttt -95.11 -19.32 20.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.3 pttt -73.06 -30.39 63.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.893 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.482 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 44.4 m-85 -74.1 -37.12 64.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.15 -110.52 0.23 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.49 113.08 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.87 0.367 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.597 HG21 ' HA ' ' A' ' 130' ' ' ARG . 57.3 t -74.84 99.88 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 19.2 p -74.8 -42.11 58.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -142.96 155.08 44.63 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.877 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 159' ' ' ILE . 78.2 t -134.76 104.7 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.121 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.4 t -90.24 144.97 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.156 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.48 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.0 mtt -143.87 135.13 25.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 69.9 mt -98.38 133.35 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.165 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.452 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.68 165.35 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.449 ' O ' ' C ' ' A' ' 148' ' ' ALA . 22.1 t0 -81.61 110.11 16.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.82 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.449 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.69 -58.15 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.122 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -43.13 -43.67 4.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' LYS . . . . . 0.443 ' N ' ' O ' ' A' ' 147' ' ' ASP . 35.0 mttm -78.0 -40.35 39.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 59.97 50.28 6.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.933 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.452 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.0 ttt85 -161.65 138.01 6.1 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.627 0.727 . . . . 0.0 110.899 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 121.64 8.33 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.657 2.238 . . . . 0.0 112.349 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.475 ' HD3' ' CZ ' ' A' ' 156' ' ' PHE . 50.5 mtp180 -65.67 -53.95 34.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.869 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.91 38.25 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.45 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.475 ' CZ ' ' HD3' ' A' ' 154' ' ' ARG . 37.1 p90 -168.12 162.84 13.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.857 0.36 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.88 -155.18 26.42 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.467 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -139.55 169.46 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.794 0.33 . . . . 0.0 110.912 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 142' ' ' VAL . 11.0 mt -151.79 135.44 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.164 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 31.6 m -102.18 140.38 36.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -111.46 172.84 6.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -73.05 -34.72 66.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -137.94 152.68 49.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 165' ' ' GLN . 12.0 tm-20 -56.36 -49.64 73.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 165' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 164' ' ' GLU . 2.0 tp-100 -34.81 -47.28 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 1.2 m -48.34 -54.55 13.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.652 HG13 HG22 ' A' ' 115' ' ' ILE . 69.8 t -43.4 -49.9 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.126 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 169' ' ' GLN . 1.2 m-20 -54.37 -61.54 2.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 169' ' ' GLN . . . . . 0.482 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -35.99 -45.57 0.43 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.934 -179.919 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.39 -63.12 1.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.092 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 172' ' ' ASN . 85.1 t -43.16 -54.96 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 171' ' ' VAL . 32.2 t30 -34.65 -50.91 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 41.2 mtp -74.36 -39.91 62.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 16.3 t-160 59.54 27.44 16.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.6 m-85 -169.84 152.68 4.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' HIS . . . . . 0.434 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 56.8 m80 -157.94 151.74 23.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -107.4 93.55 4.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' ILE . . . . . 0.824 HD12 HG21 ' A' ' 183' ' ' VAL . 53.6 mt -116.23 119.46 62.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 6.9 mmt 56.83 47.47 17.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 56.43 56.16 25.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.529 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 25.5 tptt -165.21 149.33 8.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.84 0.352 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 182' ' ' LYS . . . . . 0.426 ' HE3' ' CG ' ' A' ' 175' ' ' PHE . 14.4 tptt -90.43 110.39 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 183' ' ' VAL . . . . . 0.824 HG21 HD12 ' A' ' 178' ' ' ILE . 4.1 t -95.21 131.07 43.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.103 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -88.65 146.01 25.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 117' ' ' VAL . 54.9 t -140.6 127.18 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.098 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 3.9 mtmp? -142.89 143.57 32.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.915 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.61 ' HD3' HG11 ' A' ' 167' ' ' VAL . 3.1 mmt85 -46.76 139.67 5.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.931 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.3 t -108.41 166.31 10.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.861 0.363 . . . . 0.0 110.852 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 29.5 t -123.38 90.84 3.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.868 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 178.02 97.09 0.11 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.465 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.8 p -144.68 124.86 13.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.895 0.378 . . . . 0.0 110.865 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 77.0 p -98.4 -44.58 6.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -43.3 107.22 0.11 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.497 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 m -43.8 -43.59 6.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 51.1 mttm -68.86 139.33 55.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 52.1 p -104.06 96.25 6.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.21 38.74 0.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -102.38 143.28 32.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 167' ' ' VAL . 33.0 pt -126.55 152.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -97.08 109.03 21.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 185' ' ' VAL . 90.5 t -104.43 113.02 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.65 176.51 16.38 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.95 5.42 46.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.459 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.2 mt -52.75 138.02 43.38 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 111.161 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.606 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.52 24.22 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.712 2.275 . . . . 0.0 112.363 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.456 ' CE1' HH11 ' A' ' 152' ' ' ARG . 41.1 t-80 -82.93 10.34 8.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.39 -20.21 8.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.482 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 11.6 t -80.5 142.15 34.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.09 -171.88 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -48.16 -57.93 5.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.6 m -47.01 -60.14 2.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 129' ' ' LEU . 1.7 mp0 -53.83 -63.45 1.15 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.89 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 128' ' ' GLU . 63.5 mt -34.31 -62.5 0.33 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.654 ' CG ' HG21 ' A' ' 142' ' ' VAL . 51.0 mtp180 -59.02 -52.03 67.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -50.5 -22.52 1.98 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.45 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 13.4 t80 -104.65 -20.62 13.59 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.468 ' CE2' HD12 ' A' ' 159' ' ' ILE . 20.8 m-85 -102.49 15.49 29.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.937 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 32.1 pttt -94.14 -16.44 23.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 3.7 pttm -76.14 -36.67 58.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -67.95 -26.57 66.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.876 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.39 -114.69 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 66.3 t -144.16 116.71 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 111.137 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 43.3 t -79.82 113.53 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 76.5 p -90.11 -36.0 15.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -143.52 152.29 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.869 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.654 HG21 ' CG ' ' A' ' 130' ' ' ARG . 57.8 t -134.82 101.99 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.7 t -87.92 143.86 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.147 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.621 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 6.0 mtt -144.94 131.47 19.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.54 HD11 ' HE1' ' A' ' 158' ' ' PHE . 71.1 mt -96.12 131.89 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.108 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.443 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.58 164.52 10.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 43.9 t0 -85.99 112.14 20.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.81 -60.9 0.36 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 148' ' ' ALA . 0.3 OUTLIER -36.14 -45.44 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -81.44 -39.33 25.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 59.73 54.27 4.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.456 HH11 ' CE1' ' A' ' 122' ' ' HIS . 9.0 ttm180 -165.37 138.74 3.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.612 0.72 . . . . 0.0 110.878 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.621 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.6 Cg_endo -69.76 114.22 3.63 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.739 2.292 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.4 mtt180 -56.09 -54.42 45.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.04 39.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.527 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -169.39 166.59 10.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.874 0.369 . . . . 0.0 110.916 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.24 -157.26 28.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.54 ' HE1' HD11 ' A' ' 145' ' ' ILE . 32.1 m-85 -137.36 165.91 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.468 HD12 ' CE2' ' A' ' 133' ' ' PHE . 11.8 mt -149.2 134.07 10.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.0 m -101.34 145.06 29.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -114.52 -177.7 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -86.85 -41.97 13.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' ASP . . . . . 0.416 ' O ' ' C ' ' A' ' 164' ' ' GLU . 0.8 OUTLIER -125.25 128.54 48.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.868 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 163' ' ' ASP . 10.1 tm-20 -36.3 -37.7 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.917 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.423 ' O ' ' C ' ' A' ' 166' ' ' SER . 15.7 mt-30 -42.08 -60.45 1.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 1.3 m -36.67 -53.43 0.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 115' ' ' ILE . 70.5 t -45.24 -58.68 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.144 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -50.21 -55.01 17.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.841 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -45.44 -51.08 11.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.906 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.53 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -64.58 -51.39 63.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 39.8 t -47.63 -60.5 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -41.83 -51.95 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -59.26 -41.98 90.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 48.17 28.17 1.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.849 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 5.1 m-85 -173.0 151.35 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.507 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 50.1 m80 -160.29 147.64 16.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.832 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -102.33 90.0 3.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.813 HD12 HG21 ' A' ' 183' ' ' VAL . 72.5 mt -110.23 110.31 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 10.2 mtt 63.48 44.81 5.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.875 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.93 43.11 99.64 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.471 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.8 tppt? -149.61 145.46 26.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.19 107.83 19.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.813 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -93.54 129.12 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -87.32 135.79 33.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.905 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 117' ' ' VAL . 56.1 t -132.62 132.48 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 7.5 mmmm -136.21 159.73 40.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -67.89 114.22 6.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -87.21 160.29 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -123.86 151.77 65.14 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.657 0.742 . . . . 0.0 110.882 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 144.25 53.51 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.658 2.238 . . . . 0.0 112.337 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 30.9 ttp85 -167.67 138.59 2.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.831 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -152.18 162.23 41.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 10.5 t -116.7 40.27 2.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.846 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -115.28 149.86 37.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.4 t -144.29 166.21 25.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.875 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 74.4 p -87.55 152.18 22.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -132.48 146.28 18.05 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.488 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -50.24 0.48 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.677 2.251 . . . . 0.0 112.34 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 82.5 p -172.05 -175.78 1.54 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 4.0 m -62.67 125.14 22.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 77.6 p -99.75 92.47 5.34 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.908 0.385 . . . . 0.0 110.907 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.3 p -153.62 149.95 28.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.51 134.47 12.83 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.431 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.8 m -127.21 117.52 22.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 0.0 110.874 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 m -105.45 43.07 1.15 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.841 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.45 -25.37 6.62 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.483 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 5.0 t -78.76 107.29 11.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.943 0.401 . . . . 0.0 110.824 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 6.5 mtmp? -106.58 132.04 53.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.854 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.0 t -125.97 102.22 7.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.859 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -92.33 34.6 1.03 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.91 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 tttt -97.88 144.52 27.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.913 HG22 HG13 ' A' ' 167' ' ' VAL . 20.2 pt -126.07 149.14 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.099 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.3 t80 -96.39 113.71 25.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.918 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 185' ' ' VAL . 87.4 t -110.28 116.31 52.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.131 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.54 -179.54 16.06 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.85 14.46 44.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.472 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.631 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.3 mt -62.45 138.36 96.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.629 0.728 . . . . 0.0 111.128 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.78 159.96 51.46 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.67 2.246 . . . . 0.0 112.337 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -68.2 -4.1 12.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.833 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.411 ' O ' ' C ' ' A' ' 124' ' ' CYS . 9.5 m120 -100.23 -62.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.446 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 35.3 t -37.62 120.96 0.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.4 -172.24 13.76 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -46.24 -65.68 0.52 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.3 m -44.13 -59.13 2.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 129' ' ' LEU . 67.1 mm-40 -49.67 -65.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.847 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.605 HD11 ' CE ' ' A' ' 144' ' ' MET . 39.5 mt -34.38 -54.63 0.52 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.493 ' CG ' HG21 ' A' ' 142' ' ' VAL . 14.4 mtp180 -63.69 -59.99 3.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -42.75 -25.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 12.2 t80 -100.66 -24.82 14.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 159' ' ' ILE . 14.3 m-85 -97.91 13.76 29.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -93.12 -29.77 15.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.6 pttt -61.67 -33.85 74.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -68.87 -42.85 76.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.898 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -166.19 -108.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.485 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.65 109.91 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 29.1 t -75.21 119.55 23.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.163 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 33.2 p -93.81 -36.31 12.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.149 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -140.55 153.03 45.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.493 HG21 ' CG ' ' A' ' 130' ' ' ARG . 61.2 t -133.63 101.95 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 62.3 t -88.73 141.14 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.088 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.605 ' CE ' HD11 ' A' ' 129' ' ' LEU . 4.3 mtt -143.33 138.99 29.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.417 HD11 ' HE1' ' A' ' 158' ' ' PHE . 64.6 mt -105.48 132.4 52.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -171.69 165.06 6.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.882 -179.972 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 26.2 t0 -84.39 113.9 21.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.85 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.74 -58.48 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -42.5 -43.56 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 10.5 tppt? -77.48 -41.33 39.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 60.02 46.92 10.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 0.4 OUTLIER -160.6 138.58 7.21 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.577 0.704 . . . . 0.0 110.862 -179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.47 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.84 110.77 2.65 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.7 2.267 . . . . 0.0 112.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 19.1 mtt-85 -50.3 -55.79 13.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.99 42.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -173.29 159.94 3.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.882 0.373 . . . . 0.0 110.85 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.04 -158.66 31.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.495 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.417 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.6 m-85 -139.64 162.18 35.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.548 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.4 mt -144.91 139.37 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.1 m -105.29 141.29 37.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.565 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 34.5 m-85 -112.51 174.01 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -79.91 -40.39 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.915 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' ASP . . . . . 0.44 ' O ' ' C ' ' A' ' 164' ' ' GLU . 27.4 m-20 -126.16 123.37 38.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.865 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.44 ' C ' ' O ' ' A' ' 163' ' ' ASP . 8.4 tp10 -35.18 -41.15 0.15 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.838 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.427 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.5 mm100 -35.79 -60.89 0.5 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.565 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 68.7 m -39.29 -59.25 1.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.913 HG13 HG22 ' A' ' 115' ' ' ILE . 67.1 t -35.32 -47.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.135 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -65.53 -52.33 53.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -43.43 -50.46 6.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.404 ' O ' ' C ' ' A' ' 171' ' ' VAL . . . -68.04 -66.0 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 167' ' ' VAL . 88.8 t -37.1 -52.37 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 59.9 t-20 -37.41 -65.49 0.31 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 7.5 mtm -57.91 -32.24 67.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.914 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.513 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 18.2 t-160 50.17 26.81 2.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.52 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 7.8 m-85 -169.45 150.31 4.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 19.7 m80 -160.9 150.03 16.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.843 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -105.73 94.48 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.913 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.725 HD12 HG21 ' A' ' 183' ' ' VAL . 70.3 mt -111.4 114.43 47.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 13.5 mtt 61.86 39.64 13.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.94 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.04 54.07 29.88 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -164.64 142.95 6.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.41 117.95 23.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.923 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.725 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -105.43 122.52 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -80.79 138.18 36.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 117' ' ' VAL . 94.4 t -139.72 135.61 39.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.123 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -147.21 169.41 19.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 22.1 mtt180 -69.12 114.22 7.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.853 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -79.51 177.85 8.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.096 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -134.21 146.31 59.12 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.67 0.747 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 153.04 69.5 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.651 2.234 . . . . 0.0 112.359 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.99 63.71 6.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.48 133.93 15.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.3 t -90.82 -59.01 2.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 46.0 mtmt -98.56 151.68 20.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.2 m -121.11 114.03 20.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 44.6 t -63.06 -55.02 29.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.871 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 131.3 156.29 8.43 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.47 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -24.8 29.21 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.691 2.261 . . . . 0.0 112.354 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -39.65 -53.36 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.821 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 17.2 p 45.78 52.08 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.466 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.9 t -126.3 128.31 46.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.885 0.374 . . . . 0.0 110.832 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.3 t -79.74 156.32 27.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.863 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -172.24 -74.33 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.502 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.9 m -57.37 100.84 0.06 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.892 0.377 . . . . 0.0 110.875 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 t -135.68 156.3 49.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -83.66 52.45 4.72 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.499 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.6 p -92.99 40.28 1.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.894 0.378 . . . . 0.0 110.84 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -53.13 108.99 0.38 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 16.4 m -136.94 119.01 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -82.63 41.94 0.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -91.43 143.38 26.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.707 HG22 HG13 ' A' ' 167' ' ' VAL . 22.7 pt -127.56 148.13 32.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.408 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 17.1 t80 -92.53 112.95 25.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.815 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 185' ' ' VAL . 91.1 t -109.51 117.3 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.136 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.86 -177.47 15.21 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.508 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.41 23.07 47.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.461 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.604 HG23 ' HD2' ' A' ' 121' ' ' PRO . 64.3 mt -69.85 137.45 87.68 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.657 0.742 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.604 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.691 2.261 . . . . 0.0 112.31 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -81.6 3.63 24.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -110.07 -27.14 9.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.5 t -74.89 123.99 26.07 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.35 -173.55 13.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.72 -62.37 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.972 0.415 . . . . 0.0 110.885 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 51.9 m -43.14 -63.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.088 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 129' ' ' LEU . 0.9 OUTLIER -49.47 -62.24 1.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.735 HD11 ' HE3' ' A' ' 144' ' ' MET . 35.3 mt -34.35 -49.21 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.89 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.493 ' HE ' HG23 ' A' ' 142' ' ' VAL . 50.4 mtt180 -67.49 -51.44 51.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' GLU . . . . . 0.405 ' HA ' ' CE ' ' A' ' 134' ' ' LYS . 34.4 mt-10 -55.2 -16.71 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.469 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 15.9 t80 -108.74 -20.83 12.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.522 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.4 m-85 -105.5 16.49 25.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.875 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.405 ' CE ' ' HA ' ' A' ' 131' ' ' GLU . 12.2 ptpt -94.76 -26.17 16.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -68.06 -38.46 82.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.883 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -63.26 -35.11 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.574 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -173.45 -98.08 0.11 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.476 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 137' ' ' GLY . 56.2 t -161.42 109.99 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.876 0.37 . . . . 0.0 111.134 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.489 HG21 ' HA ' ' A' ' 130' ' ' ARG . 17.0 t -75.23 113.52 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 17.7 p -90.55 -37.73 13.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -141.23 153.04 45.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.493 HG23 ' HE ' ' A' ' 130' ' ' ARG . 63.5 t -134.28 100.69 3.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.8 t -85.71 142.16 13.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.735 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.7 mtt -145.03 133.24 21.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.837 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.515 HD11 ' HE1' ' A' ' 158' ' ' PHE . 59.2 mt -97.95 136.85 27.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.451 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.9 3.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.944 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.453 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -86.3 113.72 22.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.453 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.27 -62.27 0.28 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 17.7 tt0 -36.25 -47.29 0.57 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.837 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -77.33 -40.77 43.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 60.08 51.71 5.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.451 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 2.1 ttp180 -163.89 138.86 4.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.634 0.731 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 110.56 2.6 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.643 2.229 . . . . 0.0 112.316 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.3 mtt180 -50.97 -52.4 43.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.4 40.24 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -170.2 162.35 8.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.868 0.366 . . . . 0.0 110.893 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.408 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.73 -150.79 19.75 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.515 ' HE1' HD11 ' A' ' 145' ' ' ILE . 15.9 m-85 -145.97 168.99 19.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 0.0 110.901 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.597 HD11 HD22 ' A' ' 129' ' ' LEU . 20.5 mt -151.55 138.16 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.7 m -103.49 142.92 33.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.138 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.516 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 57.7 m-85 -113.27 170.03 8.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -73.98 -38.73 64.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.861 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -131.02 137.2 49.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.448 ' O ' ' N ' ' A' ' 167' ' ' VAL . 11.4 tm-20 -44.93 -47.17 11.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.8 tt0 -34.74 -48.42 0.38 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.94 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.516 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 66.0 m -50.35 -46.7 55.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.707 HG13 HG22 ' A' ' 115' ' ' ILE . 58.0 t -50.89 -55.56 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.157 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -53.62 -47.36 70.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.813 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -49.08 -55.79 11.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.907 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.95 -58.26 6.6 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.793 HG21 ' HG3' ' A' ' 187' ' ' ARG . 94.0 t -44.17 -61.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.108 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 171' ' ' VAL . 28.3 t30 -35.76 -46.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.2 mmm -69.9 -43.42 71.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.538 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 16.5 t-160 59.06 26.94 15.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.0 m-85 -171.55 154.32 3.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.865 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 62.2 m80 -160.66 162.77 32.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.832 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -117.95 92.4 3.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.819 HD12 HG21 ' A' ' 183' ' ' VAL . 55.9 mt -112.21 127.24 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.143 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.0 mmt 52.63 33.38 13.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.96 52.06 25.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.482 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -159.03 145.81 17.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.863 0.364 . . . . 0.0 110.869 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.2 tppt? -82.17 111.17 18.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.854 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.819 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -100.97 121.58 51.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -80.79 144.86 31.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 117' ' ' VAL . 52.7 t -141.1 131.72 27.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.156 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.5 mtpt -142.95 144.48 32.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.915 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.793 ' HG3' HG21 ' A' ' 171' ' ' VAL . 7.4 mtp-105 -50.62 120.81 5.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.73 17.06 1.95 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.082 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -114.49 152.23 45.95 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.64 0.733 . . . . 0.0 110.904 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 157.32 60.75 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.703 2.269 . . . . 0.0 112.32 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 7.4 ptp180 -108.3 86.43 2.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -124.9 -43.96 1.96 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 16.5 m -105.6 91.71 3.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.55 145.65 2.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.927 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 195' ' ' SER . . . . . 0.434 ' O ' ' C ' ' A' ' 196' ' ' SER . 32.0 t -86.37 -48.49 8.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.815 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 196' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 195' ' ' SER . 30.8 t -35.46 143.78 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.859 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.0 164.67 9.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.453 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.84 -27.27 26.31 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.657 2.238 . . . . 0.0 112.343 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 29.0 t -69.48 148.81 49.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 1.2 t -121.58 97.85 5.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.908 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.472 -179.959 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 74.6 p -155.29 139.47 16.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.877 0.37 . . . . 0.0 110.864 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.6 p -71.89 90.63 1.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.832 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -102.2 -91.62 2.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.514 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.8 t -94.15 168.59 10.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.858 0.361 . . . . 0.0 110.86 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 70.6 m -129.63 99.2 5.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -85.7 -148.55 11.13 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.452 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 21.7 t -171.35 109.87 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.939 0.399 . . . . 0.0 110.859 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 42.7 mttt 53.04 40.13 30.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.2 t -85.39 176.01 8.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 -119.82 39.5 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 18.9 ttmt -93.24 151.93 19.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.673 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -134.7 152.25 32.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.11 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 27.7 t80 -98.95 108.74 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 185' ' ' VAL . 90.8 t -104.48 114.36 43.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.84 170.83 16.12 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 72.36 14.19 77.07 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.442 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.579 HG23 ' HD2' ' A' ' 121' ' ' PRO . 34.2 mt -62.74 137.41 96.64 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.641 0.734 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.77 161.0 47.6 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.707 2.271 . . . . 0.0 112.324 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.0 2.41 10.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.404 ' C ' ' SD ' ' A' ' 179' ' ' MET . 8.8 m-20 -107.72 -23.56 12.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.864 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.478 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 25.4 t -82.07 143.1 31.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -145.51 -171.98 15.54 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.534 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.418 ' HA ' HD12 ' A' ' 129' ' ' LEU . 45.9 tt0 -42.95 -66.18 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.7 m -40.17 -65.73 0.38 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 129' ' ' LEU . 3.9 mp0 -48.33 -61.68 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.757 HD11 ' HE3' ' A' ' 144' ' ' MET . 80.7 mt -34.4 -50.61 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.911 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.488 ' CG ' HG21 ' A' ' 142' ' ' VAL . 47.0 mtp180 -71.32 -53.4 14.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 41.4 mm-40 -46.99 -22.31 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.524 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 32.6 t80 -103.85 -36.79 7.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.897 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.551 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.8 m-85 -84.9 10.23 12.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.885 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 8.6 ptpt -91.0 -29.78 17.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.453 ' N ' ' HG3' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -69.97 -17.42 63.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.913 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -89.54 -19.88 24.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.22 -118.07 0.65 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.538 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.6 t -146.02 106.88 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.89 0.376 . . . . 0.0 111.119 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.429 HG21 ' HA ' ' A' ' 130' ' ' ARG . 5.2 t -73.52 111.09 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' THR . . . . . 0.404 HG22 ' OE1' ' A' ' 162' ' ' GLU . 43.3 p -88.03 -39.76 14.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.152 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -136.97 151.11 48.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.488 HG21 ' CG ' ' A' ' 130' ' ' ARG . 86.4 t -134.36 106.22 7.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.7 t -96.7 139.31 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.191 179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.757 ' HE3' HD11 ' A' ' 129' ' ' LEU . 14.4 mtp -141.1 130.57 23.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -91.46 137.21 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.447 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.72 165.13 4.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.937 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.443 ' O ' ' C ' ' A' ' 148' ' ' ALA . 39.3 t0 -85.13 113.49 21.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.59 -58.72 0.41 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.107 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -41.47 -43.87 2.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.436 ' N ' ' O ' ' A' ' 147' ' ' ASP . 9.5 tptm -78.14 -40.85 36.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 60.01 48.02 9.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.447 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.6 ttp85 -161.63 138.95 6.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.626 0.727 . . . . 0.0 110.816 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.503 ' CB ' ' CE ' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 113.8 3.49 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.645 2.23 . . . . 0.0 112.348 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 33.7 mtp85 -55.48 -57.04 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 167.8 41.66 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.503 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -172.55 157.13 3.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.918 0.39 . . . . 0.0 110.834 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.41 -154.42 24.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.507 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -140.1 166.13 25.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.813 0.34 . . . . 0.0 110.919 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.551 HD12 ' CD2' ' A' ' 133' ' ' PHE . 17.3 mt -150.0 142.39 17.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.102 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.4 m -109.82 141.12 42.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.11 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.581 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 39.4 m-85 -110.39 176.98 4.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.404 ' OE1' HG22 ' A' ' 140' ' ' THR . 17.8 tp10 -82.47 -36.17 26.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -131.96 131.34 42.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.849 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -40.8 -41.49 1.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.839 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -37.56 -53.95 1.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.581 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 22.4 m -46.27 -54.37 8.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.673 HG13 HG22 ' A' ' 115' ' ' ILE . 63.8 t -40.71 -56.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.134 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 169' ' ' GLN . 38.8 t0 -56.29 -64.13 0.96 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 168' ' ' ASP . 50.9 mt-30 -34.69 -43.92 0.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -75.15 -62.47 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.084 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.527 HG21 ' CG ' ' A' ' 187' ' ' ARG . 51.4 t -42.74 -54.24 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -40.64 -51.61 2.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.4 mmm -64.37 -31.97 73.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 13.3 t-160 48.61 26.46 1.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.1 m-85 -169.28 148.46 3.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.848 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.524 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 68.2 m80 -155.07 152.43 29.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.84 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -108.13 104.07 13.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.996 HD12 HG21 ' A' ' 183' ' ' VAL . 52.4 mt -126.23 113.09 32.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.404 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 9.1 mtt 60.62 42.56 13.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 46.74 93.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.495 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.8 tptt -153.41 145.93 24.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -87.25 110.74 20.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.996 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -97.8 115.03 36.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -76.77 141.6 40.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 117' ' ' VAL . 20.3 t -138.57 131.55 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 11.4 mtmt -138.34 149.99 46.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.947 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.527 ' CG ' HG21 ' A' ' 171' ' ' VAL . 14.0 mtt180 -53.07 123.77 12.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . -89.04 15.56 8.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -80.97 152.48 71.65 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.627 0.727 . . . . 0.0 110.879 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -41.75 4.03 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 0.0 112.356 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -145.36 133.81 21.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -38.47 132.07 1.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.826 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.1 t -72.61 142.06 48.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 194' ' ' LYS . . . . . 0.406 ' NZ ' ' HB3' ' A' ' 194' ' ' LYS . 8.9 mtpm? -149.3 158.75 44.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 17.1 t -104.54 80.44 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.863 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 30.7 t -79.22 150.87 31.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.873 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 47.0 -168.8 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.476 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 131.04 20.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 38.0 t -100.51 -46.87 5.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.1 t -61.93 -55.86 25.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.861 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.461 -179.975 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.3 m -110.68 103.17 11.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.863 0.363 . . . . 0.0 110.837 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.0 m -131.71 115.78 16.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -101.85 44.2 1.57 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.48 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.3 t -45.94 -56.86 4.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.857 0.361 . . . . 0.0 110.856 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 7.3 m -132.8 164.7 26.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.84 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -84.21 111.68 3.5 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.444 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 6.4 t -97.1 87.44 4.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.945 0.402 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 8.8 ptpt -80.48 -21.3 42.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.0 m -56.01 110.54 0.76 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -90.41 48.19 1.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.7 ttmt -100.14 137.18 38.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.728 HG22 HG13 ' A' ' 167' ' ' VAL . 29.2 pt -119.65 153.38 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.147 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -101.87 107.61 18.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 185' ' ' VAL . 88.1 t -103.36 117.65 49.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.141 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.69 -177.42 15.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.52 13.73 39.1 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.467 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.567 HG23 ' HD2' ' A' ' 121' ' ' PRO . 35.5 mt -61.65 137.15 94.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 0.0 111.15 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.567 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.1 Cg_endo -69.67 161.85 44.32 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.433 ' ND1' ' O ' ' A' ' 122' ' ' HIS . 2.8 p80 -77.58 8.66 4.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.873 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.459 ' O ' ' CE ' ' A' ' 179' ' ' MET . 47.5 t30 -117.09 -15.12 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 2.7 t -83.55 153.22 24.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -158.92 169.6 35.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.517 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 125' ' ' GLY . 0.6 OUTLIER -35.97 -59.4 0.6 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.893 0.377 . . . . 0.0 110.893 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.9 m -42.62 -53.94 4.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -65.25 -55.93 15.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.476 HD13 HD11 ' A' ' 159' ' ' ILE . 60.6 mt -42.6 -58.85 2.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.933 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.642 ' HA ' HG21 ' A' ' 139' ' ' VAL . 68.1 mtp180 -54.51 -56.72 15.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -50.87 -33.5 24.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.504 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.0 t80 -89.64 -20.06 24.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.431 ' CD2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-85 -105.31 17.74 23.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -92.59 -39.15 11.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.3 ptpt -57.39 -31.14 65.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.869 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -73.99 -32.48 63.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.891 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.55 -118.9 0.54 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 60.2 t -145.04 106.23 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.642 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.5 t -68.71 108.66 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.117 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 16.5 p -86.03 -38.0 18.33 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -140.67 155.53 46.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.416 HG21 ' CG ' ' A' ' 130' ' ' ARG . 85.0 t -136.89 106.35 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.166 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.5 t -93.96 138.7 19.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.122 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.8 mtt -139.17 136.33 34.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.1 mt -101.43 131.76 48.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.445 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.16 164.84 7.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.3 t0 -85.41 112.4 20.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.865 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.5 -60.56 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 tm-20 -38.52 -45.45 1.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 9.3 tppt? -78.52 -40.51 34.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 60.07 53.11 4.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.911 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 15.4 ttp85 -165.44 138.34 3.56 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.601 0.715 . . . . 0.0 110.922 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 111.44 2.82 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.684 2.256 . . . . 0.0 112.315 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.6 mtp85 -52.0 -50.77 60.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 161.27 39.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -169.69 161.45 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.519 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 165.42 -151.05 19.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.459 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.519 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 10.1 m-85 -146.03 166.31 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.869 0.366 . . . . 0.0 110.866 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.476 HD11 HD13 ' A' ' 129' ' ' LEU . 18.2 mt -150.4 136.78 12.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.13 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 36.5 m -103.82 143.4 32.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.536 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.9 m-85 -112.44 176.46 5.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.925 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -77.91 -39.04 44.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.71 145.21 49.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 165' ' ' GLN . 34.8 tt0 -48.81 -44.39 39.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.918 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.418 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.1 tt0 -34.76 -49.6 0.43 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.536 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 20.0 m -53.65 -52.08 61.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.728 HG13 HG22 ' A' ' 115' ' ' ILE . 70.4 t -47.41 -47.1 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -63.56 -52.62 60.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -47.67 -51.58 21.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.891 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.89 -56.44 7.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.647 HG23 ' O ' ' A' ' 167' ' ' VAL . 40.3 t -43.6 -57.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -38.74 -62.04 0.66 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.885 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.3 mmm -48.6 -42.45 33.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.6 t-160 54.01 25.72 5.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.521 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -172.37 144.8 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.898 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.504 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 64.8 m-70 -156.21 158.74 38.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -110.33 103.68 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.772 HD12 HG21 ' A' ' 183' ' ' VAL . 34.2 mt -130.05 131.34 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.089 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 123' ' ' ASN . 11.9 mmt 62.52 25.74 15.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.914 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.01 85.01 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.46 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 9.1 ttmm -128.29 162.17 27.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.866 0.365 . . . . 0.0 110.876 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 5.8 tptm -88.74 128.68 35.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.772 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -112.46 121.61 65.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.096 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -81.37 145.21 30.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 117' ' ' VAL . 42.7 t -142.29 126.91 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mmmt -138.04 143.92 40.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -56.69 118.54 4.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.842 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -77.29 169.38 18.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -111.45 147.95 37.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 191' ' ' ARG . 53.8 Cg_endo -69.78 124.47 11.11 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 0.0 112.341 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.438 ' C ' ' O ' ' A' ' 190' ' ' PRO . 0.0 OUTLIER -35.5 125.24 0.65 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -50.99 142.57 11.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 78.8 p -122.2 110.16 15.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -141.05 145.72 36.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.891 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 51.4 m -152.3 167.25 29.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.886 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.7 t -118.92 133.57 55.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 81.24 159.59 23.22 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.87 2.08 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.683 2.255 . . . . 0.0 112.349 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 28.8 m -40.6 131.77 2.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.855 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 25.7 m -89.86 104.73 17.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.843 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.484 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.8 m -76.53 159.93 29.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.351 . . . . 0.0 110.885 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 85.0 p -164.35 141.48 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.57 -143.34 16.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.5 t 53.55 42.53 31.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.855 0.359 . . . . 0.0 110.847 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.8 t -91.51 -44.43 9.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.41 161.17 53.55 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.485 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.0 t -80.87 -54.39 5.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.95 0.405 . . . . 0.0 110.856 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -109.14 88.95 2.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.931 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.5 m -114.42 142.21 46.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.425 ' O ' HG23 ' A' ' 160' ' ' THR . 0.5 OUTLIER -95.66 62.38 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.7 ttmt -117.67 148.65 41.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.79 HG22 HG13 ' A' ' 167' ' ' VAL . 21.7 pt -129.22 155.33 41.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 7.3 t80 -104.74 102.37 11.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 185' ' ' VAL . 84.8 t -93.3 125.42 45.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.109 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.1 -177.28 14.79 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.52 8.69 10.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.629 HD11 HG12 ' A' ' 117' ' ' VAL . 55.3 mt -58.71 137.61 86.58 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.638 0.732 . . . . 0.0 111.117 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.593 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.76 169.79 18.09 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.0 p-80 -85.92 15.21 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.3 m120 -123.67 -26.86 4.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.498 ' SG ' HG21 ' A' ' 178' ' ' ILE . 24.1 t -72.18 118.92 15.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.68 -174.32 16.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.495 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -41.45 -63.94 0.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.951 0.405 . . . . 0.0 110.863 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 46.0 m -41.9 -54.9 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.102 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 129' ' ' LEU . 61.1 mm-40 -54.41 -66.18 0.44 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.663 HD11 ' CE ' ' A' ' 144' ' ' MET . 51.5 mt -34.53 -60.34 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.613 ' HA ' HG21 ' A' ' 139' ' ' VAL . 5.6 mtp-105 -58.9 -57.0 15.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.863 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -46.44 -25.8 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.568 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.3 t80 -102.46 -20.7 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.928 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.569 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.6 m-85 -104.47 9.8 35.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 130' ' ' ARG . 48.2 pttt -91.33 -17.61 25.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.88 -38.57 57.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.915 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -69.18 -29.38 67.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.31 -124.17 0.79 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.7 t -138.61 105.3 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.126 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.613 HG21 ' HA ' ' A' ' 130' ' ' ARG . 38.6 t -65.16 110.0 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.079 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 46.2 p -87.74 -38.46 15.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.129 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -137.38 147.43 45.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.859 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.27 94.46 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 72.3 t -89.99 137.9 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.12 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.663 ' CE ' HD11 ' A' ' 129' ' ' LEU . 8.8 mtp -137.57 142.7 41.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 73.3 mt -106.58 133.53 50.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.37 165.08 5.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.903 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 29.1 t0 -85.83 113.5 22.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.33 -62.13 0.29 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.108 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 148' ' ' ALA . 42.5 tt0 -36.38 -46.26 0.53 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -78.99 -40.55 31.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 60.0 47.84 9.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.9 ttp180 -158.29 138.32 8.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.623 0.725 . . . . 0.0 110.893 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.462 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.75 110.6 2.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.724 2.282 . . . . 0.0 112.32 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -51.62 -53.53 37.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.851 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 120' ' ' ILE . . . 163.03 41.39 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.534 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -170.7 160.6 7.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.914 0.388 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.23 -159.01 32.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 15.8 m-85 -137.81 161.11 37.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.82 0.343 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.569 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.1 mt -148.19 140.73 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.073 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 113' ' ' ASN . 23.6 m -107.13 144.23 34.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.437 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 54.8 m-85 -113.29 167.52 10.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -70.53 -43.17 70.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -122.06 140.53 52.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 165' ' ' GLN . 7.9 tp10 -49.67 -46.39 49.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.401 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.4 tt0 -38.24 -51.88 1.48 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.437 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 50.6 m -44.58 -57.05 3.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.79 HG13 HG22 ' A' ' 115' ' ' ILE . 38.4 t -37.68 -59.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 169' ' ' GLN . 46.9 t0 -50.53 -61.65 2.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.807 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 168' ' ' ASP . 76.0 mt-30 -35.73 -48.91 0.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.62 -57.89 4.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.118 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 174' ' ' HIS . 75.2 t -47.13 -60.39 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 171' ' ' VAL . 7.5 t30 -35.07 -61.08 0.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 27.5 mmm -51.08 -41.45 59.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.904 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.522 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.6 t-160 55.94 26.23 9.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.8 m-85 -171.87 148.32 2.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.568 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 52.7 m-70 -155.44 155.83 34.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -112.37 85.84 2.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.897 HD12 HG21 ' A' ' 183' ' ' VAL . 78.8 mt -96.66 126.24 49.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.15 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.833 ' HG2' HG22 ' A' ' 178' ' ' ILE . 2.0 ptm 38.81 48.22 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.5 67.74 1.94 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.41 ' NZ ' ' HB2' ' A' ' 181' ' ' LYS . 0.3 OUTLIER -175.13 142.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.815 0.34 . . . . 0.0 110.897 -179.946 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.8 tptm -85.04 102.37 13.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.884 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.897 HG21 HD12 ' A' ' 178' ' ' ILE . 3.0 t -95.08 117.34 38.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.139 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 184' ' ' GLU . . . . . 0.543 ' O ' HG23 ' A' ' 185' ' ' VAL . 10.1 tt0 -72.92 162.19 29.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.906 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 117' ' ' VAL . 72.3 t -161.12 131.02 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mttm -137.19 143.31 42.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.434 ' HB2' ' NH1' ' A' ' 187' ' ' ARG . 10.4 ttm105 -56.96 114.16 1.99 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.862 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -76.4 97.79 4.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -175.02 155.38 1.83 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.668 0.747 . . . . 0.0 110.858 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 179.45 3.7 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.716 2.277 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -112.62 -59.44 2.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -83.41 99.93 10.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 74.0 p -129.71 128.31 42.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.867 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 25.8 tttm -91.93 86.14 5.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 62.7 p -160.28 152.73 20.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 48.5 t -124.06 83.75 2.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.867 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 75.76 -158.3 49.88 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.431 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 128.85 16.6 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.642 2.228 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.8 m -91.14 105.33 17.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.836 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 18.9 t -104.39 154.47 19.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.882 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.986 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.392 0 N-CA-C 112.519 -0.232 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.9 m -66.9 101.55 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 110.87 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.2 m -69.02 85.04 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.868 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 156.13 96.29 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.3 m -72.14 -59.56 2.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.821 0.343 . . . . 0.0 110.887 -179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.5 t -82.79 85.74 7.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.837 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -74.86 85.27 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.5 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 23.9 p -100.71 -62.97 1.18 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.952 0.406 . . . . 0.0 110.86 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.23 97.34 5.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.0 t -147.02 132.03 18.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.853 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -104.11 56.46 0.72 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.438 ' HG2' ' N ' ' A' ' 115' ' ' ILE . 21.3 ttmt -105.23 149.55 25.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.647 HG22 HG13 ' A' ' 167' ' ' VAL . 24.0 pt -129.6 156.85 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.454 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 8.0 t80 -104.58 106.45 16.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 185' ' ' VAL . 89.3 t -103.05 114.42 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -118.43 -177.64 16.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.432 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.04 26.63 58.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.471 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.623 HG23 ' HD2' ' A' ' 121' ' ' PRO . 60.7 mt -75.46 137.9 71.12 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.631 0.729 . . . . 0.0 111.12 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.72 165.11 32.02 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.706 2.27 . . . . 0.0 112.374 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -77.3 0.54 21.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -105.42 -32.89 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 21.4 t -68.8 118.81 12.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.39 -179.27 15.85 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.52 ' HA ' HD12 ' A' ' 129' ' ' LEU . 55.9 tt0 -39.89 -67.59 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.876 0.369 . . . . 0.0 110.853 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.1 m -40.67 -60.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.121 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 16.7 mm-40 -49.73 -61.22 2.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.612 HD11 ' CE ' ' A' ' 144' ' ' MET . 41.9 mt -35.97 -55.67 0.74 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.486 ' HG2' HG11 ' A' ' 139' ' ' VAL . 11.1 mtp-105 -64.03 -54.7 30.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -47.52 -20.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -107.46 -25.42 11.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.591 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.4 m-85 -97.98 15.34 24.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.8 ptpt -95.22 -10.69 29.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.94 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.2 pttm -81.69 -34.56 30.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -72.14 -23.29 61.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.33 -118.96 0.69 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 88.2 t -140.03 116.14 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' A' ' 130' ' ' ARG . 24.9 t -80.66 111.12 16.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.6 p -89.1 -34.95 16.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -142.02 157.82 44.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.424 HG21 ' CG ' ' A' ' 130' ' ' ARG . 99.3 t -139.05 104.94 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.172 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.79 139.27 17.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.149 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.612 ' CE ' HD11 ' A' ' 129' ' ' LEU . 5.3 mtt -142.25 133.7 26.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.438 HD11 ' HE1' ' A' ' 158' ' ' PHE . 70.7 mt -99.21 133.82 40.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.22 165.96 5.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.941 -179.987 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.455 ' O ' ' C ' ' A' ' 148' ' ' ALA . 21.8 t0 -84.88 113.23 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.455 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.16 -58.29 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.056 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -42.41 -44.45 3.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 147' ' ' ASP . 2.8 mptm? -77.22 -40.82 43.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 60.09 43.5 14.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.866 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 3.8 ttp180 -155.92 138.47 10.38 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.6 0.714 . . . . 0.0 110.886 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.589 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.77 110.87 2.66 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.335 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.9 mtp85 -50.86 -55.89 14.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.18 41.77 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -172.34 162.95 5.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.449 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 162.79 -154.51 25.49 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.451 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 4.7 m-85 -141.95 167.03 23.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.891 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.591 HD12 ' CD2' ' A' ' 133' ' ' PHE . 8.9 mt -150.1 139.85 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.137 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.3 m -106.33 144.82 32.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.471 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 53.1 m-85 -115.13 175.02 5.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -78.65 -43.25 26.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 164' ' ' GLU . 3.4 m-20 -123.97 125.59 44.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.874 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 163' ' ' ASP . 23.1 tt0 -35.17 -39.03 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.419 ' C ' ' O ' ' A' ' 164' ' ' GLU . 3.8 mm100 -36.03 -59.33 0.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.471 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 1.1 m -41.87 -58.35 2.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.809 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 171' ' ' VAL . 58.6 t -36.12 -54.42 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -58.54 -60.3 4.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.1 mt-30 -39.9 -48.84 2.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.92 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.48 -54.94 13.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 167' ' ' VAL . 67.9 t -46.21 -60.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.167 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.428 ' C ' ' O ' ' A' ' 171' ' ' VAL . 12.3 t-20 -35.84 -67.8 0.15 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.832 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 86.2 mtp -46.44 -42.14 14.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.3 t-160 54.74 30.61 13.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.824 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -173.57 155.17 2.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.525 ' CD2' ' O ' ' A' ' 175' ' ' PHE . 39.3 m80 -160.57 162.82 33.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -119.39 91.52 3.57 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 183' ' ' VAL . 58.2 mt -112.23 135.09 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.7 mmm 46.14 40.78 7.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.885 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.34 57.4 18.42 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.412 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.2 tmtm? -166.09 151.33 8.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 182' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.5 OUTLIER -84.5 116.7 23.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.895 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.854 HG21 HD12 ' A' ' 178' ' ' ILE . 3.9 t -105.78 120.41 56.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -82.15 146.78 29.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 117' ' ' VAL . 69.2 t -144.49 134.31 19.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -139.18 149.1 44.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 28.7 ttp180 -59.9 119.21 7.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.932 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.69 15.59 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.116 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -109.6 146.8 34.77 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.637 0.732 . . . . 0.0 110.868 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 170.96 15.38 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.636 2.224 . . . . 0.0 112.324 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -85.65 102.75 13.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -103.57 162.3 13.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.9 m -114.39 -41.25 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 31.7 tptt -156.34 146.18 21.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.89 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 55.5 m -79.96 173.9 12.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 10.6 t -144.62 140.11 28.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.855 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 108.38 147.72 12.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.537 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 126.41 13.28 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.1 t -57.49 145.86 31.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.7 t -111.57 111.76 23.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 -179.999 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 93.0 p -140.93 130.96 24.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.88 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -161.07 131.46 5.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 107.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.501 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 20.2 m -84.58 -49.68 8.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 110.812 -179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 51.1 m -155.55 130.38 9.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -145.88 -111.08 0.69 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.486 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 80.7 p -158.27 121.92 3.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.919 0.39 . . . . 0.0 110.859 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 13.4 pttt -153.38 164.21 38.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.6 t -129.42 142.66 50.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.812 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -88.6 34.2 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -92.72 150.01 20.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.908 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.863 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -131.09 155.16 41.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -104.39 105.54 15.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 185' ' ' VAL . 94.8 t -101.11 115.32 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.146 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.01 177.98 16.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.06 11.69 55.7 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.668 HG23 ' HD2' ' A' ' 121' ' ' PRO . 55.9 mt -57.85 138.84 82.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.642 0.734 . . . . 0.0 111.13 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.668 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.2 Cg_endo -69.79 171.96 13.55 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.658 2.239 . . . . 0.0 112.359 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 122' ' ' HIS . 3.4 t-80 -76.58 -5.14 46.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.452 ' O ' ' C ' ' A' ' 124' ' ' CYS . 7.7 m120 -102.43 -62.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.472 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.3 t -34.38 128.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -127.34 -154.82 8.62 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.444 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -66.33 -60.87 2.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.942 0.401 . . . . 0.0 110.921 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 53.3 m -48.55 -58.36 4.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.091 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.41 ' CD ' ' H ' ' A' ' 128' ' ' GLU . 6.2 mp0 -46.63 -61.95 1.6 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 35.5 mt -39.74 -52.13 2.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.917 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.589 ' HG2' HG11 ' A' ' 139' ' ' VAL . 74.0 mtm180 -59.85 -52.42 65.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 -53.38 -27.84 26.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.927 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.518 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 9.0 t80 -96.51 -18.96 19.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.946 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.486 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.4 m-85 -108.17 7.99 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.871 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.481 ' N ' ' O ' ' A' ' 130' ' ' ARG . 32.3 pttt -90.77 -28.46 18.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.2 ptpt -66.47 -25.94 66.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.867 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -78.66 -37.8 41.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -167.92 -112.25 0.26 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.463 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 86.5 t -147.47 112.33 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 111.056 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 70.7 t -75.16 103.78 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.112 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -79.24 -40.9 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.18 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.25 152.98 46.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.5 t -132.46 102.43 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.08 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.8 t -89.44 143.59 10.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.44 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.4 mtt -145.41 134.18 22.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.413 HD11 ' HE1' ' A' ' 158' ' ' PHE . 55.6 mt -98.76 130.66 47.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.169 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.454 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -170.09 164.66 9.34 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 150' ' ' LYS . 46.0 t0 -82.91 113.34 20.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.841 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.9 -52.46 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -48.0 -42.47 28.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.442 ' N ' ' O ' ' A' ' 147' ' ' ASP . 63.3 mttt -79.19 -38.43 35.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.948 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 58.19 51.41 8.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 13.1 ttm180 -164.95 138.42 3.88 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.61 0.719 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.44 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.72 113.54 3.4 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.742 2.295 . . . . 0.0 112.364 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.1 mtt180 -54.69 -55.47 29.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.32 40.59 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CA ' HD12 ' A' ' 120' ' ' ILE . 35.8 p90 -171.39 164.76 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.902 0.382 . . . . 0.0 110.877 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.74 -161.04 33.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.413 ' HE1' HD11 ' A' ' 145' ' ' ILE . 12.8 m-85 -137.73 162.85 32.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.486 HD12 ' CD2' ' A' ' 133' ' ' PHE . 15.8 mt -146.39 140.49 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.095 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.0 m -108.78 139.88 42.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -109.27 172.51 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.901 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.43 -30.03 47.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.928 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -137.43 147.21 45.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -55.56 -45.77 77.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.878 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -41.59 -42.29 2.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 6.1 m -55.84 -54.38 45.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.863 HG13 HG22 ' A' ' 115' ' ' ILE . 42.1 t -47.34 -51.31 6.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.154 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 18.6 t0 -52.92 -52.53 57.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 14.3 mm-40 -42.27 -44.37 3.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.12 -64.55 1.11 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.405 HG11 ' HB2' ' A' ' 187' ' ' ARG . 68.8 t -37.81 -50.25 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.097 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -39.2 -67.99 0.19 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 9.0 mtm -54.76 -43.41 72.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 17.6 t-160 61.17 26.48 16.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.1 m-85 -172.01 134.72 0.77 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.518 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 51.4 m80 -145.41 161.58 39.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -114.24 98.24 6.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.787 HD12 HG21 ' A' ' 183' ' ' VAL . 38.7 mt -118.65 129.07 75.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 51.07 41.89 27.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 60.73 63.65 4.79 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.489 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -174.15 149.21 1.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 9.7 tppt? -85.74 102.36 13.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.787 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -89.71 115.61 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -77.82 144.17 37.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.904 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 117' ' ' VAL . 88.2 t -143.44 128.44 15.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 186' ' ' LYS . . . . . 0.413 ' HD3' ' CD2' ' A' ' 174' ' ' HIS . 21.8 mmmt -133.34 151.48 51.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.405 ' HB2' HG11 ' A' ' 171' ' ' VAL . 12.1 ttt-85 -66.4 108.53 2.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -64.82 172.02 3.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -106.0 146.22 32.48 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.69 0.757 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 132.91 24.35 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.639 2.226 . . . . 0.0 112.382 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -71.5 118.55 14.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -107.09 75.71 1.05 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 32.0 t -66.85 151.79 46.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.84 96.35 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.899 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 48.8 m -77.23 123.44 26.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 10.9 t -153.26 134.99 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -169.8 143.6 8.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.465 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 115.04 3.9 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.665 2.243 . . . . 0.0 112.375 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.1 t -121.32 106.19 11.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.885 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 12.5 t -72.76 -57.7 3.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 85.7 p -173.74 156.4 2.87 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.359 . . . . 0.0 110.854 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.8 p -116.66 42.1 2.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 66.75 133.85 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.455 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -108.86 131.45 54.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.366 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -53.94 113.84 1.37 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.831 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 142.54 130.13 2.44 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.463 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 4.1 m -101.44 -51.04 3.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.932 0.396 . . . . 0.0 110.818 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 pttt -86.91 127.0 35.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 113' ' ' ASN . 53.4 p -98.47 -21.83 16.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.879 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.429 ' C ' ' O ' ' A' ' 112' ' ' SER . 2.0 m-20 34.42 41.75 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -105.19 145.23 30.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.573 HG22 HG13 ' A' ' 167' ' ' VAL . 16.2 pt -126.79 155.34 37.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.156 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -104.7 106.1 16.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 185' ' ' VAL . 99.5 t -102.74 122.97 55.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -125.83 -174.94 14.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.07 16.77 14.55 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.503 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.627 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.9 mt -64.45 138.1 97.34 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.651 0.739 . . . . 0.0 111.143 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.627 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.06 25.56 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.633 2.222 . . . . 0.0 112.349 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -81.38 2.59 27.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.853 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -107.48 -29.02 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.481 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.1 t -72.96 135.39 45.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -139.26 175.71 21.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.473 ' HA ' HD12 ' A' ' 129' ' ' LEU . 22.8 tt0 -34.57 -70.17 0.08 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.888 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 126' ' ' GLU . 22.0 m -36.36 -65.34 0.28 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.121 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 129' ' ' LEU . 36.8 mm-40 -47.65 -63.07 1.15 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.67 HD11 ' HE3' ' A' ' 144' ' ' MET . 67.8 mt -34.38 -45.15 0.22 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.478 ' HE ' HG23 ' A' ' 142' ' ' VAL . 22.5 mtt180 -67.39 -56.73 8.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -46.88 -26.66 1.03 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.949 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -98.26 -31.41 12.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CD2' HD12 ' A' ' 159' ' ' ILE . 24.8 m-85 -97.02 16.86 18.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 17.0 pttp -95.32 -27.9 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -68.08 -34.05 75.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.922 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -66.65 -31.53 72.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -178.86 -106.14 0.2 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 83.2 t -151.74 111.53 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.406 HG21 ' HA ' ' A' ' 130' ' ' ARG . 42.6 t -76.96 114.67 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 72.5 p -91.81 -38.29 12.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.161 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -140.51 154.16 46.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.478 HG23 ' HE ' ' A' ' 130' ' ' ARG . 84.5 t -134.7 100.92 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 65.3 t -83.28 141.9 14.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.67 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.8 mtt -145.3 135.02 23.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.4 mt -101.02 136.45 32.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.105 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.06 166.03 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.45 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -88.88 113.52 24.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.52 -58.71 0.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.104 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.403 ' C ' ' O ' ' A' ' 148' ' ' ALA . 34.2 tt0 -37.52 -45.25 0.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.863 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 6.4 tptm -82.35 -39.08 23.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.09 47.11 9.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.7 ttp85 -157.74 139.07 9.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.652 0.739 . . . . 0.0 110.864 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 109.75 2.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.717 2.278 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 30.7 mtp180 -49.39 -54.11 19.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.888 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.0 42.34 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -172.88 160.03 4.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.884 0.374 . . . . 0.0 110.866 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.15 -152.82 22.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.507 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -142.34 167.25 22.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.936 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.7 mt -148.81 138.52 16.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 61.9 m -103.0 148.77 25.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.464 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 67.2 m-85 -119.83 175.43 5.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -79.49 -42.7 24.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.905 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -126.47 134.78 50.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 165' ' ' GLN . 39.2 tt0 -43.52 -44.25 5.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 164' ' ' GLU . 65.1 tt0 -35.66 -45.73 0.39 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.464 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 3.8 m -51.6 -55.69 17.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.573 HG13 HG22 ' A' ' 115' ' ' ILE . 80.0 t -40.75 -57.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -50.21 -51.77 41.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.867 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 20.6 mm100 -48.0 -57.77 5.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -59.51 -58.92 6.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 174' ' ' HIS . 70.3 t -44.28 -62.88 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.2 t-20 -34.65 -55.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.87 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 25.6 mmm -57.29 -42.84 82.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 14.0 t-160 54.53 26.71 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.4 m-85 -172.5 154.39 3.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.53 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 88.3 m-70 -159.81 157.76 29.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -116.29 84.04 2.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.998 HD12 HG21 ' A' ' 183' ' ' VAL . 66.8 mt -97.33 108.68 21.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.162 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 23.7 mtm 61.01 44.86 9.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.98 37.96 94.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 35.0 tptt -139.29 136.69 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 110.883 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.22 100.99 10.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.998 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -93.21 129.63 43.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -87.67 148.01 24.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 117' ' ' VAL . 67.1 t -147.58 138.75 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.109 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.1 mtmm -141.15 169.57 17.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.0 tmm_? -80.83 114.03 19.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.54 167.11 18.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.127 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -119.0 147.06 41.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.684 0.754 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 176.84 6.24 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.02 172.22 13.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -91.13 121.7 33.14 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.89 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 55.8 p -145.76 140.35 27.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 33.9 tttm -55.4 133.99 50.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 93.4 p -51.68 118.08 3.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 15.5 t -105.39 152.25 23.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -118.83 146.03 18.33 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.24 14.31 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 0.0 112.37 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.1 p -120.11 83.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 41.5 p -89.34 127.54 35.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.451 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.4 m -132.45 88.76 2.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.955 0.407 . . . . 0.0 110.874 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.8 m -122.51 97.23 5.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.868 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 175.58 -124.34 0.99 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.4 m -115.67 42.21 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.834 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 24.5 t -102.67 82.91 2.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.832 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 110' ' ' SER . . . -119.89 -162.88 12.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.491 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 109' ' ' GLY . 40.8 t -35.27 115.06 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.97 0.414 . . . . 0.0 110.895 -179.762 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -39.34 111.48 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 90.5 p -120.42 116.06 24.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.852 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -100.37 37.49 1.67 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -102.22 145.55 29.26 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.754 HG22 HG13 ' A' ' 167' ' ' VAL . 25.1 pt -126.08 154.3 35.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -104.21 101.98 11.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 185' ' ' VAL . 98.2 t -95.66 119.11 43.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.129 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.71 177.43 16.43 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.516 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.87 28.62 63.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.492 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.55 HG23 ' HD2' ' A' ' 121' ' ' PRO . 32.3 mt -75.82 137.01 69.95 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.606 0.717 . . . . 0.0 111.104 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.55 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.72 166.98 25.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.657 2.238 . . . . 0.0 112.351 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -77.1 -3.49 39.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.878 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -100.82 -37.34 8.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.1 t -67.93 125.35 26.01 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.442 ' N ' ' OE1' ' A' ' 128' ' ' GLU . . . -129.9 -165.61 11.66 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.528 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -53.53 -64.53 0.79 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.92 0.39 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 87.3 m -44.14 -54.29 5.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.442 ' OE1' ' N ' ' A' ' 125' ' ' GLY . 12.2 mp0 -57.16 -63.44 1.22 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 133' ' ' PHE . 61.0 mt -34.31 -46.96 0.28 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 30.7 mtp85 -69.74 -51.14 36.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -50.22 -19.2 0.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.921 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.427 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 12.6 t80 -108.97 -24.05 11.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.566 ' CE2' HD12 ' A' ' 159' ' ' ILE . 17.1 m-85 -98.35 9.99 41.8 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -86.85 -25.47 24.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -69.45 -39.61 77.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -64.58 -25.94 68.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.904 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 176.5 -113.79 0.45 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.465 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.5 t -147.95 106.14 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.848 0.356 . . . . 0.0 111.154 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.18 116.51 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.172 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 79.5 p -93.68 -35.42 12.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.108 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.69 152.61 45.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.93 97.69 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.139 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' A' ' 158' ' ' PHE . 59.3 t -81.84 142.74 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.095 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.3 mtt -145.15 136.7 25.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 56.8 mt -104.36 131.36 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.45 166.75 6.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 148' ' ' ALA . 48.0 t0 -91.49 109.75 21.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.13 -46.24 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 148' ' ' ALA . 1.5 tm-20 -35.3 -47.03 0.39 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -99.31 -28.69 13.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 59.78 50.06 7.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.0 ttp85 -149.73 138.58 12.53 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.613 0.72 . . . . 0.0 110.891 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.519 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.5 Cg_endo -69.71 110.62 2.59 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.352 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -50.24 -54.02 24.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.844 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.49 40.67 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.482 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -172.61 160.12 4.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 168.03 -155.56 26.44 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.441 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' A' ' 143' ' ' VAL . 29.2 m-85 -142.52 162.45 35.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.787 0.327 . . . . 0.0 110.879 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.566 HD12 ' CE2' ' A' ' 133' ' ' PHE . 13.9 mt -146.0 139.72 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.089 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 84.7 m -106.87 139.72 40.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.554 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 55.1 m-85 -109.08 179.24 4.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -86.23 -38.17 17.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' ASP . . . . . 0.415 ' O ' ' C ' ' A' ' 164' ' ' GLU . 6.5 m-20 -128.77 127.53 42.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.849 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 163' ' ' ASP . 26.8 tt0 -36.04 -42.19 0.28 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.403 ' O ' ' C ' ' A' ' 166' ' ' SER . 3.9 mt-30 -36.93 -61.42 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.554 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 7.2 m -38.32 -59.52 0.88 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.754 HG13 HG22 ' A' ' 115' ' ' ILE . 53.6 t -38.88 -63.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.157 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -43.9 -60.77 1.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -40.14 -53.41 2.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.36 -55.4 24.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.416 HG21 ' CB ' ' A' ' 187' ' ' ARG . 69.4 t -47.26 -61.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 171' ' ' VAL . 16.2 t-20 -37.67 -64.91 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 74.8 mtp -49.29 -45.43 45.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.835 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.8 t-160 60.03 28.07 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.5 m-85 -171.72 154.1 3.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.477 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 80.0 m-70 -159.38 156.64 28.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -113.09 91.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 183' ' ' VAL . 56.7 mt -111.05 134.21 54.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.113 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 47.99 36.19 5.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.78 46.04 85.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.463 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.424 ' HZ2' ' CA ' ' A' ' 121' ' ' PRO . 0.0 OUTLIER -153.61 147.18 25.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.875 -179.963 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.13 113.65 20.78 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.913 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -105.16 127.39 59.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -83.81 150.53 25.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.86 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 117' ' ' VAL . 23.8 t -151.14 131.93 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -136.86 149.05 47.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.416 ' CB ' HG21 ' A' ' 171' ' ' VAL . 12.1 ttt180 -62.87 124.89 22.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.21 162.08 21.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.132 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.433 ' CD ' ' H ' ' A' ' 189' ' ' GLU . 0.0 OUTLIER -100.49 161.09 25.12 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.927 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.444 ' O ' ' C ' ' A' ' 191' ' ' ARG . 54.0 Cg_endo -69.71 -50.8 0.44 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.684 2.256 . . . . 0.0 112.33 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.444 ' C ' ' O ' ' A' ' 190' ' ' PRO . 64.8 mtt-85 34.3 39.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -51.76 147.01 7.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 42.5 m -154.92 143.86 20.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 23.3 ttpt -173.02 136.85 0.68 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.913 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 70.9 m -110.19 100.01 8.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 16.5 t -154.33 131.8 11.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -133.15 78.71 0.35 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -6.87 19.62 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.653 2.235 . . . . 0.0 112.399 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.4 t -109.73 118.16 35.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 3.8 t -129.28 88.51 2.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.83 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.512 -179.974 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.0 m -93.57 92.59 7.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.5 t 64.65 42.45 4.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.84 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -119.56 -134.71 4.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.1 m -39.42 -43.69 1.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 71.6 m -101.11 148.65 24.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.868 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 113.25 -71.45 0.22 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 31.3 m -71.58 156.35 39.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 pttt -39.39 125.53 1.7 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 56.8 m -107.03 120.24 41.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.832 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -86.84 42.51 1.02 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -99.95 150.54 22.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.867 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.502 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.33 154.79 41.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -103.76 102.98 12.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 185' ' ' VAL . 83.8 t -97.95 112.84 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.24 173.7 15.37 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.479 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.01 63.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.439 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.596 HG23 ' HD2' ' A' ' 121' ' ' PRO . 42.1 mt -54.91 137.8 64.93 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.629 0.728 . . . . 0.0 111.152 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 163.99 36.25 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.644 2.229 . . . . 0.0 112.353 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.6 t-160 -68.99 -6.28 26.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.836 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 124' ' ' CYS . 19.6 t-20 -100.25 -64.22 1.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 43.7 t -35.13 126.57 0.56 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.75 -164.11 11.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -54.8 -66.24 0.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -42.54 -61.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.166 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 129' ' ' LEU . 9.5 mm-40 -49.42 -63.23 1.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.526 HD11 ' CE ' ' A' ' 144' ' ' MET . 44.9 mt -37.84 -55.16 1.22 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.708 ' HA ' HG21 ' A' ' 139' ' ' VAL . 63.8 mtp180 -56.11 -56.0 26.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -50.33 -44.34 54.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.583 ' CD2' HG12 ' A' ' 178' ' ' ILE . 6.4 t80 -74.03 -22.54 59.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 159' ' ' ILE . 25.2 m-85 -105.32 15.8 26.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.5 ptmt -90.48 -37.79 13.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.92 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -60.47 -37.93 82.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -67.28 -30.01 69.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.85 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.63 -116.48 0.48 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.528 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 19.7 t -148.57 106.61 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.708 HG21 ' HA ' ' A' ' 130' ' ' ARG . 8.1 t -69.42 119.06 14.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.175 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 78.3 p -99.77 -37.57 9.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -134.03 141.31 47.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.876 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.537 HG21 ' CG ' ' A' ' 130' ' ' ARG . 94.0 t -127.74 93.62 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.17 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.7 t -89.42 134.41 28.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.543 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 8.3 mtp -135.96 133.39 37.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.531 HD11 ' HE1' ' A' ' 158' ' ' PHE . 57.5 mt -92.11 134.24 30.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.52 165.91 5.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.981 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 16.5 t0 -84.53 112.62 20.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.856 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.24 -59.98 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -40.87 -45.8 2.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 23.7 mttp -75.75 -41.01 54.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 60.07 48.02 8.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.3 ttm180 -160.4 138.55 7.35 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.563 0.697 . . . . 0.0 110.9 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.543 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.79 116.35 4.52 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.718 2.279 . . . . 0.0 112.346 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.5 mtp180 -58.76 -55.36 36.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.62 39.37 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.4 p90 -170.4 160.95 7.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.876 0.369 . . . . 0.0 110.893 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -158.15 30.96 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.531 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.8 m-85 -138.86 161.62 36.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.359 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 133' ' ' PHE . 8.6 mt -147.59 139.28 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.14 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 m -109.21 140.02 43.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.47 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.8 m-85 -108.53 169.45 8.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -75.81 -34.55 60.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 34.6 m-20 -129.62 141.5 50.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -52.31 -45.14 65.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.914 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -40.68 -44.66 2.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.9 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.47 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 17.4 m -54.04 -41.91 68.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 115' ' ' ILE . 38.5 t -58.53 -58.94 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.139 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -49.95 -42.87 49.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -55.23 -55.35 32.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.0 -56.57 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 98.4 t -48.06 -44.56 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.186 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -50.23 -51.53 43.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.914 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.2 mmm -62.59 -36.07 81.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.8 t-160 49.31 25.22 1.2 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 8.7 m-85 -170.13 145.99 2.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.493 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 49.0 m80 -155.94 162.8 40.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -119.74 94.2 4.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.743 HD12 HG21 ' A' ' 183' ' ' VAL . 44.8 mt -113.34 120.61 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.5 mmt 59.9 34.25 21.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.69 46.97 58.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -153.5 148.55 26.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 8.2 tptm -86.84 108.51 18.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.743 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -98.51 120.99 48.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -82.73 147.58 28.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 117' ' ' VAL . 41.1 t -143.17 132.49 20.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.146 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mttp -137.06 136.71 38.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.419 ' HG3' ' CG1' ' A' ' 167' ' ' VAL . 34.9 ttt180 -52.45 123.16 10.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.97 17.0 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.126 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -114.69 144.04 31.13 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.66 0.743 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 127.8 15.05 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.703 2.269 . . . . 0.0 112.294 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 5.7 ttm105 -116.97 90.99 3.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.838 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 22.9 m-20 -139.91 161.47 37.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 99.0 p -45.54 168.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -100.97 126.26 47.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 36.0 p -150.79 130.56 13.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 19.9 t -71.0 -67.33 0.51 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.87 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 137.1 80.8 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.537 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -168.67 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.377 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -103.38 -2.26 27.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.848 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 32.3 t -99.47 -69.19 0.77 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.835 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.507 -179.965 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 85.9 p -82.9 149.7 26.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.857 0.361 . . . . 0.0 110.88 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 43.6 m -57.81 159.13 5.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.88 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 139.89 -154.45 23.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 83.9 p -99.05 133.81 42.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.872 0.367 . . . . 0.0 110.883 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.5 m -88.43 -54.96 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 174.2 162.85 26.61 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.5 t 45.77 40.9 6.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.884 0.373 . . . . 0.0 110.836 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 40.0 tttm -97.82 -35.4 10.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.3 m -149.96 170.73 18.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.871 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.853 ' O ' HG23 ' A' ' 160' ' ' THR . 0.8 OUTLIER -125.54 81.28 1.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.92 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt -127.67 141.13 51.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.425 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -121.08 151.51 24.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.497 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 6.4 t80 -101.88 105.02 15.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.877 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 185' ' ' VAL . 94.0 t -97.92 121.73 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.129 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -127.6 175.42 18.28 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.95 18.89 62.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.56 HG23 ' HD2' ' A' ' 121' ' ' PRO . 40.2 mt -65.76 136.83 95.98 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.639 0.733 . . . . 0.0 111.144 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.56 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 0.0 112.344 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -75.29 1.62 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.444 ' C ' ' SD ' ' A' ' 179' ' ' MET . 27.7 t-20 -107.29 -23.1 12.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 13.5 t -80.48 128.45 33.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -130.8 176.83 18.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.5 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.603 ' HG3' HG11 ' A' ' 142' ' ' VAL . 30.5 tt0 -35.99 -61.01 0.51 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.909 0.385 . . . . 0.0 110.863 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 65.9 m -46.39 -60.15 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 35.8 mm-40 -49.98 -61.9 1.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.895 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.439 HD13 HD11 ' A' ' 159' ' ' ILE . 62.5 mt -35.73 -56.01 0.69 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.944 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.535 ' HA ' HG21 ' A' ' 139' ' ' VAL . 62.3 mtp180 -61.76 -55.03 34.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -44.34 -29.53 0.69 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.878 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.449 ' CD2' HG12 ' A' ' 178' ' ' ILE . 11.9 t80 -98.53 -27.4 14.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.935 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.563 ' CE2' HD12 ' A' ' 159' ' ' ILE . 21.4 m-85 -95.1 13.34 25.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptpt -93.93 -9.73 36.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 pttt -84.71 -36.5 21.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -65.02 -35.04 79.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.487 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -172.58 -102.14 0.15 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.461 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 137' ' ' GLY . 40.9 t -157.95 105.73 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.535 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.2 t -66.18 119.24 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.14 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 14.4 p -99.09 -37.14 9.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.189 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -135.31 148.78 49.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.872 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.603 HG11 ' HG3' ' A' ' 126' ' ' GLU . 97.6 t -132.07 94.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.135 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.9 t -90.48 138.09 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.104 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.401 ' HE3' HD11 ' A' ' 129' ' ' LEU . 9.2 mtp -137.37 136.06 37.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.562 HD11 ' HE1' ' A' ' 158' ' ' PHE . 58.7 mt -97.66 135.27 32.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.467 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -173.57 164.58 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.91 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.4 t0 -83.05 112.73 20.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.65 -62.75 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.125 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -38.91 -42.96 0.9 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 147' ' ' ASP . 70.0 mttt -79.44 -37.42 37.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 54.88 53.09 10.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.956 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.467 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 11.5 ttt180 -164.72 137.98 3.9 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.578 0.704 . . . . 0.0 110.894 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 116.99 4.81 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.338 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -59.89 -54.64 43.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.28 39.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -169.3 164.92 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.826 0.346 . . . . 0.0 110.91 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.71 -163.33 35.69 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.562 ' HE1' HD11 ' A' ' 145' ' ' ILE . 45.4 m-85 -133.22 161.82 33.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.784 0.326 . . . . 0.0 110.94 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.563 HD12 ' CE2' ' A' ' 133' ' ' PHE . 10.2 mt -148.63 137.51 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 113' ' ' ASN . 32.8 m -106.15 143.14 34.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.456 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 39.2 m-85 -111.23 176.14 5.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.4 tt0 -77.67 -44.83 26.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.896 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' ASP . . . . . 0.467 ' CB ' ' HG2' ' A' ' 165' ' ' GLN . 0.9 OUTLIER -121.54 128.56 52.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -42.02 -23.77 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.467 ' HG2' ' CB ' ' A' ' 163' ' ' ASP . 5.4 pt20 -48.51 -53.4 18.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.921 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.456 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 5.1 m -49.26 -55.95 10.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.846 -179.756 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 171' ' ' VAL . 53.3 t -37.68 -55.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.078 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ASP . . . . . 0.426 ' OD1' ' C ' ' A' ' 168' ' ' ASP . 0.6 OUTLIER -62.13 -46.3 89.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.874 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -52.0 -52.51 50.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.49 -56.45 15.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.075 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 167' ' ' VAL . 43.2 t -44.63 -55.83 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -38.07 -67.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 83.4 mtp -48.38 -46.29 36.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 19.0 t-160 62.04 26.89 16.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 9.2 m-85 -171.31 150.83 2.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.855 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.4 m-70 -156.7 151.38 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.849 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -107.67 98.98 8.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.888 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.851 HD12 HG21 ' A' ' 183' ' ' VAL . 71.0 mt -119.89 122.08 67.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.444 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 12.4 mtt 54.67 41.58 31.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.05 42.65 99.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 15.2 tptp -148.92 148.65 30.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.826 0.346 . . . . 0.0 110.923 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 7.6 tppt? -88.34 107.21 18.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.906 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.851 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -95.45 112.38 27.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.174 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -74.87 149.48 39.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 117' ' ' VAL . 46.3 t -147.13 136.09 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mtmm -139.89 151.66 45.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.893 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -65.25 125.1 23.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.915 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.09 9.56 6.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.084 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -89.82 150.07 43.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.63 0.729 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 159.82 51.97 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.691 2.261 . . . . 0.0 112.33 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 3.7 mmp_? -56.04 154.27 7.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.421 ' OD1' ' N ' ' A' ' 192' ' ' ASP . 0.4 OUTLIER -70.87 147.14 49.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 7.7 t -133.77 146.05 50.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.876 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.8 mmmm -41.31 152.97 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.891 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 16.7 t -159.52 163.72 34.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 48.9 m -102.71 107.21 18.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 79.56 -169.41 53.49 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.77 -46.86 1.07 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.65 2.233 . . . . 0.0 112.401 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 4.4 m -110.89 169.75 8.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 34.9 p -146.98 177.24 9.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.265 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.995 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.3 t -164.95 132.38 3.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 110.873 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.0 t -78.21 109.62 12.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -95.73 88.23 1.05 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 53.3 p -41.54 126.97 3.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.895 0.379 . . . . 0.0 110.827 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 18.7 t -118.98 -56.53 2.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -67.96 -174.38 8.06 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.481 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.7 t -95.87 -52.96 3.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.939 0.399 . . . . 0.0 110.876 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.4 tmmm? -161.7 119.73 2.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.904 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 49.5 p -155.3 132.02 10.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.869 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -116.34 39.53 3.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.893 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -88.45 146.6 25.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.76 HG22 HG13 ' A' ' 167' ' ' VAL . 21.1 pt -132.29 146.64 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.141 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -89.74 111.98 23.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.928 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 185' ' ' VAL . 83.6 t -108.72 114.88 47.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.103 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -119.24 -173.29 15.47 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.69 24.14 31.56 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 121' ' ' PRO . 63.0 mt -69.48 138.19 88.76 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.668 0.747 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.641 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.73 170.33 16.79 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.731 2.287 . . . . 0.0 112.35 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -86.91 24.17 1.57 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -133.63 -33.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.434 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.9 t -66.9 117.79 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.894 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.47 -175.73 16.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.457 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -42.69 -56.17 3.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 0.0 110.856 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 86.7 m -51.3 -57.69 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 mm-40 -51.73 -52.95 44.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.528 HD22 HD11 ' A' ' 159' ' ' ILE . 85.9 mt -44.54 -48.18 10.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.964 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.564 ' HG2' HG11 ' A' ' 139' ' ' VAL . 69.5 mtt180 -69.66 -55.07 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -45.45 -23.98 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.572 ' CD2' HG12 ' A' ' 178' ' ' ILE . 4.3 t80 -103.68 -35.2 8.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.582 ' CE2' HD12 ' A' ' 159' ' ' ILE . 23.7 m-85 -90.33 16.22 9.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -95.23 -23.64 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -71.19 -35.23 71.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.471 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 34.9 m-85 -68.41 -32.59 72.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.77 -111.56 0.29 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.476 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 75.7 t -146.35 110.24 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.837 0.351 . . . . 0.0 111.152 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.564 HG11 ' HG2' ' A' ' 130' ' ' ARG . 93.0 t -72.89 106.05 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.146 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.8 p -79.46 -39.71 31.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -144.73 156.43 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.409 HG11 HD12 ' A' ' 129' ' ' LEU . 96.1 t -134.8 102.56 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.111 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.5 143.53 11.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.5 mtt -145.44 139.03 26.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.872 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.443 HD11 ' HE1' ' A' ' 158' ' ' PHE . 75.4 mt -107.9 136.22 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.15 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.464 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.91 165.34 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.934 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.9 t0 -86.19 114.29 22.9 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.87 -61.52 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 28.3 tt0 -36.08 -46.01 0.47 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 27.6 mttp -80.08 -40.29 27.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 60.0 48.27 8.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.1 ttp180 -158.98 138.8 8.65 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.609 0.719 . . . . 0.0 110.884 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 109.92 2.43 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.271 . . . . 0.0 112.334 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.8 mtt180 -50.17 -50.6 48.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.843 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 159.89 39.89 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -169.0 161.98 10.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.882 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.429 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.15 -150.2 18.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.469 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.443 ' HE1' HD11 ' A' ' 145' ' ' ILE . 11.3 m-85 -147.72 169.82 18.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.882 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.582 HD12 ' CE2' ' A' ' 133' ' ' PHE . 23.0 mt -151.13 141.81 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.103 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.2 m -106.95 142.27 36.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.15 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.577 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 50.1 m-85 -113.83 169.35 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -77.33 -38.37 50.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -130.05 136.57 49.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 165' ' ' GLN . 8.6 tm-20 -45.67 -45.37 14.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.924 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 164' ' ' GLU . 26.3 tt0 -35.29 -47.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.577 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 42.9 m -53.15 -54.07 41.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.847 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.76 HG13 HG22 ' A' ' 115' ' ' ILE . 53.3 t -43.88 -45.46 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -65.65 -45.49 82.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' GLN . . . . . 0.471 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 44.3 mm-40 -48.48 -45.42 36.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -76.43 -59.79 2.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.633 HG21 ' HG3' ' A' ' 187' ' ' ARG . 86.4 t -43.12 -51.4 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.14 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -39.71 -63.2 0.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.891 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 15.3 mtm -59.31 -38.33 80.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 15.0 t-160 59.27 25.46 14.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.473 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.9 m-85 -169.82 153.14 4.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.836 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.473 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 37.9 m80 -159.2 159.42 34.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -116.49 90.31 3.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 183' ' ' VAL . 51.3 mt -105.69 111.78 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 7.4 mtt 61.84 42.33 10.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.41 47.13 87.57 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.453 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.404 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 12.2 tppt? -151.47 140.29 20.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.894 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -84.83 102.94 13.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.92 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -92.99 132.86 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.169 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -92.54 144.95 24.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.877 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 117' ' ' VAL . 32.6 t -141.15 131.34 26.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -143.45 141.53 30.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.633 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.2 mtm105 -45.79 115.93 1.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.826 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -76.19 128.64 35.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.076 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -48.42 153.47 1.32 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 131.5 21.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.71 2.274 . . . . 0.0 112.366 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 26.2 ttm180 -75.88 100.75 4.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.849 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -115.98 87.14 2.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.7 t -131.29 121.0 23.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.822 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 2.4 ttmm -104.06 156.76 17.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.898 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 50.9 m -149.87 176.91 10.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 51.6 p -117.71 -40.97 2.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.851 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -171.25 -148.79 6.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -0.64 7.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.659 2.239 . . . . 0.0 112.316 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 37.2 m -50.57 135.33 23.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 69.7 m -91.42 -53.14 4.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 179.986 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.413 ' O ' ' C ' ' A' ' 104' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 103' ' ' GLY . 20.9 m -36.45 123.09 0.78 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.911 0.386 . . . . 0.0 110.843 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.8 p -41.6 126.14 2.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -117.7 148.51 18.67 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.452 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.9 m -79.12 90.65 4.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.854 0.359 . . . . 0.0 110.847 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 74.4 p -47.14 169.07 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 158.08 -83.23 0.14 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.486 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 7.4 t -79.4 111.12 15.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.89 0.376 . . . . 0.0 110.807 -179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.3 ttmt -105.66 110.59 22.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.86 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.4 p -101.92 108.06 19.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.835 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -113.14 39.58 2.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttpp -92.97 140.99 28.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.622 HG22 HG13 ' A' ' 167' ' ' VAL . 28.2 pt -124.49 151.15 29.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.143 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -98.44 108.37 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.912 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 185' ' ' VAL . 95.4 t -101.21 121.8 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.15 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.7 175.72 18.58 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.67 13.34 60.92 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.561 HG23 ' HD2' ' A' ' 121' ' ' PRO . 31.2 mt -61.87 137.15 95.26 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.718 . . . . 0.0 111.142 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.561 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.74 163.52 37.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.691 2.261 . . . . 0.0 112.344 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -77.44 1.35 19.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -106.65 -23.72 12.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 14.0 t -79.85 133.39 36.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.77 -165.59 11.79 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.593 ' HG3' HG11 ' A' ' 142' ' ' VAL . 38.2 tt0 -52.57 -68.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 34.9 m -38.69 -67.8 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.13 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 17.5 mp0 -38.68 -61.33 0.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 ' CE ' ' A' ' 144' ' ' MET . 73.7 mt -40.68 -46.56 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.909 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.482 ' HA ' HG21 ' A' ' 139' ' ' VAL . 14.3 mtp-105 -70.0 -52.3 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -51.92 -23.94 5.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -100.24 -30.21 12.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.531 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.1 m-85 -94.24 13.75 22.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -94.03 -13.75 26.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.0 pttm -79.83 -37.54 34.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -68.62 -33.9 74.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.98 -116.33 0.38 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.474 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 36.1 t -146.16 106.31 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.879 0.371 . . . . 0.0 111.152 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 130' ' ' ARG . 39.0 t -68.12 115.26 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.094 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 41.8 p -95.94 -39.0 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -133.59 144.06 49.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.593 HG11 ' HG3' ' A' ' 126' ' ' GLU . 72.6 t -130.34 94.44 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.129 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.0 t -88.7 141.52 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.116 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.511 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 7.6 mtt -140.58 137.1 33.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.9 mt -99.89 126.81 53.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -167.07 165.42 15.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.917 -179.984 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.441 ' O ' ' C ' ' A' ' 148' ' ' ALA . 19.2 t0 -85.33 113.58 21.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.44 -59.13 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.077 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -41.39 -42.88 2.38 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.92 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.427 ' N ' ' O ' ' A' ' 147' ' ' ASP . 19.4 mttp -79.25 -41.08 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.01 50.14 6.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.0 ttm-85 -162.88 138.02 5.2 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.598 0.713 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.511 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.76 112.12 2.99 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.748 2.298 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 67.5 mtp180 -52.65 -57.03 11.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.845 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 169.5 40.54 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.422 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.5 p90 -171.69 165.54 6.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.856 0.36 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.98 -153.97 24.61 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 59.6 m-85 -143.94 160.6 40.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.915 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.531 HD12 ' CD2' ' A' ' 133' ' ' PHE . 7.8 mt -148.42 135.93 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.9 m -103.87 142.98 33.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -112.22 168.39 9.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 58.4 tt0 -69.75 -38.65 76.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -131.1 143.68 50.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 165' ' ' GLN . 11.4 tt0 -50.66 -44.31 57.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.417 ' C ' ' O ' ' A' ' 164' ' ' GLU . 34.5 tt0 -36.1 -52.67 0.78 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.1 m -46.37 -55.68 6.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.622 HG13 HG22 ' A' ' 115' ' ' ILE . 40.6 t -38.48 -56.57 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.13 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -52.87 -59.09 4.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -39.12 -38.3 0.47 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.931 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.457 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -77.6 -65.37 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.111 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.66 HG21 ' HG3' ' A' ' 187' ' ' ARG . 84.1 t -43.98 -55.41 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.129 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.451 ' C ' ' O ' ' A' ' 171' ' ' VAL . 0.7 OUTLIER -34.48 -59.48 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.865 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 60.1 mtp -65.33 -35.18 80.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.515 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.6 t-160 54.69 27.39 8.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.7 m-85 -167.89 152.21 6.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 55.1 m80 -159.8 147.61 16.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.854 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -103.73 99.24 9.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.81 HD12 HG21 ' A' ' 183' ' ' VAL . 58.0 mt -120.66 124.35 72.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.165 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.4 mmt 57.03 34.89 25.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.814 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 67.15 48.84 57.24 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 5.1 tmtm? -161.01 150.21 16.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 182' ' ' LYS . . . . . 0.461 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -83.02 126.46 32.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.81 HG21 HD12 ' A' ' 178' ' ' ILE . 5.5 t -114.19 110.87 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.121 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -70.94 143.97 50.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 117' ' ' VAL . 40.0 t -143.34 131.31 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.161 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.0 mmmt -145.61 144.06 30.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.933 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.66 ' HG3' HG21 ' A' ' 171' ' ' VAL . 14.0 mtp180 -48.17 125.43 9.26 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.73 -179.68 7.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.109 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -99.88 149.79 36.27 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.641 0.734 . . . . 0.0 110.863 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 141.51 45.43 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.56 -65.2 1.04 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.838 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 34.1 t0 -87.0 107.17 18.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 85.1 p -92.87 112.03 23.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.858 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.49 140.53 29.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.912 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 77.6 p -90.96 172.43 8.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.853 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 45.9 m -108.76 172.22 6.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -79.11 -78.29 0.86 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 126.48 13.36 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.721 2.281 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 3.8 m -67.99 -48.21 66.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 3.9 t -96.61 147.55 23.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.89 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.474 -179.963 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 51.4 p -105.35 171.62 7.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.883 0.373 . . . . 0.0 110.859 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 17.3 m -112.67 99.69 8.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.859 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -111.83 112.31 3.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.525 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 69.5 m 62.86 41.3 8.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 m -110.53 81.76 1.49 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 136.61 148.95 5.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.462 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.3 t -110.07 164.79 12.28 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.99 0.424 . . . . 0.0 110.845 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.2 mtmm 50.55 50.24 19.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.929 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 m -102.31 -23.18 14.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 58.71 40.6 23.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 4.4 ttpm? -104.12 143.7 32.57 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.848 HG22 HG13 ' A' ' 167' ' ' VAL . 22.5 pt -125.75 155.37 35.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -103.38 104.48 14.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 185' ' ' VAL . 79.1 t -99.4 118.85 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -124.54 -172.53 13.59 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.477 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.28 17.78 19.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.479 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.634 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.4 mt -64.7 138.31 97.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.68 0.752 . . . . 0.0 111.101 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.5 Cg_endo -69.69 165.62 30.27 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.485 ' ND1' ' NH2' ' A' ' 152' ' ' ARG . 63.9 m-70 -80.58 13.91 2.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.434 ' C ' ' HG3' ' A' ' 179' ' ' MET . 3.3 m120 -122.02 -25.1 5.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.453 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -74.74 133.48 42.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.28 -161.06 10.09 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.508 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.13 -63.52 1.23 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.942 0.401 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 64.1 m -44.49 -59.17 2.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.142 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.44 ' O ' ' C ' ' A' ' 129' ' ' LEU . 57.1 mm-40 -50.35 -63.91 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 128' ' ' GLU . 50.0 mt -34.91 -52.39 0.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.447 ' O ' ' N ' ' A' ' 134' ' ' LYS . 62.7 mtp180 -66.19 -54.15 28.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.864 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 44.2 mm-40 -48.16 -26.5 1.92 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.483 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.7 t80 -100.79 -21.79 15.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -105.79 14.45 28.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.447 ' N ' ' O ' ' A' ' 130' ' ' ARG . 15.5 pttp -94.81 -17.56 22.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.37 -37.98 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -65.17 -34.36 78.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.17 -114.61 0.31 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.43 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 37.5 t -148.1 109.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.834 0.35 . . . . 0.0 111.172 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.418 HG11 ' HG2' ' A' ' 130' ' ' ARG . 47.3 t -74.55 105.99 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.0 p -81.21 -33.05 33.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.12 153.2 37.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.411 HG21 ' CG ' ' A' ' 130' ' ' ARG . 95.6 t -131.34 105.97 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 49.0 t -91.73 143.16 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.405 ' HE3' HD11 ' A' ' 129' ' ' LEU . 7.1 mtt -143.34 133.71 24.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.887 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 158' ' ' PHE . 63.2 mt -97.09 139.82 18.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.449 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -175.05 165.88 3.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.926 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.432 ' O ' ' C ' ' A' ' 148' ' ' ALA . 35.4 t0 -86.67 110.07 19.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.432 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.23 -57.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' ALA . 30.7 tt0 -37.06 -45.35 0.59 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.91 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.33 -37.14 20.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 60.05 52.79 4.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.485 ' NH2' ' ND1' ' A' ' 122' ' ' HIS . 2.1 ttt85 -160.86 138.9 7.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.646 0.736 . . . . 0.0 110.869 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 117.86 5.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.669 2.246 . . . . 0.0 112.355 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -61.1 -54.27 46.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.14 41.49 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.536 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -173.13 162.46 4.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.19 -153.47 23.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.557 ' HE1' HD11 ' A' ' 145' ' ' ILE . 53.9 m-85 -139.96 164.5 29.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 21.3 mt -147.13 139.7 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 57.0 m -105.08 142.98 33.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.434 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 46.8 m-85 -115.86 166.35 12.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.903 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -67.39 -42.77 82.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -131.14 141.06 50.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.864 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 165' ' ' GLN . 30.5 tt0 -46.04 -44.39 15.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 164' ' ' GLU . 23.8 tp60 -36.43 -55.67 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.434 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 16.4 m -44.31 -52.41 7.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.848 HG13 HG22 ' A' ' 115' ' ' ILE . 73.4 t -44.65 -54.86 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -52.82 -50.67 63.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.1 mm100 -45.86 -50.48 14.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.918 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.06 -53.86 15.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.094 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.84 HG21 ' HG3' ' A' ' 187' ' ' ARG . 70.1 t -44.31 -61.79 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.107 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 171' ' ' VAL . 62.7 t30 -35.61 -56.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 1.3 tpt -58.28 -41.51 84.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.92 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.9 t-160 51.15 30.75 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.551 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 4.9 m-85 -173.35 150.62 1.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 56.1 m80 -161.9 156.97 23.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -111.04 102.36 10.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.922 HD12 HG21 ' A' ' 183' ' ' VAL . 31.4 mt -129.06 134.91 63.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.15 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.434 ' HG3' ' C ' ' A' ' 123' ' ' ASN . 9.8 mmt 54.83 30.55 13.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.63 45.76 65.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.404 ' NZ ' ' HA ' ' A' ' 121' ' ' PRO . 19.9 ttmt -160.15 161.93 33.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.909 0.385 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.62 125.57 34.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.922 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -110.35 115.02 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.157 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 184' ' ' GLU . . . . . 0.404 ' HG2' ' CD2' ' A' ' 174' ' ' HIS . 9.4 tt0 -77.32 148.32 35.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.886 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 117' ' ' VAL . 41.9 t -146.89 133.12 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.4 mttm -139.69 169.75 17.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.84 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.9 mtp180 -78.3 117.25 19.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . -86.0 16.89 3.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.1 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -123.47 152.46 64.8 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.612 0.72 . . . . 0.0 110.901 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 165.1 32.12 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.689 2.259 . . . . 0.0 112.341 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.44 ' O ' ' C ' ' A' ' 192' ' ' ASP . 2.4 tmm_? -70.01 132.04 45.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.44 ' C ' ' O ' ' A' ' 191' ' ' ARG . 26.2 t70 -35.17 148.28 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.858 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.2 m -98.02 120.53 38.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.851 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -75.45 138.67 41.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.906 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.9 t -132.96 153.88 51.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.798 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 39.6 t -116.33 150.95 36.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.893 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 116.81 141.6 7.09 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.68 117.38 5.05 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.72 2.28 . . . . 0.0 112.315 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 67.0 m -131.64 86.0 2.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.8 m -69.97 -50.81 38.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.491 -179.97 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.416 ' O ' ' C ' ' A' ' 104' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 105' ' ' SER . 33.7 m -36.6 -45.9 0.54 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.893 0.378 . . . . 0.0 110.855 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 104' ' ' SER . 9.7 m -35.21 113.31 0.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -114.75 101.29 1.06 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.518 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.3 t -98.87 38.29 1.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.91 0.386 . . . . 0.0 110.897 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 64.8 m -74.85 82.6 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.832 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 144.23 114.31 0.94 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.522 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.9 t -63.16 177.75 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 110.837 -179.684 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -83.23 -41.69 18.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.2 t -50.76 108.8 0.26 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 m-20 -86.0 50.51 1.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.864 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -98.33 142.38 30.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.925 HG22 HG13 ' A' ' 167' ' ' VAL . 30.1 pt -125.24 153.05 32.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.09 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.414 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 30.8 t80 -98.97 105.53 17.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 185' ' ' VAL . 94.4 t -101.92 114.08 40.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.111 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.06 177.02 16.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.531 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.59 13.26 60.62 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.558 HG23 ' HD2' ' A' ' 121' ' ' PRO . 29.7 mt -61.86 137.14 95.24 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.558 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.4 Cg_endo -69.72 165.41 31.02 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.354 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.7 m-70 -78.68 0.65 25.76 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.827 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -106.04 -23.8 12.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.889 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.486 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.4 t -81.16 133.1 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.73 -166.81 11.72 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.431 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.463 ' HG2' ' CZ ' ' A' ' 130' ' ' ARG . 12.4 tt0 -54.21 -59.96 3.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.874 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 35.9 m -45.78 -61.78 1.58 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.17 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 129' ' ' LEU . 53.8 mm-40 -47.91 -64.7 0.72 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.441 HD22 ' HE2' ' A' ' 133' ' ' PHE . 62.6 mt -36.22 -58.46 0.68 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.521 ' HG2' HG11 ' A' ' 139' ' ' VAL . 59.7 mtm180 -58.6 -51.06 71.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.3 mm-40 -57.29 -17.42 11.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.491 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 21.5 t80 -108.0 -17.45 14.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.542 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.3 m-85 -104.18 -6.35 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.885 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.5 pttp -76.58 -21.26 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -69.91 -36.32 75.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.869 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -70.55 -32.25 69.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.75 -111.25 0.26 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.545 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.0 t -150.05 108.12 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.912 0.387 . . . . 0.0 111.117 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.521 HG11 ' HG2' ' A' ' 130' ' ' ARG . 74.0 t -72.53 104.91 2.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.14 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -81.29 -36.8 29.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.146 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -141.33 154.76 45.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.06 105.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 42.9 t -92.83 137.12 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.436 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 5.2 mtt -137.7 136.79 37.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.904 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.401 HD11 ' HE1' ' A' ' 158' ' ' PHE . 62.7 mt -102.1 135.0 41.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.437 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.17 165.44 4.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.973 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 150' ' ' LYS . 48.5 t0 -81.92 113.64 19.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.871 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.409 ' O ' ' HG3' ' A' ' 151' ' ' GLN . . . -37.31 -41.85 0.44 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.09 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -42.78 86.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 147' ' ' ASP . 3.0 mptp? -80.45 -31.41 37.45 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 148' ' ' ALA . 6.1 mt-30 52.3 44.01 30.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.4 ttm-85 -155.51 138.68 10.77 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.672 0.749 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.436 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.4 Cg_endo -69.77 111.01 2.7 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.655 2.237 . . . . 0.0 112.37 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.419 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 36.0 mtt180 -52.34 -53.08 49.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.73 40.73 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.419 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 35.6 p90 -169.29 163.85 10.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.931 0.396 . . . . 0.0 110.866 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 161.67 -157.87 29.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.506 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.414 ' CD2' ' HA ' ' A' ' 116' ' ' PHE . 12.5 m-85 -139.51 169.98 16.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.542 HD12 ' CE2' ' A' ' 133' ' ' PHE . 12.6 mt -152.68 136.68 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 19.2 m -105.03 135.9 45.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.52 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 35.0 m-85 -104.67 174.11 6.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.82 -40.32 48.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -127.55 137.54 52.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 165' ' ' GLN . 16.1 tm-20 -44.64 -45.71 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.0 tp60 -36.99 -55.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.904 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.52 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 13.1 m -45.58 -49.34 14.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.925 HG13 HG22 ' A' ' 115' ' ' ILE . 71.0 t -48.81 -47.17 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.091 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -62.88 -49.35 75.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 31.5 mm-40 -47.82 -48.5 30.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -74.33 -43.95 54.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.62 HG23 ' O ' ' A' ' 167' ' ' VAL . 25.6 t -55.36 -62.35 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 171' ' ' VAL . 2.1 t-20 -36.76 -55.67 0.87 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 98.2 mtp -55.12 -44.0 74.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.879 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.523 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.4 t-160 58.31 25.14 12.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.885 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.523 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.3 m-85 -169.65 152.62 4.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.85 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.491 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.6 m80 -158.5 154.15 26.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.806 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.63 93.8 4.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.856 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.933 HD12 HG21 ' A' ' 183' ' ' VAL . 59.2 mt -110.39 115.43 49.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 11.9 mtp 60.87 36.13 19.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.898 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.79 50.49 35.52 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.492 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.464 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.6 tmtt? -158.01 146.96 19.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.864 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 182' ' ' LYS . . . . . 0.464 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.1 OUTLIER -85.03 117.12 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.94 179.838 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.933 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -106.31 118.88 54.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.15 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -76.0 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 117' ' ' VAL . 44.6 t -146.65 127.4 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt -135.76 146.45 47.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 19.7 ttp180 -55.69 108.93 0.49 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.881 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -67.49 142.21 56.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.135 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -85.64 152.57 57.35 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.674 0.75 . . . . 0.0 110.896 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 119.67 6.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.713 2.275 . . . . 0.0 112.354 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 13.2 mmm180 -73.51 92.65 1.91 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -166.44 120.96 1.12 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 54.2 p -90.64 48.89 1.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.825 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 28.5 mtmt 55.59 43.84 27.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.936 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 11.8 t -44.41 124.19 3.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.892 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 29.9 t -99.1 121.37 40.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.841 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -133.91 145.34 17.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.456 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 104.93 1.4 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.722 2.281 . . . . 0.0 112.303 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.2 m -164.72 127.12 2.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 29.8 m -113.84 138.38 50.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.492 -179.973 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 t 50.47 42.2 26.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.871 0.367 . . . . 0.0 110.829 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 m -68.77 97.9 0.86 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -98.9 108.64 3.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.504 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 5.0 t -75.0 147.12 41.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.878 0.37 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 65.1 p -93.74 -42.51 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.889 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 53.84 -147.76 19.37 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.501 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 78.7 p -135.23 143.98 46.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.983 0.421 . . . . 0.0 110.847 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 11.7 pttt -59.25 99.73 0.06 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.945 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.1 m -149.46 -175.39 4.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.889 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -80.74 55.34 2.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -110.84 150.86 28.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.417 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.85 154.05 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.135 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 10.2 t80 -102.73 103.42 13.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 185' ' ' VAL . 86.2 t -97.76 115.87 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.97 174.24 16.04 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.95 26.02 71.08 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.485 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.624 HG23 ' HD2' ' A' ' 121' ' ' PRO . 52.7 mt -73.17 138.22 78.84 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.634 0.731 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.624 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.77 158.76 55.84 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.72 3.43 6.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -106.89 -37.14 6.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.544 ' SG ' HG21 ' A' ' 178' ' ' ILE . 44.0 t -67.68 136.95 55.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.429 ' H ' ' CG ' ' A' ' 128' ' ' GLU . . . -135.66 179.54 17.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 125' ' ' GLY . 24.0 tt0 -35.75 -69.68 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.4 m -40.84 -60.0 1.28 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.159 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.429 ' CG ' ' H ' ' A' ' 125' ' ' GLY . 49.1 mm-40 -44.74 -64.77 0.63 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.55 HD11 ' HE3' ' A' ' 144' ' ' MET . 65.7 mt -35.92 -47.04 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.523 ' HA ' HG21 ' A' ' 139' ' ' VAL . 36.7 mtm180 -67.38 -60.75 2.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.866 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -41.81 -25.69 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 11.6 t80 -102.77 -24.18 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.584 ' CE2' HD12 ' A' ' 159' ' ' ILE . 12.8 m-85 -99.74 16.3 24.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.923 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 3.9 ptpp? -95.31 -14.79 23.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -79.09 -37.68 38.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.896 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.416 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 39.0 m-85 -67.65 -25.06 65.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.06 -114.69 0.48 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 96.3 t -145.73 111.56 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.097 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.523 HG21 ' HA ' ' A' ' 130' ' ' ARG . 15.6 t -74.53 114.46 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 42.8 p -93.01 -37.29 12.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.75 152.72 45.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -135.02 100.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 81.4 t -84.98 143.2 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.109 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.55 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.2 mtt -144.29 132.61 21.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.476 HD11 ' HE1' ' A' ' 158' ' ' PHE . 68.4 mt -98.49 134.64 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -172.84 164.56 5.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.96 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' ALA . 24.3 t0 -85.35 115.6 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.422 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.65 -57.32 0.65 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -42.67 -41.9 3.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.412 ' N ' ' O ' ' A' ' 147' ' ' ASP . 16.3 ttmt -80.14 -41.18 25.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 60.08 50.41 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 8.2 ttp85 -164.99 138.93 4.0 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.618 0.723 . . . . 0.0 110.843 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.428 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.77 109.64 2.36 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.734 2.289 . . . . 0.0 112.357 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 32.5 mtp180 -49.58 -51.43 37.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 162.05 39.46 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.499 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -171.2 159.83 6.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.82 -155.08 25.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.476 ' HE1' HD11 ' A' ' 145' ' ' ILE . 51.2 m-85 -139.62 161.45 37.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.7 mt -145.0 141.56 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 42.5 m -109.43 141.03 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.173 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.508 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 51.9 m-85 -110.42 177.95 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -80.3 -40.31 27.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.871 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -127.85 146.41 50.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.807 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 165' ' ' GLN . 43.1 tp10 -51.58 -47.05 63.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.0 tt0 -36.63 -44.97 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.508 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 14.6 m -53.49 -47.93 69.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.883 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.417 HG13 HG22 ' A' ' 115' ' ' ILE . 37.6 t -51.3 -46.95 34.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.173 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -51.03 -65.73 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.867 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 41.7 mt-30 -42.95 -53.58 4.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.627 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -52.04 -45.48 64.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.045 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.8 HG21 ' HG3' ' A' ' 187' ' ' ARG . 93.5 t -70.0 -63.88 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.109 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 171' ' ' VAL . 8.3 m-20 -34.16 -43.99 0.17 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 5.2 ttt -68.36 -47.27 67.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.54 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 12.0 t-160 56.85 27.22 12.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.824 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.54 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.0 m-85 -174.18 151.45 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.459 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 45.6 m80 -158.87 161.49 36.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -117.0 87.15 2.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.857 HD12 HG21 ' A' ' 183' ' ' VAL . 63.7 mt -106.61 126.41 62.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.111 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.409 ' HG2' HG22 ' A' ' 178' ' ' ILE . 3.8 mmt 52.36 40.12 28.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.69 47.67 87.34 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.416 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 2.5 tmtt? -155.07 146.93 23.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.808 0.337 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 182' ' ' LYS . . . . . 0.416 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 6.2 tptm -81.18 117.38 21.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.888 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.857 HG21 HD12 ' A' ' 178' ' ' ILE . 2.9 t -109.41 120.55 60.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -80.45 153.47 28.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 117' ' ' VAL . 41.4 t -149.48 130.96 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -141.46 144.26 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.91 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.8 ' HG3' HG21 ' A' ' 171' ' ' VAL . 8.7 mtm180 -45.93 124.44 5.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.861 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.31 11.97 6.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -82.07 151.2 66.42 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.616 0.722 . . . . 0.0 110.9 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.7 127.9 15.32 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.706 2.271 . . . . 0.0 112.374 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 24.4 mmt180 -75.91 100.99 5.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -174.87 172.49 2.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 95.9 p -100.69 114.11 27.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.4 ptpp? -79.9 173.07 12.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 3.0 m -118.41 -58.13 2.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.906 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 46.9 t -144.97 117.98 8.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.864 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -98.56 -148.54 23.65 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 112.91 3.22 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.653 2.235 . . . . 0.0 112.359 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 19.8 m -56.0 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 4.2 t -39.47 149.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.809 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.491 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.1 p -122.95 91.09 3.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.914 0.388 . . . . 0.0 110.832 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 49.2 m -117.96 83.99 2.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.78 -104.06 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.533 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.0 p -139.99 139.07 35.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.899 0.38 . . . . 0.0 110.855 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -158.05 175.95 13.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -57.18 -175.26 0.31 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 72.7 p -118.49 -35.25 3.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.965 0.412 . . . . 0.0 110.88 -179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.82 146.92 2.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 70.6 p -99.3 114.92 28.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.869 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -90.64 40.2 1.01 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.9 ttpt -97.01 139.1 33.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.939 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -123.42 154.59 29.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -99.65 103.65 15.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 185' ' ' VAL . 93.2 t -100.41 111.7 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.02 -173.05 15.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.506 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.42 12.81 14.1 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.481 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.65 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.7 mt -57.3 138.42 80.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.653 0.74 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.65 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.9 Cg_endo -69.76 172.42 12.67 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.35 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.449 ' O ' ' NH2' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -85.0 17.89 2.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.823 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -128.29 -29.8 2.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.866 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.456 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -68.06 128.77 37.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.53 173.11 21.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.452 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.444 ' C ' ' O ' ' A' ' 125' ' ' GLY . 29.9 tt0 -34.34 -65.87 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.873 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 99.7 m -40.85 -61.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 129' ' ' LEU . 5.5 mp0 -54.31 -60.58 3.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.644 HD11 ' HE3' ' A' ' 144' ' ' MET . 59.9 mt -34.39 -45.92 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HA ' HG21 ' A' ' 139' ' ' VAL . 26.6 mtt180 -70.38 -55.75 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -46.5 -24.75 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.56 ' CD2' HG12 ' A' ' 178' ' ' ILE . 5.1 t80 -100.95 -29.78 12.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.576 ' CE2' HD12 ' A' ' 159' ' ' ILE . 19.7 m-85 -96.17 15.45 20.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.3 ptpt -95.27 -25.07 16.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.906 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.1 pttm -69.44 -38.83 77.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.867 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -66.02 -31.36 72.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -174.94 -115.24 0.4 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.5 t -146.13 106.42 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.882 0.373 . . . . 0.0 111.088 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.452 HG21 ' HA ' ' A' ' 130' ' ' ARG . 22.9 t -71.22 109.4 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.088 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 20.1 p -85.92 -39.78 16.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -139.84 151.98 46.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.9 t -134.01 102.46 4.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.137 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 158' ' ' PHE . 98.6 t -87.33 145.27 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.644 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.7 mtt -145.58 133.75 21.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.816 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.38 139.63 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.456 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.88 167.03 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 180.0 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.4 t0 -87.16 112.49 22.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.891 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.09 -60.0 0.34 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -39.38 -44.69 1.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 21.1 tttm -79.43 -40.13 30.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.92 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 60.05 45.08 12.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.456 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.8 ttt180 -155.37 138.21 10.48 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.654 0.74 . . . . 0.0 110.848 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 116.02 4.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.675 2.25 . . . . 0.0 112.371 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 41.6 mtp180 -58.67 -56.87 16.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.03 42.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.473 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -173.23 158.17 3.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.92 0.391 . . . . 0.0 110.866 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -151.44 19.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.489 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' PHE . . . . . 0.4 ' O ' ' O ' ' A' ' 143' ' ' VAL . 86.7 m-85 -138.36 164.69 28.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.823 0.344 . . . . 0.0 110.894 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.576 HD12 ' CE2' ' A' ' 133' ' ' PHE . 19.5 mt -148.31 134.12 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 17.9 m -102.34 143.13 32.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.159 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 41.5 m-85 -113.19 174.46 5.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.825 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -74.32 -38.76 63.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -135.17 151.38 50.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 165' ' ' GLN . 23.3 tt0 -51.9 -50.69 60.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.441 ' C ' ' O ' ' A' ' 164' ' ' GLU . 31.6 tp60 -34.54 -54.83 0.54 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.545 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 18.6 m -41.54 -58.71 1.83 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.86 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.939 HG13 HG22 ' A' ' 115' ' ' ILE . 62.2 t -42.27 -54.87 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.105 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 169' ' ' GLN . 27.5 t0 -47.14 -62.53 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 169' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 168' ' ' ASP . 49.1 mt-30 -36.98 -51.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.882 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.79 -67.55 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.448 ' O ' ' C ' ' A' ' 172' ' ' ASN . 98.8 t -39.36 -58.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.9 t30 -34.44 -56.53 0.52 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 85.3 mtp -61.55 -45.02 95.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 62.01 25.97 15.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.3 m-85 -172.85 147.5 1.71 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' HIS . . . . . . . . . . . . . 45.7 m80 -156.62 164.56 38.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.87 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -118.76 90.96 3.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.666 HD12 HG21 ' A' ' 183' ' ' VAL . 67.9 mt -111.06 119.23 59.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.151 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.5 mmt 60.07 39.63 19.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 54.64 32.69 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.436 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 7.7 tppt? -163.23 145.51 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.367 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 11.7 tptt -82.54 109.0 16.36 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.902 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.666 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -97.07 127.46 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -87.65 140.09 29.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 117' ' ' VAL . 25.4 t -139.2 136.33 41.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 24.6 mtmt -144.71 175.0 10.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.866 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.429 ' CG ' HG21 ' A' ' 171' ' ' VAL . 8.4 mtp180 -81.17 120.39 24.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.875 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.98 174.92 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -97.7 153.45 38.27 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.611 0.72 . . . . 0.0 110.944 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 0.0 6.29 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.663 2.242 . . . . 0.0 112.355 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? 54.93 48.36 20.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.905 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.421 ' O ' ' CG ' ' A' ' 192' ' ' ASP . 0.6 OUTLIER -119.31 116.54 26.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.865 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 22.1 t -117.47 88.15 2.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.834 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 32.7 tttp 40.59 41.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.918 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 1.4 t -64.03 102.24 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.886 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 2.1 t -108.16 115.93 31.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.829 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -162.8 -157.72 9.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 97.0 0.61 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.706 2.271 . . . . 0.0 112.367 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 80.7 p -106.31 43.96 1.1 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.825 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 64.3 m -56.63 157.17 5.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.869 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 179.99 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.2 t -73.05 87.46 1.37 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.889 0.376 . . . . 0.0 110.878 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -79.91 94.83 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -113.76 127.11 7.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.496 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 61.6 m -99.24 -56.99 2.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.92 0.391 . . . . 0.0 110.835 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 9.3 t -45.84 -60.71 2.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -48.79 -60.8 5.69 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.527 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 89.9 p -97.38 112.68 24.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.965 0.412 . . . . 0.0 110.896 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 4.0 mtmp? -90.08 130.23 36.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 7.3 t -124.72 126.54 45.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 -87.47 43.14 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -89.58 142.55 27.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.977 HG22 HG13 ' A' ' 167' ' ' VAL . 18.7 pt -128.12 148.04 32.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.151 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -93.96 114.61 26.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 185' ' ' VAL . 81.2 t -111.1 117.16 54.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.115 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.61 176.7 16.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.519 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.39 24.72 69.41 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.636 HG23 ' HD2' ' A' ' 121' ' ' PRO . 57.0 mt -71.87 138.48 82.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.617 0.722 . . . . 0.0 111.142 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.636 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.4 Cg_endo -69.78 165.35 31.31 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -78.96 10.99 2.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.87 -34.48 4.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.1 t -68.96 121.43 16.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -121.68 -169.29 13.59 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.98 -59.1 3.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -47.24 -61.19 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.127 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HG3' ' CE ' ' A' ' 179' ' ' MET . 65.2 mm-40 -47.67 -65.14 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 40.7 mt -34.03 -49.83 0.36 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.944 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -68.72 -53.99 18.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 23.0 mm-40 -46.2 -23.73 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.507 ' CZ ' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -103.56 -34.65 8.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.02 16.86 8.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -95.29 -23.39 17.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.23 -39.04 68.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.94 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -60.56 -35.5 76.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -173.04 -107.71 0.21 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 93.4 t -152.24 107.9 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.26 107.71 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.133 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.5 p -82.08 -37.16 26.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -143.89 154.8 43.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.7 t -134.96 102.81 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 59.7 t -89.33 143.65 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.458 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.1 mtt -144.31 135.92 25.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.0 mt -102.26 135.75 37.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.481 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.72 3.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' ALA . 28.8 t0 -85.19 110.4 18.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.857 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.457 ' O ' ' C ' ' A' ' 149' ' ' GLU . . . -34.7 -57.22 0.53 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.066 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.457 ' C ' ' O ' ' A' ' 148' ' ' ALA . 7.9 mm-40 -33.31 -48.32 0.23 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -87.55 -34.93 18.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 5.5 mm-40 59.0 54.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.481 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.9 ttm-85 -158.16 137.65 8.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' PRO . . . . . 0.458 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.77 110.18 2.49 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.438 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 42.1 mtt180 -51.86 -47.63 64.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 157.93 38.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.489 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 41.4 p90 -166.52 167.7 15.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.903 0.382 . . . . 0.0 110.907 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.3 -156.72 27.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.499 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -139.48 166.92 23.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.933 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.0 mt -149.53 138.98 15.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 27.3 m -106.87 140.53 39.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.142 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' PHE . . . . . 0.551 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -110.84 176.67 4.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -78.18 -44.42 25.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -124.82 133.45 53.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -41.26 -43.49 2.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -39.24 -47.77 1.7 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.551 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 70.8 m -50.59 -49.48 56.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.866 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.977 HG13 HG22 ' A' ' 115' ' ' ILE . 78.5 t -47.4 -62.39 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -44.96 -53.98 7.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -46.18 -47.48 17.72 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -69.87 -56.06 8.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.1 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 172' ' ' ASN . 91.1 t -49.78 -61.82 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 171' ' ' VAL . 15.0 t-20 -34.35 -62.88 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.875 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 24.2 mmm -49.9 -42.73 48.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.9 t-160 56.18 26.03 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.514 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 6.2 m-85 -169.91 154.01 5.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 84.8 m-70 -160.81 153.97 21.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -112.26 89.31 3.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.858 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.959 HD12 HG21 ' A' ' 183' ' ' VAL . 59.6 mt -106.23 109.57 28.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.154 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.468 ' CE ' ' HG3' ' A' ' 128' ' ' GLU . 5.0 mtm 62.14 43.22 8.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.69 50.72 59.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.468 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.4 tmtt? -155.9 144.83 20.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.846 0.355 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 182' ' ' LYS . . . . . 0.468 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 9.0 tppt? -87.77 112.74 22.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.959 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -102.79 119.56 51.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.149 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -79.24 140.73 37.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 117' ' ' VAL . 67.4 t -139.67 140.2 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.16 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -142.27 162.45 35.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.863 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 17.1 ttt180 -78.01 121.47 24.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.15 15.54 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -118.58 150.73 48.68 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.89 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 26.0 ptt85 -52.65 128.9 27.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.896 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.14 110.37 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.89 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.2 m -85.18 92.61 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.854 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 20.6 mtpt -115.68 177.08 4.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.867 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 46.6 t -100.73 84.11 2.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 51.6 p -39.09 148.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.844 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -147.39 84.88 0.17 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.446 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -0.13 6.44 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.674 2.25 . . . . 0.0 112.345 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 70.6 p -57.8 144.08 39.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.821 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 16.7 m -107.55 141.4 39.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.803 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 179.995 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -77.18 121.14 23.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.89 0.376 . . . . 0.0 110.796 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 86.2 p -83.41 139.88 32.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.866 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 161.65 -58.67 0.3 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.459 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 m -83.04 81.27 8.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.853 0.359 . . . . 0.0 110.854 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.2 m -154.36 150.61 28.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.914 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.15 -83.62 0.18 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.454 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.6 m -47.83 168.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.859 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -42.13 127.16 3.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.2 m -148.04 134.38 19.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -105.82 24.27 12.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.841 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.4 ttpt -85.29 142.82 29.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ILE . . . . . 0.652 HG22 HG13 ' A' ' 167' ' ' VAL . 21.8 pt -125.91 158.7 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.104 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 12.3 t80 -105.07 104.65 14.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 185' ' ' VAL . 71.9 t -100.63 114.33 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.112 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.14 -169.52 13.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.86 12.92 4.03 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.44 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.653 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.4 mt -57.39 138.41 81.08 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.609 0.719 . . . . 0.0 111.121 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.653 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.78 -174.24 0.87 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.248 . . . . 0.0 112.339 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.07 3.12 53.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -115.38 -10.71 11.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' CYS . . . . . 0.474 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.7 t -87.05 125.46 34.12 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.42 -172.86 13.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.512 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.416 ' HA ' HD12 ' A' ' 129' ' ' LEU . 47.2 tt0 -51.18 -66.06 0.45 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.8 m -44.14 -63.59 0.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.152 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -40.55 -58.42 1.6 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.881 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.48 HD11 ' HE3' ' A' ' 144' ' ' MET . 50.2 mt -40.99 -47.04 2.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.597 ' HA ' HG21 ' A' ' 139' ' ' VAL . 49.0 mtm180 -66.39 -61.25 2.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.882 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -43.31 -23.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' TYR . . . . . 0.405 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.2 t80 -101.08 -32.83 10.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.933 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.409 ' CD2' HD12 ' A' ' 159' ' ' ILE . 12.2 m-85 -93.52 15.3 16.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.851 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 pttt -95.11 -19.32 20.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.3 pttt -73.06 -30.39 63.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.893 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.482 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 44.4 m-85 -74.1 -37.12 64.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.15 -110.52 0.23 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.49 113.08 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.87 0.367 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.597 HG21 ' HA ' ' A' ' 130' ' ' ARG . 57.3 t -74.84 99.88 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 19.2 p -74.8 -42.11 58.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -142.96 155.08 44.63 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.877 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 159' ' ' ILE . 78.2 t -134.76 104.7 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.121 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.4 t -90.24 144.97 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.156 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.48 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.0 mtt -143.87 135.13 25.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 69.9 mt -98.38 133.35 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.165 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.452 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.68 165.35 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.449 ' O ' ' C ' ' A' ' 148' ' ' ALA . 22.1 t0 -81.61 110.11 16.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.82 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.449 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.69 -58.15 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.122 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -43.13 -43.67 4.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' LYS . . . . . 0.443 ' N ' ' O ' ' A' ' 147' ' ' ASP . 35.0 mttm -78.0 -40.35 39.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 59.97 50.28 6.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.933 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.452 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.0 ttt85 -161.65 138.01 6.1 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.627 0.727 . . . . 0.0 110.899 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 121.64 8.33 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.657 2.238 . . . . 0.0 112.349 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.475 ' HD3' ' CZ ' ' A' ' 156' ' ' PHE . 50.5 mtp180 -65.67 -53.95 34.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.869 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.91 38.25 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.45 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.475 ' CZ ' ' HD3' ' A' ' 154' ' ' ARG . 37.1 p90 -168.12 162.84 13.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.857 0.36 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.88 -155.18 26.42 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.467 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -139.55 169.46 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.794 0.33 . . . . 0.0 110.912 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 142' ' ' VAL . 11.0 mt -151.79 135.44 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.164 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 31.6 m -102.18 140.38 36.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -111.46 172.84 6.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -73.05 -34.72 66.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -137.94 152.68 49.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 165' ' ' GLN . 12.0 tm-20 -56.36 -49.64 73.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 164' ' ' GLU . 2.0 tp-100 -34.81 -47.28 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 1.2 m -48.34 -54.55 13.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.652 HG13 HG22 ' A' ' 115' ' ' ILE . 69.8 t -43.4 -49.9 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.126 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 169' ' ' GLN . 1.2 m-20 -54.37 -61.54 2.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' GLN . . . . . 0.482 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -35.99 -45.57 0.43 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.934 -179.919 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.39 -63.12 1.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.092 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 172' ' ' ASN . 85.1 t -43.16 -54.96 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 171' ' ' VAL . 32.2 t30 -34.65 -50.91 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 41.2 mtp -74.36 -39.91 62.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 16.3 t-160 59.54 27.44 16.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.6 m-85 -169.84 152.68 4.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' HIS . . . . . 0.434 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 56.8 m80 -157.94 151.74 23.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -107.4 93.55 4.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' ILE . . . . . 0.824 HD12 HG21 ' A' ' 183' ' ' VAL . 53.6 mt -116.23 119.46 62.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 6.9 mmt 56.83 47.47 17.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 56.43 56.16 25.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.529 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 25.5 tptt -165.21 149.33 8.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.84 0.352 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' LYS . . . . . 0.426 ' HE3' ' CG ' ' A' ' 175' ' ' PHE . 14.4 tptt -90.43 110.39 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.824 HG21 HD12 ' A' ' 178' ' ' ILE . 4.1 t -95.21 131.07 43.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.103 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -88.65 146.01 25.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 117' ' ' VAL . 54.9 t -140.6 127.18 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.098 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 3.9 mtmp? -142.89 143.57 32.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.915 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.61 ' HD3' HG11 ' A' ' 167' ' ' VAL . 3.1 mmt85 -46.76 139.67 5.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -105.65 16.4 25.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.41 ' CG ' ' HD2' ' A' ' 187' ' ' ARG . 10.5 pt-20 -126.9 151.43 73.87 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.61 0.719 . . . . 0.0 110.884 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 164.13 35.66 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.241 . . . . 0.0 112.384 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 28.3 ptt-85 -84.34 168.17 15.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -67.74 129.76 40.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 17.0 m -104.42 -56.4 2.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.814 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 67.9 tttt -80.73 136.48 36.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.936 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 8.6 t -107.91 106.44 16.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 47.5 m -107.03 -58.16 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.896 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 111.21 -175.9 18.05 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.485 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 172.89 11.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.644 2.229 . . . . 0.0 112.376 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.5 t -48.71 -48.72 40.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.899 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 88.3 p 43.17 42.11 3.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.861 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.466 -179.951 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.909 0.385 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -102.38 143.28 32.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 167' ' ' VAL . 33.0 pt -126.55 152.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -97.08 109.03 21.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 185' ' ' VAL . 90.5 t -104.43 113.02 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.65 176.51 16.38 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.95 5.42 46.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.459 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.2 mt -52.75 138.02 43.38 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 111.161 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.606 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.52 24.22 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.712 2.275 . . . . 0.0 112.363 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.456 ' CE1' HH11 ' A' ' 152' ' ' ARG . 41.1 t-80 -82.93 10.34 8.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.39 -20.21 8.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.482 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 11.6 t -80.5 142.15 34.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.09 -171.88 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -48.16 -57.93 5.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.6 m -47.01 -60.14 2.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 129' ' ' LEU . 1.7 mp0 -53.83 -63.45 1.15 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.89 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 128' ' ' GLU . 63.5 mt -34.31 -62.5 0.33 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.654 ' CG ' HG21 ' A' ' 142' ' ' VAL . 51.0 mtp180 -59.02 -52.03 67.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -50.5 -22.52 1.98 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.45 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 13.4 t80 -104.65 -20.62 13.59 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.468 ' CE2' HD12 ' A' ' 159' ' ' ILE . 20.8 m-85 -102.49 15.49 29.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.937 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 32.1 pttt -94.14 -16.44 23.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 3.7 pttm -76.14 -36.67 58.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -67.95 -26.57 66.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.876 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.39 -114.69 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 66.3 t -144.16 116.71 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 111.137 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 43.3 t -79.82 113.53 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 76.5 p -90.11 -36.0 15.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -143.52 152.29 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.869 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.654 HG21 ' CG ' ' A' ' 130' ' ' ARG . 57.8 t -134.82 101.99 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.7 t -87.92 143.86 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.147 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.621 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 6.0 mtt -144.94 131.47 19.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.54 HD11 ' HE1' ' A' ' 158' ' ' PHE . 71.1 mt -96.12 131.89 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.108 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.443 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.58 164.52 10.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 43.9 t0 -85.99 112.14 20.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.81 -60.9 0.36 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 148' ' ' ALA . 0.3 OUTLIER -36.14 -45.44 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -81.44 -39.33 25.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 59.73 54.27 4.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.456 HH11 ' CE1' ' A' ' 122' ' ' HIS . 9.0 ttm180 -165.37 138.74 3.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.612 0.72 . . . . 0.0 110.878 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.621 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.6 Cg_endo -69.76 114.22 3.63 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.739 2.292 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.4 mtt180 -56.09 -54.42 45.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.04 39.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.527 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -169.39 166.59 10.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.874 0.369 . . . . 0.0 110.916 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.24 -157.26 28.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.54 ' HE1' HD11 ' A' ' 145' ' ' ILE . 32.1 m-85 -137.36 165.91 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.468 HD12 ' CE2' ' A' ' 133' ' ' PHE . 11.8 mt -149.2 134.07 10.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.0 m -101.34 145.06 29.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -114.52 -177.7 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -86.85 -41.97 13.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . 0.416 ' O ' ' C ' ' A' ' 164' ' ' GLU . 0.8 OUTLIER -125.25 128.54 48.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.868 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 163' ' ' ASP . 10.1 tm-20 -36.3 -37.7 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.917 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.423 ' O ' ' C ' ' A' ' 166' ' ' SER . 15.7 mt-30 -42.08 -60.45 1.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 1.3 m -36.67 -53.43 0.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 115' ' ' ILE . 70.5 t -45.24 -58.68 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.144 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -50.21 -55.01 17.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.841 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -45.44 -51.08 11.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.906 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.53 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -64.58 -51.39 63.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 39.8 t -47.63 -60.5 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -41.83 -51.95 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -59.26 -41.98 90.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 48.17 28.17 1.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.849 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 5.1 m-85 -173.0 151.35 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.507 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 74.5 m-70 -160.29 147.64 16.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.832 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -102.33 90.0 3.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.813 HD12 HG21 ' A' ' 183' ' ' VAL . 72.5 mt -110.23 110.31 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 10.2 mtt 63.48 44.81 5.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.875 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.93 43.11 99.64 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.471 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.8 tppt? -149.61 145.46 26.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.19 107.83 19.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.813 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -93.54 129.12 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -87.32 135.79 33.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.905 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 117' ' ' VAL . 56.1 t -132.62 132.48 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 7.5 mmmm -136.21 159.73 40.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -67.89 114.22 6.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 179.943 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.942 0.401 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 tttt -97.88 144.52 27.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.913 HG22 HG13 ' A' ' 167' ' ' VAL . 20.2 pt -126.07 149.14 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.099 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.3 t80 -96.39 113.71 25.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.918 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 185' ' ' VAL . 87.4 t -110.28 116.31 52.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.131 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.54 -179.54 16.06 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.85 14.46 44.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.472 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.631 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.3 mt -62.45 138.36 96.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.629 0.728 . . . . 0.0 111.128 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.78 159.96 51.46 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.67 2.246 . . . . 0.0 112.337 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -68.2 -4.1 12.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.833 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.411 ' O ' ' C ' ' A' ' 124' ' ' CYS . 9.5 m120 -100.23 -62.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.446 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 35.3 t -37.62 120.96 0.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.4 -172.24 13.76 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -46.24 -65.68 0.52 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.3 m -44.13 -59.13 2.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 129' ' ' LEU . 67.1 mm-40 -49.67 -65.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.847 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.605 HD11 ' CE ' ' A' ' 144' ' ' MET . 39.5 mt -34.38 -54.63 0.52 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.493 ' CG ' HG21 ' A' ' 142' ' ' VAL . 14.4 mtp180 -63.69 -59.99 3.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -42.75 -25.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 12.2 t80 -100.66 -24.82 14.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 159' ' ' ILE . 14.3 m-85 -97.91 13.76 29.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -93.12 -29.77 15.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.6 pttt -61.67 -33.85 74.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -68.87 -42.85 76.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.898 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -166.19 -108.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.485 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.65 109.91 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 29.1 t -75.21 119.55 23.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.163 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 33.2 p -93.81 -36.31 12.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.149 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -140.55 153.03 45.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.493 HG21 ' CG ' ' A' ' 130' ' ' ARG . 61.2 t -133.63 101.95 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 62.3 t -88.73 141.14 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.088 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.605 ' CE ' HD11 ' A' ' 129' ' ' LEU . 4.3 mtt -143.33 138.99 29.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.417 HD11 ' HE1' ' A' ' 158' ' ' PHE . 64.6 mt -105.48 132.4 52.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -171.69 165.06 6.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.882 -179.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 26.2 t0 -84.39 113.9 21.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.85 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.74 -58.48 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -42.5 -43.56 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 10.5 tppt? -77.48 -41.33 39.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 60.02 46.92 10.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 0.4 OUTLIER -160.6 138.58 7.21 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.577 0.704 . . . . 0.0 110.862 -179.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.47 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.84 110.77 2.65 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.7 2.267 . . . . 0.0 112.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 19.1 mtt-85 -50.3 -55.79 13.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.99 42.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -173.29 159.94 3.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.882 0.373 . . . . 0.0 110.85 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.04 -158.66 31.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.495 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.417 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.6 m-85 -139.64 162.18 35.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.548 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.4 mt -144.91 139.37 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.1 m -105.29 141.29 37.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.565 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 34.5 m-85 -112.51 174.01 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -79.91 -40.39 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.915 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . 0.44 ' O ' ' C ' ' A' ' 164' ' ' GLU . 27.4 m-20 -126.16 123.37 38.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.865 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.44 ' C ' ' O ' ' A' ' 163' ' ' ASP . 8.4 tp10 -35.18 -41.15 0.15 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.838 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.427 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.0 mm-40 -35.79 -60.89 0.5 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.565 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 68.7 m -39.29 -59.25 1.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.913 HG13 HG22 ' A' ' 115' ' ' ILE . 67.1 t -35.32 -47.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.135 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -65.53 -52.33 53.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -43.43 -50.46 6.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.404 ' O ' ' C ' ' A' ' 171' ' ' VAL . . . -68.04 -66.0 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 167' ' ' VAL . 88.8 t -37.1 -52.37 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 59.9 t-20 -37.41 -65.49 0.31 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 7.5 mtm -57.91 -32.24 67.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.914 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.513 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 18.2 t-160 50.17 26.81 2.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.524 ' C ' ' CD2' ' A' ' 176' ' ' HIS . 7.8 m-85 -169.45 150.31 4.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.524 ' CD2' ' C ' ' A' ' 175' ' ' PHE . 24.1 m-70 -160.9 150.03 16.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.843 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -105.73 94.48 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.913 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.725 HD12 HG21 ' A' ' 183' ' ' VAL . 70.3 mt -111.4 114.43 47.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 13.5 mtt 61.86 39.64 13.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.94 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.04 54.07 29.88 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -164.64 142.95 6.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.41 117.95 23.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.923 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.725 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -105.43 122.52 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -80.79 138.18 36.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 117' ' ' VAL . 94.4 t -139.72 135.61 39.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.123 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -147.21 169.41 19.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 22.1 mtt180 -69.12 114.22 7.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.853 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.096 179.9 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.923 0.392 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -91.43 143.38 26.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.707 HG22 HG13 ' A' ' 167' ' ' VAL . 22.7 pt -127.56 148.13 32.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.408 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 17.1 t80 -92.53 112.95 25.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.815 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 185' ' ' VAL . 91.1 t -109.51 117.3 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.136 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.86 -177.47 15.21 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.508 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.41 23.07 47.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.461 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.604 HG23 ' HD2' ' A' ' 121' ' ' PRO . 64.3 mt -69.85 137.45 87.68 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.657 0.742 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.604 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.691 2.261 . . . . 0.0 112.31 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -81.6 3.63 24.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -110.07 -27.14 9.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.5 t -74.89 123.99 26.07 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.35 -173.55 13.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.72 -62.37 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.972 0.415 . . . . 0.0 110.885 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 51.9 m -43.14 -63.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.088 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 129' ' ' LEU . 0.9 OUTLIER -49.47 -62.24 1.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.735 HD11 ' HE3' ' A' ' 144' ' ' MET . 35.3 mt -34.35 -49.21 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.89 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.493 ' HE ' HG23 ' A' ' 142' ' ' VAL . 50.4 mtt180 -67.49 -51.44 51.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . 0.405 ' HA ' ' CE ' ' A' ' 134' ' ' LYS . 34.4 mt-10 -55.2 -16.71 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.469 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 15.9 t80 -108.74 -20.83 12.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.522 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.4 m-85 -105.5 16.49 25.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.875 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.405 ' CE ' ' HA ' ' A' ' 131' ' ' GLU . 12.2 ptpt -94.76 -26.17 16.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -68.06 -38.46 82.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.883 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -63.26 -35.11 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . 0.574 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -173.45 -98.08 0.11 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.476 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 137' ' ' GLY . 56.2 t -161.42 109.99 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.876 0.37 . . . . 0.0 111.134 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.489 HG21 ' HA ' ' A' ' 130' ' ' ARG . 17.0 t -75.23 113.52 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 17.7 p -90.55 -37.73 13.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -141.23 153.04 45.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.493 HG23 ' HE ' ' A' ' 130' ' ' ARG . 63.5 t -134.28 100.69 3.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.8 t -85.71 142.16 13.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.735 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.7 mtt -145.03 133.24 21.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.837 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.515 HD11 ' HE1' ' A' ' 158' ' ' PHE . 59.2 mt -97.95 136.85 27.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.451 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.9 3.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.944 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.453 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -86.3 113.72 22.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.453 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.27 -62.27 0.28 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 17.7 tt0 -36.25 -47.29 0.57 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.837 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -77.33 -40.77 43.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 60.08 51.71 5.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.451 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 2.1 ttp180 -163.89 138.86 4.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.634 0.731 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 110.56 2.6 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.643 2.229 . . . . 0.0 112.316 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.3 mtt180 -50.97 -52.4 43.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.4 40.24 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -170.2 162.35 8.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.868 0.366 . . . . 0.0 110.893 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.408 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.73 -150.79 19.75 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.515 ' HE1' HD11 ' A' ' 145' ' ' ILE . 15.9 m-85 -145.97 168.99 19.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 0.0 110.901 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.597 HD11 HD22 ' A' ' 129' ' ' LEU . 20.5 mt -151.55 138.16 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.7 m -103.49 142.92 33.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.138 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.516 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 57.7 m-85 -113.27 170.03 8.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -73.98 -38.73 64.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.861 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -131.02 137.2 49.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.448 ' O ' ' N ' ' A' ' 167' ' ' VAL . 11.4 tm-20 -44.93 -47.17 11.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.8 tt0 -34.74 -48.42 0.38 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.94 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.516 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 66.0 m -50.35 -46.7 55.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.707 HG13 HG22 ' A' ' 115' ' ' ILE . 58.0 t -50.89 -55.56 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.157 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -53.62 -47.36 70.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.813 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -49.08 -55.79 11.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.907 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.95 -58.26 6.6 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.793 HG21 ' HG3' ' A' ' 187' ' ' ARG . 94.0 t -44.17 -61.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.108 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 171' ' ' VAL . 28.3 t30 -35.76 -46.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.2 mmm -69.9 -43.42 71.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.538 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 16.5 t-160 59.06 26.94 15.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.0 m-85 -171.55 154.32 3.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.865 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 93.2 m-70 -160.66 162.77 32.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.832 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -117.95 92.4 3.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.819 HD12 HG21 ' A' ' 183' ' ' VAL . 55.9 mt -112.21 127.24 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.143 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.0 mmt 52.63 33.38 13.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.96 52.06 25.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.482 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -159.03 145.81 17.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.863 0.364 . . . . 0.0 110.869 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.2 tppt? -82.17 111.17 18.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.854 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.819 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -100.97 121.58 51.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -80.79 144.86 31.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 117' ' ' VAL . 52.7 t -141.1 131.72 27.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.156 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.5 mtpt -142.95 144.48 32.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.915 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.793 ' HG3' HG21 ' A' ' 171' ' ' VAL . 7.4 mtp-105 -50.62 120.81 5.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.082 179.956 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.864 0.364 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 18.9 ttmt -93.24 151.93 19.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.673 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -134.7 152.25 32.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.11 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 27.7 t80 -98.95 108.74 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 185' ' ' VAL . 90.8 t -104.48 114.36 43.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.84 170.83 16.12 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 72.36 14.19 77.07 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.442 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.579 HG23 ' HD2' ' A' ' 121' ' ' PRO . 34.2 mt -62.74 137.41 96.64 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.641 0.734 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.77 161.0 47.6 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.707 2.271 . . . . 0.0 112.324 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.0 2.41 10.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.404 ' C ' ' SD ' ' A' ' 179' ' ' MET . 8.8 m-20 -107.72 -23.56 12.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.864 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.478 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 25.4 t -82.07 143.1 31.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -145.51 -171.98 15.54 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.534 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.418 ' HA ' HD12 ' A' ' 129' ' ' LEU . 45.9 tt0 -42.95 -66.18 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.7 m -40.17 -65.73 0.38 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 129' ' ' LEU . 3.9 mp0 -48.33 -61.68 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.757 HD11 ' HE3' ' A' ' 144' ' ' MET . 80.7 mt -34.4 -50.61 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.911 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.488 ' CG ' HG21 ' A' ' 142' ' ' VAL . 47.0 mtp180 -71.32 -53.4 14.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 41.4 mm-40 -46.99 -22.31 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.524 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 32.6 t80 -103.85 -36.79 7.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.897 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.551 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.8 m-85 -84.9 10.23 12.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.885 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 8.6 ptpt -91.0 -29.78 17.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . 0.453 ' N ' ' HG3' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -69.97 -17.42 63.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.913 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -89.54 -19.88 24.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.22 -118.07 0.65 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.538 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.6 t -146.02 106.88 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.89 0.376 . . . . 0.0 111.119 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.429 HG21 ' HA ' ' A' ' 130' ' ' ARG . 5.2 t -73.52 111.09 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . 0.404 HG22 ' OE1' ' A' ' 162' ' ' GLU . 43.3 p -88.03 -39.76 14.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.152 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -136.97 151.11 48.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.488 HG21 ' CG ' ' A' ' 130' ' ' ARG . 86.4 t -134.36 106.22 7.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.7 t -96.7 139.31 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.191 179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.757 ' HE3' HD11 ' A' ' 129' ' ' LEU . 14.4 mtp -141.1 130.57 23.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -91.46 137.21 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.447 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.72 165.13 4.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.937 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.443 ' O ' ' C ' ' A' ' 148' ' ' ALA . 39.3 t0 -85.13 113.49 21.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.59 -58.72 0.41 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.107 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -41.47 -43.87 2.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.436 ' N ' ' O ' ' A' ' 147' ' ' ASP . 9.5 tptm -78.14 -40.85 36.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 60.01 48.02 9.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.447 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.6 ttp85 -161.63 138.95 6.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.626 0.727 . . . . 0.0 110.816 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.503 ' CB ' ' CE ' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 113.8 3.49 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.645 2.23 . . . . 0.0 112.348 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 33.7 mtp85 -55.48 -57.04 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 167.8 41.66 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.503 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -172.55 157.13 3.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.918 0.39 . . . . 0.0 110.834 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.41 -154.42 24.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.507 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -140.1 166.13 25.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.813 0.34 . . . . 0.0 110.919 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.551 HD12 ' CD2' ' A' ' 133' ' ' PHE . 17.3 mt -150.0 142.39 17.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.102 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.4 m -109.82 141.12 42.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.11 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.581 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 39.4 m-85 -110.39 176.98 4.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.404 ' OE1' HG22 ' A' ' 140' ' ' THR . 17.8 tp10 -82.47 -36.17 26.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -131.96 131.34 42.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.849 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -40.8 -41.49 1.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.839 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -37.56 -53.95 1.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.581 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 22.4 m -46.27 -54.37 8.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.673 HG13 HG22 ' A' ' 115' ' ' ILE . 63.8 t -40.71 -56.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.134 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 169' ' ' GLN . 38.8 t0 -56.29 -64.13 0.96 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 168' ' ' ASP . 50.9 mt-30 -34.69 -43.92 0.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -75.15 -62.47 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.084 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.527 HG21 ' CG ' ' A' ' 187' ' ' ARG . 51.4 t -42.74 -54.24 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -40.64 -51.61 2.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.4 mmm -64.37 -31.97 73.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 13.3 t-160 48.61 26.46 1.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.1 m-85 -169.28 148.46 3.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.848 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.524 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 91.9 m-70 -155.07 152.43 29.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.84 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -108.13 104.07 13.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.996 HD12 HG21 ' A' ' 183' ' ' VAL . 52.4 mt -126.23 113.09 32.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.404 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 9.1 mtt 60.62 42.56 13.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 46.74 93.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.495 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.8 tptt -153.41 145.93 24.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -87.25 110.74 20.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.996 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -97.8 115.03 36.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -76.77 141.6 40.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 117' ' ' VAL . 20.3 t -138.57 131.55 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 11.4 mtmt -138.34 149.99 46.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.947 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.527 ' CG ' HG21 ' A' ' 171' ' ' VAL . 14.0 mtt180 -53.07 123.77 12.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.7 ttmt -100.14 137.18 38.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.728 HG22 HG13 ' A' ' 167' ' ' VAL . 29.2 pt -119.65 153.38 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.147 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -101.87 107.61 18.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 185' ' ' VAL . 88.1 t -103.36 117.65 49.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.141 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.69 -177.42 15.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.52 13.73 39.1 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.467 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.567 HG23 ' HD2' ' A' ' 121' ' ' PRO . 35.5 mt -61.65 137.15 94.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 0.0 111.15 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.567 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.1 Cg_endo -69.67 161.85 44.32 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.433 ' ND1' ' O ' ' A' ' 122' ' ' HIS . 2.8 p80 -77.58 8.66 4.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.873 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.459 ' O ' ' CE ' ' A' ' 179' ' ' MET . 47.5 t30 -117.09 -15.12 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 2.7 t -83.55 153.22 24.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -158.92 169.6 35.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.517 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 125' ' ' GLY . 0.6 OUTLIER -35.97 -59.4 0.6 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.893 0.377 . . . . 0.0 110.893 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.9 m -42.62 -53.94 4.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -65.25 -55.93 15.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.476 HD13 HD11 ' A' ' 159' ' ' ILE . 60.6 mt -42.6 -58.85 2.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.933 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.642 ' HA ' HG21 ' A' ' 139' ' ' VAL . 68.1 mtp180 -54.51 -56.72 15.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -50.87 -33.5 24.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.504 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.0 t80 -89.64 -20.06 24.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.431 ' CD2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-85 -105.31 17.74 23.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -92.59 -39.15 11.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.3 ptpt -57.39 -31.14 65.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.869 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -73.99 -32.48 63.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.891 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.55 -118.9 0.54 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 60.2 t -145.04 106.23 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.642 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.5 t -68.71 108.66 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.117 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 16.5 p -86.03 -38.0 18.33 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -140.67 155.53 46.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.416 HG21 ' CG ' ' A' ' 130' ' ' ARG . 85.0 t -136.89 106.35 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.166 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.5 t -93.96 138.7 19.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.122 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.8 mtt -139.17 136.33 34.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.1 mt -101.43 131.76 48.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.445 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.16 164.84 7.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.3 t0 -85.41 112.4 20.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.865 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.5 -60.56 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 tm-20 -38.52 -45.45 1.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 9.3 tppt? -78.52 -40.51 34.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 60.07 53.11 4.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.911 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 15.4 ttp85 -165.44 138.34 3.56 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.601 0.715 . . . . 0.0 110.922 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 111.44 2.82 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.684 2.256 . . . . 0.0 112.315 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.6 mtp85 -52.0 -50.77 60.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 161.27 39.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -169.69 161.45 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.519 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 165.42 -151.05 19.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.459 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.519 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 10.1 m-85 -146.03 166.31 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.869 0.366 . . . . 0.0 110.866 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.476 HD11 HD13 ' A' ' 129' ' ' LEU . 18.2 mt -150.4 136.78 12.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.13 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 36.5 m -103.82 143.4 32.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.536 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.9 m-85 -112.44 176.46 5.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.925 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -77.91 -39.04 44.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.71 145.21 49.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 165' ' ' GLN . 34.8 tt0 -48.81 -44.39 39.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.918 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.418 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.1 tt0 -34.76 -49.6 0.43 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.536 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 20.0 m -53.65 -52.08 61.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.728 HG13 HG22 ' A' ' 115' ' ' ILE . 70.4 t -47.41 -47.1 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -63.56 -52.62 60.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -47.67 -51.58 21.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.891 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.89 -56.44 7.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.647 HG23 ' O ' ' A' ' 167' ' ' VAL . 40.3 t -43.6 -57.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -38.74 -62.04 0.66 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.885 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.3 mmm -48.6 -42.45 33.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.528 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 14.6 t-160 54.01 25.72 5.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.521 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -172.37 144.8 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.898 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.504 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 64.8 m-70 -156.21 158.74 38.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -110.33 103.68 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.772 HD12 HG21 ' A' ' 183' ' ' VAL . 34.2 mt -130.05 131.34 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.089 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 123' ' ' ASN . 11.9 mmt 62.52 25.74 15.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.914 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.01 85.01 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.46 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 9.1 ttmm -128.29 162.17 27.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.866 0.365 . . . . 0.0 110.876 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 5.8 tptm -88.74 128.68 35.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.772 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -112.46 121.61 65.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.096 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -81.37 145.21 30.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 117' ' ' VAL . 42.7 t -142.29 126.91 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mmmt -138.04 143.92 40.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -56.69 118.54 4.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.842 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 179.905 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.425 ' O ' HG23 ' A' ' 160' ' ' THR . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.918 0.389 . . . . 0.0 110.874 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.7 ttmt -117.67 148.65 41.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.79 HG22 HG13 ' A' ' 167' ' ' VAL . 21.7 pt -129.22 155.33 41.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 7.3 t80 -104.74 102.37 11.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 185' ' ' VAL . 84.8 t -93.3 125.42 45.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.109 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.1 -177.28 14.79 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.52 8.69 10.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.629 HD11 HG12 ' A' ' 117' ' ' VAL . 55.3 mt -58.71 137.61 86.58 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.638 0.732 . . . . 0.0 111.117 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.593 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.76 169.79 18.09 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.0 p-80 -85.92 15.21 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -123.67 -26.86 4.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.498 ' SG ' HG21 ' A' ' 178' ' ' ILE . 24.1 t -72.18 118.92 15.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.68 -174.32 16.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.495 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -41.45 -63.94 0.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.951 0.405 . . . . 0.0 110.863 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 46.0 m -41.9 -54.9 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.102 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 129' ' ' LEU . 61.1 mm-40 -54.41 -66.18 0.44 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.663 HD11 ' CE ' ' A' ' 144' ' ' MET . 51.5 mt -34.53 -60.34 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.613 ' HA ' HG21 ' A' ' 139' ' ' VAL . 5.6 mtp-105 -58.9 -57.0 15.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.863 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -46.44 -25.8 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.568 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.3 t80 -102.46 -20.7 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.928 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.569 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.6 m-85 -104.47 9.8 35.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 130' ' ' ARG . 48.2 pttt -91.33 -17.61 25.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.88 -38.57 57.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.915 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -69.18 -29.38 67.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.31 -124.17 0.79 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.7 t -138.61 105.3 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.126 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.613 HG21 ' HA ' ' A' ' 130' ' ' ARG . 38.6 t -65.16 110.0 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.079 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 46.2 p -87.74 -38.46 15.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.129 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -137.38 147.43 45.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.859 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.27 94.46 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 72.3 t -89.99 137.9 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.12 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.663 ' CE ' HD11 ' A' ' 129' ' ' LEU . 8.8 mtp -137.57 142.7 41.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 73.3 mt -106.58 133.53 50.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.37 165.08 5.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.903 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 29.1 t0 -85.83 113.5 22.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.33 -62.13 0.29 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.108 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 148' ' ' ALA . 42.5 tt0 -36.38 -46.26 0.53 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -78.99 -40.55 31.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 60.0 47.84 9.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.9 ttp180 -158.29 138.32 8.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.623 0.725 . . . . 0.0 110.893 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.462 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.75 110.6 2.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.724 2.282 . . . . 0.0 112.32 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -51.62 -53.53 37.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.851 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 120' ' ' ILE . . . 163.03 41.39 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.534 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -170.7 160.6 7.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.914 0.388 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.23 -159.01 32.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 15.8 m-85 -137.81 161.11 37.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.82 0.343 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.569 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.1 mt -148.19 140.73 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.073 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 113' ' ' ASN . 23.6 m -107.13 144.23 34.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.437 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 54.8 m-85 -113.29 167.52 10.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -70.53 -43.17 70.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -122.06 140.53 52.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 165' ' ' GLN . 7.9 tp10 -49.67 -46.39 49.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.401 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.4 tt0 -38.24 -51.88 1.48 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.437 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 50.6 m -44.58 -57.05 3.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.79 HG13 HG22 ' A' ' 115' ' ' ILE . 38.4 t -37.68 -59.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 169' ' ' GLN . 46.9 t0 -50.53 -61.65 2.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.807 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 168' ' ' ASP . 76.0 mt-30 -35.73 -48.91 0.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.62 -57.89 4.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.118 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 174' ' ' HIS . 75.2 t -47.13 -60.39 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 171' ' ' VAL . 7.5 t30 -35.07 -61.08 0.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 27.5 mmm -51.08 -41.45 59.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.904 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.522 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 11.6 t-160 55.94 26.23 9.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.8 m-85 -171.87 148.32 2.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.568 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 52.7 m-70 -155.44 155.83 34.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -112.37 85.84 2.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.897 HD12 HG21 ' A' ' 183' ' ' VAL . 78.8 mt -96.66 126.24 49.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.15 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.833 ' HG2' HG22 ' A' ' 178' ' ' ILE . 2.0 ptm 38.81 48.22 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.5 67.74 1.94 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.41 ' NZ ' ' HB2' ' A' ' 181' ' ' LYS . 0.3 OUTLIER -175.13 142.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.815 0.34 . . . . 0.0 110.897 -179.946 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.8 tptm -85.04 102.37 13.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.884 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.897 HG21 HD12 ' A' ' 178' ' ' ILE . 3.0 t -95.08 117.34 38.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.139 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . 0.543 ' O ' HG23 ' A' ' 185' ' ' VAL . 10.1 tt0 -72.92 162.19 29.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.906 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 117' ' ' VAL . 72.3 t -161.12 131.02 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mttm -137.19 143.31 42.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.434 ' NH1' ' HB2' ' A' ' 187' ' ' ARG . 10.4 ttm105 -56.96 114.16 1.99 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.862 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 179.904 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.438 ' HG2' ' N ' ' A' ' 115' ' ' ILE . 21.3 ttmt -105.23 149.55 25.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.647 HG22 HG13 ' A' ' 167' ' ' VAL . 24.0 pt -129.6 156.85 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.454 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 8.0 t80 -104.58 106.45 16.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 185' ' ' VAL . 89.3 t -103.05 114.42 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -118.43 -177.64 16.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.432 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.04 26.63 58.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.471 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.623 HG23 ' HD2' ' A' ' 121' ' ' PRO . 60.7 mt -75.46 137.9 71.12 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.631 0.729 . . . . 0.0 111.12 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.72 165.11 32.02 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.706 2.27 . . . . 0.0 112.374 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -77.3 0.54 21.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -105.42 -32.89 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 21.4 t -68.8 118.81 12.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.39 -179.27 15.85 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.52 ' HA ' HD12 ' A' ' 129' ' ' LEU . 55.9 tt0 -39.89 -67.59 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.876 0.369 . . . . 0.0 110.853 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.1 m -40.67 -60.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.121 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 16.7 mm-40 -49.73 -61.22 2.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.612 HD11 ' CE ' ' A' ' 144' ' ' MET . 41.9 mt -35.97 -55.67 0.74 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.486 ' HG2' HG11 ' A' ' 139' ' ' VAL . 11.1 mtp-105 -64.03 -54.7 30.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -47.52 -20.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -107.46 -25.42 11.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.591 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.4 m-85 -97.98 15.34 24.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.8 ptpt -95.22 -10.69 29.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.94 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.2 pttm -81.69 -34.56 30.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -72.14 -23.29 61.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.33 -118.96 0.69 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 88.2 t -140.03 116.14 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' A' ' 130' ' ' ARG . 24.9 t -80.66 111.12 16.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.6 p -89.1 -34.95 16.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -142.02 157.82 44.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.424 HG21 ' CG ' ' A' ' 130' ' ' ARG . 99.3 t -139.05 104.94 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.172 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.79 139.27 17.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.149 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.612 ' CE ' HD11 ' A' ' 129' ' ' LEU . 5.3 mtt -142.25 133.7 26.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.438 HD11 ' HE1' ' A' ' 158' ' ' PHE . 70.7 mt -99.21 133.82 40.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.22 165.96 5.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.941 -179.987 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.455 ' O ' ' C ' ' A' ' 148' ' ' ALA . 21.8 t0 -84.88 113.23 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.455 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.16 -58.29 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.056 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -42.41 -44.45 3.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 147' ' ' ASP . 2.8 mptm? -77.22 -40.82 43.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 60.09 43.5 14.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.866 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 3.8 ttp180 -155.92 138.47 10.38 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.6 0.714 . . . . 0.0 110.886 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.589 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.77 110.87 2.66 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.335 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.9 mtp85 -50.86 -55.89 14.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.18 41.77 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -172.34 162.95 5.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.449 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 162.79 -154.51 25.49 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.451 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 4.7 m-85 -141.95 167.03 23.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.891 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.591 HD12 ' CD2' ' A' ' 133' ' ' PHE . 8.9 mt -150.1 139.85 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.137 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.3 m -106.33 144.82 32.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.471 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 53.1 m-85 -115.13 175.02 5.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -78.65 -43.25 26.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 164' ' ' GLU . 3.4 m-20 -123.97 125.59 44.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.874 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 163' ' ' ASP . 23.1 tt0 -35.17 -39.03 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.419 ' C ' ' O ' ' A' ' 164' ' ' GLU . 3.8 mm100 -36.03 -59.33 0.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.471 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 1.1 m -41.87 -58.35 2.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.809 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 171' ' ' VAL . 58.6 t -36.12 -54.42 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -58.54 -60.3 4.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.1 mt-30 -39.9 -48.84 2.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.92 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.48 -54.94 13.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 167' ' ' VAL . 67.9 t -46.21 -60.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.167 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.428 ' C ' ' O ' ' A' ' 171' ' ' VAL . 12.3 t-20 -35.84 -67.8 0.15 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.832 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 86.2 mtp -46.44 -42.14 14.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.3 t-160 54.74 30.61 13.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.824 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -173.57 155.17 2.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 77.8 m-70 -160.57 162.82 33.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -119.39 91.52 3.57 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 183' ' ' VAL . 58.2 mt -112.23 135.09 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.7 mmm 46.14 40.78 7.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.885 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.34 57.4 18.42 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.412 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.2 tmtm? -166.09 151.33 8.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.5 OUTLIER -84.5 116.7 23.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.895 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.854 HG21 HD12 ' A' ' 178' ' ' ILE . 3.9 t -105.78 120.41 56.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -82.15 146.78 29.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 117' ' ' VAL . 69.2 t -144.49 134.31 19.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -139.18 149.1 44.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 28.7 ttp180 -59.9 119.21 7.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.932 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.116 179.978 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.919 0.39 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -92.72 150.01 20.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.908 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.863 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -131.09 155.16 41.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -104.39 105.54 15.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 185' ' ' VAL . 94.8 t -101.11 115.32 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.146 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.01 177.98 16.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.06 11.69 55.7 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.668 HG23 ' HD2' ' A' ' 121' ' ' PRO . 55.9 mt -57.85 138.84 82.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.642 0.734 . . . . 0.0 111.13 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.668 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.2 Cg_endo -69.79 171.96 13.55 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.658 2.239 . . . . 0.0 112.359 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 122' ' ' HIS . 12.1 t60 -76.58 -5.14 46.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.452 ' O ' ' C ' ' A' ' 124' ' ' CYS . 7.7 m120 -102.43 -62.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.472 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.3 t -34.38 128.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -127.34 -154.82 8.62 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.444 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -66.33 -60.87 2.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.942 0.401 . . . . 0.0 110.921 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 53.3 m -48.55 -58.36 4.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.091 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.41 ' CD ' ' H ' ' A' ' 128' ' ' GLU . 6.2 mp0 -46.63 -61.95 1.6 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 35.5 mt -39.74 -52.13 2.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.917 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.589 ' HG2' HG11 ' A' ' 139' ' ' VAL . 74.0 mtm180 -59.85 -52.42 65.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 -53.38 -27.84 26.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.927 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.518 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 9.0 t80 -96.51 -18.96 19.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.946 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.486 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.4 m-85 -108.17 7.99 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.871 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.481 ' N ' ' O ' ' A' ' 130' ' ' ARG . 32.3 pttt -90.77 -28.46 18.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.2 ptpt -66.47 -25.94 66.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.867 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -78.66 -37.8 41.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -167.92 -112.25 0.26 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.463 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 86.5 t -147.47 112.33 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 111.056 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 70.7 t -75.16 103.78 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.112 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -79.24 -40.9 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.18 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.25 152.98 46.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.5 t -132.46 102.43 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.08 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.8 t -89.44 143.59 10.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.44 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.4 mtt -145.41 134.18 22.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.413 HD11 ' HE1' ' A' ' 158' ' ' PHE . 55.6 mt -98.76 130.66 47.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.169 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.454 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -170.09 164.66 9.34 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 150' ' ' LYS . 46.0 t0 -82.91 113.34 20.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.841 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.9 -52.46 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -48.0 -42.47 28.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.442 ' N ' ' O ' ' A' ' 147' ' ' ASP . 63.3 mttt -79.19 -38.43 35.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.948 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 58.19 51.41 8.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 13.1 ttm180 -164.95 138.42 3.88 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.61 0.719 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.44 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.72 113.54 3.4 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.742 2.295 . . . . 0.0 112.364 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.1 mtt180 -54.69 -55.47 29.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.32 40.59 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CA ' HD12 ' A' ' 120' ' ' ILE . 35.8 p90 -171.39 164.76 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.902 0.382 . . . . 0.0 110.877 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.74 -161.04 33.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.413 ' HE1' HD11 ' A' ' 145' ' ' ILE . 12.8 m-85 -137.73 162.85 32.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.486 HD12 ' CD2' ' A' ' 133' ' ' PHE . 15.8 mt -146.39 140.49 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.095 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.0 m -108.78 139.88 42.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -109.27 172.51 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.901 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.43 -30.03 47.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.928 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -137.43 147.21 45.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -55.56 -45.77 77.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.878 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -41.59 -42.29 2.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 6.1 m -55.84 -54.38 45.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.863 HG13 HG22 ' A' ' 115' ' ' ILE . 42.1 t -47.34 -51.31 6.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.154 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 18.6 t0 -52.92 -52.53 57.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 14.3 mm-40 -42.27 -44.37 3.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.12 -64.55 1.11 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.405 HG11 ' HB2' ' A' ' 187' ' ' ARG . 68.8 t -37.81 -50.25 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.097 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -39.2 -67.99 0.19 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 9.0 mtm -54.76 -43.41 72.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 17.6 t-160 61.17 26.48 16.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.1 m-85 -172.01 134.72 0.77 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.518 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 57.0 m-70 -145.41 161.58 39.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -114.24 98.24 6.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.787 HD12 HG21 ' A' ' 183' ' ' VAL . 38.7 mt -118.65 129.07 75.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 51.07 41.89 27.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 60.73 63.65 4.79 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.489 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -174.15 149.21 1.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 9.7 tppt? -85.74 102.36 13.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.787 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -89.71 115.61 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -77.82 144.17 37.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.904 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 117' ' ' VAL . 88.2 t -143.44 128.44 15.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . 0.413 ' HD3' ' CD2' ' A' ' 174' ' ' HIS . 21.8 mmmt -133.34 151.48 51.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.405 ' HB2' HG11 ' A' ' 171' ' ' VAL . 12.1 ttt-85 -66.4 108.53 2.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.908 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.889 0.376 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -105.19 145.23 30.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.573 HG22 HG13 ' A' ' 167' ' ' VAL . 16.2 pt -126.79 155.34 37.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.156 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -104.7 106.1 16.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 185' ' ' VAL . 99.5 t -102.74 122.97 55.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -125.83 -174.94 14.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.07 16.77 14.55 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.503 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.627 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.9 mt -64.45 138.1 97.34 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.651 0.739 . . . . 0.0 111.143 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.627 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.06 25.56 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.633 2.222 . . . . 0.0 112.349 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -81.38 2.59 27.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.853 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -107.48 -29.02 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.481 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.1 t -72.96 135.39 45.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -139.26 175.71 21.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.473 ' HA ' HD12 ' A' ' 129' ' ' LEU . 22.8 tt0 -34.57 -70.17 0.08 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.888 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 126' ' ' GLU . 22.0 m -36.36 -65.34 0.28 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.121 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 129' ' ' LEU . 36.8 mm-40 -47.65 -63.07 1.15 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.67 HD11 ' HE3' ' A' ' 144' ' ' MET . 67.8 mt -34.38 -45.15 0.22 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.478 ' HE ' HG23 ' A' ' 142' ' ' VAL . 22.5 mtt180 -67.39 -56.73 8.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -46.88 -26.66 1.03 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.949 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -98.26 -31.41 12.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CD2' HD12 ' A' ' 159' ' ' ILE . 24.8 m-85 -97.02 16.86 18.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 17.0 pttp -95.32 -27.9 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -68.08 -34.05 75.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.922 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -66.65 -31.53 72.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -178.86 -106.14 0.2 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 83.2 t -151.74 111.53 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.406 HG21 ' HA ' ' A' ' 130' ' ' ARG . 42.6 t -76.96 114.67 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 72.5 p -91.81 -38.29 12.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.161 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -140.51 154.16 46.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.478 HG23 ' HE ' ' A' ' 130' ' ' ARG . 84.5 t -134.7 100.92 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 65.3 t -83.28 141.9 14.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.67 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.8 mtt -145.3 135.02 23.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.4 mt -101.02 136.45 32.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.105 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.06 166.03 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.45 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -88.88 113.52 24.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.52 -58.71 0.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.104 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.403 ' C ' ' O ' ' A' ' 148' ' ' ALA . 34.2 tt0 -37.52 -45.25 0.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.863 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 6.4 tptm -82.35 -39.08 23.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.09 47.11 9.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.7 ttp85 -157.74 139.07 9.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.652 0.739 . . . . 0.0 110.864 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 109.75 2.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.717 2.278 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 30.7 mtp180 -49.39 -54.11 19.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.888 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.0 42.34 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -172.88 160.03 4.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.884 0.374 . . . . 0.0 110.866 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.15 -152.82 22.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.507 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -142.34 167.25 22.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.936 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.7 mt -148.81 138.52 16.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 61.9 m -103.0 148.77 25.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.464 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 67.2 m-85 -119.83 175.43 5.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -79.49 -42.7 24.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.905 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -126.47 134.78 50.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 165' ' ' GLN . 39.2 tt0 -43.52 -44.25 5.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 164' ' ' GLU . 65.1 tt0 -35.66 -45.73 0.39 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.464 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 3.8 m -51.6 -55.69 17.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.573 HG13 HG22 ' A' ' 115' ' ' ILE . 80.0 t -40.75 -57.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -50.21 -51.77 41.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.867 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 20.6 mm100 -48.0 -57.77 5.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -59.51 -58.92 6.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 174' ' ' HIS . 70.3 t -44.28 -62.88 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.2 t-20 -34.65 -55.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.87 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 25.6 mmm -57.29 -42.84 82.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 14.0 t-160 54.53 26.71 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.4 m-85 -172.5 154.39 3.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.53 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 88.3 m-70 -159.81 157.76 29.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -116.29 84.04 2.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.998 HD12 HG21 ' A' ' 183' ' ' VAL . 66.8 mt -97.33 108.68 21.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.162 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 23.7 mtm 61.01 44.86 9.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.98 37.96 94.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 35.0 tptt -139.29 136.69 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 110.883 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.22 100.99 10.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.998 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -93.21 129.63 43.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -87.67 148.01 24.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 117' ' ' VAL . 67.1 t -147.58 138.75 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.109 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.1 mtmm -141.15 169.57 17.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.0 tmm_? -80.83 114.03 19.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.127 179.928 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.876 0.37 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -102.22 145.55 29.26 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.754 HG22 HG13 ' A' ' 167' ' ' VAL . 25.1 pt -126.08 154.3 35.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -104.21 101.98 11.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 185' ' ' VAL . 98.2 t -95.66 119.11 43.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.129 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.71 177.43 16.43 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.516 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.87 28.62 63.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.492 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.55 HG23 ' HD2' ' A' ' 121' ' ' PRO . 32.3 mt -75.82 137.01 69.95 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.606 0.717 . . . . 0.0 111.104 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.55 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.72 166.98 25.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.657 2.238 . . . . 0.0 112.351 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -77.1 -3.49 39.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.878 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -100.82 -37.34 8.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.1 t -67.93 125.35 26.01 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.442 ' N ' ' OE1' ' A' ' 128' ' ' GLU . . . -129.9 -165.61 11.66 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.528 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -53.53 -64.53 0.79 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.92 0.39 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 87.3 m -44.14 -54.29 5.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.442 ' OE1' ' N ' ' A' ' 125' ' ' GLY . 12.2 mp0 -57.16 -63.44 1.22 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 133' ' ' PHE . 61.0 mt -34.31 -46.96 0.28 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 30.7 mtp85 -69.74 -51.14 36.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -50.22 -19.2 0.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.921 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.427 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 12.6 t80 -108.97 -24.05 11.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.566 ' CE2' HD12 ' A' ' 159' ' ' ILE . 17.1 m-85 -98.35 9.99 41.8 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -86.85 -25.47 24.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -69.45 -39.61 77.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -64.58 -25.94 68.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.904 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 176.5 -113.79 0.45 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.465 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.5 t -147.95 106.14 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.848 0.356 . . . . 0.0 111.154 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.18 116.51 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.172 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 79.5 p -93.68 -35.42 12.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.108 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.69 152.61 45.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.93 97.69 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.139 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' A' ' 158' ' ' PHE . 59.3 t -81.84 142.74 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.095 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.3 mtt -145.15 136.7 25.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 56.8 mt -104.36 131.36 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.45 166.75 6.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 148' ' ' ALA . 48.0 t0 -91.49 109.75 21.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.13 -46.24 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 148' ' ' ALA . 1.5 tm-20 -35.3 -47.03 0.39 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -99.31 -28.69 13.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 59.78 50.06 7.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.0 ttp85 -149.73 138.58 12.53 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.613 0.72 . . . . 0.0 110.891 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.519 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.5 Cg_endo -69.71 110.62 2.59 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.352 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -50.24 -54.02 24.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.844 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.49 40.67 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.482 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -172.61 160.12 4.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 168.03 -155.56 26.44 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.441 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' A' ' 143' ' ' VAL . 29.2 m-85 -142.52 162.45 35.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.787 0.327 . . . . 0.0 110.879 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.566 HD12 ' CE2' ' A' ' 133' ' ' PHE . 13.9 mt -146.0 139.72 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.089 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 84.7 m -106.87 139.72 40.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.554 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 55.1 m-85 -109.08 179.24 4.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -86.23 -38.17 17.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . 0.415 ' O ' ' C ' ' A' ' 164' ' ' GLU . 6.5 m-20 -128.77 127.53 42.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.849 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 163' ' ' ASP . 26.8 tt0 -36.04 -42.19 0.28 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.403 ' O ' ' C ' ' A' ' 166' ' ' SER . 3.9 mt-30 -36.93 -61.42 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.554 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 7.2 m -38.32 -59.52 0.88 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.754 HG13 HG22 ' A' ' 115' ' ' ILE . 53.6 t -38.88 -63.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.157 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -43.9 -60.77 1.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -40.14 -53.41 2.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.36 -55.4 24.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.416 HG21 ' CB ' ' A' ' 187' ' ' ARG . 69.4 t -47.26 -61.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 171' ' ' VAL . 16.2 t-20 -37.67 -64.91 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 74.8 mtp -49.29 -45.43 45.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.835 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.8 t-160 60.03 28.07 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.5 m-85 -171.72 154.1 3.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.477 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 80.0 m-70 -159.38 156.64 28.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -113.09 91.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 183' ' ' VAL . 56.7 mt -111.05 134.21 54.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.113 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 47.99 36.19 5.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.78 46.04 85.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.463 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.424 ' HZ2' ' CA ' ' A' ' 121' ' ' PRO . 0.0 OUTLIER -153.61 147.18 25.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.875 -179.963 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.13 113.65 20.78 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.913 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -105.16 127.39 59.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -83.81 150.53 25.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.86 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 117' ' ' VAL . 23.8 t -151.14 131.93 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -136.86 149.05 47.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.416 ' CB ' HG21 ' A' ' 171' ' ' VAL . 12.1 ttt180 -62.87 124.89 22.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.132 179.906 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.855 0.359 . . . . 0.0 110.854 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -99.95 150.54 22.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.867 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.502 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.33 154.79 41.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -103.76 102.98 12.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 185' ' ' VAL . 83.8 t -97.95 112.84 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.24 173.7 15.37 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.479 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.01 63.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.439 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.596 HG23 ' HD2' ' A' ' 121' ' ' PRO . 42.1 mt -54.91 137.8 64.93 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.629 0.728 . . . . 0.0 111.152 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 163.99 36.25 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.644 2.229 . . . . 0.0 112.353 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.6 t-160 -68.99 -6.28 26.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.836 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 124' ' ' CYS . 19.6 t-20 -100.25 -64.22 1.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 43.7 t -35.13 126.57 0.56 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.75 -164.11 11.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -54.8 -66.24 0.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -42.54 -61.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.166 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 129' ' ' LEU . 9.5 mm-40 -49.42 -63.23 1.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.526 HD11 ' CE ' ' A' ' 144' ' ' MET . 44.9 mt -37.84 -55.16 1.22 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.708 ' HA ' HG21 ' A' ' 139' ' ' VAL . 63.8 mtp180 -56.11 -56.0 26.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -50.33 -44.34 54.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.583 ' CD2' HG12 ' A' ' 178' ' ' ILE . 6.4 t80 -74.03 -22.54 59.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 159' ' ' ILE . 25.2 m-85 -105.32 15.8 26.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.5 ptmt -90.48 -37.79 13.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.92 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -60.47 -37.93 82.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -67.28 -30.01 69.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.85 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.63 -116.48 0.48 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.528 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 19.7 t -148.57 106.61 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.708 HG21 ' HA ' ' A' ' 130' ' ' ARG . 8.1 t -69.42 119.06 14.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.175 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 78.3 p -99.77 -37.57 9.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -134.03 141.31 47.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.876 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.537 HG21 ' CG ' ' A' ' 130' ' ' ARG . 94.0 t -127.74 93.62 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.17 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.7 t -89.42 134.41 28.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.543 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 8.3 mtp -135.96 133.39 37.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.531 HD11 ' HE1' ' A' ' 158' ' ' PHE . 57.5 mt -92.11 134.24 30.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.52 165.91 5.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.981 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 16.5 t0 -84.53 112.62 20.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.856 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.24 -59.98 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -40.87 -45.8 2.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 23.7 mttp -75.75 -41.01 54.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 60.07 48.02 8.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.3 ttm180 -160.4 138.55 7.35 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.563 0.697 . . . . 0.0 110.9 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.543 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.79 116.35 4.52 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.718 2.279 . . . . 0.0 112.346 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.5 mtp180 -58.76 -55.36 36.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.62 39.37 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.4 p90 -170.4 160.95 7.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.876 0.369 . . . . 0.0 110.893 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -158.15 30.96 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.531 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.8 m-85 -138.86 161.62 36.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.359 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 133' ' ' PHE . 8.6 mt -147.59 139.28 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.14 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 m -109.21 140.02 43.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.47 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.8 m-85 -108.53 169.45 8.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -75.81 -34.55 60.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 34.6 m-20 -129.62 141.5 50.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -52.31 -45.14 65.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.914 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -40.68 -44.66 2.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.9 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.47 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 17.4 m -54.04 -41.91 68.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 115' ' ' ILE . 38.5 t -58.53 -58.94 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.139 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -49.95 -42.87 49.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -55.23 -55.35 32.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.0 -56.57 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 98.4 t -48.06 -44.56 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.186 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -50.23 -51.53 43.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.914 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.2 mmm -62.59 -36.07 81.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.8 t-160 49.31 25.22 1.2 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 8.7 m-85 -170.13 145.99 2.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.493 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 46.9 m-70 -155.94 162.8 40.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -119.74 94.2 4.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.743 HD12 HG21 ' A' ' 183' ' ' VAL . 44.8 mt -113.34 120.61 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.5 mmt 59.9 34.25 21.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.69 46.97 58.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -153.5 148.55 26.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 8.2 tptm -86.84 108.51 18.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.743 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -98.51 120.99 48.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -82.73 147.58 28.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 117' ' ' VAL . 41.1 t -143.17 132.49 20.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.146 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mttp -137.06 136.71 38.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.419 ' HG3' ' CG1' ' A' ' 167' ' ' VAL . 34.9 ttt180 -52.45 123.16 10.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.126 179.912 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.853 ' O ' HG23 ' A' ' 160' ' ' THR . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.95 0.405 . . . . 0.0 110.92 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt -127.67 141.13 51.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.425 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -121.08 151.51 24.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.497 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 6.4 t80 -101.88 105.02 15.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.877 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 185' ' ' VAL . 94.0 t -97.92 121.73 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.129 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -127.6 175.42 18.28 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.95 18.89 62.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.56 HG23 ' HD2' ' A' ' 121' ' ' PRO . 40.2 mt -65.76 136.83 95.98 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.639 0.733 . . . . 0.0 111.144 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.56 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 0.0 112.344 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -75.29 1.62 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.444 ' C ' ' SD ' ' A' ' 179' ' ' MET . 27.7 t-20 -107.29 -23.1 12.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 13.5 t -80.48 128.45 33.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -130.8 176.83 18.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.5 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.603 ' HG3' HG11 ' A' ' 142' ' ' VAL . 30.5 tt0 -35.99 -61.01 0.51 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.909 0.385 . . . . 0.0 110.863 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 65.9 m -46.39 -60.15 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 35.8 mm-40 -49.98 -61.9 1.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.895 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.439 HD13 HD11 ' A' ' 159' ' ' ILE . 62.5 mt -35.73 -56.01 0.69 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.944 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.535 ' HA ' HG21 ' A' ' 139' ' ' VAL . 62.3 mtp180 -61.76 -55.03 34.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -44.34 -29.53 0.69 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.878 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.449 ' CD2' HG12 ' A' ' 178' ' ' ILE . 11.9 t80 -98.53 -27.4 14.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.935 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.563 ' CE2' HD12 ' A' ' 159' ' ' ILE . 21.4 m-85 -95.1 13.34 25.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptpt -93.93 -9.73 36.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 pttt -84.71 -36.5 21.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -65.02 -35.04 79.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . 0.487 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -172.58 -102.14 0.15 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.461 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 137' ' ' GLY . 40.9 t -157.95 105.73 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.535 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.2 t -66.18 119.24 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.14 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 14.4 p -99.09 -37.14 9.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.189 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -135.31 148.78 49.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.872 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.603 HG11 ' HG3' ' A' ' 126' ' ' GLU . 97.6 t -132.07 94.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.135 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.9 t -90.48 138.09 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.104 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.401 ' HE3' HD11 ' A' ' 129' ' ' LEU . 9.2 mtp -137.37 136.06 37.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.562 HD11 ' HE1' ' A' ' 158' ' ' PHE . 58.7 mt -97.66 135.27 32.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.467 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -173.57 164.58 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.91 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.4 t0 -83.05 112.73 20.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.65 -62.75 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.125 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -38.91 -42.96 0.9 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 147' ' ' ASP . 70.0 mttt -79.44 -37.42 37.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 54.88 53.09 10.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.956 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.467 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 11.5 ttt180 -164.72 137.98 3.9 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.578 0.704 . . . . 0.0 110.894 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 116.99 4.81 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.338 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -59.89 -54.64 43.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.28 39.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -169.3 164.92 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.826 0.346 . . . . 0.0 110.91 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.71 -163.33 35.69 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.562 ' HE1' HD11 ' A' ' 145' ' ' ILE . 45.4 m-85 -133.22 161.82 33.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.784 0.326 . . . . 0.0 110.94 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.563 HD12 ' CE2' ' A' ' 133' ' ' PHE . 10.2 mt -148.63 137.51 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 113' ' ' ASN . 32.8 m -106.15 143.14 34.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.456 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 39.2 m-85 -111.23 176.14 5.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.4 tt0 -77.67 -44.83 26.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.896 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . 0.467 ' CB ' ' HG2' ' A' ' 165' ' ' GLN . 0.9 OUTLIER -121.54 128.56 52.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -42.02 -23.77 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.467 ' HG2' ' CB ' ' A' ' 163' ' ' ASP . 5.4 pt20 -48.51 -53.4 18.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.921 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.456 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 5.1 m -49.26 -55.95 10.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.846 -179.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 171' ' ' VAL . 53.3 t -37.68 -55.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.078 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . 0.426 ' C ' ' OD1' ' A' ' 168' ' ' ASP . 0.6 OUTLIER -62.13 -46.3 89.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.874 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -52.0 -52.51 50.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.49 -56.45 15.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.075 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 167' ' ' VAL . 43.2 t -44.63 -55.83 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -38.07 -67.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 83.4 mtp -48.38 -46.29 36.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 19.0 t-160 62.04 26.89 16.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 9.2 m-85 -171.31 150.83 2.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.855 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.4 m-70 -156.7 151.38 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.849 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -107.67 98.98 8.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.888 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.851 HD12 HG21 ' A' ' 183' ' ' VAL . 71.0 mt -119.89 122.08 67.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.444 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 12.4 mtt 54.67 41.58 31.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.05 42.65 99.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 15.2 tptp -148.92 148.65 30.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.826 0.346 . . . . 0.0 110.923 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 7.6 tppt? -88.34 107.21 18.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.906 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.851 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -95.45 112.38 27.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.174 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -74.87 149.48 39.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 117' ' ' VAL . 46.3 t -147.13 136.09 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mtmm -139.89 151.66 45.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.893 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -65.25 125.1 23.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.915 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.084 179.931 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.909 0.385 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -88.45 146.6 25.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.76 HG22 HG13 ' A' ' 167' ' ' VAL . 21.1 pt -132.29 146.64 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.141 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -89.74 111.98 23.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.928 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 185' ' ' VAL . 83.6 t -108.72 114.88 47.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.103 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -119.24 -173.29 15.47 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.69 24.14 31.56 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 121' ' ' PRO . 63.0 mt -69.48 138.19 88.76 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.668 0.747 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.641 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.73 170.33 16.79 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.731 2.287 . . . . 0.0 112.35 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -86.91 24.17 1.57 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -133.63 -33.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.434 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.9 t -66.9 117.79 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.894 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.47 -175.73 16.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.457 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -42.69 -56.17 3.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 0.0 110.856 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 86.7 m -51.3 -57.69 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 mm-40 -51.73 -52.95 44.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.528 HD22 HD11 ' A' ' 159' ' ' ILE . 85.9 mt -44.54 -48.18 10.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.964 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.564 ' HG2' HG11 ' A' ' 139' ' ' VAL . 69.5 mtt180 -69.66 -55.07 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -45.45 -23.98 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.572 ' CD2' HG12 ' A' ' 178' ' ' ILE . 4.3 t80 -103.68 -35.2 8.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.582 ' CE2' HD12 ' A' ' 159' ' ' ILE . 23.7 m-85 -90.33 16.22 9.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -95.23 -23.64 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -71.19 -35.23 71.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.471 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 34.9 m-85 -68.41 -32.59 72.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.77 -111.56 0.29 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.476 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 75.7 t -146.35 110.24 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.837 0.351 . . . . 0.0 111.152 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.564 HG11 ' HG2' ' A' ' 130' ' ' ARG . 93.0 t -72.89 106.05 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.146 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.8 p -79.46 -39.71 31.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -144.73 156.43 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.409 HG11 HD12 ' A' ' 129' ' ' LEU . 96.1 t -134.8 102.56 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.111 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.5 143.53 11.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.5 mtt -145.44 139.03 26.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.872 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.443 HD11 ' HE1' ' A' ' 158' ' ' PHE . 75.4 mt -107.9 136.22 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.15 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.464 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.91 165.34 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.934 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.9 t0 -86.19 114.29 22.9 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.87 -61.52 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 28.3 tt0 -36.08 -46.01 0.47 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 27.6 mttp -80.08 -40.29 27.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 60.0 48.27 8.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.1 ttp180 -158.98 138.8 8.65 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.609 0.719 . . . . 0.0 110.884 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 109.92 2.43 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.271 . . . . 0.0 112.334 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.8 mtt180 -50.17 -50.6 48.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.843 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 159.89 39.89 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -169.0 161.98 10.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.882 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.429 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.15 -150.2 18.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.469 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.443 ' HE1' HD11 ' A' ' 145' ' ' ILE . 11.3 m-85 -147.72 169.82 18.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.882 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.582 HD12 ' CE2' ' A' ' 133' ' ' PHE . 23.0 mt -151.13 141.81 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.103 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.2 m -106.95 142.27 36.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.15 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.577 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 50.1 m-85 -113.83 169.35 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -77.33 -38.37 50.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -130.05 136.57 49.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 165' ' ' GLN . 8.6 tm-20 -45.67 -45.37 14.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.924 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 164' ' ' GLU . 26.3 tt0 -35.29 -47.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.577 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 42.9 m -53.15 -54.07 41.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.847 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.76 HG13 HG22 ' A' ' 115' ' ' ILE . 53.3 t -43.88 -45.46 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -65.65 -45.49 82.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . 0.471 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 44.3 mm-40 -48.48 -45.42 36.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -76.43 -59.79 2.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.633 HG21 ' HG3' ' A' ' 187' ' ' ARG . 86.4 t -43.12 -51.4 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.14 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -39.71 -63.2 0.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.891 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 15.3 mtm -59.31 -38.33 80.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.537 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 15.0 t-160 59.27 25.46 14.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.473 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.9 m-85 -169.82 153.14 4.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.836 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.473 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 62.8 m-70 -159.2 159.42 34.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -116.49 90.31 3.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 183' ' ' VAL . 51.3 mt -105.69 111.78 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 7.4 mtt 61.84 42.33 10.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.41 47.13 87.57 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.453 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.404 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 12.2 tppt? -151.47 140.29 20.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.894 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -84.83 102.94 13.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.92 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -92.99 132.86 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.169 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -92.54 144.95 24.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.877 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 117' ' ' VAL . 32.6 t -141.15 131.34 26.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -143.45 141.53 30.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.633 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.2 mtm105 -45.79 115.93 1.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.826 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.076 179.913 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.946 0.403 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttpp -92.97 140.99 28.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.622 HG22 HG13 ' A' ' 167' ' ' VAL . 28.2 pt -124.49 151.15 29.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.143 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -98.44 108.37 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.912 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 185' ' ' VAL . 95.4 t -101.21 121.8 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.15 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.7 175.72 18.58 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.67 13.34 60.92 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.561 HG23 ' HD2' ' A' ' 121' ' ' PRO . 31.2 mt -61.87 137.15 95.26 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.718 . . . . 0.0 111.142 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.561 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.74 163.52 37.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.691 2.261 . . . . 0.0 112.344 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -77.44 1.35 19.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -106.65 -23.72 12.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 14.0 t -79.85 133.39 36.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.77 -165.59 11.79 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.593 ' HG3' HG11 ' A' ' 142' ' ' VAL . 38.2 tt0 -52.57 -68.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 34.9 m -38.69 -67.8 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.13 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 17.5 mp0 -38.68 -61.33 0.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 ' CE ' ' A' ' 144' ' ' MET . 73.7 mt -40.68 -46.56 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.909 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.482 ' HA ' HG21 ' A' ' 139' ' ' VAL . 14.3 mtp-105 -70.0 -52.3 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -51.92 -23.94 5.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -100.24 -30.21 12.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.531 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.1 m-85 -94.24 13.75 22.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -94.03 -13.75 26.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.0 pttm -79.83 -37.54 34.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -68.62 -33.9 74.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.98 -116.33 0.38 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.474 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 36.1 t -146.16 106.31 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.879 0.371 . . . . 0.0 111.152 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 130' ' ' ARG . 39.0 t -68.12 115.26 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.094 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 41.8 p -95.94 -39.0 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -133.59 144.06 49.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.593 HG11 ' HG3' ' A' ' 126' ' ' GLU . 72.6 t -130.34 94.44 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.129 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.0 t -88.7 141.52 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.116 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.511 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 7.6 mtt -140.58 137.1 33.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.9 mt -99.89 126.81 53.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -167.07 165.42 15.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.917 -179.984 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.441 ' O ' ' C ' ' A' ' 148' ' ' ALA . 19.2 t0 -85.33 113.58 21.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.44 -59.13 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.077 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -41.39 -42.88 2.38 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.92 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.427 ' N ' ' O ' ' A' ' 147' ' ' ASP . 19.4 mttp -79.25 -41.08 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.01 50.14 6.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.0 ttm-85 -162.88 138.02 5.2 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.598 0.713 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.511 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.76 112.12 2.99 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.748 2.298 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 67.5 mtp180 -52.65 -57.03 11.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.845 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 169.5 40.54 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.422 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.5 p90 -171.69 165.54 6.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.856 0.36 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.98 -153.97 24.61 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 59.6 m-85 -143.94 160.6 40.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.915 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.531 HD12 ' CD2' ' A' ' 133' ' ' PHE . 7.8 mt -148.42 135.93 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.9 m -103.87 142.98 33.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -112.22 168.39 9.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 58.4 tt0 -69.75 -38.65 76.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -131.1 143.68 50.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 165' ' ' GLN . 11.4 tt0 -50.66 -44.31 57.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.417 ' C ' ' O ' ' A' ' 164' ' ' GLU . 34.5 tt0 -36.1 -52.67 0.78 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.1 m -46.37 -55.68 6.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.622 HG13 HG22 ' A' ' 115' ' ' ILE . 40.6 t -38.48 -56.57 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.13 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -52.87 -59.09 4.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -39.12 -38.3 0.47 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.931 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.457 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -77.6 -65.37 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.111 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.66 HG21 ' HG3' ' A' ' 187' ' ' ARG . 84.1 t -43.98 -55.41 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.129 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.451 ' C ' ' O ' ' A' ' 171' ' ' VAL . 0.7 OUTLIER -34.48 -59.48 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.865 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 60.1 mtp -65.33 -35.18 80.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.515 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.6 t-160 54.69 27.39 8.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.7 m-85 -167.89 152.21 6.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 86.1 m-70 -159.8 147.61 16.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.854 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -103.73 99.24 9.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.81 HD12 HG21 ' A' ' 183' ' ' VAL . 58.0 mt -120.66 124.35 72.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.165 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.4 mmt 57.03 34.89 25.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.814 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 67.15 48.84 57.24 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 5.1 tmtm? -161.01 150.21 16.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . 0.461 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -83.02 126.46 32.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.81 HG21 HD12 ' A' ' 178' ' ' ILE . 5.5 t -114.19 110.87 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.121 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -70.94 143.97 50.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 117' ' ' VAL . 40.0 t -143.34 131.31 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.161 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.0 mmmt -145.61 144.06 30.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.933 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.66 ' HG3' HG21 ' A' ' 171' ' ' VAL . 14.0 mtp180 -48.17 125.43 9.26 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.109 179.899 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.865 0.364 . . . . 0.0 110.861 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 4.4 ttpm? -104.12 143.7 32.57 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.848 HG22 HG13 ' A' ' 167' ' ' VAL . 22.5 pt -125.75 155.37 35.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -103.38 104.48 14.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 185' ' ' VAL . 79.1 t -99.4 118.85 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -124.54 -172.53 13.59 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.477 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.28 17.78 19.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.479 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.634 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.4 mt -64.7 138.31 97.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.68 0.752 . . . . 0.0 111.101 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.5 Cg_endo -69.69 165.62 30.27 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.485 ' ND1' ' NH2' ' A' ' 152' ' ' ARG . 63.9 m-70 -80.58 13.91 2.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.434 ' C ' ' HG3' ' A' ' 179' ' ' MET . 3.3 m120 -122.02 -25.1 5.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.453 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -74.74 133.48 42.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.28 -161.06 10.09 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.508 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.13 -63.52 1.23 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.942 0.401 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 64.1 m -44.49 -59.17 2.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.142 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.44 ' O ' ' C ' ' A' ' 129' ' ' LEU . 57.1 mm-40 -50.35 -63.91 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 128' ' ' GLU . 50.0 mt -34.91 -52.39 0.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.447 ' O ' ' N ' ' A' ' 134' ' ' LYS . 62.7 mtp180 -66.19 -54.15 28.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.864 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 44.2 mm-40 -48.16 -26.5 1.92 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.483 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.7 t80 -100.79 -21.79 15.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -105.79 14.45 28.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.447 ' N ' ' O ' ' A' ' 130' ' ' ARG . 15.5 pttp -94.81 -17.56 22.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.37 -37.98 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -65.17 -34.36 78.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.17 -114.61 0.31 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.43 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 37.5 t -148.1 109.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.834 0.35 . . . . 0.0 111.172 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.418 HG11 ' HG2' ' A' ' 130' ' ' ARG . 47.3 t -74.55 105.99 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.0 p -81.21 -33.05 33.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.12 153.2 37.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.411 HG21 ' CG ' ' A' ' 130' ' ' ARG . 95.6 t -131.34 105.97 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 49.0 t -91.73 143.16 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.405 ' HE3' HD11 ' A' ' 129' ' ' LEU . 7.1 mtt -143.34 133.71 24.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.887 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 158' ' ' PHE . 63.2 mt -97.09 139.82 18.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.449 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -175.05 165.88 3.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.926 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.432 ' O ' ' C ' ' A' ' 148' ' ' ALA . 35.4 t0 -86.67 110.07 19.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.432 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.23 -57.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' ALA . 30.7 tt0 -37.06 -45.35 0.59 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.91 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.33 -37.14 20.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 60.05 52.79 4.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.485 ' NH2' ' ND1' ' A' ' 122' ' ' HIS . 2.1 ttt85 -160.86 138.9 7.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.646 0.736 . . . . 0.0 110.869 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 117.86 5.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.669 2.246 . . . . 0.0 112.355 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -61.1 -54.27 46.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.14 41.49 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.536 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -173.13 162.46 4.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.19 -153.47 23.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.557 ' HE1' HD11 ' A' ' 145' ' ' ILE . 53.9 m-85 -139.96 164.5 29.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 21.3 mt -147.13 139.7 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 57.0 m -105.08 142.98 33.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.434 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 46.8 m-85 -115.86 166.35 12.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.903 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -67.39 -42.77 82.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -131.14 141.06 50.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.864 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 165' ' ' GLN . 30.5 tt0 -46.04 -44.39 15.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 164' ' ' GLU . 23.8 tp60 -36.43 -55.67 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.434 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 16.4 m -44.31 -52.41 7.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.848 HG13 HG22 ' A' ' 115' ' ' ILE . 73.4 t -44.65 -54.86 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -52.82 -50.67 63.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.1 mm100 -45.86 -50.48 14.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.918 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.06 -53.86 15.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.094 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.84 HG21 ' HG3' ' A' ' 187' ' ' ARG . 70.1 t -44.31 -61.79 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.107 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 171' ' ' VAL . 62.7 t30 -35.61 -56.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 1.3 tpt -58.28 -41.51 84.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.92 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.9 t-160 51.15 30.75 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.551 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 4.9 m-85 -173.35 150.62 1.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 89.1 m-70 -161.9 156.97 23.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -111.04 102.36 10.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.922 HD12 HG21 ' A' ' 183' ' ' VAL . 31.4 mt -129.06 134.91 63.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.15 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.434 ' HG3' ' C ' ' A' ' 123' ' ' ASN . 9.8 mmt 54.83 30.55 13.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.63 45.76 65.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.404 ' NZ ' ' HA ' ' A' ' 121' ' ' PRO . 19.9 ttmt -160.15 161.93 33.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.909 0.385 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.62 125.57 34.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.922 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -110.35 115.02 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.157 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . 0.404 ' HG2' ' CD2' ' A' ' 174' ' ' HIS . 9.4 tt0 -77.32 148.32 35.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.886 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 117' ' ' VAL . 41.9 t -146.89 133.12 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.4 mttm -139.69 169.75 17.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.84 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.9 mtp180 -78.3 117.25 19.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.1 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 m-20 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.864 0.364 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -98.33 142.38 30.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.925 HG22 HG13 ' A' ' 167' ' ' VAL . 30.1 pt -125.24 153.05 32.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.09 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.414 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 30.8 t80 -98.97 105.53 17.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 185' ' ' VAL . 94.4 t -101.92 114.08 40.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.111 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.06 177.02 16.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.531 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.59 13.26 60.62 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.558 HG23 ' HD2' ' A' ' 121' ' ' PRO . 29.7 mt -61.86 137.14 95.24 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.558 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.4 Cg_endo -69.72 165.41 31.02 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.354 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.7 m-70 -78.68 0.65 25.76 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.827 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.437 ' ND2' ' HB2' ' A' ' 121' ' ' PRO . 0.2 OUTLIER -106.04 -23.8 12.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.889 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.486 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.4 t -81.16 133.1 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.73 -166.81 11.72 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.431 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.463 ' HG2' ' CZ ' ' A' ' 130' ' ' ARG . 12.4 tt0 -54.21 -59.96 3.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.874 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 35.9 m -45.78 -61.78 1.58 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.17 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 129' ' ' LEU . 53.8 mm-40 -47.91 -64.7 0.72 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.441 HD22 ' HE2' ' A' ' 133' ' ' PHE . 62.6 mt -36.22 -58.46 0.68 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.521 ' HG2' HG11 ' A' ' 139' ' ' VAL . 59.7 mtm180 -58.6 -51.06 71.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.3 mm-40 -57.29 -17.42 11.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.491 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 21.5 t80 -108.0 -17.45 14.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.542 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.3 m-85 -104.18 -6.35 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.885 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.5 pttp -76.58 -21.26 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -69.91 -36.32 75.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.869 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -70.55 -32.25 69.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.75 -111.25 0.26 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.545 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.0 t -150.05 108.12 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.912 0.387 . . . . 0.0 111.117 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.521 HG11 ' HG2' ' A' ' 130' ' ' ARG . 74.0 t -72.53 104.91 2.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.14 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -81.29 -36.8 29.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.146 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -141.33 154.76 45.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.06 105.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 42.9 t -92.83 137.12 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.436 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 5.2 mtt -137.7 136.79 37.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.904 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.401 HD11 ' HE1' ' A' ' 158' ' ' PHE . 62.7 mt -102.1 135.0 41.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.437 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.17 165.44 4.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.973 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 150' ' ' LYS . 48.5 t0 -81.92 113.64 19.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.871 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.409 ' O ' ' HG3' ' A' ' 151' ' ' GLN . . . -37.31 -41.85 0.44 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.09 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -42.78 86.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 147' ' ' ASP . 3.0 mptp? -80.45 -31.41 37.45 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 148' ' ' ALA . 6.1 mt-30 52.3 44.01 30.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.4 ttm-85 -155.51 138.68 10.77 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.672 0.749 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.436 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.4 Cg_endo -69.77 111.01 2.7 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.655 2.237 . . . . 0.0 112.37 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.419 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 36.0 mtt180 -52.34 -53.08 49.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.73 40.73 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.419 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 35.6 p90 -169.29 163.85 10.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.931 0.396 . . . . 0.0 110.866 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 161.67 -157.87 29.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.506 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.414 ' CD2' ' HA ' ' A' ' 116' ' ' PHE . 12.5 m-85 -139.51 169.98 16.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.542 HD12 ' CE2' ' A' ' 133' ' ' PHE . 12.6 mt -152.68 136.68 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 19.2 m -105.03 135.9 45.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.52 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 35.0 m-85 -104.67 174.11 6.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.82 -40.32 48.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -127.55 137.54 52.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 165' ' ' GLN . 16.1 tm-20 -44.64 -45.71 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.0 tp60 -36.99 -55.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.904 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.52 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 13.1 m -45.58 -49.34 14.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.925 HG13 HG22 ' A' ' 115' ' ' ILE . 71.0 t -48.81 -47.17 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.091 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -62.88 -49.35 75.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 31.5 mm-40 -47.82 -48.5 30.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -74.33 -43.95 54.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.62 HG23 ' O ' ' A' ' 167' ' ' VAL . 25.6 t -55.36 -62.35 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 171' ' ' VAL . 2.1 t-20 -36.76 -55.67 0.87 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 98.2 mtp -55.12 -44.0 74.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.879 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.523 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.4 t-160 58.31 25.14 12.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.885 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.523 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.3 m-85 -169.65 152.62 4.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.85 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.491 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 85.3 m-70 -158.5 154.15 26.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.806 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.63 93.8 4.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.856 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.933 HD12 HG21 ' A' ' 183' ' ' VAL . 59.2 mt -110.39 115.43 49.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 11.9 mtp 60.87 36.13 19.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.898 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.79 50.49 35.52 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.492 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.464 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.6 tmtt? -158.01 146.96 19.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.864 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . 0.464 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.1 OUTLIER -85.03 117.12 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.94 179.838 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.933 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -106.31 118.88 54.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.15 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -76.0 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 117' ' ' VAL . 44.6 t -146.65 127.4 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt -135.76 146.45 47.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 19.7 ttp180 -55.69 108.93 0.49 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.881 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.135 179.878 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.845 0.355 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -110.84 150.86 28.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.417 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.85 154.05 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.135 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 10.2 t80 -102.73 103.42 13.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 185' ' ' VAL . 86.2 t -97.76 115.87 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.97 174.24 16.04 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.95 26.02 71.08 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.485 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.624 HG23 ' HD2' ' A' ' 121' ' ' PRO . 52.7 mt -73.17 138.22 78.84 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.634 0.731 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.624 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.77 158.76 55.84 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.72 3.43 6.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -106.89 -37.14 6.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.544 ' SG ' HG21 ' A' ' 178' ' ' ILE . 44.0 t -67.68 136.95 55.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.429 ' H ' ' CG ' ' A' ' 128' ' ' GLU . . . -135.66 179.54 17.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 125' ' ' GLY . 24.0 tt0 -35.75 -69.68 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.4 m -40.84 -60.0 1.28 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.159 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.429 ' CG ' ' H ' ' A' ' 125' ' ' GLY . 49.1 mm-40 -44.74 -64.77 0.63 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.55 HD11 ' HE3' ' A' ' 144' ' ' MET . 65.7 mt -35.92 -47.04 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.523 ' HA ' HG21 ' A' ' 139' ' ' VAL . 36.7 mtm180 -67.38 -60.75 2.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.866 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -41.81 -25.69 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 11.6 t80 -102.77 -24.18 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.584 ' CE2' HD12 ' A' ' 159' ' ' ILE . 12.8 m-85 -99.74 16.3 24.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.923 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 3.9 ptpp? -95.31 -14.79 23.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -79.09 -37.68 38.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.896 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.416 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 39.0 m-85 -67.65 -25.06 65.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.06 -114.69 0.48 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 96.3 t -145.73 111.56 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.097 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.523 HG21 ' HA ' ' A' ' 130' ' ' ARG . 15.6 t -74.53 114.46 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 42.8 p -93.01 -37.29 12.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.75 152.72 45.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -135.02 100.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 81.4 t -84.98 143.2 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.109 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.55 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.2 mtt -144.29 132.61 21.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.476 HD11 ' HE1' ' A' ' 158' ' ' PHE . 68.4 mt -98.49 134.64 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -172.84 164.56 5.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.96 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' ALA . 24.3 t0 -85.35 115.6 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.422 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.65 -57.32 0.65 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -42.67 -41.9 3.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.412 ' N ' ' O ' ' A' ' 147' ' ' ASP . 16.3 ttmt -80.14 -41.18 25.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 60.08 50.41 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 8.2 ttp85 -164.99 138.93 4.0 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.618 0.723 . . . . 0.0 110.843 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.428 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.77 109.64 2.36 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.734 2.289 . . . . 0.0 112.357 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 32.5 mtp180 -49.58 -51.43 37.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 162.05 39.46 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.499 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -171.2 159.83 6.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.82 -155.08 25.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.476 ' HE1' HD11 ' A' ' 145' ' ' ILE . 51.2 m-85 -139.62 161.45 37.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.7 mt -145.0 141.56 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 42.5 m -109.43 141.03 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.173 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.508 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 51.9 m-85 -110.42 177.95 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -80.3 -40.31 27.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.871 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -127.85 146.41 50.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.807 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 165' ' ' GLN . 43.1 tp10 -51.58 -47.05 63.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.0 tt0 -36.63 -44.97 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.508 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 14.6 m -53.49 -47.93 69.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.883 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.417 HG13 HG22 ' A' ' 115' ' ' ILE . 37.6 t -51.3 -46.95 34.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.173 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -51.03 -65.73 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.867 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 41.7 mt-30 -42.95 -53.58 4.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.627 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -52.04 -45.48 64.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.045 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.8 HG21 ' HG3' ' A' ' 187' ' ' ARG . 93.5 t -70.0 -63.88 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.109 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 171' ' ' VAL . 8.3 m-20 -34.16 -43.99 0.17 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 5.2 ttt -68.36 -47.27 67.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.54 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 12.0 t-160 56.85 27.22 12.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.824 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.54 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.0 m-85 -174.18 151.45 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.459 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 72.0 m-70 -158.87 161.49 36.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -117.0 87.15 2.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.857 HD12 HG21 ' A' ' 183' ' ' VAL . 63.7 mt -106.61 126.41 62.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.111 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.409 ' HG2' HG22 ' A' ' 178' ' ' ILE . 3.8 mmt 52.36 40.12 28.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.69 47.67 87.34 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.416 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 2.5 tmtt? -155.07 146.93 23.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.808 0.337 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . 0.416 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 6.2 tptm -81.18 117.38 21.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.888 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.857 HG21 HD12 ' A' ' 178' ' ' ILE . 2.9 t -109.41 120.55 60.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -80.45 153.47 28.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 117' ' ' VAL . 41.4 t -149.48 130.96 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -141.46 144.26 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.91 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.8 ' HG3' HG21 ' A' ' 171' ' ' VAL . 8.7 mtm180 -45.93 124.44 5.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.861 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.897 0.38 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.9 ttpt -97.01 139.1 33.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.939 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -123.42 154.59 29.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -99.65 103.65 15.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 185' ' ' VAL . 93.2 t -100.41 111.7 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.02 -173.05 15.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.506 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.42 12.81 14.1 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.481 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.65 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.7 mt -57.3 138.42 80.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.653 0.74 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.65 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.9 Cg_endo -69.76 172.42 12.67 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.35 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.449 ' O ' ' NH2' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -85.0 17.89 2.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.823 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -128.29 -29.8 2.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.866 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.456 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -68.06 128.77 37.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.53 173.11 21.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.452 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.444 ' C ' ' O ' ' A' ' 125' ' ' GLY . 29.9 tt0 -34.34 -65.87 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.873 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 99.7 m -40.85 -61.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 129' ' ' LEU . 5.5 mp0 -54.31 -60.58 3.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.644 HD11 ' HE3' ' A' ' 144' ' ' MET . 59.9 mt -34.39 -45.92 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HA ' HG21 ' A' ' 139' ' ' VAL . 26.6 mtt180 -70.38 -55.75 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -46.5 -24.75 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.56 ' CD2' HG12 ' A' ' 178' ' ' ILE . 5.1 t80 -100.95 -29.78 12.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.576 ' CE2' HD12 ' A' ' 159' ' ' ILE . 19.7 m-85 -96.17 15.45 20.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.3 ptpt -95.27 -25.07 16.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.906 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.1 pttm -69.44 -38.83 77.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.867 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -66.02 -31.36 72.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -174.94 -115.24 0.4 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.5 t -146.13 106.42 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.882 0.373 . . . . 0.0 111.088 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.452 HG21 ' HA ' ' A' ' 130' ' ' ARG . 22.9 t -71.22 109.4 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.088 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 20.1 p -85.92 -39.78 16.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -139.84 151.98 46.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.9 t -134.01 102.46 4.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.137 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 158' ' ' PHE . 98.6 t -87.33 145.27 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.644 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.7 mtt -145.58 133.75 21.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.816 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.38 139.63 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.456 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.88 167.03 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 180.0 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.4 t0 -87.16 112.49 22.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.891 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.09 -60.0 0.34 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -39.38 -44.69 1.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 21.1 tttm -79.43 -40.13 30.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.92 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 60.05 45.08 12.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.456 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.8 ttt180 -155.37 138.21 10.48 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.654 0.74 . . . . 0.0 110.848 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 116.02 4.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.675 2.25 . . . . 0.0 112.371 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 41.6 mtp180 -58.67 -56.87 16.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.03 42.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.473 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -173.23 158.17 3.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.92 0.391 . . . . 0.0 110.866 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -151.44 19.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.489 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . 0.4 ' O ' ' O ' ' A' ' 143' ' ' VAL . 86.7 m-85 -138.36 164.69 28.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.823 0.344 . . . . 0.0 110.894 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.576 HD12 ' CE2' ' A' ' 133' ' ' PHE . 19.5 mt -148.31 134.12 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 17.9 m -102.34 143.13 32.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.159 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 41.5 m-85 -113.19 174.46 5.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.825 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -74.32 -38.76 63.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -135.17 151.38 50.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 165' ' ' GLN . 23.3 tt0 -51.9 -50.69 60.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.441 ' C ' ' O ' ' A' ' 164' ' ' GLU . 31.6 tp60 -34.54 -54.83 0.54 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.545 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 18.6 m -41.54 -58.71 1.83 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.86 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.939 HG13 HG22 ' A' ' 115' ' ' ILE . 62.2 t -42.27 -54.87 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.105 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 169' ' ' GLN . 27.5 t0 -47.14 -62.53 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 168' ' ' ASP . 49.1 mt-30 -36.98 -51.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.882 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.79 -67.55 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.448 ' O ' ' C ' ' A' ' 172' ' ' ASN . 98.8 t -39.36 -58.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.9 t30 -34.44 -56.53 0.52 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 85.3 mtp -61.55 -45.02 95.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 62.01 25.97 15.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.3 m-85 -172.85 147.5 1.71 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -156.62 164.56 38.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.87 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -118.76 90.96 3.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.666 HD12 HG21 ' A' ' 183' ' ' VAL . 67.9 mt -111.06 119.23 59.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.151 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.5 mmt 60.07 39.63 19.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 54.64 32.69 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.436 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 7.7 tppt? -163.23 145.51 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.367 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 11.7 tptt -82.54 109.0 16.36 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.902 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.666 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -97.07 127.46 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -87.65 140.09 29.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 117' ' ' VAL . 25.4 t -139.2 136.33 41.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 24.6 mtmt -144.71 175.0 10.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.866 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.429 ' CG ' HG21 ' A' ' 171' ' ' VAL . 8.4 mtp180 -81.17 120.39 24.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.875 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.907 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.884 0.374 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -89.58 142.55 27.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.977 HG22 HG13 ' A' ' 167' ' ' VAL . 18.7 pt -128.12 148.04 32.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.151 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -93.96 114.61 26.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 185' ' ' VAL . 81.2 t -111.1 117.16 54.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.115 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.61 176.7 16.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.519 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.39 24.72 69.41 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.636 HG23 ' HD2' ' A' ' 121' ' ' PRO . 57.0 mt -71.87 138.48 82.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.617 0.722 . . . . 0.0 111.142 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.636 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.4 Cg_endo -69.78 165.35 31.31 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -78.96 10.99 2.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.87 -34.48 4.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.1 t -68.96 121.43 16.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -121.68 -169.29 13.59 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.98 -59.1 3.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -47.24 -61.19 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.127 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HG3' ' CE ' ' A' ' 179' ' ' MET . 65.2 mm-40 -47.67 -65.14 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 40.7 mt -34.03 -49.83 0.36 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.944 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -68.72 -53.99 18.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 23.0 mm-40 -46.2 -23.73 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.507 ' CZ ' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -103.56 -34.65 8.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.02 16.86 8.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -95.29 -23.39 17.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.23 -39.04 68.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.94 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -60.56 -35.5 76.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -173.04 -107.71 0.21 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 93.4 t -152.24 107.9 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.26 107.71 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.133 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.5 p -82.08 -37.16 26.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -143.89 154.8 43.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.7 t -134.96 102.81 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 59.7 t -89.33 143.65 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.458 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.1 mtt -144.31 135.92 25.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.0 mt -102.26 135.75 37.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.481 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.72 3.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' ALA . 28.8 t0 -85.19 110.4 18.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.857 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.457 ' O ' ' C ' ' A' ' 149' ' ' GLU . . . -34.7 -57.22 0.53 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.066 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.457 ' C ' ' O ' ' A' ' 148' ' ' ALA . 7.9 mm-40 -33.31 -48.32 0.23 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -87.55 -34.93 18.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 5.5 mm-40 59.0 54.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.481 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.9 ttm-85 -158.16 137.65 8.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . 0.458 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.77 110.18 2.49 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.438 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 42.1 mtt180 -51.86 -47.63 64.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 157.93 38.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.489 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 41.4 p90 -166.52 167.7 15.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.903 0.382 . . . . 0.0 110.907 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.3 -156.72 27.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.499 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -139.48 166.92 23.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.933 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.0 mt -149.53 138.98 15.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 27.3 m -106.87 140.53 39.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.142 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . 0.551 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -110.84 176.67 4.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -78.18 -44.42 25.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -124.82 133.45 53.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -41.26 -43.49 2.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -39.24 -47.77 1.7 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.551 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 70.8 m -50.59 -49.48 56.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.866 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.977 HG13 HG22 ' A' ' 115' ' ' ILE . 78.5 t -47.4 -62.39 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -44.96 -53.98 7.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -46.18 -47.48 17.72 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -69.87 -56.06 8.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.1 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 172' ' ' ASN . 91.1 t -49.78 -61.82 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 171' ' ' VAL . 15.0 t-20 -34.35 -62.88 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.875 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 24.2 mmm -49.9 -42.73 48.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.514 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 12.9 t-160 56.18 26.03 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.514 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 6.2 m-85 -169.91 154.01 5.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 84.8 m-70 -160.81 153.97 21.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -112.26 89.31 3.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.858 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.959 HD12 HG21 ' A' ' 183' ' ' VAL . 59.6 mt -106.23 109.57 28.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.154 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.468 ' CE ' ' HG3' ' A' ' 128' ' ' GLU . 5.0 mtm 62.14 43.22 8.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.69 50.72 59.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . 0.468 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.4 tmtt? -155.9 144.83 20.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.846 0.355 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . 0.468 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 9.0 tppt? -87.77 112.74 22.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.959 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -102.79 119.56 51.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.149 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -79.24 140.73 37.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 117' ' ' VAL . 67.4 t -139.67 140.2 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.16 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -142.27 162.45 35.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.863 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 17.1 ttt180 -78.01 121.47 24.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.926 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.86 0.362 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.4 ttpt -85.29 142.82 29.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ILE . . . . . 0.652 HG22 HG13 ' A' ' 167' ' ' VAL . 21.8 pt -125.91 158.7 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.104 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 12.3 t80 -105.07 104.65 14.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 185' ' ' VAL . 71.9 t -100.63 114.33 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.112 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.14 -169.52 13.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.86 12.92 4.03 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.44 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.653 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.4 mt -57.39 138.41 81.08 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.609 0.719 . . . . 0.0 111.121 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.653 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.78 -174.24 0.87 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.248 . . . . 0.0 112.339 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.07 3.12 53.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -115.38 -10.71 11.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . 0.474 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.7 t -87.05 125.46 34.12 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.42 -172.86 13.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.512 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.416 ' HA ' HD12 ' A' ' 129' ' ' LEU . 47.2 tt0 -51.18 -66.06 0.45 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.8 m -44.14 -63.59 0.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.152 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -40.55 -58.42 1.6 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.881 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.48 HD11 ' HE3' ' A' ' 144' ' ' MET . 50.2 mt -40.99 -47.04 2.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.597 ' HA ' HG21 ' A' ' 139' ' ' VAL . 49.0 mtm180 -66.39 -61.25 2.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.882 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -43.31 -23.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' TYR . . . . . 0.405 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.2 t80 -101.08 -32.83 10.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.933 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.409 ' CD2' HD12 ' A' ' 159' ' ' ILE . 12.2 m-85 -93.52 15.3 16.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.851 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 pttt -95.11 -19.32 20.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.3 pttt -73.06 -30.39 63.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.893 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.482 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 44.4 m-85 -74.1 -37.12 64.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.15 -110.52 0.23 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.49 113.08 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.87 0.367 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.597 HG21 ' HA ' ' A' ' 130' ' ' ARG . 57.3 t -74.84 99.88 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 19.2 p -74.8 -42.11 58.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -142.96 155.08 44.63 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.877 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 159' ' ' ILE . 78.2 t -134.76 104.7 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.121 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.4 t -90.24 144.97 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.156 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.48 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.0 mtt -143.87 135.13 25.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 69.9 mt -98.38 133.35 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.165 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.452 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.68 165.35 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.449 ' O ' ' C ' ' A' ' 148' ' ' ALA . 22.1 t0 -81.61 110.11 16.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.82 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.449 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.69 -58.15 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.122 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -43.13 -43.67 4.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' LYS . . . . . 0.443 ' N ' ' O ' ' A' ' 147' ' ' ASP . 35.0 mttm -78.0 -40.35 39.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 59.97 50.28 6.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.933 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.452 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.0 ttt85 -161.65 138.01 6.1 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.627 0.727 . . . . 0.0 110.899 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 121.64 8.33 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.657 2.238 . . . . 0.0 112.349 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.475 ' HD3' ' CZ ' ' A' ' 156' ' ' PHE . 50.5 mtp180 -65.67 -53.95 34.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.869 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.91 38.25 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.45 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.475 ' CZ ' ' HD3' ' A' ' 154' ' ' ARG . 37.1 p90 -168.12 162.84 13.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.857 0.36 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.88 -155.18 26.42 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.467 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -139.55 169.46 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.794 0.33 . . . . 0.0 110.912 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 142' ' ' VAL . 11.0 mt -151.79 135.44 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.164 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 31.6 m -102.18 140.38 36.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -111.46 172.84 6.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -73.05 -34.72 66.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -137.94 152.68 49.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 165' ' ' GLN . 12.0 tm-20 -56.36 -49.64 73.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 164' ' ' GLU . 2.0 tp-100 -34.81 -47.28 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 1.2 m -48.34 -54.55 13.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.652 HG13 HG22 ' A' ' 115' ' ' ILE . 69.8 t -43.4 -49.9 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.126 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 169' ' ' GLN . 1.2 m-20 -54.37 -61.54 2.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' GLN . . . . . 0.482 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -35.99 -45.57 0.43 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.934 -179.919 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.39 -63.12 1.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.092 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 172' ' ' ASN . 85.1 t -43.16 -54.96 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 171' ' ' VAL . 32.2 t30 -34.65 -50.91 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 41.2 mtp -74.36 -39.91 62.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 16.3 t-160 59.54 27.44 16.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.6 m-85 -169.84 152.68 4.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' HIS . . . . . 0.434 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 90.7 m-70 -157.94 151.74 23.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -107.4 93.55 4.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' ILE . . . . . 0.824 HD12 HG21 ' A' ' 183' ' ' VAL . 53.6 mt -116.23 119.46 62.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 6.9 mmt 56.83 47.47 17.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 56.43 56.16 25.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.529 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 25.5 tptt -165.21 149.33 8.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.84 0.352 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' LYS . . . . . 0.426 ' HE3' ' CG ' ' A' ' 175' ' ' PHE . 14.4 tptt -90.43 110.39 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' VAL . . . . . 0.824 HG21 HD12 ' A' ' 178' ' ' ILE . 4.1 t -95.21 131.07 43.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.103 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -88.65 146.01 25.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 117' ' ' VAL . 54.9 t -140.6 127.18 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.098 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 3.9 mtmp? -142.89 143.57 32.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.915 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.61 ' HD3' HG11 ' A' ' 167' ' ' VAL . 3.1 mmt85 -46.76 139.67 5.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.931 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.3 t -108.41 166.31 10.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.861 0.363 . . . . 0.0 110.852 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 29.5 t -123.38 90.84 3.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.868 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 178.02 97.09 0.11 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.465 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.8 p -144.68 124.86 13.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.895 0.378 . . . . 0.0 110.865 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 77.0 p -98.4 -44.58 6.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -43.3 107.22 0.11 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.497 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 m -43.8 -43.59 6.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 51.1 mttm -68.86 139.33 55.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 52.1 p -104.06 96.25 6.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.21 38.74 0.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -102.38 143.28 32.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 167' ' ' VAL . 33.0 pt -126.55 152.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -97.08 109.03 21.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 185' ' ' VAL . 90.5 t -104.43 113.02 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.65 176.51 16.38 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.95 5.42 46.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.459 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.2 mt -52.75 138.02 43.38 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 111.161 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.606 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.52 24.22 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.712 2.275 . . . . 0.0 112.363 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.456 ' CE1' HH11 ' A' ' 152' ' ' ARG . 41.1 t-80 -82.93 10.34 8.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.39 -20.21 8.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.482 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 11.6 t -80.5 142.15 34.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.09 -171.88 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -48.16 -57.93 5.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.6 m -47.01 -60.14 2.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 129' ' ' LEU . 1.7 mp0 -53.83 -63.45 1.15 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.89 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 128' ' ' GLU . 63.5 mt -34.31 -62.5 0.33 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.654 ' CG ' HG21 ' A' ' 142' ' ' VAL . 51.0 mtp180 -59.02 -52.03 67.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -50.5 -22.52 1.98 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.45 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 13.4 t80 -104.65 -20.62 13.59 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.468 ' CE2' HD12 ' A' ' 159' ' ' ILE . 20.8 m-85 -102.49 15.49 29.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.937 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 32.1 pttt -94.14 -16.44 23.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 3.7 pttm -76.14 -36.67 58.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -67.95 -26.57 66.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.876 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.39 -114.69 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 66.3 t -144.16 116.71 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 111.137 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 43.3 t -79.82 113.53 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 76.5 p -90.11 -36.0 15.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -143.52 152.29 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.869 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.654 HG21 ' CG ' ' A' ' 130' ' ' ARG . 57.8 t -134.82 101.99 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.7 t -87.92 143.86 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.147 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.621 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 6.0 mtt -144.94 131.47 19.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.54 HD11 ' HE1' ' A' ' 158' ' ' PHE . 71.1 mt -96.12 131.89 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.108 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.443 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.58 164.52 10.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 43.9 t0 -85.99 112.14 20.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.81 -60.9 0.36 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 148' ' ' ALA . 0.3 OUTLIER -36.14 -45.44 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -81.44 -39.33 25.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 59.73 54.27 4.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.456 HH11 ' CE1' ' A' ' 122' ' ' HIS . 9.0 ttm180 -165.37 138.74 3.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.612 0.72 . . . . 0.0 110.878 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.621 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.6 Cg_endo -69.76 114.22 3.63 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.739 2.292 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.4 mtt180 -56.09 -54.42 45.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.04 39.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.527 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -169.39 166.59 10.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.874 0.369 . . . . 0.0 110.916 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.24 -157.26 28.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.54 ' HE1' HD11 ' A' ' 145' ' ' ILE . 32.1 m-85 -137.36 165.91 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.468 HD12 ' CE2' ' A' ' 133' ' ' PHE . 11.8 mt -149.2 134.07 10.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.0 m -101.34 145.06 29.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -114.52 -177.7 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -86.85 -41.97 13.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . 0.416 ' O ' ' C ' ' A' ' 164' ' ' GLU . 0.8 OUTLIER -125.25 128.54 48.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.868 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 163' ' ' ASP . 10.1 tm-20 -36.3 -37.7 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.917 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.423 ' O ' ' C ' ' A' ' 166' ' ' SER . 15.7 mt-30 -42.08 -60.45 1.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 1.3 m -36.67 -53.43 0.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 115' ' ' ILE . 70.5 t -45.24 -58.68 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.144 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -50.21 -55.01 17.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.841 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -45.44 -51.08 11.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.906 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.53 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -64.58 -51.39 63.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 39.8 t -47.63 -60.5 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -41.83 -51.95 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -59.26 -41.98 90.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 48.17 28.17 1.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.849 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 5.1 m-85 -173.0 151.35 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.507 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 74.5 m-70 -160.29 147.64 16.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.832 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -102.33 90.0 3.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.813 HD12 HG21 ' A' ' 183' ' ' VAL . 72.5 mt -110.23 110.31 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 10.2 mtt 63.48 44.81 5.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.875 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.93 43.11 99.64 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.471 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.8 tppt? -149.61 145.46 26.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.19 107.83 19.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.813 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -93.54 129.12 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -87.32 135.79 33.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.905 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.719 HG22 HG22 ' A' ' 117' ' ' VAL . 56.1 t -132.62 132.48 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 7.5 mmmm -136.21 159.73 40.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -67.89 114.22 6.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -87.21 160.29 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -123.86 151.77 65.14 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.657 0.742 . . . . 0.0 110.882 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 144.25 53.51 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.658 2.238 . . . . 0.0 112.337 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 30.9 ttp85 -167.67 138.59 2.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.831 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -152.18 162.23 41.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 10.5 t -116.7 40.27 2.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.846 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -115.28 149.86 37.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.4 t -144.29 166.21 25.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.875 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 74.4 p -87.55 152.18 22.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -132.48 146.28 18.05 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.488 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -50.24 0.48 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.677 2.251 . . . . 0.0 112.34 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 82.5 p -172.05 -175.78 1.54 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 4.0 m -62.67 125.14 22.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 77.6 p -99.75 92.47 5.34 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.908 0.385 . . . . 0.0 110.907 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.3 p -153.62 149.95 28.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.51 134.47 12.83 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.431 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.8 m -127.21 117.52 22.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 0.0 110.874 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 m -105.45 43.07 1.15 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.841 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.45 -25.37 6.62 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.483 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 5.0 t -78.76 107.29 11.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.943 0.401 . . . . 0.0 110.824 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 6.5 mtmp? -106.58 132.04 53.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.854 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.0 t -125.97 102.22 7.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.859 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -92.33 34.6 1.03 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.91 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 tttt -97.88 144.52 27.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.913 HG22 HG13 ' A' ' 167' ' ' VAL . 20.2 pt -126.07 149.14 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.099 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.3 t80 -96.39 113.71 25.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.918 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 185' ' ' VAL . 87.4 t -110.28 116.31 52.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.131 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.54 -179.54 16.06 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.85 14.46 44.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.472 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.631 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.3 mt -62.45 138.36 96.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.629 0.728 . . . . 0.0 111.128 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.78 159.96 51.46 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.67 2.246 . . . . 0.0 112.337 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -68.2 -4.1 12.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.833 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.411 ' O ' ' C ' ' A' ' 124' ' ' CYS . 9.5 m120 -100.23 -62.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.446 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 35.3 t -37.62 120.96 0.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.4 -172.24 13.76 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -46.24 -65.68 0.52 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.3 m -44.13 -59.13 2.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 129' ' ' LEU . 67.1 mm-40 -49.67 -65.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.847 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.605 HD11 ' CE ' ' A' ' 144' ' ' MET . 39.5 mt -34.38 -54.63 0.52 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.493 ' CG ' HG21 ' A' ' 142' ' ' VAL . 14.4 mtp180 -63.69 -59.99 3.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -42.75 -25.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 12.2 t80 -100.66 -24.82 14.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 159' ' ' ILE . 14.3 m-85 -97.91 13.76 29.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -93.12 -29.77 15.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.6 pttt -61.67 -33.85 74.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -68.87 -42.85 76.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.898 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -166.19 -108.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.485 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.65 109.91 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 29.1 t -75.21 119.55 23.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.163 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 33.2 p -93.81 -36.31 12.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.149 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -140.55 153.03 45.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.493 HG21 ' CG ' ' A' ' 130' ' ' ARG . 61.2 t -133.63 101.95 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 62.3 t -88.73 141.14 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.088 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.605 ' CE ' HD11 ' A' ' 129' ' ' LEU . 4.3 mtt -143.33 138.99 29.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.417 HD11 ' HE1' ' A' ' 158' ' ' PHE . 64.6 mt -105.48 132.4 52.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -171.69 165.06 6.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.882 -179.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 26.2 t0 -84.39 113.9 21.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.85 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.74 -58.48 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -42.5 -43.56 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.448 ' N ' ' O ' ' A' ' 147' ' ' ASP . 10.5 tppt? -77.48 -41.33 39.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 60.02 46.92 10.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 0.4 OUTLIER -160.6 138.58 7.21 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.577 0.704 . . . . 0.0 110.862 -179.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.47 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.84 110.77 2.65 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.7 2.267 . . . . 0.0 112.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 19.1 mtt-85 -50.3 -55.79 13.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.99 42.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -173.29 159.94 3.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.882 0.373 . . . . 0.0 110.85 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.04 -158.66 31.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.495 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.417 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.6 m-85 -139.64 162.18 35.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.548 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.4 mt -144.91 139.37 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.1 m -105.29 141.29 37.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.565 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 34.5 m-85 -112.51 174.01 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -79.91 -40.39 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.915 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . 0.44 ' O ' ' C ' ' A' ' 164' ' ' GLU . 27.4 m-20 -126.16 123.37 38.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.865 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.44 ' C ' ' O ' ' A' ' 163' ' ' ASP . 8.4 tp10 -35.18 -41.15 0.15 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.838 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.427 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.0 mm-40 -35.79 -60.89 0.5 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.565 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 68.7 m -39.29 -59.25 1.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.913 HG13 HG22 ' A' ' 115' ' ' ILE . 67.1 t -35.32 -47.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.135 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -65.53 -52.33 53.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -43.43 -50.46 6.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.404 ' O ' ' C ' ' A' ' 171' ' ' VAL . . . -68.04 -66.0 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 167' ' ' VAL . 88.8 t -37.1 -52.37 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 59.9 t-20 -37.41 -65.49 0.31 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 7.5 mtm -57.91 -32.24 67.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.914 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.513 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 18.2 t-160 50.17 26.81 2.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.524 ' C ' ' CD2' ' A' ' 176' ' ' HIS . 7.8 m-85 -169.45 150.31 4.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.524 ' CD2' ' C ' ' A' ' 175' ' ' PHE . 24.1 m-70 -160.9 150.03 16.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.843 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -105.73 94.48 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.913 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.725 HD12 HG21 ' A' ' 183' ' ' VAL . 70.3 mt -111.4 114.43 47.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 13.5 mtt 61.86 39.64 13.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.94 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.04 54.07 29.88 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -164.64 142.95 6.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.41 117.95 23.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.923 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.725 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -105.43 122.52 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -80.79 138.18 36.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.759 HG22 HG22 ' A' ' 117' ' ' VAL . 94.4 t -139.72 135.61 39.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.123 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -147.21 169.41 19.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 22.1 mtt180 -69.12 114.22 7.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.853 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -79.51 177.85 8.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.096 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -134.21 146.31 59.12 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.67 0.747 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 153.04 69.5 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.651 2.234 . . . . 0.0 112.359 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.99 63.71 6.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.48 133.93 15.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.3 t -90.82 -59.01 2.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 46.0 mtmt -98.56 151.68 20.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.2 m -121.11 114.03 20.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 44.6 t -63.06 -55.02 29.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.871 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 131.3 156.29 8.43 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.47 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -24.8 29.21 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.691 2.261 . . . . 0.0 112.354 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -39.65 -53.36 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.821 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 17.2 p 45.78 52.08 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.466 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.9 t -126.3 128.31 46.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.885 0.374 . . . . 0.0 110.832 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.3 t -79.74 156.32 27.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.863 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -172.24 -74.33 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.502 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.9 m -57.37 100.84 0.06 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.892 0.377 . . . . 0.0 110.875 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 t -135.68 156.3 49.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -83.66 52.45 4.72 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.499 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.6 p -92.99 40.28 1.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.894 0.378 . . . . 0.0 110.84 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -53.13 108.99 0.38 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 16.4 m -136.94 119.01 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -82.63 41.94 0.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -91.43 143.38 26.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.707 HG22 HG13 ' A' ' 167' ' ' VAL . 22.7 pt -127.56 148.13 32.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.408 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 17.1 t80 -92.53 112.95 25.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.815 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 185' ' ' VAL . 91.1 t -109.51 117.3 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.136 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.86 -177.47 15.21 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.508 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.41 23.07 47.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.461 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.604 HG23 ' HD2' ' A' ' 121' ' ' PRO . 64.3 mt -69.85 137.45 87.68 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.657 0.742 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.604 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.691 2.261 . . . . 0.0 112.31 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -81.6 3.63 24.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -110.07 -27.14 9.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.5 t -74.89 123.99 26.07 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.35 -173.55 13.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.72 -62.37 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.972 0.415 . . . . 0.0 110.885 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 51.9 m -43.14 -63.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.088 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 129' ' ' LEU . 0.9 OUTLIER -49.47 -62.24 1.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.735 HD11 ' HE3' ' A' ' 144' ' ' MET . 35.3 mt -34.35 -49.21 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.89 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.493 ' HE ' HG23 ' A' ' 142' ' ' VAL . 50.4 mtt180 -67.49 -51.44 51.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . 0.405 ' HA ' ' CE ' ' A' ' 134' ' ' LYS . 34.4 mt-10 -55.2 -16.71 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.469 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 15.9 t80 -108.74 -20.83 12.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.522 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.4 m-85 -105.5 16.49 25.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.875 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.405 ' CE ' ' HA ' ' A' ' 131' ' ' GLU . 12.2 ptpt -94.76 -26.17 16.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -68.06 -38.46 82.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.883 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -63.26 -35.11 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.574 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -173.45 -98.08 0.11 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.476 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 137' ' ' GLY . 56.2 t -161.42 109.99 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.876 0.37 . . . . 0.0 111.134 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.489 HG21 ' HA ' ' A' ' 130' ' ' ARG . 17.0 t -75.23 113.52 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 17.7 p -90.55 -37.73 13.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -141.23 153.04 45.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.493 HG23 ' HE ' ' A' ' 130' ' ' ARG . 63.5 t -134.28 100.69 3.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.8 t -85.71 142.16 13.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.735 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.7 mtt -145.03 133.24 21.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.837 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.515 HD11 ' HE1' ' A' ' 158' ' ' PHE . 59.2 mt -97.95 136.85 27.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.451 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.9 3.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.944 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.453 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -86.3 113.72 22.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.453 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.27 -62.27 0.28 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 17.7 tt0 -36.25 -47.29 0.57 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.837 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -77.33 -40.77 43.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 60.08 51.71 5.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.451 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 2.1 ttp180 -163.89 138.86 4.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.634 0.731 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 110.56 2.6 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.643 2.229 . . . . 0.0 112.316 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.3 mtt180 -50.97 -52.4 43.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.4 40.24 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -170.2 162.35 8.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.868 0.366 . . . . 0.0 110.893 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.408 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.73 -150.79 19.75 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.515 ' HE1' HD11 ' A' ' 145' ' ' ILE . 15.9 m-85 -145.97 168.99 19.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 0.0 110.901 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.597 HD11 HD22 ' A' ' 129' ' ' LEU . 20.5 mt -151.55 138.16 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 28.7 m -103.49 142.92 33.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.138 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.516 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 57.7 m-85 -113.27 170.03 8.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -73.98 -38.73 64.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.861 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -131.02 137.2 49.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.448 ' O ' ' N ' ' A' ' 167' ' ' VAL . 11.4 tm-20 -44.93 -47.17 11.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 164' ' ' GLU . 6.8 tt0 -34.74 -48.42 0.38 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.94 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.516 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 66.0 m -50.35 -46.7 55.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.707 HG13 HG22 ' A' ' 115' ' ' ILE . 58.0 t -50.89 -55.56 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.157 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -53.62 -47.36 70.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.813 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -49.08 -55.79 11.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.907 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.95 -58.26 6.6 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.793 HG21 ' HG3' ' A' ' 187' ' ' ARG . 94.0 t -44.17 -61.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.108 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 171' ' ' VAL . 28.3 t30 -35.76 -46.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.2 mmm -69.9 -43.42 71.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.538 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 16.5 t-160 59.06 26.94 15.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.0 m-85 -171.55 154.32 3.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.865 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 93.2 m-70 -160.66 162.77 32.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.832 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -117.95 92.4 3.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.819 HD12 HG21 ' A' ' 183' ' ' VAL . 55.9 mt -112.21 127.24 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.143 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.0 mmt 52.63 33.38 13.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.96 52.06 25.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.482 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -159.03 145.81 17.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.863 0.364 . . . . 0.0 110.869 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.2 tppt? -82.17 111.17 18.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.854 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.819 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -100.97 121.58 51.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -80.79 144.86 31.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.726 HG22 HG22 ' A' ' 117' ' ' VAL . 52.7 t -141.1 131.72 27.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.156 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.5 mtpt -142.95 144.48 32.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.915 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.793 ' HG3' HG21 ' A' ' 171' ' ' VAL . 7.4 mtp-105 -50.62 120.81 5.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.73 17.06 1.95 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.082 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -114.49 152.23 45.95 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.64 0.733 . . . . 0.0 110.904 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 157.32 60.75 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.703 2.269 . . . . 0.0 112.32 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 7.4 ptp180 -108.3 86.43 2.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -124.9 -43.96 1.96 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 16.5 m -105.6 91.71 3.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.55 145.65 2.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.927 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . 0.434 ' O ' ' C ' ' A' ' 196' ' ' SER . 32.0 t -86.37 -48.49 8.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.815 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 195' ' ' SER . 30.8 t -35.46 143.78 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.859 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.0 164.67 9.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.453 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.84 -27.27 26.31 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.657 2.238 . . . . 0.0 112.343 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 29.0 t -69.48 148.81 49.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 1.2 t -121.58 97.85 5.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.908 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.472 -179.959 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 74.6 p -155.29 139.47 16.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.877 0.37 . . . . 0.0 110.864 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.6 p -71.89 90.63 1.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.832 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -102.2 -91.62 2.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.514 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.8 t -94.15 168.59 10.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.858 0.361 . . . . 0.0 110.86 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 70.6 m -129.63 99.2 5.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -85.7 -148.55 11.13 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.452 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 21.7 t -171.35 109.87 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.939 0.399 . . . . 0.0 110.859 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 42.7 mttt 53.04 40.13 30.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.2 t -85.39 176.01 8.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 -119.82 39.5 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 18.9 ttmt -93.24 151.93 19.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.673 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -134.7 152.25 32.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.11 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 27.7 t80 -98.95 108.74 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 185' ' ' VAL . 90.8 t -104.48 114.36 43.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.84 170.83 16.12 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 72.36 14.19 77.07 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.442 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.579 HG23 ' HD2' ' A' ' 121' ' ' PRO . 34.2 mt -62.74 137.41 96.64 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.641 0.734 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.77 161.0 47.6 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.707 2.271 . . . . 0.0 112.324 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.0 2.41 10.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.404 ' C ' ' SD ' ' A' ' 179' ' ' MET . 8.8 m-20 -107.72 -23.56 12.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.864 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.478 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 25.4 t -82.07 143.1 31.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -145.51 -171.98 15.54 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.534 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.418 ' HA ' HD12 ' A' ' 129' ' ' LEU . 45.9 tt0 -42.95 -66.18 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 81.7 m -40.17 -65.73 0.38 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 129' ' ' LEU . 3.9 mp0 -48.33 -61.68 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.757 HD11 ' HE3' ' A' ' 144' ' ' MET . 80.7 mt -34.4 -50.61 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.911 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.488 ' CG ' HG21 ' A' ' 142' ' ' VAL . 47.0 mtp180 -71.32 -53.4 14.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 41.4 mm-40 -46.99 -22.31 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.524 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 32.6 t80 -103.85 -36.79 7.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.897 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.551 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.8 m-85 -84.9 10.23 12.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.885 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 8.6 ptpt -91.0 -29.78 17.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.453 ' N ' ' HG3' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -69.97 -17.42 63.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.913 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -89.54 -19.88 24.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.22 -118.07 0.65 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.538 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.6 t -146.02 106.88 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.89 0.376 . . . . 0.0 111.119 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.429 HG21 ' HA ' ' A' ' 130' ' ' ARG . 5.2 t -73.52 111.09 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . 0.404 HG22 ' OE1' ' A' ' 162' ' ' GLU . 43.3 p -88.03 -39.76 14.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.152 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -136.97 151.11 48.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.488 HG21 ' CG ' ' A' ' 130' ' ' ARG . 86.4 t -134.36 106.22 7.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.7 t -96.7 139.31 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.191 179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.757 ' HE3' HD11 ' A' ' 129' ' ' LEU . 14.4 mtp -141.1 130.57 23.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.2 mt -91.46 137.21 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.447 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.72 165.13 4.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.937 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.443 ' O ' ' C ' ' A' ' 148' ' ' ALA . 39.3 t0 -85.13 113.49 21.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.59 -58.72 0.41 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.107 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -41.47 -43.87 2.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.436 ' N ' ' O ' ' A' ' 147' ' ' ASP . 9.5 tptm -78.14 -40.85 36.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 60.01 48.02 9.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.447 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.6 ttp85 -161.63 138.95 6.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.626 0.727 . . . . 0.0 110.816 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.503 ' CB ' ' CE ' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.74 113.8 3.49 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.645 2.23 . . . . 0.0 112.348 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 33.7 mtp85 -55.48 -57.04 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 167.8 41.66 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.503 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -172.55 157.13 3.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.918 0.39 . . . . 0.0 110.834 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.41 -154.42 24.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.507 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -140.1 166.13 25.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.813 0.34 . . . . 0.0 110.919 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.551 HD12 ' CD2' ' A' ' 133' ' ' PHE . 17.3 mt -150.0 142.39 17.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.102 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.4 m -109.82 141.12 42.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.11 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.581 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 39.4 m-85 -110.39 176.98 4.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.404 ' OE1' HG22 ' A' ' 140' ' ' THR . 17.8 tp10 -82.47 -36.17 26.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -131.96 131.34 42.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.849 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -40.8 -41.49 1.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.839 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -37.56 -53.95 1.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.581 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 22.4 m -46.27 -54.37 8.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.673 HG13 HG22 ' A' ' 115' ' ' ILE . 63.8 t -40.71 -56.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.134 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 169' ' ' GLN . 38.8 t0 -56.29 -64.13 0.96 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 168' ' ' ASP . 50.9 mt-30 -34.69 -43.92 0.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -75.15 -62.47 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.084 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.527 HG21 ' CG ' ' A' ' 187' ' ' ARG . 51.4 t -42.74 -54.24 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -40.64 -51.61 2.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.4 mmm -64.37 -31.97 73.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 13.3 t-160 48.61 26.46 1.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 11.1 m-85 -169.28 148.46 3.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.848 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.524 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 91.9 m-70 -155.07 152.43 29.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.84 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -108.13 104.07 13.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.996 HD12 HG21 ' A' ' 183' ' ' VAL . 52.4 mt -126.23 113.09 32.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.404 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 9.1 mtt 60.62 42.56 13.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 46.74 93.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.495 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.8 tptt -153.41 145.93 24.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -87.25 110.74 20.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.996 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -97.8 115.03 36.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -76.77 141.6 40.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 117' ' ' VAL . 20.3 t -138.57 131.55 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 11.4 mtmt -138.34 149.99 46.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.947 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.527 ' CG ' HG21 ' A' ' 171' ' ' VAL . 14.0 mtt180 -53.07 123.77 12.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . -89.04 15.56 8.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -80.97 152.48 71.65 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.627 0.727 . . . . 0.0 110.879 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -41.75 4.03 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 0.0 112.356 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -145.36 133.81 21.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -38.47 132.07 1.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.826 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.1 t -72.61 142.06 48.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . 0.406 ' NZ ' ' HB3' ' A' ' 194' ' ' LYS . 8.9 mtpm? -149.3 158.75 44.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 17.1 t -104.54 80.44 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.863 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 30.7 t -79.22 150.87 31.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.873 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 47.0 -168.8 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.476 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 131.04 20.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 38.0 t -100.51 -46.87 5.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.1 t -61.93 -55.86 25.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.861 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.461 -179.975 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.3 m -110.68 103.17 11.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.863 0.363 . . . . 0.0 110.837 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.0 m -131.71 115.78 16.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -101.85 44.2 1.57 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.48 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.3 t -45.94 -56.86 4.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.857 0.361 . . . . 0.0 110.856 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 7.3 m -132.8 164.7 26.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.84 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -84.21 111.68 3.5 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.444 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 6.4 t -97.1 87.44 4.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.945 0.402 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 8.8 ptpt -80.48 -21.3 42.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.0 m -56.01 110.54 0.76 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -90.41 48.19 1.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.7 ttmt -100.14 137.18 38.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.728 HG22 HG13 ' A' ' 167' ' ' VAL . 29.2 pt -119.65 153.38 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.147 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -101.87 107.61 18.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 185' ' ' VAL . 88.1 t -103.36 117.65 49.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.141 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.69 -177.42 15.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 61.52 13.73 39.1 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.467 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.567 HG23 ' HD2' ' A' ' 121' ' ' PRO . 35.5 mt -61.65 137.15 94.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 0.0 111.15 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.567 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.1 Cg_endo -69.67 161.85 44.32 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.433 ' ND1' ' O ' ' A' ' 122' ' ' HIS . 2.8 p80 -77.58 8.66 4.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.873 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.459 ' O ' ' CE ' ' A' ' 179' ' ' MET . 47.5 t30 -117.09 -15.12 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.466 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 2.7 t -83.55 153.22 24.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -158.92 169.6 35.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.517 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 125' ' ' GLY . 0.6 OUTLIER -35.97 -59.4 0.6 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.893 0.377 . . . . 0.0 110.893 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.9 m -42.62 -53.94 4.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -65.25 -55.93 15.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.476 HD13 HD11 ' A' ' 159' ' ' ILE . 60.6 mt -42.6 -58.85 2.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.933 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.642 ' HA ' HG21 ' A' ' 139' ' ' VAL . 68.1 mtp180 -54.51 -56.72 15.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -50.87 -33.5 24.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.504 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.0 t80 -89.64 -20.06 24.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.431 ' CD2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-85 -105.31 17.74 23.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -92.59 -39.15 11.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.3 ptpt -57.39 -31.14 65.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.869 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -73.99 -32.48 63.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.891 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.55 -118.9 0.54 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 60.2 t -145.04 106.23 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.642 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.5 t -68.71 108.66 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.117 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 16.5 p -86.03 -38.0 18.33 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -140.67 155.53 46.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.416 HG21 ' CG ' ' A' ' 130' ' ' ARG . 85.0 t -136.89 106.35 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.166 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 47.5 t -93.96 138.7 19.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.122 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.8 mtt -139.17 136.33 34.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.1 mt -101.43 131.76 48.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.445 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.16 164.84 7.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.3 t0 -85.41 112.4 20.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.865 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.5 -60.56 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 tm-20 -38.52 -45.45 1.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 9.3 tppt? -78.52 -40.51 34.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 60.07 53.11 4.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.911 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 15.4 ttp85 -165.44 138.34 3.56 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.601 0.715 . . . . 0.0 110.922 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 111.44 2.82 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.684 2.256 . . . . 0.0 112.315 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.6 mtp85 -52.0 -50.77 60.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 161.27 39.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -169.69 161.45 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.519 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 165.42 -151.05 19.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.459 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.519 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 10.1 m-85 -146.03 166.31 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.869 0.366 . . . . 0.0 110.866 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.476 HD11 HD13 ' A' ' 129' ' ' LEU . 18.2 mt -150.4 136.78 12.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.13 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 36.5 m -103.82 143.4 32.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.536 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.9 m-85 -112.44 176.46 5.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.925 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -77.91 -39.04 44.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.71 145.21 49.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 165' ' ' GLN . 34.8 tt0 -48.81 -44.39 39.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.918 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.418 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.1 tt0 -34.76 -49.6 0.43 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.536 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 20.0 m -53.65 -52.08 61.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.728 HG13 HG22 ' A' ' 115' ' ' ILE . 70.4 t -47.41 -47.1 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -63.56 -52.62 60.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -47.67 -51.58 21.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.891 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.89 -56.44 7.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.647 HG23 ' O ' ' A' ' 167' ' ' VAL . 40.3 t -43.6 -57.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -38.74 -62.04 0.66 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.885 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 18.3 mmm -48.6 -42.45 33.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.528 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 14.6 t-160 54.01 25.72 5.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.521 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -172.37 144.8 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.898 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.504 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 64.8 m-70 -156.21 158.74 38.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -110.33 103.68 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.772 HD12 HG21 ' A' ' 183' ' ' VAL . 34.2 mt -130.05 131.34 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.089 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 123' ' ' ASN . 11.9 mmt 62.52 25.74 15.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.914 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.01 85.01 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.46 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 9.1 ttmm -128.29 162.17 27.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.866 0.365 . . . . 0.0 110.876 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 5.8 tptm -88.74 128.68 35.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.772 HG21 HD12 ' A' ' 178' ' ' ILE . 3.5 t -112.46 121.61 65.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.096 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -81.37 145.21 30.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.973 HG22 HG22 ' A' ' 117' ' ' VAL . 42.7 t -142.29 126.91 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mmmt -138.04 143.92 40.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -56.69 118.54 4.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.842 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -77.29 169.38 18.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -111.45 147.95 37.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 191' ' ' ARG . 53.8 Cg_endo -69.78 124.47 11.11 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 0.0 112.341 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.438 ' C ' ' O ' ' A' ' 190' ' ' PRO . 0.0 OUTLIER -35.5 125.24 0.65 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -50.99 142.57 11.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 78.8 p -122.2 110.16 15.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -141.05 145.72 36.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.891 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 51.4 m -152.3 167.25 29.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.886 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.7 t -118.92 133.57 55.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 81.24 159.59 23.22 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.87 2.08 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.683 2.255 . . . . 0.0 112.349 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 28.8 m -40.6 131.77 2.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.855 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 25.7 m -89.86 104.73 17.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.843 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.484 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.8 m -76.53 159.93 29.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.351 . . . . 0.0 110.885 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 85.0 p -164.35 141.48 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.57 -143.34 16.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.5 t 53.55 42.53 31.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.855 0.359 . . . . 0.0 110.847 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.8 t -91.51 -44.43 9.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.41 161.17 53.55 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.485 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.0 t -80.87 -54.39 5.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.95 0.405 . . . . 0.0 110.856 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -109.14 88.95 2.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.931 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.5 m -114.42 142.21 46.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.425 ' O ' HG23 ' A' ' 160' ' ' THR . 0.5 OUTLIER -95.66 62.38 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.7 ttmt -117.67 148.65 41.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.79 HG22 HG13 ' A' ' 167' ' ' VAL . 21.7 pt -129.22 155.33 41.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 7.3 t80 -104.74 102.37 11.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 185' ' ' VAL . 84.8 t -93.3 125.42 45.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.109 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.1 -177.28 14.79 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.52 8.69 10.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.629 HD11 HG12 ' A' ' 117' ' ' VAL . 55.3 mt -58.71 137.61 86.58 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.638 0.732 . . . . 0.0 111.117 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.593 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.76 169.79 18.09 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.0 p-80 -85.92 15.21 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -123.67 -26.86 4.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.498 ' SG ' HG21 ' A' ' 178' ' ' ILE . 24.1 t -72.18 118.92 15.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.68 -174.32 16.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.495 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -41.45 -63.94 0.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.951 0.405 . . . . 0.0 110.863 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 46.0 m -41.9 -54.9 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.102 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 129' ' ' LEU . 61.1 mm-40 -54.41 -66.18 0.44 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.663 HD11 ' CE ' ' A' ' 144' ' ' MET . 51.5 mt -34.53 -60.34 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.613 ' HA ' HG21 ' A' ' 139' ' ' VAL . 5.6 mtp-105 -58.9 -57.0 15.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.863 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -46.44 -25.8 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.568 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.3 t80 -102.46 -20.7 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.928 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.569 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.6 m-85 -104.47 9.8 35.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 130' ' ' ARG . 48.2 pttt -91.33 -17.61 25.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.88 -38.57 57.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.915 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -69.18 -29.38 67.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -175.31 -124.17 0.79 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.7 t -138.61 105.3 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.126 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.613 HG21 ' HA ' ' A' ' 130' ' ' ARG . 38.6 t -65.16 110.0 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.079 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 46.2 p -87.74 -38.46 15.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.129 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -137.38 147.43 45.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.859 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.27 94.46 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 72.3 t -89.99 137.9 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.12 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.663 ' CE ' HD11 ' A' ' 129' ' ' LEU . 8.8 mtp -137.57 142.7 41.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 73.3 mt -106.58 133.53 50.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.37 165.08 5.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.903 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.448 ' O ' ' C ' ' A' ' 148' ' ' ALA . 29.1 t0 -85.83 113.5 22.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.448 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.33 -62.13 0.29 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.108 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 148' ' ' ALA . 42.5 tt0 -36.38 -46.26 0.53 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -78.99 -40.55 31.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 60.0 47.84 9.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.9 ttp180 -158.29 138.32 8.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.623 0.725 . . . . 0.0 110.893 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.462 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.75 110.6 2.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.724 2.282 . . . . 0.0 112.32 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -51.62 -53.53 37.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.851 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 120' ' ' ILE . . . 163.03 41.39 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.534 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -170.7 160.6 7.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.914 0.388 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.23 -159.01 32.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' A' ' 143' ' ' VAL . 15.8 m-85 -137.81 161.11 37.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.82 0.343 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.569 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.1 mt -148.19 140.73 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.073 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 113' ' ' ASN . 23.6 m -107.13 144.23 34.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.437 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 54.8 m-85 -113.29 167.52 10.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -70.53 -43.17 70.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -122.06 140.53 52.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 165' ' ' GLN . 7.9 tp10 -49.67 -46.39 49.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.401 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.4 tt0 -38.24 -51.88 1.48 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.437 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 50.6 m -44.58 -57.05 3.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.79 HG13 HG22 ' A' ' 115' ' ' ILE . 38.4 t -37.68 -59.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 169' ' ' GLN . 46.9 t0 -50.53 -61.65 2.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.807 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 168' ' ' ASP . 76.0 mt-30 -35.73 -48.91 0.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.62 -57.89 4.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.118 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 174' ' ' HIS . 75.2 t -47.13 -60.39 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 171' ' ' VAL . 7.5 t30 -35.07 -61.08 0.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 27.5 mmm -51.08 -41.45 59.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.904 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.522 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 11.6 t-160 55.94 26.23 9.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.8 m-85 -171.87 148.32 2.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.568 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 52.7 m-70 -155.44 155.83 34.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -112.37 85.84 2.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.897 HD12 HG21 ' A' ' 183' ' ' VAL . 78.8 mt -96.66 126.24 49.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.15 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.833 ' HG2' HG22 ' A' ' 178' ' ' ILE . 2.0 ptm 38.81 48.22 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.5 67.74 1.94 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.482 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.41 ' NZ ' ' HB2' ' A' ' 181' ' ' LYS . 0.3 OUTLIER -175.13 142.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.815 0.34 . . . . 0.0 110.897 -179.946 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 4.8 tptm -85.04 102.37 13.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.884 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.897 HG21 HD12 ' A' ' 178' ' ' ILE . 3.0 t -95.08 117.34 38.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.139 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . 0.543 ' O ' HG23 ' A' ' 185' ' ' VAL . 10.1 tt0 -72.92 162.19 29.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.906 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.671 HG22 HG22 ' A' ' 117' ' ' VAL . 72.3 t -161.12 131.02 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mttm -137.19 143.31 42.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.434 ' NH1' ' HB2' ' A' ' 187' ' ' ARG . 10.4 ttm105 -56.96 114.16 1.99 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.862 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -76.4 97.79 4.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -175.02 155.38 1.83 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.668 0.747 . . . . 0.0 110.858 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 179.45 3.7 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.716 2.277 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -112.62 -59.44 2.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -83.41 99.93 10.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 74.0 p -129.71 128.31 42.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.867 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 25.8 tttm -91.93 86.14 5.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 62.7 p -160.28 152.73 20.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 48.5 t -124.06 83.75 2.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.867 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 75.76 -158.3 49.88 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.431 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 128.85 16.6 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.642 2.228 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.8 m -91.14 105.33 17.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.836 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 18.9 t -104.39 154.47 19.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.882 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.986 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.392 0 N-CA-C 112.519 -0.232 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.9 m -66.9 101.55 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 110.87 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.2 m -69.02 85.04 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.868 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 156.13 96.29 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.3 m -72.14 -59.56 2.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.821 0.343 . . . . 0.0 110.887 -179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.5 t -82.79 85.74 7.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.837 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -74.86 85.27 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.5 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 23.9 p -100.71 -62.97 1.18 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.952 0.406 . . . . 0.0 110.86 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.23 97.34 5.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.0 t -147.02 132.03 18.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.853 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -104.11 56.46 0.72 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.438 ' HG2' ' N ' ' A' ' 115' ' ' ILE . 21.3 ttmt -105.23 149.55 25.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.647 HG22 HG13 ' A' ' 167' ' ' VAL . 24.0 pt -129.6 156.85 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.454 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 8.0 t80 -104.58 106.45 16.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 185' ' ' VAL . 89.3 t -103.05 114.42 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -118.43 -177.64 16.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.432 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.04 26.63 58.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.471 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.623 HG23 ' HD2' ' A' ' 121' ' ' PRO . 60.7 mt -75.46 137.9 71.12 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.631 0.729 . . . . 0.0 111.12 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.72 165.11 32.02 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.706 2.27 . . . . 0.0 112.374 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -77.3 0.54 21.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -105.42 -32.89 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 21.4 t -68.8 118.81 12.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.39 -179.27 15.85 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.52 ' HA ' HD12 ' A' ' 129' ' ' LEU . 55.9 tt0 -39.89 -67.59 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.876 0.369 . . . . 0.0 110.853 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 52.1 m -40.67 -60.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.121 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 16.7 mm-40 -49.73 -61.22 2.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.612 HD11 ' CE ' ' A' ' 144' ' ' MET . 41.9 mt -35.97 -55.67 0.74 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.486 ' HG2' HG11 ' A' ' 139' ' ' VAL . 11.1 mtp-105 -64.03 -54.7 30.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -47.52 -20.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -107.46 -25.42 11.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.591 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.4 m-85 -97.98 15.34 24.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 10.8 ptpt -95.22 -10.69 29.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.94 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.2 pttm -81.69 -34.56 30.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -72.14 -23.29 61.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 175.33 -118.96 0.69 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 88.2 t -140.03 116.14 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' A' ' 130' ' ' ARG . 24.9 t -80.66 111.12 16.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.6 p -89.1 -34.95 16.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -142.02 157.82 44.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.424 HG21 ' CG ' ' A' ' 130' ' ' ARG . 99.3 t -139.05 104.94 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.172 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.79 139.27 17.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.149 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.612 ' CE ' HD11 ' A' ' 129' ' ' LEU . 5.3 mtt -142.25 133.7 26.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.438 HD11 ' HE1' ' A' ' 158' ' ' PHE . 70.7 mt -99.21 133.82 40.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.22 165.96 5.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.941 -179.987 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.455 ' O ' ' C ' ' A' ' 148' ' ' ALA . 21.8 t0 -84.88 113.23 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.455 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.16 -58.29 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.056 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -42.41 -44.45 3.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 147' ' ' ASP . 2.8 mptm? -77.22 -40.82 43.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 60.09 43.5 14.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.866 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 3.8 ttp180 -155.92 138.47 10.38 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.6 0.714 . . . . 0.0 110.886 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.589 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.77 110.87 2.66 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.335 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.9 mtp85 -50.86 -55.89 14.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.18 41.77 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -172.34 162.95 5.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.449 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 162.79 -154.51 25.49 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.451 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 157' ' ' GLY . 4.7 m-85 -141.95 167.03 23.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.891 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.591 HD12 ' CD2' ' A' ' 133' ' ' PHE . 8.9 mt -150.1 139.85 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.137 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.3 m -106.33 144.82 32.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.471 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 53.1 m-85 -115.13 175.02 5.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -78.65 -43.25 26.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 164' ' ' GLU . 3.4 m-20 -123.97 125.59 44.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.874 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 163' ' ' ASP . 23.1 tt0 -35.17 -39.03 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.419 ' C ' ' O ' ' A' ' 164' ' ' GLU . 3.8 mm100 -36.03 -59.33 0.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.471 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 1.1 m -41.87 -58.35 2.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.809 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 171' ' ' VAL . 58.6 t -36.12 -54.42 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -58.54 -60.3 4.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.1 mt-30 -39.9 -48.84 2.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.92 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.48 -54.94 13.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 167' ' ' VAL . 67.9 t -46.21 -60.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.167 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.428 ' C ' ' O ' ' A' ' 171' ' ' VAL . 12.3 t-20 -35.84 -67.8 0.15 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.832 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 86.2 mtp -46.44 -42.14 14.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.3 t-160 54.74 30.61 13.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.824 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.543 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.7 m-85 -173.57 155.17 2.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 77.8 m-70 -160.57 162.82 33.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -119.39 91.52 3.57 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 183' ' ' VAL . 58.2 mt -112.23 135.09 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 4.7 mmm 46.14 40.78 7.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.885 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 61.34 57.4 18.42 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.412 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.2 tmtm? -166.09 151.33 8.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.5 OUTLIER -84.5 116.7 23.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.895 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.854 HG21 HD12 ' A' ' 178' ' ' ILE . 3.9 t -105.78 120.41 56.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -82.15 146.78 29.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.803 HG22 HG22 ' A' ' 117' ' ' VAL . 69.2 t -144.49 134.31 19.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -139.18 149.1 44.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 28.7 ttp180 -59.9 119.21 7.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.932 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.69 15.59 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.116 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -109.6 146.8 34.77 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.637 0.732 . . . . 0.0 110.868 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 170.96 15.38 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.636 2.224 . . . . 0.0 112.324 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -85.65 102.75 13.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -103.57 162.3 13.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.9 m -114.39 -41.25 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 31.7 tptt -156.34 146.18 21.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.89 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 55.5 m -79.96 173.9 12.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 10.6 t -144.62 140.11 28.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.855 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 108.38 147.72 12.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.537 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 126.41 13.28 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.1 t -57.49 145.86 31.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.7 t -111.57 111.76 23.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 -179.999 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 93.0 p -140.93 130.96 24.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.88 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -161.07 131.46 5.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 107.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.501 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 20.2 m -84.58 -49.68 8.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 110.812 -179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 51.1 m -155.55 130.38 9.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -145.88 -111.08 0.69 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.486 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 80.7 p -158.27 121.92 3.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.919 0.39 . . . . 0.0 110.859 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 13.4 pttt -153.38 164.21 38.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.6 t -129.42 142.66 50.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.812 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -88.6 34.2 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -92.72 150.01 20.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.908 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.863 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -131.09 155.16 41.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -104.39 105.54 15.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 185' ' ' VAL . 94.8 t -101.11 115.32 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.146 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.01 177.98 16.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.06 11.69 55.7 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.668 HG23 ' HD2' ' A' ' 121' ' ' PRO . 55.9 mt -57.85 138.84 82.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.642 0.734 . . . . 0.0 111.13 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.668 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.2 Cg_endo -69.79 171.96 13.55 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.658 2.239 . . . . 0.0 112.359 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 122' ' ' HIS . 12.1 t60 -76.58 -5.14 46.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.452 ' O ' ' C ' ' A' ' 124' ' ' CYS . 7.7 m120 -102.43 -62.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.472 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.3 t -34.38 128.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -127.34 -154.82 8.62 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.444 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -66.33 -60.87 2.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.942 0.401 . . . . 0.0 110.921 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 53.3 m -48.55 -58.36 4.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.091 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.41 ' CD ' ' H ' ' A' ' 128' ' ' GLU . 6.2 mp0 -46.63 -61.95 1.6 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 35.5 mt -39.74 -52.13 2.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.917 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.589 ' HG2' HG11 ' A' ' 139' ' ' VAL . 74.0 mtm180 -59.85 -52.42 65.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 -53.38 -27.84 26.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.927 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.518 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 9.0 t80 -96.51 -18.96 19.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.946 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.486 ' CD2' HD12 ' A' ' 159' ' ' ILE . 16.4 m-85 -108.17 7.99 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.871 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.481 ' N ' ' O ' ' A' ' 130' ' ' ARG . 32.3 pttt -90.77 -28.46 18.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.2 ptpt -66.47 -25.94 66.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.867 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -78.66 -37.8 41.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -167.92 -112.25 0.26 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.463 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 86.5 t -147.47 112.33 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 111.056 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.589 HG11 ' HG2' ' A' ' 130' ' ' ARG . 70.7 t -75.16 103.78 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.112 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -79.24 -40.9 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.18 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.25 152.98 46.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.5 t -132.46 102.43 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.08 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.8 t -89.44 143.59 10.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.44 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.4 mtt -145.41 134.18 22.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.413 HD11 ' HE1' ' A' ' 158' ' ' PHE . 55.6 mt -98.76 130.66 47.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.169 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.454 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -170.09 164.66 9.34 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 150' ' ' LYS . 46.0 t0 -82.91 113.34 20.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.841 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.9 -52.46 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -48.0 -42.47 28.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.442 ' N ' ' O ' ' A' ' 147' ' ' ASP . 63.3 mttt -79.19 -38.43 35.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.948 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 58.19 51.41 8.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 13.1 ttm180 -164.95 138.42 3.88 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.61 0.719 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.44 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.9 Cg_endo -69.72 113.54 3.4 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.742 2.295 . . . . 0.0 112.364 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.1 mtt180 -54.69 -55.47 29.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.32 40.59 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CA ' HD12 ' A' ' 120' ' ' ILE . 35.8 p90 -171.39 164.76 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.902 0.382 . . . . 0.0 110.877 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.74 -161.04 33.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.413 ' HE1' HD11 ' A' ' 145' ' ' ILE . 12.8 m-85 -137.73 162.85 32.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.486 HD12 ' CD2' ' A' ' 133' ' ' PHE . 15.8 mt -146.39 140.49 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.095 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.0 m -108.78 139.88 42.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -109.27 172.51 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.901 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.43 -30.03 47.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.928 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -137.43 147.21 45.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -55.56 -45.77 77.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.878 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -41.59 -42.29 2.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 6.1 m -55.84 -54.38 45.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.863 HG13 HG22 ' A' ' 115' ' ' ILE . 42.1 t -47.34 -51.31 6.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.154 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 18.6 t0 -52.92 -52.53 57.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 14.3 mm-40 -42.27 -44.37 3.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -77.12 -64.55 1.11 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.405 HG11 ' HB2' ' A' ' 187' ' ' ARG . 68.8 t -37.81 -50.25 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.097 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -39.2 -67.99 0.19 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 9.0 mtm -54.76 -43.41 72.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.543 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 17.6 t-160 61.17 26.48 16.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.1 m-85 -172.01 134.72 0.77 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.518 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 57.0 m-70 -145.41 161.58 39.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -114.24 98.24 6.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.787 HD12 HG21 ' A' ' 183' ' ' VAL . 38.7 mt -118.65 129.07 75.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 51.07 41.89 27.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 60.73 63.65 4.79 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.489 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -174.15 149.21 1.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 9.7 tppt? -85.74 102.36 13.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.787 HG21 HD12 ' A' ' 178' ' ' ILE . 3.2 t -89.71 115.61 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -77.82 144.17 37.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.904 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.742 HG22 HG22 ' A' ' 117' ' ' VAL . 88.2 t -143.44 128.44 15.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . 0.413 ' HD3' ' CD2' ' A' ' 174' ' ' HIS . 21.8 mmmt -133.34 151.48 51.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.405 ' HB2' HG11 ' A' ' 171' ' ' VAL . 12.1 ttt-85 -66.4 108.53 2.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -64.82 172.02 3.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -106.0 146.22 32.48 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.69 0.757 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 132.91 24.35 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.639 2.226 . . . . 0.0 112.382 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -71.5 118.55 14.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -107.09 75.71 1.05 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 32.0 t -66.85 151.79 46.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.84 96.35 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.899 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 48.8 m -77.23 123.44 26.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 10.9 t -153.26 134.99 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -169.8 143.6 8.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.465 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 115.04 3.9 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.665 2.243 . . . . 0.0 112.375 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.1 t -121.32 106.19 11.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.885 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 12.5 t -72.76 -57.7 3.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 85.7 p -173.74 156.4 2.87 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.359 . . . . 0.0 110.854 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.8 p -116.66 42.1 2.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 66.75 133.85 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.455 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -108.86 131.45 54.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.366 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -53.94 113.84 1.37 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.831 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 142.54 130.13 2.44 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.463 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 4.1 m -101.44 -51.04 3.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.932 0.396 . . . . 0.0 110.818 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 pttt -86.91 127.0 35.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 113' ' ' ASN . 53.4 p -98.47 -21.83 16.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.879 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.429 ' C ' ' O ' ' A' ' 112' ' ' SER . 2.0 m-20 34.42 41.75 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -105.19 145.23 30.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.573 HG22 HG13 ' A' ' 167' ' ' VAL . 16.2 pt -126.79 155.34 37.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.156 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -104.7 106.1 16.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 185' ' ' VAL . 99.5 t -102.74 122.97 55.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -125.83 -174.94 14.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.07 16.77 14.55 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.503 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.627 HG23 ' HD2' ' A' ' 121' ' ' PRO . 59.9 mt -64.45 138.1 97.34 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.651 0.739 . . . . 0.0 111.143 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.627 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.78 167.06 25.56 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.633 2.222 . . . . 0.0 112.349 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -81.38 2.59 27.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.853 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -107.48 -29.02 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.481 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.1 t -72.96 135.39 45.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -139.26 175.71 21.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.473 ' HA ' HD12 ' A' ' 129' ' ' LEU . 22.8 tt0 -34.57 -70.17 0.08 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.888 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 126' ' ' GLU . 22.0 m -36.36 -65.34 0.28 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.121 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 129' ' ' LEU . 36.8 mm-40 -47.65 -63.07 1.15 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.67 HD11 ' HE3' ' A' ' 144' ' ' MET . 67.8 mt -34.38 -45.15 0.22 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.478 ' HE ' HG23 ' A' ' 142' ' ' VAL . 22.5 mtt180 -67.39 -56.73 8.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -46.88 -26.66 1.03 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.949 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -98.26 -31.41 12.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CD2' HD12 ' A' ' 159' ' ' ILE . 24.8 m-85 -97.02 16.86 18.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 17.0 pttp -95.32 -27.9 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -68.08 -34.05 75.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.922 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -66.65 -31.53 72.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -178.86 -106.14 0.2 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 83.2 t -151.74 111.53 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.406 HG21 ' HA ' ' A' ' 130' ' ' ARG . 42.6 t -76.96 114.67 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 72.5 p -91.81 -38.29 12.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.161 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -140.51 154.16 46.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.478 HG23 ' HE ' ' A' ' 130' ' ' ARG . 84.5 t -134.7 100.92 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 65.3 t -83.28 141.9 14.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.67 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.8 mtt -145.3 135.02 23.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.4 mt -101.02 136.45 32.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.105 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.06 166.03 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.45 ' O ' ' C ' ' A' ' 148' ' ' ALA . 25.3 t0 -88.88 113.52 24.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.52 -58.71 0.4 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.104 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.403 ' C ' ' O ' ' A' ' 148' ' ' ALA . 34.2 tt0 -37.52 -45.25 0.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.863 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 6.4 tptm -82.35 -39.08 23.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.09 47.11 9.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.7 ttp85 -157.74 139.07 9.71 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.652 0.739 . . . . 0.0 110.864 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 109.75 2.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.717 2.278 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 30.7 mtp180 -49.39 -54.11 19.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.888 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.0 42.34 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -172.88 160.03 4.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.884 0.374 . . . . 0.0 110.866 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 165.15 -152.82 22.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.507 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -142.34 167.25 22.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.936 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CD2' ' A' ' 133' ' ' PHE . 13.7 mt -148.81 138.52 16.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 61.9 m -103.0 148.77 25.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.464 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 67.2 m-85 -119.83 175.43 5.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -79.49 -42.7 24.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.905 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -126.47 134.78 50.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 165' ' ' GLN . 39.2 tt0 -43.52 -44.25 5.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 164' ' ' GLU . 65.1 tt0 -35.66 -45.73 0.39 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.464 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 3.8 m -51.6 -55.69 17.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.573 HG13 HG22 ' A' ' 115' ' ' ILE . 80.0 t -40.75 -57.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -50.21 -51.77 41.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.867 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 20.6 mm100 -48.0 -57.77 5.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -59.51 -58.92 6.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 174' ' ' HIS . 70.3 t -44.28 -62.88 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.2 t-20 -34.65 -55.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.87 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 25.6 mmm -57.29 -42.84 82.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 14.0 t-160 54.53 26.71 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.4 m-85 -172.5 154.39 3.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.53 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 88.3 m-70 -159.81 157.76 29.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -116.29 84.04 2.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.998 HD12 HG21 ' A' ' 183' ' ' VAL . 66.8 mt -97.33 108.68 21.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.162 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 23.7 mtm 61.01 44.86 9.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.98 37.96 94.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 35.0 tptt -139.29 136.69 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 110.883 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.22 100.99 10.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.998 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -93.21 129.63 43.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -87.67 148.01 24.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.88 HG22 HG22 ' A' ' 117' ' ' VAL . 67.1 t -147.58 138.75 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.109 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.1 mtmm -141.15 169.57 17.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 2.0 tmm_? -80.83 114.03 19.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.54 167.11 18.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.127 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -119.0 147.06 41.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.684 0.754 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 176.84 6.24 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.02 172.22 13.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -91.13 121.7 33.14 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.89 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 55.8 p -145.76 140.35 27.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 33.9 tttm -55.4 133.99 50.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 93.4 p -51.68 118.08 3.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 15.5 t -105.39 152.25 23.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -118.83 146.03 18.33 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.24 14.31 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 0.0 112.37 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.1 p -120.11 83.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 41.5 p -89.34 127.54 35.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.451 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.4 m -132.45 88.76 2.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.955 0.407 . . . . 0.0 110.874 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.8 m -122.51 97.23 5.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.868 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 175.58 -124.34 0.99 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.4 m -115.67 42.21 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.834 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 24.5 t -102.67 82.91 2.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.832 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 110' ' ' SER . . . -119.89 -162.88 12.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.491 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 109' ' ' GLY . 40.8 t -35.27 115.06 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.97 0.414 . . . . 0.0 110.895 -179.762 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -39.34 111.48 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 90.5 p -120.42 116.06 24.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.852 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -100.37 37.49 1.67 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -102.22 145.55 29.26 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.754 HG22 HG13 ' A' ' 167' ' ' VAL . 25.1 pt -126.08 154.3 35.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -104.21 101.98 11.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 185' ' ' VAL . 98.2 t -95.66 119.11 43.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.129 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.71 177.43 16.43 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.516 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.87 28.62 63.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.492 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.55 HG23 ' HD2' ' A' ' 121' ' ' PRO . 32.3 mt -75.82 137.01 69.95 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.606 0.717 . . . . 0.0 111.104 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.55 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.72 166.98 25.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.657 2.238 . . . . 0.0 112.351 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -77.1 -3.49 39.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.878 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -100.82 -37.34 8.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 42.1 t -67.93 125.35 26.01 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.442 ' N ' ' OE1' ' A' ' 128' ' ' GLU . . . -129.9 -165.61 11.66 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.528 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -53.53 -64.53 0.79 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.92 0.39 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 87.3 m -44.14 -54.29 5.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.442 ' OE1' ' N ' ' A' ' 125' ' ' GLY . 12.2 mp0 -57.16 -63.44 1.22 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 133' ' ' PHE . 61.0 mt -34.31 -46.96 0.28 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 30.7 mtp85 -69.74 -51.14 36.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -50.22 -19.2 0.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.921 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.427 ' CD1' ' O ' ' A' ' 132' ' ' TYR . 12.6 t80 -108.97 -24.05 11.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.566 ' CE2' HD12 ' A' ' 159' ' ' ILE . 17.1 m-85 -98.35 9.99 41.8 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -86.85 -25.47 24.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -69.45 -39.61 77.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -64.58 -25.94 68.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.904 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 176.5 -113.79 0.45 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.465 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.5 t -147.95 106.14 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.848 0.356 . . . . 0.0 111.154 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.18 116.51 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.172 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 79.5 p -93.68 -35.42 12.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.108 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.69 152.61 45.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.93 97.69 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.139 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' A' ' 158' ' ' PHE . 59.3 t -81.84 142.74 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.095 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.3 mtt -145.15 136.7 25.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 56.8 mt -104.36 131.36 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.439 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -171.45 166.75 6.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.435 ' O ' ' C ' ' A' ' 148' ' ' ALA . 48.0 t0 -91.49 109.75 21.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.13 -46.24 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 148' ' ' ALA . 1.5 tm-20 -35.3 -47.03 0.39 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -99.31 -28.69 13.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 59.78 50.06 7.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.439 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 5.0 ttp85 -149.73 138.58 12.53 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.613 0.72 . . . . 0.0 110.891 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.519 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.5 Cg_endo -69.71 110.62 2.59 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.352 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -50.24 -54.02 24.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.844 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.49 40.67 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.482 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -172.61 160.12 4.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 168.03 -155.56 26.44 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.441 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' A' ' 143' ' ' VAL . 29.2 m-85 -142.52 162.45 35.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.787 0.327 . . . . 0.0 110.879 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.566 HD12 ' CE2' ' A' ' 133' ' ' PHE . 13.9 mt -146.0 139.72 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.089 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 84.7 m -106.87 139.72 40.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.554 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 55.1 m-85 -109.08 179.24 4.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -86.23 -38.17 17.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . 0.415 ' O ' ' C ' ' A' ' 164' ' ' GLU . 6.5 m-20 -128.77 127.53 42.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.849 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 163' ' ' ASP . 26.8 tt0 -36.04 -42.19 0.28 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.403 ' O ' ' C ' ' A' ' 166' ' ' SER . 3.9 mt-30 -36.93 -61.42 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.554 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 7.2 m -38.32 -59.52 0.88 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.754 HG13 HG22 ' A' ' 115' ' ' ILE . 53.6 t -38.88 -63.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.157 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -43.9 -60.77 1.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -40.14 -53.41 2.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.36 -55.4 24.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.416 HG21 ' CB ' ' A' ' 187' ' ' ARG . 69.4 t -47.26 -61.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 171' ' ' VAL . 16.2 t-20 -37.67 -64.91 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.873 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 74.8 mtp -49.29 -45.43 45.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.835 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.8 t-160 60.03 28.07 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.5 m-85 -171.72 154.1 3.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.477 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 80.0 m-70 -159.38 156.64 28.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -113.09 91.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 183' ' ' VAL . 56.7 mt -111.05 134.21 54.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.113 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.2 mmt 47.99 36.19 5.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 65.78 46.04 85.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.463 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.424 ' HZ2' ' CA ' ' A' ' 121' ' ' PRO . 0.0 OUTLIER -153.61 147.18 25.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.875 -179.963 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.13 113.65 20.78 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.913 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 178' ' ' ILE . 3.1 t -105.16 127.39 59.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -83.81 150.53 25.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.86 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.998 HG22 HG22 ' A' ' 117' ' ' VAL . 23.8 t -151.14 131.93 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -136.86 149.05 47.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.416 ' CB ' HG21 ' A' ' 171' ' ' VAL . 12.1 ttt180 -62.87 124.89 22.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.21 162.08 21.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.132 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.433 ' CD ' ' H ' ' A' ' 189' ' ' GLU . 0.0 OUTLIER -100.49 161.09 25.12 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.927 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.444 ' O ' ' C ' ' A' ' 191' ' ' ARG . 54.0 Cg_endo -69.71 -50.8 0.44 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.684 2.256 . . . . 0.0 112.33 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.444 ' C ' ' O ' ' A' ' 190' ' ' PRO . 64.8 mtt-85 34.3 39.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -51.76 147.01 7.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 42.5 m -154.92 143.86 20.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 23.3 ttpt -173.02 136.85 0.68 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.913 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 70.9 m -110.19 100.01 8.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 16.5 t -154.33 131.8 11.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -133.15 78.71 0.35 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -6.87 19.62 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.653 2.235 . . . . 0.0 112.399 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.4 t -109.73 118.16 35.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 3.8 t -129.28 88.51 2.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.83 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.512 -179.974 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.0 m -93.57 92.59 7.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.5 t 64.65 42.45 4.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.84 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -119.56 -134.71 4.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.1 m -39.42 -43.69 1.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 71.6 m -101.11 148.65 24.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.868 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 113.25 -71.45 0.22 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 31.3 m -71.58 156.35 39.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 pttt -39.39 125.53 1.7 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 56.8 m -107.03 120.24 41.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.832 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -86.84 42.51 1.02 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -99.95 150.54 22.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.867 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.502 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.33 154.79 41.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -103.76 102.98 12.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 185' ' ' VAL . 83.8 t -97.95 112.84 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.24 173.7 15.37 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.479 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.01 63.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.439 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.596 HG23 ' HD2' ' A' ' 121' ' ' PRO . 42.1 mt -54.91 137.8 64.93 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.629 0.728 . . . . 0.0 111.152 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 163.99 36.25 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.644 2.229 . . . . 0.0 112.353 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.6 t-160 -68.99 -6.28 26.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.836 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 124' ' ' CYS . 19.6 t-20 -100.25 -64.22 1.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 43.7 t -35.13 126.57 0.56 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.75 -164.11 11.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -54.8 -66.24 0.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.932 0.396 . . . . 0.0 110.879 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -42.54 -61.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.166 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 129' ' ' LEU . 9.5 mm-40 -49.42 -63.23 1.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.526 HD11 ' CE ' ' A' ' 144' ' ' MET . 44.9 mt -37.84 -55.16 1.22 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.708 ' HA ' HG21 ' A' ' 139' ' ' VAL . 63.8 mtp180 -56.11 -56.0 26.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -50.33 -44.34 54.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.583 ' CD2' HG12 ' A' ' 178' ' ' ILE . 6.4 t80 -74.03 -22.54 59.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 159' ' ' ILE . 25.2 m-85 -105.32 15.8 26.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.5 ptmt -90.48 -37.79 13.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.92 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -60.47 -37.93 82.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -67.28 -30.01 69.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.85 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.63 -116.48 0.48 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.528 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 19.7 t -148.57 106.61 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.708 HG21 ' HA ' ' A' ' 130' ' ' ARG . 8.1 t -69.42 119.06 14.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.175 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 78.3 p -99.77 -37.57 9.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -134.03 141.31 47.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.876 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.537 HG21 ' CG ' ' A' ' 130' ' ' ARG . 94.0 t -127.74 93.62 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.17 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.7 t -89.42 134.41 28.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.543 ' HE2' ' CB ' ' A' ' 153' ' ' PRO . 8.3 mtp -135.96 133.39 37.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.531 HD11 ' HE1' ' A' ' 158' ' ' PHE . 57.5 mt -92.11 134.24 30.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -172.52 165.91 5.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.981 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 16.5 t0 -84.53 112.62 20.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.856 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.24 -59.98 0.35 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -40.87 -45.8 2.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 23.7 mttp -75.75 -41.01 54.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 60.07 48.02 8.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.3 ttm180 -160.4 138.55 7.35 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.563 0.697 . . . . 0.0 110.9 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.543 ' CB ' ' HE2' ' A' ' 144' ' ' MET . 53.7 Cg_endo -69.79 116.35 4.52 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.718 2.279 . . . . 0.0 112.346 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.5 mtp180 -58.76 -55.36 36.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.62 39.37 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.4 p90 -170.4 160.95 7.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.876 0.369 . . . . 0.0 110.893 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -158.15 30.96 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.531 ' HE1' HD11 ' A' ' 145' ' ' ILE . 31.8 m-85 -138.86 161.62 36.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.359 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 133' ' ' PHE . 8.6 mt -147.59 139.28 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.14 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 m -109.21 140.02 43.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.47 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 43.8 m-85 -108.53 169.45 8.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -75.81 -34.55 60.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 34.6 m-20 -129.62 141.5 50.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -52.31 -45.14 65.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.914 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -40.68 -44.66 2.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.9 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.47 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 17.4 m -54.04 -41.91 68.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 115' ' ' ILE . 38.5 t -58.53 -58.94 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.139 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -49.95 -42.87 49.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -55.23 -55.35 32.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -64.0 -56.57 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 98.4 t -48.06 -44.56 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.186 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -50.23 -51.53 43.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.914 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 22.2 mmm -62.59 -36.07 81.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.8 t-160 49.31 25.22 1.2 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 8.7 m-85 -170.13 145.99 2.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.493 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 46.9 m-70 -155.94 162.8 40.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -119.74 94.2 4.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.743 HD12 HG21 ' A' ' 183' ' ' VAL . 44.8 mt -113.34 120.61 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 3.5 mmt 59.9 34.25 21.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.69 46.97 58.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -153.5 148.55 26.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 8.2 tptm -86.84 108.51 18.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.743 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -98.51 120.99 48.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -82.73 147.58 28.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.896 HG22 HG22 ' A' ' 117' ' ' VAL . 41.1 t -143.17 132.49 20.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.146 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.9 mttp -137.06 136.71 38.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.419 ' HG3' ' CG1' ' A' ' 167' ' ' VAL . 34.9 ttt180 -52.45 123.16 10.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.97 17.0 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.126 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -114.69 144.04 31.13 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.66 0.743 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 127.8 15.05 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.703 2.269 . . . . 0.0 112.294 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 5.7 ttm105 -116.97 90.99 3.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.838 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 22.9 m-20 -139.91 161.47 37.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 99.0 p -45.54 168.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -100.97 126.26 47.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 36.0 p -150.79 130.56 13.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 19.9 t -71.0 -67.33 0.51 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.87 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 137.1 80.8 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.537 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -168.67 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.377 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -103.38 -2.26 27.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.848 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 32.3 t -99.47 -69.19 0.77 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.835 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.507 -179.965 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 85.9 p -82.9 149.7 26.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.857 0.361 . . . . 0.0 110.88 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 43.6 m -57.81 159.13 5.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.88 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 139.89 -154.45 23.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 83.9 p -99.05 133.81 42.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.872 0.367 . . . . 0.0 110.883 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.5 m -88.43 -54.96 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 174.2 162.85 26.61 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.5 t 45.77 40.9 6.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.884 0.373 . . . . 0.0 110.836 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 40.0 tttm -97.82 -35.4 10.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.3 m -149.96 170.73 18.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.871 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.853 ' O ' HG23 ' A' ' 160' ' ' THR . 0.8 OUTLIER -125.54 81.28 1.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.92 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt -127.67 141.13 51.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.425 HG22 HG13 ' A' ' 167' ' ' VAL . 18.1 pt -121.08 151.51 24.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.497 ' O ' ' CD1' ' A' ' 116' ' ' PHE . 6.4 t80 -101.88 105.02 15.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.877 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 185' ' ' VAL . 94.0 t -97.92 121.73 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.129 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -127.6 175.42 18.28 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.95 18.89 62.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.56 HG23 ' HD2' ' A' ' 121' ' ' PRO . 40.2 mt -65.76 136.83 95.98 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.639 0.733 . . . . 0.0 111.144 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.56 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.8 Cg_endo -69.81 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 0.0 112.344 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -75.29 1.62 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.444 ' C ' ' SD ' ' A' ' 179' ' ' MET . 27.7 t-20 -107.29 -23.1 12.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 13.5 t -80.48 128.45 33.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -130.8 176.83 18.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.5 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.603 ' HG3' HG11 ' A' ' 142' ' ' VAL . 30.5 tt0 -35.99 -61.01 0.51 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.909 0.385 . . . . 0.0 110.863 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 65.9 m -46.39 -60.15 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 129' ' ' LEU . 35.8 mm-40 -49.98 -61.9 1.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.895 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.439 HD13 HD11 ' A' ' 159' ' ' ILE . 62.5 mt -35.73 -56.01 0.69 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.944 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.535 ' HA ' HG21 ' A' ' 139' ' ' VAL . 62.3 mtp180 -61.76 -55.03 34.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -44.34 -29.53 0.69 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.878 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.449 ' CD2' HG12 ' A' ' 178' ' ' ILE . 11.9 t80 -98.53 -27.4 14.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.935 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.563 ' CE2' HD12 ' A' ' 159' ' ' ILE . 21.4 m-85 -95.1 13.34 25.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptpt -93.93 -9.73 36.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 pttt -84.71 -36.5 21.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -65.02 -35.04 79.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.487 ' O ' HG23 ' A' ' 138' ' ' VAL . . . -172.58 -102.14 0.15 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.461 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 137' ' ' GLY . 40.9 t -157.95 105.73 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.535 HG21 ' HA ' ' A' ' 130' ' ' ARG . 21.2 t -66.18 119.24 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.14 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 14.4 p -99.09 -37.14 9.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.189 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -135.31 148.78 49.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.872 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.603 HG11 ' HG3' ' A' ' 126' ' ' GLU . 97.6 t -132.07 94.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.135 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.9 t -90.48 138.09 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.104 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.401 ' HE3' HD11 ' A' ' 129' ' ' LEU . 9.2 mtp -137.37 136.06 37.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.562 HD11 ' HE1' ' A' ' 158' ' ' PHE . 58.7 mt -97.66 135.27 32.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.467 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -173.57 164.58 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.91 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.452 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.4 t0 -83.05 112.73 20.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.452 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.65 -62.75 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.125 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -38.91 -42.96 0.9 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 147' ' ' ASP . 70.0 mttt -79.44 -37.42 37.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 54.88 53.09 10.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.956 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.467 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 11.5 ttt180 -164.72 137.98 3.9 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.578 0.704 . . . . 0.0 110.894 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 116.99 4.81 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.338 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -59.89 -54.64 43.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 168.28 39.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -169.3 164.92 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.826 0.346 . . . . 0.0 110.91 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.71 -163.33 35.69 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.562 ' HE1' HD11 ' A' ' 145' ' ' ILE . 45.4 m-85 -133.22 161.82 33.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.784 0.326 . . . . 0.0 110.94 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.563 HD12 ' CE2' ' A' ' 133' ' ' PHE . 10.2 mt -148.63 137.51 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 113' ' ' ASN . 32.8 m -106.15 143.14 34.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.456 ' CD2' ' CB ' ' A' ' 166' ' ' SER . 39.2 m-85 -111.23 176.14 5.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.4 tt0 -77.67 -44.83 26.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.896 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . 0.467 ' CB ' ' HG2' ' A' ' 165' ' ' GLN . 0.9 OUTLIER -121.54 128.56 52.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -42.02 -23.77 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.467 ' HG2' ' CB ' ' A' ' 163' ' ' ASP . 5.4 pt20 -48.51 -53.4 18.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.921 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.456 ' CB ' ' CD2' ' A' ' 161' ' ' PHE . 5.1 m -49.26 -55.95 10.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.846 -179.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 171' ' ' VAL . 53.3 t -37.68 -55.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.078 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . 0.426 ' C ' ' OD1' ' A' ' 168' ' ' ASP . 0.6 OUTLIER -62.13 -46.3 89.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.874 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -52.0 -52.51 50.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -63.49 -56.45 15.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.075 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 167' ' ' VAL . 43.2 t -44.63 -55.83 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -38.07 -67.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 83.4 mtp -48.38 -46.29 36.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 19.0 t-160 62.04 26.89 16.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 9.2 m-85 -171.31 150.83 2.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.855 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 63.4 m-70 -156.7 151.38 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.849 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -107.67 98.98 8.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.888 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.851 HD12 HG21 ' A' ' 183' ' ' VAL . 71.0 mt -119.89 122.08 67.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.444 ' SD ' ' C ' ' A' ' 123' ' ' ASN . 12.4 mtt 54.67 41.58 31.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.05 42.65 99.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 15.2 tptp -148.92 148.65 30.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.826 0.346 . . . . 0.0 110.923 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 7.6 tppt? -88.34 107.21 18.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.906 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.851 HG21 HD12 ' A' ' 178' ' ' ILE . 3.3 t -95.45 112.38 27.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.174 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -74.87 149.48 39.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.807 HG22 HG22 ' A' ' 117' ' ' VAL . 46.3 t -147.13 136.09 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 15.0 mtmm -139.89 151.66 45.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.893 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -65.25 125.1 23.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.915 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.09 9.56 6.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.084 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -89.82 150.07 43.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.63 0.729 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 159.82 51.97 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.691 2.261 . . . . 0.0 112.33 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 3.7 mmp_? -56.04 154.27 7.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.421 ' OD1' ' N ' ' A' ' 192' ' ' ASP . 0.4 OUTLIER -70.87 147.14 49.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 7.7 t -133.77 146.05 50.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.876 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.8 mmmm -41.31 152.97 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.891 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 16.7 t -159.52 163.72 34.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 48.9 m -102.71 107.21 18.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 79.56 -169.41 53.49 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.77 -46.86 1.07 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.65 2.233 . . . . 0.0 112.401 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 4.4 m -110.89 169.75 8.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 34.9 p -146.98 177.24 9.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.265 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.995 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.3 t -164.95 132.38 3.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 110.873 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.0 t -78.21 109.62 12.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -95.73 88.23 1.05 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 53.3 p -41.54 126.97 3.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.895 0.379 . . . . 0.0 110.827 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 18.7 t -118.98 -56.53 2.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -67.96 -174.38 8.06 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.481 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.7 t -95.87 -52.96 3.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.939 0.399 . . . . 0.0 110.876 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.4 tmmm? -161.7 119.73 2.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.904 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 49.5 p -155.3 132.02 10.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.869 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -116.34 39.53 3.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.893 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -88.45 146.6 25.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.76 HG22 HG13 ' A' ' 167' ' ' VAL . 21.1 pt -132.29 146.64 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.141 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -89.74 111.98 23.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.928 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 185' ' ' VAL . 83.6 t -108.72 114.88 47.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.103 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -119.24 -173.29 15.47 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.69 24.14 31.56 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 121' ' ' PRO . 63.0 mt -69.48 138.19 88.76 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.668 0.747 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.641 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.7 Cg_endo -69.73 170.33 16.79 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.731 2.287 . . . . 0.0 112.35 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -86.91 24.17 1.57 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -133.63 -33.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.434 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.9 t -66.9 117.79 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.894 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -118.47 -175.73 16.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.457 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -42.69 -56.17 3.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 0.0 110.856 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 86.7 m -51.3 -57.69 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 mm-40 -51.73 -52.95 44.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.876 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.528 HD22 HD11 ' A' ' 159' ' ' ILE . 85.9 mt -44.54 -48.18 10.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.964 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.564 ' HG2' HG11 ' A' ' 139' ' ' VAL . 69.5 mtt180 -69.66 -55.07 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -45.45 -23.98 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.572 ' CD2' HG12 ' A' ' 178' ' ' ILE . 4.3 t80 -103.68 -35.2 8.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.582 ' CE2' HD12 ' A' ' 159' ' ' ILE . 23.7 m-85 -90.33 16.22 9.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -95.23 -23.64 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -71.19 -35.23 71.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.471 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 34.9 m-85 -68.41 -32.59 72.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.77 -111.56 0.29 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.476 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 75.7 t -146.35 110.24 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.837 0.351 . . . . 0.0 111.152 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.564 HG11 ' HG2' ' A' ' 130' ' ' ARG . 93.0 t -72.89 106.05 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.146 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.8 p -79.46 -39.71 31.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -144.73 156.43 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.409 HG11 HD12 ' A' ' 129' ' ' LEU . 96.1 t -134.8 102.56 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.111 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.5 143.53 11.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 4.5 mtt -145.44 139.03 26.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.872 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.443 HD11 ' HE1' ' A' ' 158' ' ' PHE . 75.4 mt -107.9 136.22 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.15 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.464 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.91 165.34 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.934 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 148' ' ' ALA . 37.9 t0 -86.19 114.29 22.9 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.87 -61.52 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 148' ' ' ALA . 28.3 tt0 -36.08 -46.01 0.47 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 27.6 mttp -80.08 -40.29 27.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 60.0 48.27 8.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.1 ttp180 -158.98 138.8 8.65 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.609 0.719 . . . . 0.0 110.884 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 109.92 2.43 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.271 . . . . 0.0 112.334 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.8 mtt180 -50.17 -50.6 48.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.843 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 159.89 39.89 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -169.0 161.98 10.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.882 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.429 ' C ' ' CD1' ' A' ' 158' ' ' PHE . . . 163.15 -150.2 18.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.469 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.443 ' HE1' HD11 ' A' ' 145' ' ' ILE . 11.3 m-85 -147.72 169.82 18.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.882 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.582 HD12 ' CE2' ' A' ' 133' ' ' PHE . 23.0 mt -151.13 141.81 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.103 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.2 m -106.95 142.27 36.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.15 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.577 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 50.1 m-85 -113.83 169.35 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -77.33 -38.37 50.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -130.05 136.57 49.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.857 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 165' ' ' GLN . 8.6 tm-20 -45.67 -45.37 14.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.924 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 164' ' ' GLU . 26.3 tt0 -35.29 -47.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.577 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 42.9 m -53.15 -54.07 41.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.847 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.76 HG13 HG22 ' A' ' 115' ' ' ILE . 53.3 t -43.88 -45.46 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -65.65 -45.49 82.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . 0.471 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 44.3 mm-40 -48.48 -45.42 36.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -76.43 -59.79 2.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.633 HG21 ' HG3' ' A' ' 187' ' ' ARG . 86.4 t -43.12 -51.4 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.14 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -39.71 -63.2 0.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.891 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 15.3 mtm -59.31 -38.33 80.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.537 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 15.0 t-160 59.27 25.46 14.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.473 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 6.9 m-85 -169.82 153.14 4.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.836 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.473 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 62.8 m-70 -159.2 159.42 34.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -116.49 90.31 3.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 183' ' ' VAL . 51.3 mt -105.69 111.78 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 7.4 mtt 61.84 42.33 10.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 64.41 47.13 87.57 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.453 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.404 ' CE ' ' HB3' ' A' ' 121' ' ' PRO . 12.2 tppt? -151.47 140.29 20.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.894 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -84.83 102.94 13.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.92 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -92.99 132.86 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.169 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -92.54 144.95 24.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.877 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.875 HG22 HG22 ' A' ' 117' ' ' VAL . 32.6 t -141.15 131.34 26.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -143.45 141.53 30.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.633 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.2 mtm105 -45.79 115.93 1.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.826 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -76.19 128.64 35.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.076 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -48.42 153.47 1.32 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 131.5 21.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.71 2.274 . . . . 0.0 112.366 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 26.2 ttm180 -75.88 100.75 4.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.849 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -115.98 87.14 2.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.7 t -131.29 121.0 23.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.822 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 2.4 ttmm -104.06 156.76 17.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.898 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 50.9 m -149.87 176.91 10.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 51.6 p -117.71 -40.97 2.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.851 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -171.25 -148.79 6.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -0.64 7.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.659 2.239 . . . . 0.0 112.316 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 37.2 m -50.57 135.33 23.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 69.7 m -91.42 -53.14 4.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 179.986 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.413 ' O ' ' C ' ' A' ' 104' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 103' ' ' GLY . 20.9 m -36.45 123.09 0.78 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.911 0.386 . . . . 0.0 110.843 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.8 p -41.6 126.14 2.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -117.7 148.51 18.67 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.452 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.9 m -79.12 90.65 4.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.854 0.359 . . . . 0.0 110.847 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 74.4 p -47.14 169.07 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 158.08 -83.23 0.14 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.486 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 7.4 t -79.4 111.12 15.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.89 0.376 . . . . 0.0 110.807 -179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.3 ttmt -105.66 110.59 22.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.86 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.4 p -101.92 108.06 19.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.835 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -113.14 39.58 2.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 ttpp -92.97 140.99 28.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.622 HG22 HG13 ' A' ' 167' ' ' VAL . 28.2 pt -124.49 151.15 29.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.143 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -98.44 108.37 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.912 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 185' ' ' VAL . 95.4 t -101.21 121.8 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.15 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -128.7 175.72 18.58 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.67 13.34 60.92 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.561 HG23 ' HD2' ' A' ' 121' ' ' PRO . 31.2 mt -61.87 137.15 95.26 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.718 . . . . 0.0 111.142 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.561 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.74 163.52 37.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.691 2.261 . . . . 0.0 112.344 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -77.44 1.35 19.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -106.65 -23.72 12.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.477 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 14.0 t -79.85 133.39 36.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -128.77 -165.59 11.79 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.593 ' HG3' HG11 ' A' ' 142' ' ' VAL . 38.2 tt0 -52.57 -68.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 34.9 m -38.69 -67.8 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.13 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 17.5 mp0 -38.68 -61.33 0.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 ' CE ' ' A' ' 144' ' ' MET . 73.7 mt -40.68 -46.56 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.909 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.482 ' HA ' HG21 ' A' ' 139' ' ' VAL . 14.3 mtp-105 -70.0 -52.3 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -51.92 -23.94 5.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -100.24 -30.21 12.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.531 ' CD2' HD12 ' A' ' 159' ' ' ILE . 14.1 m-85 -94.24 13.75 22.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -94.03 -13.75 26.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.0 pttm -79.83 -37.54 34.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -68.62 -33.9 74.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.98 -116.33 0.38 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.474 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 36.1 t -146.16 106.31 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.879 0.371 . . . . 0.0 111.152 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 130' ' ' ARG . 39.0 t -68.12 115.26 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.094 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 41.8 p -95.94 -39.0 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -133.59 144.06 49.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.593 HG11 ' HG3' ' A' ' 126' ' ' GLU . 72.6 t -130.34 94.44 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.129 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 86.0 t -88.7 141.52 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.116 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.511 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 7.6 mtt -140.58 137.1 33.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 63.9 mt -99.89 126.81 53.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.442 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -167.07 165.42 15.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.917 -179.984 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.441 ' O ' ' C ' ' A' ' 148' ' ' ALA . 19.2 t0 -85.33 113.58 21.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.865 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.44 -59.13 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.077 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -41.39 -42.88 2.38 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.92 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.427 ' N ' ' O ' ' A' ' 147' ' ' ASP . 19.4 mttp -79.25 -41.08 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 60.01 50.14 6.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.442 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 6.0 ttm-85 -162.88 138.02 5.2 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.598 0.713 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.511 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.76 112.12 2.99 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.748 2.298 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 67.5 mtp180 -52.65 -57.03 11.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.845 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 169.5 40.54 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.422 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.5 p90 -171.69 165.54 6.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.856 0.36 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 163.98 -153.97 24.61 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 59.6 m-85 -143.94 160.6 40.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.915 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.531 HD12 ' CD2' ' A' ' 133' ' ' PHE . 7.8 mt -148.42 135.93 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.9 m -103.87 142.98 33.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -112.22 168.39 9.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 58.4 tt0 -69.75 -38.65 76.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -131.1 143.68 50.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 165' ' ' GLN . 11.4 tt0 -50.66 -44.31 57.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.417 ' C ' ' O ' ' A' ' 164' ' ' GLU . 34.5 tt0 -36.1 -52.67 0.78 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.1 m -46.37 -55.68 6.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.622 HG13 HG22 ' A' ' 115' ' ' ILE . 40.6 t -38.48 -56.57 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.13 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -52.87 -59.09 4.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -39.12 -38.3 0.47 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.931 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.457 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -77.6 -65.37 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.111 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.66 HG21 ' HG3' ' A' ' 187' ' ' ARG . 84.1 t -43.98 -55.41 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.129 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.451 ' C ' ' O ' ' A' ' 171' ' ' VAL . 0.7 OUTLIER -34.48 -59.48 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.865 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 60.1 mtp -65.33 -35.18 80.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.515 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.6 t-160 54.69 27.39 8.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.515 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 12.7 m-85 -167.89 152.21 6.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.836 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 86.1 m-70 -159.8 147.61 16.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.854 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -103.73 99.24 9.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.81 HD12 HG21 ' A' ' 183' ' ' VAL . 58.0 mt -120.66 124.35 72.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.165 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.4 mmt 57.03 34.89 25.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.814 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 67.15 48.84 57.24 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 5.1 tmtm? -161.01 150.21 16.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . 0.461 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -83.02 126.46 32.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.81 HG21 HD12 ' A' ' 178' ' ' ILE . 5.5 t -114.19 110.87 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.121 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -70.94 143.97 50.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.792 HG22 HG22 ' A' ' 117' ' ' VAL . 40.0 t -143.34 131.31 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.161 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.0 mmmt -145.61 144.06 30.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.933 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.66 ' HG3' HG21 ' A' ' 171' ' ' VAL . 14.0 mtp180 -48.17 125.43 9.26 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.73 -179.68 7.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.109 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -99.88 149.79 36.27 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.641 0.734 . . . . 0.0 110.863 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 141.51 45.43 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.56 -65.2 1.04 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.838 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 34.1 t0 -87.0 107.17 18.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 85.1 p -92.87 112.03 23.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.858 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.49 140.53 29.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.912 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 77.6 p -90.96 172.43 8.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.853 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 45.9 m -108.76 172.22 6.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -79.11 -78.29 0.86 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 126.48 13.36 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.721 2.281 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 3.8 m -67.99 -48.21 66.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 3.9 t -96.61 147.55 23.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.89 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.474 -179.963 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 51.4 p -105.35 171.62 7.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.883 0.373 . . . . 0.0 110.859 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 17.3 m -112.67 99.69 8.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.859 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -111.83 112.31 3.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.525 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 69.5 m 62.86 41.3 8.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 m -110.53 81.76 1.49 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 136.61 148.95 5.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.462 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.3 t -110.07 164.79 12.28 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.99 0.424 . . . . 0.0 110.845 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.2 mtmm 50.55 50.24 19.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.929 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 m -102.31 -23.18 14.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 58.71 40.6 23.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 188' ' ' ALA . 4.4 ttpm? -104.12 143.7 32.57 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.848 HG22 HG13 ' A' ' 167' ' ' VAL . 22.5 pt -125.75 155.37 35.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -103.38 104.48 14.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 185' ' ' VAL . 79.1 t -99.4 118.85 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -124.54 -172.53 13.59 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.477 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 56.28 17.78 19.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.479 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.634 HG23 ' HD2' ' A' ' 121' ' ' PRO . 51.4 mt -64.7 138.31 97.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.68 0.752 . . . . 0.0 111.101 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.5 Cg_endo -69.69 165.62 30.27 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.485 ' ND1' ' NH2' ' A' ' 152' ' ' ARG . 63.9 m-70 -80.58 13.91 2.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.434 ' C ' ' HG3' ' A' ' 179' ' ' MET . 3.3 m120 -122.02 -25.1 5.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.453 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -74.74 133.48 42.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.28 -161.06 10.09 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.508 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.13 -63.52 1.23 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.942 0.401 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 64.1 m -44.49 -59.17 2.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.142 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.44 ' O ' ' C ' ' A' ' 129' ' ' LEU . 57.1 mm-40 -50.35 -63.91 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 128' ' ' GLU . 50.0 mt -34.91 -52.39 0.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.447 ' O ' ' N ' ' A' ' 134' ' ' LYS . 62.7 mtp180 -66.19 -54.15 28.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.864 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 44.2 mm-40 -48.16 -26.5 1.92 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.483 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 16.7 t80 -100.79 -21.79 15.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -105.79 14.45 28.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.447 ' N ' ' O ' ' A' ' 130' ' ' ARG . 15.5 pttp -94.81 -17.56 22.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.37 -37.98 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -65.17 -34.36 78.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.17 -114.61 0.31 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.43 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 37.5 t -148.1 109.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.834 0.35 . . . . 0.0 111.172 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.418 HG11 ' HG2' ' A' ' 130' ' ' ARG . 47.3 t -74.55 105.99 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 34.0 p -81.21 -33.05 33.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.12 153.2 37.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.411 HG21 ' CG ' ' A' ' 130' ' ' ARG . 95.6 t -131.34 105.97 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' A' ' 158' ' ' PHE . 49.0 t -91.73 143.16 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.405 ' HE3' HD11 ' A' ' 129' ' ' LEU . 7.1 mtt -143.34 133.71 24.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.887 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 158' ' ' PHE . 63.2 mt -97.09 139.82 18.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.449 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -175.05 165.88 3.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.926 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.432 ' O ' ' C ' ' A' ' 148' ' ' ALA . 35.4 t0 -86.67 110.07 19.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.432 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -34.23 -57.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' ALA . 30.7 tt0 -37.06 -45.35 0.59 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.91 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.33 -37.14 20.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 60.05 52.79 4.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.485 ' NH2' ' ND1' ' A' ' 122' ' ' HIS . 2.1 ttt85 -160.86 138.9 7.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.646 0.736 . . . . 0.0 110.869 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 117.86 5.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.669 2.246 . . . . 0.0 112.355 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -61.1 -54.27 46.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.14 41.49 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.536 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -173.13 162.46 4.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.19 -153.47 23.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.557 ' HE1' HD11 ' A' ' 145' ' ' ILE . 53.9 m-85 -139.96 164.5 29.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 21.3 mt -147.13 139.7 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 57.0 m -105.08 142.98 33.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.434 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 46.8 m-85 -115.86 166.35 12.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.903 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -67.39 -42.77 82.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -131.14 141.06 50.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.864 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 165' ' ' GLN . 30.5 tt0 -46.04 -44.39 15.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 164' ' ' GLU . 23.8 tp60 -36.43 -55.67 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.434 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 16.4 m -44.31 -52.41 7.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.848 HG13 HG22 ' A' ' 115' ' ' ILE . 73.4 t -44.65 -54.86 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -52.82 -50.67 63.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 16.1 mm100 -45.86 -50.48 14.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.918 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.06 -53.86 15.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.094 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.84 HG21 ' HG3' ' A' ' 187' ' ' ARG . 70.1 t -44.31 -61.79 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.107 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 171' ' ' VAL . 62.7 t30 -35.61 -56.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 1.3 tpt -58.28 -41.51 84.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.92 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.548 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 15.9 t-160 51.15 30.75 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.551 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 4.9 m-85 -173.35 150.62 1.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 89.1 m-70 -161.9 156.97 23.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -111.04 102.36 10.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.922 HD12 HG21 ' A' ' 183' ' ' VAL . 31.4 mt -129.06 134.91 63.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.15 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.434 ' HG3' ' C ' ' A' ' 123' ' ' ASN . 9.8 mmt 54.83 30.55 13.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.63 45.76 65.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.404 ' NZ ' ' HA ' ' A' ' 121' ' ' PRO . 19.9 ttmt -160.15 161.93 33.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.909 0.385 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.62 125.57 34.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.922 HG21 HD12 ' A' ' 178' ' ' ILE . 2.6 t -110.35 115.02 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.157 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . 0.404 ' HG2' ' CD2' ' A' ' 174' ' ' HIS . 9.4 tt0 -77.32 148.32 35.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.886 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.994 HG22 HG22 ' A' ' 117' ' ' VAL . 41.9 t -146.89 133.12 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 18.4 mttm -139.69 169.75 17.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.84 ' HG3' HG21 ' A' ' 171' ' ' VAL . 13.9 mtp180 -78.3 117.25 19.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 114' ' ' LYS . . . -86.0 16.89 3.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.1 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -123.47 152.46 64.8 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.612 0.72 . . . . 0.0 110.901 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 165.1 32.12 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.689 2.259 . . . . 0.0 112.341 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.44 ' O ' ' C ' ' A' ' 192' ' ' ASP . 2.4 tmm_? -70.01 132.04 45.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.44 ' C ' ' O ' ' A' ' 191' ' ' ARG . 26.2 t70 -35.17 148.28 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.858 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.2 m -98.02 120.53 38.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.851 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -75.45 138.67 41.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.906 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 2.9 t -132.96 153.88 51.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.798 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 39.6 t -116.33 150.95 36.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.893 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 116.81 141.6 7.09 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.68 117.38 5.05 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.72 2.28 . . . . 0.0 112.315 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 67.0 m -131.64 86.0 2.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 2.8 m -69.97 -50.81 38.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.491 -179.97 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.416 ' O ' ' C ' ' A' ' 104' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 105' ' ' SER . 33.7 m -36.6 -45.9 0.54 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.893 0.378 . . . . 0.0 110.855 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 104' ' ' SER . 9.7 m -35.21 113.31 0.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -114.75 101.29 1.06 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.518 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.3 t -98.87 38.29 1.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.91 0.386 . . . . 0.0 110.897 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 64.8 m -74.85 82.6 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.832 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 144.23 114.31 0.94 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.522 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.9 t -63.16 177.75 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 110.837 -179.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -83.23 -41.69 18.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.2 t -50.76 108.8 0.26 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 m-20 -86.0 50.51 1.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.864 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -98.33 142.38 30.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.925 HG22 HG13 ' A' ' 167' ' ' VAL . 30.1 pt -125.24 153.05 32.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.09 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.414 ' HA ' ' CD2' ' A' ' 158' ' ' PHE . 30.8 t80 -98.97 105.53 17.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 185' ' ' VAL . 94.4 t -101.92 114.08 40.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.111 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.06 177.02 16.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.531 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.59 13.26 60.62 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.558 HG23 ' HD2' ' A' ' 121' ' ' PRO . 29.7 mt -61.86 137.14 95.24 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.558 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.4 Cg_endo -69.72 165.41 31.02 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.354 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.7 m-70 -78.68 0.65 25.76 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.827 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.437 ' ND2' ' HB2' ' A' ' 121' ' ' PRO . 0.2 OUTLIER -106.04 -23.8 12.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.889 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.486 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 22.4 t -81.16 133.1 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -131.73 -166.81 11.72 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.431 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.463 ' HG2' ' CZ ' ' A' ' 130' ' ' ARG . 12.4 tt0 -54.21 -59.96 3.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.874 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 35.9 m -45.78 -61.78 1.58 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.17 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 129' ' ' LEU . 53.8 mm-40 -47.91 -64.7 0.72 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.441 HD22 ' HE2' ' A' ' 133' ' ' PHE . 62.6 mt -36.22 -58.46 0.68 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.521 ' HG2' HG11 ' A' ' 139' ' ' VAL . 59.7 mtm180 -58.6 -51.06 71.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 37.3 mm-40 -57.29 -17.42 11.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.491 ' CE1' ' HB3' ' A' ' 176' ' ' HIS . 21.5 t80 -108.0 -17.45 14.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.542 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.3 m-85 -104.18 -6.35 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.885 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.5 pttp -76.58 -21.26 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -69.91 -36.32 75.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.869 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -70.55 -32.25 69.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.75 -111.25 0.26 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.545 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 49.0 t -150.05 108.12 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.912 0.387 . . . . 0.0 111.117 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.521 HG11 ' HG2' ' A' ' 130' ' ' ARG . 74.0 t -72.53 104.91 2.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.14 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 25.4 p -81.29 -36.8 29.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.146 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -141.33 154.76 45.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.06 105.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 42.9 t -92.83 137.12 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.436 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 5.2 mtt -137.7 136.79 37.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.904 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.401 HD11 ' HE1' ' A' ' 158' ' ' PHE . 62.7 mt -102.1 135.0 41.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.437 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -173.17 165.44 4.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.973 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 150' ' ' LYS . 48.5 t0 -81.92 113.64 19.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.871 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.409 ' O ' ' HG3' ' A' ' 151' ' ' GLN . . . -37.31 -41.85 0.44 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.09 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -42.78 86.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 147' ' ' ASP . 3.0 mptp? -80.45 -31.41 37.45 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 148' ' ' ALA . 6.1 mt-30 52.3 44.01 30.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 7.4 ttm-85 -155.51 138.68 10.77 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.672 0.749 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.436 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 54.4 Cg_endo -69.77 111.01 2.7 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.655 2.237 . . . . 0.0 112.37 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.419 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 36.0 mtt180 -52.34 -53.08 49.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 163.73 40.73 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.419 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 35.6 p90 -169.29 163.85 10.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.931 0.396 . . . . 0.0 110.866 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 161.67 -157.87 29.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.506 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.414 ' CD2' ' HA ' ' A' ' 116' ' ' PHE . 12.5 m-85 -139.51 169.98 16.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.542 HD12 ' CE2' ' A' ' 133' ' ' PHE . 12.6 mt -152.68 136.68 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 19.2 m -105.03 135.9 45.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.52 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 35.0 m-85 -104.67 174.11 6.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.82 -40.32 48.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -127.55 137.54 52.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 165' ' ' GLN . 16.1 tm-20 -44.64 -45.71 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 164' ' ' GLU . 7.0 tp60 -36.99 -55.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.904 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.52 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 13.1 m -45.58 -49.34 14.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.925 HG13 HG22 ' A' ' 115' ' ' ILE . 71.0 t -48.81 -47.17 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.091 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -62.88 -49.35 75.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 31.5 mm-40 -47.82 -48.5 30.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -74.33 -43.95 54.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.62 HG23 ' O ' ' A' ' 167' ' ' VAL . 25.6 t -55.36 -62.35 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 171' ' ' VAL . 2.1 t-20 -36.76 -55.67 0.87 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 98.2 mtp -55.12 -44.0 74.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.879 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.523 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 17.4 t-160 58.31 25.14 12.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.885 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.523 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.3 m-85 -169.65 152.62 4.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.85 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.491 ' HB3' ' CE1' ' A' ' 132' ' ' TYR . 85.3 m-70 -158.5 154.15 26.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.806 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.63 93.8 4.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.856 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.933 HD12 HG21 ' A' ' 183' ' ' VAL . 59.2 mt -110.39 115.43 49.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 11.9 mtp 60.87 36.13 19.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.898 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 68.79 50.49 35.52 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.492 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.464 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.6 tmtt? -158.01 146.96 19.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.864 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . 0.464 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 0.1 OUTLIER -85.03 117.12 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.94 179.838 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.933 HG21 HD12 ' A' ' 178' ' ' ILE . 5.6 t -106.31 118.88 54.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.15 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -76.0 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.982 HG22 HG22 ' A' ' 117' ' ' VAL . 44.6 t -146.65 127.4 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt -135.76 146.45 47.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 19.7 ttp180 -55.69 108.93 0.49 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.881 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -67.49 142.21 56.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.135 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -85.64 152.57 57.35 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.674 0.75 . . . . 0.0 110.896 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 119.67 6.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.713 2.275 . . . . 0.0 112.354 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 13.2 mmm180 -73.51 92.65 1.91 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -166.44 120.96 1.12 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 54.2 p -90.64 48.89 1.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.825 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 28.5 mtmt 55.59 43.84 27.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.936 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 11.8 t -44.41 124.19 3.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.892 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 29.9 t -99.1 121.37 40.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.841 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -133.91 145.34 17.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.456 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 104.93 1.4 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.722 2.281 . . . . 0.0 112.303 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.2 m -164.72 127.12 2.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 29.8 m -113.84 138.38 50.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.492 -179.973 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 t 50.47 42.2 26.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.871 0.367 . . . . 0.0 110.829 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 m -68.77 97.9 0.86 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -98.9 108.64 3.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.504 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 5.0 t -75.0 147.12 41.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.878 0.37 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 65.1 p -93.74 -42.51 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.889 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 53.84 -147.76 19.37 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.501 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 78.7 p -135.23 143.98 46.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.983 0.421 . . . . 0.0 110.847 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 11.7 pttt -59.25 99.73 0.06 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.945 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.1 m -149.46 -175.39 4.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.889 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -80.74 55.34 2.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -110.84 150.86 28.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.417 HG22 HG13 ' A' ' 167' ' ' VAL . 21.9 pt -131.85 154.05 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.135 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 10.2 t80 -102.73 103.42 13.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 185' ' ' VAL . 86.2 t -97.76 115.87 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.97 174.24 16.04 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.95 26.02 71.08 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.485 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.624 HG23 ' HD2' ' A' ' 121' ' ' PRO . 52.7 mt -73.17 138.22 78.84 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.634 0.731 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.624 ' HD2' HG23 ' A' ' 120' ' ' ILE . 54.0 Cg_endo -69.77 158.76 55.84 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.72 3.43 6.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -106.89 -37.14 6.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.544 ' SG ' HG21 ' A' ' 178' ' ' ILE . 44.0 t -67.68 136.95 55.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.429 ' H ' ' CG ' ' A' ' 128' ' ' GLU . . . -135.66 179.54 17.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 125' ' ' GLY . 24.0 tt0 -35.75 -69.68 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.4 m -40.84 -60.0 1.28 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.159 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.429 ' CG ' ' H ' ' A' ' 125' ' ' GLY . 49.1 mm-40 -44.74 -64.77 0.63 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.55 HD11 ' HE3' ' A' ' 144' ' ' MET . 65.7 mt -35.92 -47.04 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.523 ' HA ' HG21 ' A' ' 139' ' ' VAL . 36.7 mtm180 -67.38 -60.75 2.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.866 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -41.81 -25.69 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.417 ' N ' ' O ' ' A' ' 130' ' ' ARG . 11.6 t80 -102.77 -24.18 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.584 ' CE2' HD12 ' A' ' 159' ' ' ILE . 12.8 m-85 -99.74 16.3 24.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.923 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 3.9 ptpp? -95.31 -14.79 23.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -79.09 -37.68 38.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.896 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.416 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 39.0 m-85 -67.65 -25.06 65.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 177.06 -114.69 0.48 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 96.3 t -145.73 111.56 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.097 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.523 HG21 ' HA ' ' A' ' 130' ' ' ARG . 15.6 t -74.53 114.46 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 42.8 p -93.01 -37.29 12.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.75 152.72 45.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -135.02 100.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 81.4 t -84.98 143.2 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.109 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.55 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.2 mtt -144.29 132.61 21.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.476 HD11 ' HE1' ' A' ' 158' ' ' PHE . 68.4 mt -98.49 134.64 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.45 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -172.84 164.56 5.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.96 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' ALA . 24.3 t0 -85.35 115.6 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.422 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -35.65 -57.32 0.65 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -42.67 -41.9 3.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.412 ' N ' ' O ' ' A' ' 147' ' ' ASP . 16.3 ttmt -80.14 -41.18 25.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 60.08 50.41 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.45 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 8.2 ttp85 -164.99 138.93 4.0 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.618 0.723 . . . . 0.0 110.843 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.428 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 54.1 Cg_endo -69.77 109.64 2.36 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.734 2.289 . . . . 0.0 112.357 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 32.5 mtp180 -49.58 -51.43 37.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 162.05 39.46 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.499 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -171.2 159.83 6.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 167.82 -155.08 25.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.476 ' HE1' HD11 ' A' ' 145' ' ' ILE . 51.2 m-85 -139.62 161.45 37.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 133' ' ' PHE . 14.7 mt -145.0 141.56 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 42.5 m -109.43 141.03 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.173 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.508 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 51.9 m-85 -110.42 177.95 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -80.3 -40.31 27.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.871 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -127.85 146.41 50.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.807 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 165' ' ' GLN . 43.1 tp10 -51.58 -47.05 63.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 164' ' ' GLU . 40.0 tt0 -36.63 -44.97 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.508 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 14.6 m -53.49 -47.93 69.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.883 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.417 HG13 HG22 ' A' ' 115' ' ' ILE . 37.6 t -51.3 -46.95 34.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.173 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -51.03 -65.73 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.867 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 41.7 mt-30 -42.95 -53.58 4.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.627 ' HB1' HG11 ' A' ' 185' ' ' VAL . . . -52.04 -45.48 64.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.045 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.8 HG21 ' HG3' ' A' ' 187' ' ' ARG . 93.5 t -70.0 -63.88 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.109 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 171' ' ' VAL . 8.3 m-20 -34.16 -43.99 0.17 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 5.2 ttt -68.36 -47.27 67.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.54 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 12.0 t-160 56.85 27.22 12.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.824 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.54 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.0 m-85 -174.18 151.45 1.67 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.459 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 72.0 m-70 -158.87 161.49 36.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -117.0 87.15 2.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.857 HD12 HG21 ' A' ' 183' ' ' VAL . 63.7 mt -106.61 126.41 62.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.111 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.409 ' HG2' HG22 ' A' ' 178' ' ' ILE . 3.8 mmt 52.36 40.12 28.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.69 47.67 87.34 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.416 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 2.5 tmtt? -155.07 146.93 23.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.808 0.337 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . 0.416 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 6.2 tptm -81.18 117.38 21.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.888 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.857 HG21 HD12 ' A' ' 178' ' ' ILE . 2.9 t -109.41 120.55 60.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -80.45 153.47 28.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.736 HG22 HG22 ' A' ' 117' ' ' VAL . 41.4 t -149.48 130.96 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -141.46 144.26 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.91 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.8 ' HG3' HG21 ' A' ' 171' ' ' VAL . 8.7 mtm180 -45.93 124.44 5.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.861 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -83.31 11.97 6.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -82.07 151.2 66.42 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.616 0.722 . . . . 0.0 110.9 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.7 127.9 15.32 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.706 2.271 . . . . 0.0 112.374 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 24.4 mmt180 -75.91 100.99 5.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -174.87 172.49 2.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 95.9 p -100.69 114.11 27.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 6.4 ptpp? -79.9 173.07 12.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 3.0 m -118.41 -58.13 2.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.906 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 46.9 t -144.97 117.98 8.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.864 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -98.56 -148.54 23.65 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 112.91 3.22 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.653 2.235 . . . . 0.0 112.359 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 19.8 m -56.0 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 4.2 t -39.47 149.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.809 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.491 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.1 p -122.95 91.09 3.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.914 0.388 . . . . 0.0 110.832 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 49.2 m -117.96 83.99 2.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.78 -104.06 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.533 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.0 p -139.99 139.07 35.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.899 0.38 . . . . 0.0 110.855 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -158.05 175.95 13.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -57.18 -175.26 0.31 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 72.7 p -118.49 -35.25 3.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.965 0.412 . . . . 0.0 110.88 -179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.82 146.92 2.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 70.6 p -99.3 114.92 28.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.869 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -90.64 40.2 1.01 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.9 ttpt -97.01 139.1 33.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.939 HG22 HG13 ' A' ' 167' ' ' VAL . 20.0 pt -123.42 154.59 29.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -99.65 103.65 15.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 185' ' ' VAL . 93.2 t -100.41 111.7 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.02 -173.05 15.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.506 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 58.42 12.81 14.1 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.481 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.65 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.7 mt -57.3 138.42 80.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.653 0.74 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.65 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.9 Cg_endo -69.76 172.42 12.67 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.35 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.449 ' O ' ' NH2' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -85.0 17.89 2.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.823 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -128.29 -29.8 2.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.866 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.456 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 9.2 t -68.06 128.77 37.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 126' ' ' GLU . . . -135.53 173.11 21.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.452 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.444 ' C ' ' O ' ' A' ' 125' ' ' GLY . 29.9 tt0 -34.34 -65.87 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.892 0.377 . . . . 0.0 110.873 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 99.7 m -40.85 -61.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 129' ' ' LEU . 5.5 mp0 -54.31 -60.58 3.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.644 HD11 ' HE3' ' A' ' 144' ' ' MET . 59.9 mt -34.39 -45.92 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HA ' HG21 ' A' ' 139' ' ' VAL . 26.6 mtt180 -70.38 -55.75 8.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -46.5 -24.75 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.56 ' CD2' HG12 ' A' ' 178' ' ' ILE . 5.1 t80 -100.95 -29.78 12.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.576 ' CE2' HD12 ' A' ' 159' ' ' ILE . 19.7 m-85 -96.17 15.45 20.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.3 ptpt -95.27 -25.07 16.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.906 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.1 pttm -69.44 -38.83 77.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.867 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -66.02 -31.36 72.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -174.94 -115.24 0.4 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 54.5 t -146.13 106.42 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.882 0.373 . . . . 0.0 111.088 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.452 HG21 ' HA ' ' A' ' 130' ' ' ARG . 22.9 t -71.22 109.4 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.088 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 20.1 p -85.92 -39.78 16.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -139.84 151.98 46.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.9 t -134.01 102.46 4.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.137 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 158' ' ' PHE . 98.6 t -87.33 145.27 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.644 ' HE3' HD11 ' A' ' 129' ' ' LEU . 6.7 mtt -145.58 133.75 21.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.816 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.38 139.63 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.456 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -174.88 167.03 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 180.0 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 148' ' ' ALA . 23.4 t0 -87.16 112.49 22.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.891 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.09 -60.0 0.34 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -39.38 -44.69 1.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 147' ' ' ASP . 21.1 tttm -79.43 -40.13 30.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.92 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 60.05 45.08 12.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.456 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.8 ttt180 -155.37 138.21 10.48 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.654 0.74 . . . . 0.0 110.848 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 116.02 4.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.675 2.25 . . . . 0.0 112.371 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 41.6 mtp180 -58.67 -56.87 16.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 166.03 42.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.473 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -173.23 158.17 3.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.92 0.391 . . . . 0.0 110.866 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 166.55 -151.44 19.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.489 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . 0.4 ' O ' ' O ' ' A' ' 143' ' ' VAL . 86.7 m-85 -138.36 164.69 28.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.823 0.344 . . . . 0.0 110.894 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.576 HD12 ' CE2' ' A' ' 133' ' ' PHE . 19.5 mt -148.31 134.12 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 17.9 m -102.34 143.13 32.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.159 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 41.5 m-85 -113.19 174.46 5.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.825 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -74.32 -38.76 63.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -135.17 151.38 50.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.855 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 165' ' ' GLN . 23.3 tt0 -51.9 -50.69 60.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.441 ' C ' ' O ' ' A' ' 164' ' ' GLU . 31.6 tp60 -34.54 -54.83 0.54 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.545 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 18.6 m -41.54 -58.71 1.83 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.86 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.939 HG13 HG22 ' A' ' 115' ' ' ILE . 62.2 t -42.27 -54.87 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.105 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 169' ' ' GLN . 27.5 t0 -47.14 -62.53 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 168' ' ' ASP . 49.1 mt-30 -36.98 -51.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.882 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.79 -67.55 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.448 ' O ' ' C ' ' A' ' 172' ' ' ASN . 98.8 t -39.36 -58.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 171' ' ' VAL . 10.9 t30 -34.44 -56.53 0.52 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 85.3 mtp -61.55 -45.02 95.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 175' ' ' PHE . 14.3 t-160 62.01 25.97 15.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 4.3 m-85 -172.85 147.5 1.71 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -156.62 164.56 38.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.87 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -118.76 90.96 3.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.666 HD12 HG21 ' A' ' 183' ' ' VAL . 67.9 mt -111.06 119.23 59.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.151 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 5.5 mmt 60.07 39.63 19.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 62.44 54.64 32.69 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.436 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 7.7 tppt? -163.23 145.51 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.367 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . . . . . . . . . 11.7 tptt -82.54 109.0 16.36 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.902 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.666 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -97.07 127.46 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -87.65 140.09 29.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.968 HG22 HG22 ' A' ' 117' ' ' VAL . 25.4 t -139.2 136.33 41.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 24.6 mtmt -144.71 175.0 10.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.866 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.429 ' CG ' HG21 ' A' ' 171' ' ' VAL . 8.4 mtp180 -81.17 120.39 24.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.875 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -82.98 174.92 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -97.7 153.45 38.27 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.611 0.72 . . . . 0.0 110.944 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 0.0 6.29 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.663 2.242 . . . . 0.0 112.355 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? 54.93 48.36 20.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.905 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.421 ' O ' ' CG ' ' A' ' 192' ' ' ASP . 0.6 OUTLIER -119.31 116.54 26.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.865 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 22.1 t -117.47 88.15 2.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.834 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 32.7 tttp 40.59 41.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.918 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 1.4 t -64.03 102.24 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.886 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 2.1 t -108.16 115.93 31.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.829 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -162.8 -157.72 9.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 97.0 0.61 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.706 2.271 . . . . 0.0 112.367 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 80.7 p -106.31 43.96 1.1 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.825 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 64.3 m -56.63 157.17 5.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.869 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 179.99 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.2 t -73.05 87.46 1.37 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.889 0.376 . . . . 0.0 110.878 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -79.91 94.83 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -113.76 127.11 7.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.496 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 61.6 m -99.24 -56.99 2.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.92 0.391 . . . . 0.0 110.835 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 9.3 t -45.84 -60.71 2.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -48.79 -60.8 5.69 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.527 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 89.9 p -97.38 112.68 24.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.965 0.412 . . . . 0.0 110.896 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 4.0 mtmp? -90.08 130.23 36.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 7.3 t -124.72 126.54 45.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 -87.47 43.14 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -89.58 142.55 27.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.977 HG22 HG13 ' A' ' 167' ' ' VAL . 18.7 pt -128.12 148.04 32.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.151 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -93.96 114.61 26.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 185' ' ' VAL . 81.2 t -111.1 117.16 54.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.115 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -123.61 176.7 16.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.519 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.39 24.72 69.41 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.636 HG23 ' HD2' ' A' ' 121' ' ' PRO . 57.0 mt -71.87 138.48 82.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.617 0.722 . . . . 0.0 111.142 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.636 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.4 Cg_endo -69.78 165.35 31.31 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -78.96 10.99 2.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.87 -34.48 4.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.479 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 34.1 t -68.96 121.43 16.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -121.68 -169.29 13.59 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.98 -59.1 3.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 89.1 m -47.24 -61.19 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.127 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HG3' ' CE ' ' A' ' 179' ' ' MET . 65.2 mm-40 -47.67 -65.14 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 128' ' ' GLU . 40.7 mt -34.03 -49.83 0.36 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.944 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -68.72 -53.99 18.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 23.0 mm-40 -46.2 -23.73 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.507 ' CZ ' ' HB3' ' A' ' 176' ' ' HIS . 14.1 t80 -103.56 -34.65 8.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.02 16.86 8.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -95.29 -23.39 17.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.23 -39.04 68.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.94 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -60.56 -35.5 76.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.842 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -173.04 -107.71 0.21 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 93.4 t -152.24 107.9 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.26 107.71 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.133 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 35.5 p -82.08 -37.16 26.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -143.89 154.8 43.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.7 t -134.96 102.81 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 59.7 t -89.33 143.65 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.458 ' HE1' ' CB ' ' A' ' 153' ' ' PRO . 4.1 mtt -144.31 135.92 25.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 64.0 mt -102.26 135.75 37.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.481 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.3 OUTLIER -174.47 164.72 3.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' ALA . 28.8 t0 -85.19 110.4 18.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.857 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.457 ' O ' ' C ' ' A' ' 149' ' ' GLU . . . -34.7 -57.22 0.53 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.066 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.457 ' C ' ' O ' ' A' ' 148' ' ' ALA . 7.9 mm-40 -33.31 -48.32 0.23 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -87.55 -34.93 18.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 5.5 mm-40 59.0 54.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.481 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.9 ttm-85 -158.16 137.65 8.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . 0.458 ' CB ' ' HE1' ' A' ' 144' ' ' MET . 53.8 Cg_endo -69.77 110.18 2.49 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.438 ' HB2' ' CE1' ' A' ' 156' ' ' PHE . 42.1 mtt180 -51.86 -47.63 64.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 157.93 38.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.489 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 154' ' ' ARG . 41.4 p90 -166.52 167.7 15.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.903 0.382 . . . . 0.0 110.907 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 158.3 -156.72 27.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.499 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -139.48 166.92 23.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.933 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.0 mt -149.53 138.98 15.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 27.3 m -106.87 140.53 39.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.142 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . 0.551 ' CD2' ' HB3' ' A' ' 166' ' ' SER . 53.1 m-85 -110.84 176.67 4.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -78.18 -44.42 25.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -124.82 133.45 53.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -41.26 -43.49 2.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -39.24 -47.77 1.7 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.551 ' HB3' ' CD2' ' A' ' 161' ' ' PHE . 70.8 m -50.59 -49.48 56.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.866 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.977 HG13 HG22 ' A' ' 115' ' ' ILE . 78.5 t -47.4 -62.39 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -44.96 -53.98 7.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -46.18 -47.48 17.72 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -69.87 -56.06 8.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.1 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 172' ' ' ASN . 91.1 t -49.78 -61.82 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 171' ' ' VAL . 15.0 t-20 -34.35 -62.88 0.32 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.875 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 24.2 mmm -49.9 -42.73 48.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.514 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 12.9 t-160 56.18 26.03 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.514 ' O ' ' CG ' ' A' ' 176' ' ' HIS . 6.2 m-85 -169.91 154.01 5.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 84.8 m-70 -160.81 153.97 21.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -112.26 89.31 3.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.858 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.959 HD12 HG21 ' A' ' 183' ' ' VAL . 59.6 mt -106.23 109.57 28.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.154 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.468 ' CE ' ' HG3' ' A' ' 128' ' ' GLU . 5.0 mtm 62.14 43.22 8.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 63.69 50.72 59.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.468 ' HD3' ' N ' ' A' ' 182' ' ' LYS . 4.4 tmtt? -155.9 144.83 20.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.846 0.355 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . 0.468 ' N ' ' HD3' ' A' ' 181' ' ' LYS . 9.0 tppt? -87.77 112.74 22.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.959 HG21 HD12 ' A' ' 178' ' ' ILE . 2.8 t -102.79 119.56 51.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.149 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -79.24 140.73 37.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 117' ' ' VAL . 67.4 t -139.67 140.2 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.16 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -142.27 162.45 35.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.863 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 17.1 ttt180 -78.01 121.47 24.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -81.15 15.54 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -118.58 150.73 48.68 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.89 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 26.0 ptt85 -52.65 128.9 27.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.896 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.14 110.37 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.89 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 3.2 m -85.18 92.61 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.854 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 20.6 mtpt -115.68 177.08 4.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.867 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 46.6 t -100.73 84.11 2.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 51.6 p -39.09 148.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.844 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . -147.39 84.88 0.17 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.446 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -0.13 6.44 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.674 2.25 . . . . 0.0 112.345 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 70.6 p -57.8 144.08 39.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.821 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 16.7 m -107.55 141.4 39.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.803 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 179.995 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -77.18 121.14 23.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.89 0.376 . . . . 0.0 110.796 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 86.2 p -83.41 139.88 32.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.866 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 161.65 -58.67 0.3 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.459 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 m -83.04 81.27 8.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.853 0.359 . . . . 0.0 110.854 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.2 m -154.36 150.61 28.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.914 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.15 -83.62 0.18 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.454 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.6 m -47.83 168.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.859 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -42.13 127.16 3.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.2 m -148.04 134.38 19.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -105.82 24.27 12.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.841 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.4 ttpt -85.29 142.82 29.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . 0.652 HG22 HG13 ' A' ' 167' ' ' VAL . 21.8 pt -125.91 158.7 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.104 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' A' ' 116' ' ' PHE . 12.3 t80 -105.07 104.65 14.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 185' ' ' VAL . 71.9 t -100.63 114.33 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.112 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -121.14 -169.52 13.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 54.86 12.92 4.03 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.44 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.653 HG23 ' HD2' ' A' ' 121' ' ' PRO . 54.4 mt -57.39 138.41 81.08 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.609 0.719 . . . . 0.0 111.121 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.653 ' HD2' HG23 ' A' ' 120' ' ' ILE . 53.2 Cg_endo -69.78 -174.24 0.87 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.248 . . . . 0.0 112.339 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.07 3.12 53.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -115.38 -10.71 11.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . 0.474 ' CB ' ' HG2' ' A' ' 121' ' ' PRO . 12.7 t -87.05 125.46 34.12 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -123.42 -172.86 13.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.512 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.416 ' HA ' HD12 ' A' ' 129' ' ' LEU . 47.2 tt0 -51.18 -66.06 0.45 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' THR . . . . . . . . . . . . . 96.8 m -44.14 -63.59 0.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.152 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -40.55 -58.42 1.6 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.881 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.48 HD11 ' HE3' ' A' ' 144' ' ' MET . 50.2 mt -40.99 -47.04 2.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.597 ' HA ' HG21 ' A' ' 139' ' ' VAL . 49.0 mtm180 -66.39 -61.25 2.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.882 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -43.31 -23.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' TYR . . . . . 0.405 ' N ' ' O ' ' A' ' 130' ' ' ARG . 9.2 t80 -101.08 -32.83 10.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.933 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.409 ' CD2' HD12 ' A' ' 159' ' ' ILE . 12.2 m-85 -93.52 15.3 16.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.851 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 pttt -95.11 -19.32 20.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 12.3 pttt -73.06 -30.39 63.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.893 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.482 ' CD1' ' HB3' ' A' ' 169' ' ' GLN . 44.4 m-85 -74.1 -37.12 64.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -170.15 -110.52 0.23 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.49 113.08 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.87 0.367 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.597 HG21 ' HA ' ' A' ' 130' ' ' ARG . 57.3 t -74.84 99.88 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 19.2 p -74.8 -42.11 58.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -142.96 155.08 44.63 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.877 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 159' ' ' ILE . 78.2 t -134.76 104.7 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.121 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 57.4 t -90.24 144.97 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.156 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.48 ' HE3' HD11 ' A' ' 129' ' ' LEU . 5.0 mtt -143.87 135.13 25.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . . . . . . . . . 69.9 mt -98.38 133.35 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.165 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.452 ' CB ' ' O ' ' A' ' 152' ' ' ARG . 0.2 OUTLIER -169.68 165.35 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.449 ' O ' ' C ' ' A' ' 148' ' ' ALA . 22.1 t0 -81.61 110.11 16.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.82 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.449 ' C ' ' O ' ' A' ' 147' ' ' ASP . . . -33.69 -58.15 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.122 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -43.13 -43.67 4.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' LYS . . . . . 0.443 ' N ' ' O ' ' A' ' 147' ' ' ASP . 35.0 mttm -78.0 -40.35 39.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 59.97 50.28 6.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.933 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.452 ' O ' ' CB ' ' A' ' 146' ' ' TYR . 4.0 ttt85 -161.65 138.01 6.1 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.627 0.727 . . . . 0.0 110.899 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 121.64 8.33 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.657 2.238 . . . . 0.0 112.349 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.475 ' HD3' ' CZ ' ' A' ' 156' ' ' PHE . 50.5 mtp180 -65.67 -53.95 34.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.869 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 165.91 38.25 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.45 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.475 ' CZ ' ' HD3' ' A' ' 154' ' ' ARG . 37.1 p90 -168.12 162.84 13.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.857 0.36 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 162.88 -155.18 26.42 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.467 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -139.55 169.46 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.794 0.33 . . . . 0.0 110.912 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 142' ' ' VAL . 11.0 mt -151.79 135.44 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.164 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 31.6 m -102.18 140.38 36.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -111.46 172.84 6.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -73.05 -34.72 66.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -137.94 152.68 49.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 165' ' ' GLN . 12.0 tm-20 -56.36 -49.64 73.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.435 ' C ' ' O ' ' A' ' 164' ' ' GLU . 2.0 tp-100 -34.81 -47.28 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 1.2 m -48.34 -54.55 13.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.652 HG13 HG22 ' A' ' 115' ' ' ILE . 69.8 t -43.4 -49.9 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.126 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 169' ' ' GLN . 1.2 m-20 -54.37 -61.54 2.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' GLN . . . . . 0.482 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -35.99 -45.57 0.43 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.934 -179.919 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -70.39 -63.12 1.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.092 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 172' ' ' ASN . 85.1 t -43.16 -54.96 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 171' ' ' VAL . 32.2 t30 -34.65 -50.91 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' MET . . . . . . . . . . . . . 41.2 mtp -74.36 -39.91 62.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' A' ' 174' ' ' HIS . 16.3 t-160 59.54 27.44 16.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.528 ' CG ' ' O ' ' A' ' 174' ' ' HIS . 7.6 m-85 -169.84 152.68 4.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' HIS . . . . . 0.434 ' CG ' ' O ' ' A' ' 175' ' ' PHE . 90.7 m-70 -157.94 151.74 23.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -107.4 93.55 4.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' ILE . . . . . 0.824 HD12 HG21 ' A' ' 183' ' ' VAL . 53.6 mt -116.23 119.46 62.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 6.9 mmt 56.83 47.47 17.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' GLY . . . . . . . . . . . . . . . 56.43 56.16 25.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.529 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 25.5 tptt -165.21 149.33 8.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.84 0.352 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' LYS . . . . . 0.426 ' HE3' ' CG ' ' A' ' 175' ' ' PHE . 14.4 tptt -90.43 110.39 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.824 HG21 HD12 ' A' ' 178' ' ' ILE . 4.1 t -95.21 131.07 43.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.103 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -88.65 146.01 25.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.633 HG22 HG22 ' A' ' 117' ' ' VAL . 54.9 t -140.6 127.18 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.098 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 3.9 mtmp? -142.89 143.57 32.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.915 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.61 ' HD3' HG11 ' A' ' 167' ' ' VAL . 3.1 mmt85 -46.76 139.67 5.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -105.65 16.4 25.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.41 ' CG ' ' HD2' ' A' ' 187' ' ' ARG . 10.5 pt-20 -126.9 151.43 73.87 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.61 0.719 . . . . 0.0 110.884 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 164.13 35.66 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.241 . . . . 0.0 112.384 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 28.3 ptt-85 -84.34 168.17 15.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -67.74 129.76 40.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 17.0 m -104.42 -56.4 2.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.814 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 67.9 tttt -80.73 136.48 36.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.936 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 195' ' ' SER . . . . . . . . . . . . . 8.6 t -107.91 106.44 16.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.863 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 47.5 m -107.03 -58.16 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.896 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 111.21 -175.9 18.05 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.485 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 198' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 172.89 11.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.644 2.229 . . . . 0.0 112.376 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.5 t -48.71 -48.72 40.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.899 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 200' ' ' SER . . . . . . . . . . . . . 88.3 p 43.17 42.11 3.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.861 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.466 -179.951 . . . . . . . . 0 0 . 1 stop_ save_